{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 3,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['Hepatitis', 'Hepatitis B', 'Hepatitis A', 'Hepatitis C', 'Hepatitis E']\n",
      "Hepatitis is inflammation of the liver tissue. Some people or animals with hepatitis have no symptoms, whereas others develop yellow discoloration of the skin and whites of the eyes (jaundice), poor appetite, vomiting, tiredness, abdominal pain, and diarrhea. Hepatitis is acute if it resolves within six months, and chronic if it lasts longer than six months. Acute hepatitis can resolve on its own, progress to chronic hepatitis, or (rarely) result in acute liver failure. Chronic hepatitis may progress to scarring of the liver (cirrhosis), liver failure, and liver cancer.Hepatitis is most commonly caused by the virus hepatovirus A, B, C, D, and E. Other viruses can also cause liver inflammation, including cytomegalovirus, Epstein–Barr virus, and yellow fever virus. Other common causes of hepatitis include heavy alcohol use, certain medications, toxins, other infections, autoimmune diseases, and non-alcoholic steatohepatitis (NASH). Hepatitis A and E are mainly spread by contaminated food and water. Hepatitis B is mainly sexually transmitted, but may also be passed from mother to baby during pregnancy or childbirth and spread through infected blood. Hepatitis C is commonly spread through infected blood such as may occur during needle sharing by intravenous drug users. Hepatitis D can only infect people already infected with hepatitis B.Hepatitis A, B, and D are preventable with immunization.\n"
     ]
    }
   ],
   "source": [
    "import wikipedia\n",
    "\n",
    "result = wikipedia.summary('Hepatitis', sentences=20)\n",
    "search = wikipedia.search('Hepatitis', results=5)\n",
    "\n",
    "print(search)\n",
    "print(result)\n"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-25T14:33:53.830894500Z",
     "start_time": "2023-09-25T14:33:48.239422400Z"
    }
   },
   "id": "22f69c3fb97be8c4"
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "outputs": [],
   "source": [
    "page_obj = wikipedia.page('Hepatitis')"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-25T14:33:54.948358500Z",
     "start_time": "2023-09-25T14:33:53.835920100Z"
    }
   },
   "id": "39c653df7cf68414"
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "outputs": [],
   "source": [
    "link = list(page_obj.sections)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-23T03:41:30.808402400Z",
     "start_time": "2023-09-23T03:41:29.280514500Z"
    }
   },
   "id": "c436c3ecc8f41a3c"
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Hepatitis A\n",
      "Hepatitis A causes an acute illness that does not progress to chronic liver disease. Therefore, the role of screening is to assess immune status in people who are at high risk of contracting the virus, as well as in people with known liver disease for whom hepatitis A infection could lead to liver failure. People in these groups who are not already immune can receive the hepatitis A vaccine.Those at high risk and in need of screening include:\n",
      "People in close contact (either living with or having sexual contact) with someone who has hepatitis A\n",
      "People traveling to an area with endemic hepatitis A\n",
      "People who do not have access to clean water\n",
      "People who use illicit drugs\n",
      "People with liver disease\n",
      "People with poor sanitary habits such as not washing hands after using the restroom or changing diapersThe presence of anti-hepatitis A IgG in the blood indicates past infection with the virus or prior vaccination.\n",
      "\n",
      "Hepatitis A\n",
      "Hepatitis A causes an acute illness that does not progress to chronic liver disease. Therefore, the role of screening is to assess immune status in people who are at high risk of contracting the virus, as well as in people with known liver disease for whom hepatitis A infection could lead to liver failure. People in these groups who are not already immune can receive the hepatitis A vaccine.Those at high risk and in need of screening include:\n",
      "People in close contact (either living with or having sexual contact) with someone who has hepatitis A\n",
      "People traveling to an area with endemic hepatitis A\n",
      "People who do not have access to clean water\n",
      "People who use illicit drugs\n",
      "People with liver disease\n",
      "People with poor sanitary habits such as not washing hands after using the restroom or changing diapersThe presence of anti-hepatitis A IgG in the blood indicates past infection with the virus or prior vaccination.\n",
      "\n",
      "Hepatitis A\n",
      "Hepatitis A causes an acute illness that does not progress to chronic liver disease. Therefore, the role of screening is to assess immune status in people who are at high risk of contracting the virus, as well as in people with known liver disease for whom hepatitis A infection could lead to liver failure. People in these groups who are not already immune can receive the hepatitis A vaccine.Those at high risk and in need of screening include:\n",
      "People in close contact (either living with or having sexual contact) with someone who has hepatitis A\n",
      "People traveling to an area with endemic hepatitis A\n",
      "People who do not have access to clean water\n",
      "People who use illicit drugs\n",
      "People with liver disease\n",
      "People with poor sanitary habits such as not washing hands after using the restroom or changing diapersThe presence of anti-hepatitis A IgG in the blood indicates past infection with the virus or prior vaccination.\n",
      "\n",
      "Hepatitis A\n",
      "Hepatitis A causes an acute illness that does not progress to chronic liver disease. Therefore, the role of screening is to assess immune status in people who are at high risk of contracting the virus, as well as in people with known liver disease for whom hepatitis A infection could lead to liver failure. People in these groups who are not already immune can receive the hepatitis A vaccine.Those at high risk and in need of screening include:\n",
      "People in close contact (either living with or having sexual contact) with someone who has hepatitis A\n",
      "People traveling to an area with endemic hepatitis A\n",
      "People who do not have access to clean water\n",
      "People who use illicit drugs\n",
      "People with liver disease\n",
      "People with poor sanitary habits such as not washing hands after using the restroom or changing diapersThe presence of anti-hepatitis A IgG in the blood indicates past infection with the virus or prior vaccination.\n",
      "\n",
      "Hepatitis A\n",
      "Hepatitis A causes an acute illness that does not progress to chronic liver disease. Therefore, the role of screening is to assess immune status in people who are at high risk of contracting the virus, as well as in people with known liver disease for whom hepatitis A infection could lead to liver failure. People in these groups who are not already immune can receive the hepatitis A vaccine.Those at high risk and in need of screening include:\n",
      "People in close contact (either living with or having sexual contact) with someone who has hepatitis A\n",
      "People traveling to an area with endemic hepatitis A\n",
      "People who do not have access to clean water\n",
      "People who use illicit drugs\n",
      "People with liver disease\n",
      "People with poor sanitary habits such as not washing hands after using the restroom or changing diapersThe presence of anti-hepatitis A IgG in the blood indicates past infection with the virus or prior vaccination.\n",
      "\n",
      "Hepatitis A\n",
      "Hepatitis A causes an acute illness that does not progress to chronic liver disease. Therefore, the role of screening is to assess immune status in people who are at high risk of contracting the virus, as well as in people with known liver disease for whom hepatitis A infection could lead to liver failure. People in these groups who are not already immune can receive the hepatitis A vaccine.Those at high risk and in need of screening include:\n",
      "People in close contact (either living with or having sexual contact) with someone who has hepatitis A\n",
      "People traveling to an area with endemic hepatitis A\n",
      "People who do not have access to clean water\n",
      "People who use illicit drugs\n",
      "People with liver disease\n",
      "People with poor sanitary habits such as not washing hands after using the restroom or changing diapersThe presence of anti-hepatitis A IgG in the blood indicates past infection with the virus or prior vaccination.\n"
     ]
    }
   ],
   "source": [
    "for item in link:\n",
    "    val = 'hepatitis a' in str(item).lower()\n",
    "    if val:\n",
    "        print()\n",
    "        print(item)\n",
    "        print(page_obj.section(item))"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-23T03:41:34.766922100Z",
     "start_time": "2023-09-23T03:41:30.814395300Z"
    }
   },
   "id": "28bb266d5b0889b6"
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "outputs": [
    {
     "data": {
      "text/plain": "'<div class=\"mw-parser-output\"><div class=\"shortdescription nomobile noexcerpt noprint searchaux\" style=\"display:none\">Inflammation of the liver</div>\\n<style data-mw-deduplicate=\"TemplateStyles:r1033289096\">.mw-parser-output .hatnote{font-style:italic}.mw-parser-output div.hatnote{padding-left:1.6em;margin-bottom:0.5em}.mw-parser-output .hatnote i{font-style:normal}.mw-parser-output .hatnote+link+.hatnote{margin-top:-0.5em}</style><div role=\"note\" class=\"hatnote navigation-not-searchable\">\"Hepatite\" redirects here. For the mineral of that name, see <a href=\"/wiki/Baryte\" title=\"Baryte\">Baryte</a>.</div>\\n<div class=\"shortdescription nomobile noexcerpt noprint searchaux\" style=\"display:none\">Medical condition</div><style data-mw-deduplicate=\"TemplateStyles:r1066479718\">.mw-parser-output .infobox-subbox{padding:0;border:none;margin:-3px;width:auto;min-width:100%;font-size:100%;clear:none;float:none;background-color:transparent}.mw-parser-output .infobox-3cols-child{margin:auto}.mw-parser-output .infobox .navbar{font-size:100%}body.skin-minerva .mw-parser-output .infobox-header,body.skin-minerva .mw-parser-output .infobox-subheader,body.skin-minerva .mw-parser-output .infobox-above,body.skin-minerva .mw-parser-output .infobox-title,body.skin-minerva .mw-parser-output .infobox-image,body.skin-minerva .mw-parser-output .infobox-full-data,body.skin-minerva .mw-parser-output .infobox-below{text-align:center}</style><table class=\"infobox\"><tbody><tr><th colspan=\"2\" class=\"infobox-above\" style=\"background:#ccc\">Hepatitis</th></tr><tr><td colspan=\"2\" class=\"infobox-full-data\"><span class=\"mw-default-size\" typeof=\"mw:File/Frameless\"><a href=\"/wiki/File:Alcoholic_hepatitis.jpg\" class=\"mw-file-description\"><img src=\"//upload.wikimedia.org/wikipedia/commons/thumb/7/72/Alcoholic_hepatitis.jpg/300px-Alcoholic_hepatitis.jpg\" decoding=\"async\" width=\"300\" height=\"200\" class=\"mw-file-element\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/7/72/Alcoholic_hepatitis.jpg/450px-Alcoholic_hepatitis.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/7/72/Alcoholic_hepatitis.jpg/600px-Alcoholic_hepatitis.jpg 2x\" data-file-width=\"768\" data-file-height=\"512\" /></a></span></td></tr><tr><td colspan=\"2\" class=\"infobox-full-data\"><a href=\"/wiki/Alcoholic_hepatitis\" title=\"Alcoholic hepatitis\">Alcoholic hepatitis</a> as seen with a microscope, showing fatty changes (white circles), remnants of dead liver cells, and <a href=\"/wiki/Mallory_bodies\" class=\"mw-redirect\" title=\"Mallory bodies\">Mallory bodies</a> (twisted-rope shaped inclusions within some liver cells). (<a href=\"/wiki/H%26E_stain\" title=\"H&amp;E stain\">H&amp;E stain</a>)</td></tr><tr><th scope=\"row\" class=\"infobox-label\"><a href=\"/wiki/Medical_specialty\" title=\"Medical specialty\">Specialty</a></th><td class=\"infobox-data\"><a href=\"/wiki/Infectious_disease_(medical_specialty)\" class=\"mw-redirect\" title=\"Infectious disease (medical specialty)\">Infectious disease</a>, <a href=\"/wiki/Gastroenterology\" title=\"Gastroenterology\">gastroenterology</a>, <a href=\"/wiki/Hepatology\" title=\"Hepatology\">hepatology</a></td></tr><tr><th scope=\"row\" class=\"infobox-label\"><a href=\"/wiki/Signs_and_symptoms\" title=\"Signs and symptoms\">Symptoms</a></th><td class=\"infobox-data\"><a href=\"/wiki/Jaundice\" title=\"Jaundice\">Yellowish skin</a>, poor appetite, abdominal pain<sup id=\"cite_ref-MedLine2016_1-0\" class=\"reference\"><a href=\"#cite_note-MedLine2016-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-WHO2016QA_2-0\" class=\"reference\"><a href=\"#cite_note-WHO2016QA-2\">&#91;2&#93;</a></sup></td></tr><tr><th scope=\"row\" class=\"infobox-label\"><a href=\"/wiki/Complication_(medicine)\" title=\"Complication (medicine)\">Complications</a></th><td class=\"infobox-data\"><a href=\"/wiki/Cirrhosis\" title=\"Cirrhosis\">Scarring of the liver</a>, <a href=\"/wiki/Liver_failure\" title=\"Liver failure\">liver failure</a>, <a href=\"/wiki/Liver_cancer\" title=\"Liver cancer\">liver cancer</a><sup id=\"cite_ref-NIH2016_3-0\" class=\"reference\"><a href=\"#cite_note-NIH2016-3\">&#91;3&#93;</a></sup></td></tr><tr><th scope=\"row\" class=\"infobox-label\">Duration</th><td class=\"infobox-data\">Short term or long term<sup id=\"cite_ref-MedLine2016_1-1\" class=\"reference\"><a href=\"#cite_note-MedLine2016-1\">&#91;1&#93;</a></sup></td></tr><tr><th scope=\"row\" class=\"infobox-label\">Causes</th><td class=\"infobox-data\"><a href=\"/wiki/Viruses\" class=\"mw-redirect\" title=\"Viruses\">Viruses</a>, <a href=\"/wiki/Ethanol\" title=\"Ethanol\">alcohol</a>, toxins, autoimmune<sup id=\"cite_ref-WHO2016QA_2-1\" class=\"reference\"><a href=\"#cite_note-WHO2016QA-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-NIH2016_3-1\" class=\"reference\"><a href=\"#cite_note-NIH2016-3\">&#91;3&#93;</a></sup></td></tr><tr><th scope=\"row\" class=\"infobox-label\">Prevention</th><td class=\"infobox-data\">Vaccination (for viral hepatitis),<sup id=\"cite_ref-WHO2016QA_2-2\" class=\"reference\"><a href=\"#cite_note-WHO2016QA-2\">&#91;2&#93;</a></sup> avoiding excessive alcohol</td></tr><tr><th scope=\"row\" class=\"infobox-label\">Treatment</th><td class=\"infobox-data\">Medication, <a href=\"/wiki/Liver_transplant\" class=\"mw-redirect\" title=\"Liver transplant\">liver transplant</a><sup id=\"cite_ref-MedLine2016_1-2\" class=\"reference\"><a href=\"#cite_note-MedLine2016-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-Trans2012_4-0\" class=\"reference\"><a href=\"#cite_note-Trans2012-4\">&#91;4&#93;</a></sup></td></tr><tr><th scope=\"row\" class=\"infobox-label\">Frequency</th><td class=\"infobox-data\">&gt; 500 million cases<sup id=\"cite_ref-NIH2016_3-2\" class=\"reference\"><a href=\"#cite_note-NIH2016-3\">&#91;3&#93;</a></sup></td></tr><tr><th scope=\"row\" class=\"infobox-label\">Deaths</th><td class=\"infobox-data\">&gt; One million a year<sup id=\"cite_ref-NIH2016_3-3\" class=\"reference\"><a href=\"#cite_note-NIH2016-3\">&#91;3&#93;</a></sup></td></tr></tbody></table>\\n<p><b>Hepatitis</b> is <a href=\"/wiki/Inflammation\" title=\"Inflammation\">inflammation</a> of the <a href=\"/wiki/Liver_parenchyma\" class=\"mw-redirect\" title=\"Liver parenchyma\">liver tissue</a>.<sup id=\"cite_ref-NIH2016_3-4\" class=\"reference\"><a href=\"#cite_note-NIH2016-3\">&#91;3&#93;</a></sup><sup id=\"cite_ref-MedlinePlus_2020_5-0\" class=\"reference\"><a href=\"#cite_note-MedlinePlus_2020-5\">&#91;5&#93;</a></sup> Some people or animals with hepatitis have no symptoms, whereas others develop yellow discoloration of the skin and whites of the eyes (<a href=\"/wiki/Jaundice\" title=\"Jaundice\">jaundice</a>), <a href=\"/wiki/Anorexia_(symptom)\" title=\"Anorexia (symptom)\">poor appetite</a>, <a href=\"/wiki/Vomiting\" title=\"Vomiting\">vomiting</a>, <a href=\"/wiki/Fatigue_(medicine)\" class=\"mw-redirect\" title=\"Fatigue (medicine)\">tiredness</a>, <a href=\"/wiki/Abdominal_pain\" title=\"Abdominal pain\">abdominal pain</a>, and <a href=\"/wiki/Diarrhea\" title=\"Diarrhea\">diarrhea</a>.<sup id=\"cite_ref-MedLine2016_1-3\" class=\"reference\"><a href=\"#cite_note-MedLine2016-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-WHO2016QA_2-3\" class=\"reference\"><a href=\"#cite_note-WHO2016QA-2\">&#91;2&#93;</a></sup> Hepatitis is <i><a href=\"/wiki/Acute_(medicine)\" title=\"Acute (medicine)\">acute</a></i> if it resolves within six months, and <i><a href=\"/wiki/Chronic_condition\" title=\"Chronic condition\">chronic</a></i> if it lasts longer than six months.<sup id=\"cite_ref-MedLine2016_1-4\" class=\"reference\"><a href=\"#cite_note-MedLine2016-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-6\" class=\"reference\"><a href=\"#cite_note-6\">&#91;6&#93;</a></sup> Acute hepatitis can <a href=\"/wiki/Self-limiting_(biology)\" title=\"Self-limiting (biology)\">resolve on its own</a>, progress to chronic hepatitis, or (rarely) result in <a href=\"/wiki/Acute_liver_failure\" title=\"Acute liver failure\">acute liver failure</a>.<sup id=\"cite_ref-7\" class=\"reference\"><a href=\"#cite_note-7\">&#91;7&#93;</a></sup> Chronic hepatitis may progress to scarring of the liver (<a href=\"/wiki/Cirrhosis\" title=\"Cirrhosis\">cirrhosis</a>), <a href=\"/wiki/Liver_failure\" title=\"Liver failure\">liver failure</a>, and <a href=\"/wiki/Liver_cancer\" title=\"Liver cancer\">liver cancer</a>.<sup id=\"cite_ref-NIH2016_3-5\" class=\"reference\"><a href=\"#cite_note-NIH2016-3\">&#91;3&#93;</a></sup><sup id=\"cite_ref-8\" class=\"reference\"><a href=\"#cite_note-8\">&#91;8&#93;</a></sup>\\n</p><p>Hepatitis is most commonly caused by the virus <i><a href=\"/wiki/Hepatovirus_A\" class=\"mw-redirect\" title=\"Hepatovirus A\">hepatovirus A</a></i>, <i><a href=\"/wiki/Hepatitis_B_virus\" title=\"Hepatitis B virus\">B</a></i>, <i><a href=\"/wiki/Hepatitis_C_virus\" title=\"Hepatitis C virus\">C</a></i>, <i><a href=\"/wiki/Hepatitis_D_virus\" class=\"mw-redirect\" title=\"Hepatitis D virus\">D</a></i>, and <i><a href=\"/wiki/Hepatitis_E_virus\" class=\"mw-redirect\" title=\"Hepatitis E virus\">E</a></i>.<sup id=\"cite_ref-WHO2016QA_2-4\" class=\"reference\"><a href=\"#cite_note-WHO2016QA-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-NIH2016_3-6\" class=\"reference\"><a href=\"#cite_note-NIH2016-3\">&#91;3&#93;</a></sup> Other <a href=\"/wiki/Viral_hepatitis\" title=\"Viral hepatitis\">viruses can also cause liver inflammation</a>, including <a href=\"/wiki/Cytomegalovirus\" title=\"Cytomegalovirus\">cytomegalovirus</a>, <a href=\"/wiki/Epstein%E2%80%93Barr_virus\" title=\"Epstein–Barr virus\">Epstein–Barr virus</a>, and <a href=\"/wiki/Yellow_fever\" title=\"Yellow fever\">yellow fever virus</a>. Other common causes of hepatitis include <a href=\"/wiki/Alcoholism\" title=\"Alcoholism\">heavy alcohol use</a>, certain medications, toxins, other infections, <a href=\"/wiki/Autoimmune_diseases\" class=\"mw-redirect\" title=\"Autoimmune diseases\">autoimmune diseases</a>,<sup id=\"cite_ref-WHO2016QA_2-5\" class=\"reference\"><a href=\"#cite_note-WHO2016QA-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-NIH2016_3-7\" class=\"reference\"><a href=\"#cite_note-NIH2016-3\">&#91;3&#93;</a></sup> and <a href=\"/wiki/Non-alcoholic_steatohepatitis\" class=\"mw-redirect\" title=\"Non-alcoholic steatohepatitis\">non-alcoholic steatohepatitis</a> (NASH).<sup id=\"cite_ref-NASH2014_9-0\" class=\"reference\"><a href=\"#cite_note-NASH2014-9\">&#91;9&#93;</a></sup> Hepatitis A and E are mainly spread by contaminated food and water.<sup id=\"cite_ref-NIH2016_3-8\" class=\"reference\"><a href=\"#cite_note-NIH2016-3\">&#91;3&#93;</a></sup> Hepatitis B is mainly <a href=\"/wiki/Sexually_transmitted_infection\" title=\"Sexually transmitted infection\">sexually transmitted</a>, but may also be <a href=\"/wiki/Vertically_transmitted_infection\" title=\"Vertically transmitted infection\">passed from mother to baby</a> during <a href=\"/wiki/Pregnancy\" title=\"Pregnancy\">pregnancy</a> or <a href=\"/wiki/Childbirth\" title=\"Childbirth\">childbirth</a> and spread through infected <a href=\"/wiki/Blood\" title=\"Blood\">blood</a>.<sup id=\"cite_ref-NIH2016_3-9\" class=\"reference\"><a href=\"#cite_note-NIH2016-3\">&#91;3&#93;</a></sup> Hepatitis C is commonly spread through infected blood such as may occur during <a href=\"/wiki/Needle_sharing\" title=\"Needle sharing\">needle sharing</a> by <a href=\"/wiki/Drug_injection\" title=\"Drug injection\">intravenous drug users</a>.<sup id=\"cite_ref-NIH2016_3-10\" class=\"reference\"><a href=\"#cite_note-NIH2016-3\">&#91;3&#93;</a></sup> Hepatitis D can only infect people already infected with hepatitis B.<sup id=\"cite_ref-NIH2016_3-11\" class=\"reference\"><a href=\"#cite_note-NIH2016-3\">&#91;3&#93;</a></sup>\\n</p><p>Hepatitis A, B, and D are <a href=\"/wiki/Vaccine-preventable_diseases\" class=\"mw-redirect\" title=\"Vaccine-preventable diseases\">preventable</a> with <a href=\"/wiki/Immunization\" title=\"Immunization\">immunization</a>.<sup id=\"cite_ref-WHO2016QA_2-6\" class=\"reference\"><a href=\"#cite_note-WHO2016QA-2\">&#91;2&#93;</a></sup> Medications may be used to treat chronic viral hepatitis.<sup id=\"cite_ref-MedLine2016_1-5\" class=\"reference\"><a href=\"#cite_note-MedLine2016-1\">&#91;1&#93;</a></sup> Antiviral medications are recommended in all with chronic hepatitis C, except those with conditions that limit their life expectancy.<sup id=\"cite_ref-AASLD-IDSA_10-0\" class=\"reference\"><a href=\"#cite_note-AASLD-IDSA-10\">&#91;10&#93;</a></sup> There is no specific treatment for NASH; physical activity, a <a href=\"/wiki/Healthy_diet\" title=\"Healthy diet\">healthy diet</a>, and <a href=\"/wiki/Weight_loss\" title=\"Weight loss\">weight loss</a> are recommended.<sup id=\"cite_ref-NASH2014_9-1\" class=\"reference\"><a href=\"#cite_note-NASH2014-9\">&#91;9&#93;</a></sup> <a href=\"/wiki/Autoimmune_hepatitis\" title=\"Autoimmune hepatitis\">Autoimmune hepatitis</a> may be treated with <a href=\"/wiki/Immunosuppressants\" class=\"mw-redirect\" title=\"Immunosuppressants\">medications to suppress the immune system</a>.<sup id=\"cite_ref-11\" class=\"reference\"><a href=\"#cite_note-11\">&#91;11&#93;</a></sup> A <a href=\"/wiki/Liver_transplant\" class=\"mw-redirect\" title=\"Liver transplant\">liver transplant</a> may be an option in both acute and chronic liver failure.<sup id=\"cite_ref-Trans2012_4-1\" class=\"reference\"><a href=\"#cite_note-Trans2012-4\">&#91;4&#93;</a></sup>\\n</p><p>Worldwide in 2015, hepatitis A occurred in about 114 million people, chronic hepatitis B affected about 343 million people and chronic hepatitis C about 142 million people.<sup id=\"cite_ref-12\" class=\"reference\"><a href=\"#cite_note-12\">&#91;12&#93;</a></sup> In the United States, NASH affects about 11 million people and <a href=\"/wiki/Alcoholic_hepatitis\" title=\"Alcoholic hepatitis\">alcoholic hepatitis</a> affects about 5 million people.<sup id=\"cite_ref-NASH2014_9-2\" class=\"reference\"><a href=\"#cite_note-NASH2014-9\">&#91;9&#93;</a></sup><sup id=\"cite_ref-13\" class=\"reference\"><a href=\"#cite_note-13\">&#91;13&#93;</a></sup> Hepatitis results in more than a million deaths a year, most of which occur indirectly from liver scarring or liver cancer.<sup id=\"cite_ref-NIH2016_3-12\" class=\"reference\"><a href=\"#cite_note-NIH2016-3\">&#91;3&#93;</a></sup><sup id=\"cite_ref-14\" class=\"reference\"><a href=\"#cite_note-14\">&#91;14&#93;</a></sup> In the United States, hepatitis A is estimated to occur in about 2,500 people a year and results in about 75 deaths.<sup id=\"cite_ref-15\" class=\"reference\"><a href=\"#cite_note-15\">&#91;15&#93;</a></sup> The word is derived from the <a href=\"/wiki/Ancient_Greek\" title=\"Ancient Greek\">Greek</a> <i>hêpar</i> (<span title=\"Ancient Greek (to 1453)-language text\"><span lang=\"grc\"><a href=\"https://en.wiktionary.org/wiki/%E1%BC%A7%CF%80%CE%B1%CF%81\" class=\"extiw\" title=\"wikt:ἧπαρ\">ἧπαρ</a></span></span>), meaning \"liver\", and <i><a href=\"https://en.wiktionary.org/wiki/-itis\" class=\"extiw\" title=\"wikt:-itis\">-itis</a></i> (<span title=\"Ancient Greek (to 1453)-language text\"><span lang=\"grc\">-ῖτις</span></span>), meaning \"inflammation\".<sup id=\"cite_ref-16\" class=\"reference\"><a href=\"#cite_note-16\">&#91;16&#93;</a></sup>\\n</p>\\n<style data-mw-deduplicate=\"TemplateStyles:r886046785\">.mw-parser-output .toclimit-2 .toclevel-1 ul,.mw-parser-output .toclimit-3 .toclevel-2 ul,.mw-parser-output .toclimit-4 .toclevel-3 ul,.mw-parser-output .toclimit-5 .toclevel-4 ul,.mw-parser-output .toclimit-6 .toclevel-5 ul,.mw-parser-output .toclimit-7 .toclevel-6 ul{display:none}</style><div class=\"toclimit-3\"><div id=\"toc\" class=\"toc\" role=\"navigation\" aria-labelledby=\"mw-toc-heading\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2 id=\"mw-toc-heading\">Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\\n<ul>\\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#Signs_and_symptoms\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">Signs and symptoms</span></a>\\n<ul>\\n<li class=\"toclevel-2 tocsection-2\"><a href=\"#Acute_hepatitis\"><span class=\"tocnumber\">1.1</span> <span class=\"toctext\">Acute hepatitis</span></a></li>\\n<li class=\"toclevel-2 tocsection-3\"><a href=\"#Fulminant_hepatitis\"><span class=\"tocnumber\">1.2</span> <span class=\"toctext\">Fulminant hepatitis</span></a></li>\\n<li class=\"toclevel-2 tocsection-4\"><a href=\"#Chronic_hepatitis\"><span class=\"tocnumber\">1.3</span> <span class=\"toctext\">Chronic hepatitis</span></a></li>\\n</ul>\\n</li>\\n<li class=\"toclevel-1 tocsection-5\"><a href=\"#Causes\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">Causes</span></a>\\n<ul>\\n<li class=\"toclevel-2 tocsection-6\"><a href=\"#Infectious\"><span class=\"tocnumber\">2.1</span> <span class=\"toctext\">Infectious</span></a>\\n<ul>\\n<li class=\"toclevel-3 tocsection-7\"><a href=\"#Viral_hepatitis\"><span class=\"tocnumber\">2.1.1</span> <span class=\"toctext\">Viral hepatitis</span></a></li>\\n<li class=\"toclevel-3 tocsection-8\"><a href=\"#Parasitic_hepatitis\"><span class=\"tocnumber\">2.1.2</span> <span class=\"toctext\">Parasitic hepatitis</span></a></li>\\n<li class=\"toclevel-3 tocsection-9\"><a href=\"#Bacterial_hepatitis\"><span class=\"tocnumber\">2.1.3</span> <span class=\"toctext\">Bacterial hepatitis</span></a></li>\\n</ul>\\n</li>\\n<li class=\"toclevel-2 tocsection-10\"><a href=\"#Metabolic\"><span class=\"tocnumber\">2.2</span> <span class=\"toctext\">Metabolic</span></a>\\n<ul>\\n<li class=\"toclevel-3 tocsection-11\"><a href=\"#Alcoholic_hepatitis\"><span class=\"tocnumber\">2.2.1</span> <span class=\"toctext\">Alcoholic hepatitis</span></a></li>\\n<li class=\"toclevel-3 tocsection-12\"><a href=\"#Toxic_and_drug-induced_hepatitis\"><span class=\"tocnumber\">2.2.2</span> <span class=\"toctext\">Toxic and drug-induced hepatitis</span></a></li>\\n<li class=\"toclevel-3 tocsection-13\"><a href=\"#Non-alcoholic_fatty_liver_disease\"><span class=\"tocnumber\">2.2.3</span> <span class=\"toctext\">Non-alcoholic fatty liver disease</span></a></li>\\n</ul>\\n</li>\\n<li class=\"toclevel-2 tocsection-14\"><a href=\"#Autoimmune\"><span class=\"tocnumber\">2.3</span> <span class=\"toctext\">Autoimmune</span></a></li>\\n<li class=\"toclevel-2 tocsection-15\"><a href=\"#Genetic\"><span class=\"tocnumber\">2.4</span> <span class=\"toctext\">Genetic</span></a></li>\\n<li class=\"toclevel-2 tocsection-16\"><a href=\"#Ischemic_hepatitis\"><span class=\"tocnumber\">2.5</span> <span class=\"toctext\">Ischemic hepatitis</span></a></li>\\n<li class=\"toclevel-2 tocsection-17\"><a href=\"#Other\"><span class=\"tocnumber\">2.6</span> <span class=\"toctext\">Other</span></a></li>\\n</ul>\\n</li>\\n<li class=\"toclevel-1 tocsection-18\"><a href=\"#Mechanism\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">Mechanism</span></a>\\n<ul>\\n<li class=\"toclevel-2 tocsection-19\"><a href=\"#Viral_hepatitis_2\"><span class=\"tocnumber\">3.1</span> <span class=\"toctext\">Viral hepatitis</span></a></li>\\n<li class=\"toclevel-2 tocsection-20\"><a href=\"#Steatohepatitis\"><span class=\"tocnumber\">3.2</span> <span class=\"toctext\">Steatohepatitis</span></a></li>\\n</ul>\\n</li>\\n<li class=\"toclevel-1 tocsection-21\"><a href=\"#Diagnosis\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">Diagnosis</span></a>\\n<ul>\\n<li class=\"toclevel-2 tocsection-22\"><a href=\"#Viral_hepatitis_3\"><span class=\"tocnumber\">4.1</span> <span class=\"toctext\">Viral hepatitis</span></a></li>\\n<li class=\"toclevel-2 tocsection-23\"><a href=\"#Alcoholic_versus_non-alcoholic\"><span class=\"tocnumber\">4.2</span> <span class=\"toctext\">Alcoholic versus non-alcoholic</span></a></li>\\n</ul>\\n</li>\\n<li class=\"toclevel-1 tocsection-24\"><a href=\"#Virus_screening\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">Virus screening</span></a>\\n<ul>\\n<li class=\"toclevel-2 tocsection-25\"><a href=\"#Hepatitis_A\"><span class=\"tocnumber\">5.1</span> <span class=\"toctext\">Hepatitis A</span></a></li>\\n<li class=\"toclevel-2 tocsection-26\"><a href=\"#Hepatitis_B\"><span class=\"tocnumber\">5.2</span> <span class=\"toctext\">Hepatitis B</span></a></li>\\n<li class=\"toclevel-2 tocsection-27\"><a href=\"#Hepatitis_C\"><span class=\"tocnumber\">5.3</span> <span class=\"toctext\">Hepatitis C</span></a></li>\\n<li class=\"toclevel-2 tocsection-28\"><a href=\"#Hepatitis_D\"><span class=\"tocnumber\">5.4</span> <span class=\"toctext\">Hepatitis D</span></a></li>\\n</ul>\\n</li>\\n<li class=\"toclevel-1 tocsection-29\"><a href=\"#Prevention\"><span class=\"tocnumber\">6</span> <span class=\"toctext\">Prevention</span></a>\\n<ul>\\n<li class=\"toclevel-2 tocsection-30\"><a href=\"#Vaccines\"><span class=\"tocnumber\">6.1</span> <span class=\"toctext\">Vaccines</span></a>\\n<ul>\\n<li class=\"toclevel-3 tocsection-31\"><a href=\"#Hepatitis_A_2\"><span class=\"tocnumber\">6.1.1</span> <span class=\"toctext\">Hepatitis A</span></a></li>\\n<li class=\"toclevel-3 tocsection-32\"><a href=\"#Hepatitis_B_2\"><span class=\"tocnumber\">6.1.2</span> <span class=\"toctext\">Hepatitis B</span></a></li>\\n<li class=\"toclevel-3 tocsection-33\"><a href=\"#Other_2\"><span class=\"tocnumber\">6.1.3</span> <span class=\"toctext\">Other</span></a></li>\\n</ul>\\n</li>\\n<li class=\"toclevel-2 tocsection-34\"><a href=\"#Behavioral_changes\"><span class=\"tocnumber\">6.2</span> <span class=\"toctext\">Behavioral changes</span></a>\\n<ul>\\n<li class=\"toclevel-3 tocsection-35\"><a href=\"#Hepatitis_A_3\"><span class=\"tocnumber\">6.2.1</span> <span class=\"toctext\">Hepatitis A</span></a></li>\\n<li class=\"toclevel-3 tocsection-36\"><a href=\"#Hepatitis_B_and_C\"><span class=\"tocnumber\">6.2.2</span> <span class=\"toctext\">Hepatitis B and C</span></a></li>\\n<li class=\"toclevel-3 tocsection-37\"><a href=\"#Hepatitis_D_2\"><span class=\"tocnumber\">6.2.3</span> <span class=\"toctext\">Hepatitis D</span></a></li>\\n<li class=\"toclevel-3 tocsection-38\"><a href=\"#Hepatitis_E\"><span class=\"tocnumber\">6.2.4</span> <span class=\"toctext\">Hepatitis E</span></a></li>\\n<li class=\"toclevel-3 tocsection-39\"><a href=\"#Alcoholic_and_metabolic_hepatitis\"><span class=\"tocnumber\">6.2.5</span> <span class=\"toctext\">Alcoholic and metabolic hepatitis</span></a></li>\\n</ul>\\n</li>\\n<li class=\"toclevel-2 tocsection-40\"><a href=\"#Successes\"><span class=\"tocnumber\">6.3</span> <span class=\"toctext\">Successes</span></a>\\n<ul>\\n<li class=\"toclevel-3 tocsection-41\"><a href=\"#Hepatitis_A_4\"><span class=\"tocnumber\">6.3.1</span> <span class=\"toctext\">Hepatitis A</span></a></li>\\n<li class=\"toclevel-3 tocsection-42\"><a href=\"#Hepatitis_B_3\"><span class=\"tocnumber\">6.3.2</span> <span class=\"toctext\">Hepatitis B</span></a></li>\\n<li class=\"toclevel-3 tocsection-43\"><a href=\"#Hepatitis_C_2\"><span class=\"tocnumber\">6.3.3</span> <span class=\"toctext\">Hepatitis C</span></a></li>\\n<li class=\"toclevel-3 tocsection-44\"><a href=\"#Alcoholic_hepatitis_2\"><span class=\"tocnumber\">6.3.4</span> <span class=\"toctext\">Alcoholic hepatitis</span></a></li>\\n</ul>\\n</li>\\n</ul>\\n</li>\\n<li class=\"toclevel-1 tocsection-45\"><a href=\"#Treatment\"><span class=\"tocnumber\">7</span> <span class=\"toctext\">Treatment</span></a>\\n<ul>\\n<li class=\"toclevel-2 tocsection-46\"><a href=\"#Hepatitis_A_5\"><span class=\"tocnumber\">7.1</span> <span class=\"toctext\">Hepatitis A</span></a></li>\\n<li class=\"toclevel-2 tocsection-47\"><a href=\"#Hepatitis_B_4\"><span class=\"tocnumber\">7.2</span> <span class=\"toctext\">Hepatitis B</span></a>\\n<ul>\\n<li class=\"toclevel-3 tocsection-48\"><a href=\"#Acute\"><span class=\"tocnumber\">7.2.1</span> <span class=\"toctext\">Acute</span></a></li>\\n<li class=\"toclevel-3 tocsection-49\"><a href=\"#Chronic\"><span class=\"tocnumber\">7.2.2</span> <span class=\"toctext\">Chronic</span></a></li>\\n</ul>\\n</li>\\n<li class=\"toclevel-2 tocsection-50\"><a href=\"#Hepatitis_C_3\"><span class=\"tocnumber\">7.3</span> <span class=\"toctext\">Hepatitis C</span></a></li>\\n<li class=\"toclevel-2 tocsection-51\"><a href=\"#Hepatitis_D_3\"><span class=\"tocnumber\">7.4</span> <span class=\"toctext\">Hepatitis D</span></a></li>\\n<li class=\"toclevel-2 tocsection-52\"><a href=\"#Hepatitis_E_2\"><span class=\"tocnumber\">7.5</span> <span class=\"toctext\">Hepatitis E</span></a></li>\\n<li class=\"toclevel-2 tocsection-53\"><a href=\"#Alcoholic_hepatitis_3\"><span class=\"tocnumber\">7.6</span> <span class=\"toctext\">Alcoholic hepatitis</span></a></li>\\n<li class=\"toclevel-2 tocsection-54\"><a href=\"#Metabolic_hepatitis\"><span class=\"tocnumber\">7.7</span> <span class=\"toctext\">Metabolic hepatitis</span></a></li>\\n<li class=\"toclevel-2 tocsection-55\"><a href=\"#Autoimmune_hepatitis\"><span class=\"tocnumber\">7.8</span> <span class=\"toctext\">Autoimmune hepatitis</span></a></li>\\n</ul>\\n</li>\\n<li class=\"toclevel-1 tocsection-56\"><a href=\"#Prognosis\"><span class=\"tocnumber\">8</span> <span class=\"toctext\">Prognosis</span></a>\\n<ul>\\n<li class=\"toclevel-2 tocsection-57\"><a href=\"#Acute_hepatitis_2\"><span class=\"tocnumber\">8.1</span> <span class=\"toctext\">Acute hepatitis</span></a>\\n<ul>\\n<li class=\"toclevel-3 tocsection-58\"><a href=\"#Fulminant_hepatitis_2\"><span class=\"tocnumber\">8.1.1</span> <span class=\"toctext\">Fulminant hepatitis</span></a></li>\\n</ul>\\n</li>\\n<li class=\"toclevel-2 tocsection-59\"><a href=\"#Chronic_hepatitis_2\"><span class=\"tocnumber\">8.2</span> <span class=\"toctext\">Chronic hepatitis</span></a></li>\\n</ul>\\n</li>\\n<li class=\"toclevel-1 tocsection-60\"><a href=\"#Epidemiology\"><span class=\"tocnumber\">9</span> <span class=\"toctext\">Epidemiology</span></a>\\n<ul>\\n<li class=\"toclevel-2 tocsection-61\"><a href=\"#Viral_hepatitis_4\"><span class=\"tocnumber\">9.1</span> <span class=\"toctext\">Viral hepatitis</span></a>\\n<ul>\\n<li class=\"toclevel-3 tocsection-62\"><a href=\"#Hepatitis_A_6\"><span class=\"tocnumber\">9.1.1</span> <span class=\"toctext\">Hepatitis A</span></a></li>\\n<li class=\"toclevel-3 tocsection-63\"><a href=\"#Hepatitis_B_5\"><span class=\"tocnumber\">9.1.2</span> <span class=\"toctext\">Hepatitis B</span></a></li>\\n<li class=\"toclevel-3 tocsection-64\"><a href=\"#Hepatitis_C_4\"><span class=\"tocnumber\">9.1.3</span> <span class=\"toctext\">Hepatitis C</span></a></li>\\n<li class=\"toclevel-3 tocsection-65\"><a href=\"#Hepatitis_D_4\"><span class=\"tocnumber\">9.1.4</span> <span class=\"toctext\">Hepatitis D</span></a></li>\\n<li class=\"toclevel-3 tocsection-66\"><a href=\"#Hepatitis_E_3\"><span class=\"tocnumber\">9.1.5</span> <span class=\"toctext\">Hepatitis E</span></a></li>\\n</ul>\\n</li>\\n<li class=\"toclevel-2 tocsection-67\"><a href=\"#Alcoholic_hepatitis_4\"><span class=\"tocnumber\">9.2</span> <span class=\"toctext\">Alcoholic hepatitis</span></a></li>\\n<li class=\"toclevel-2 tocsection-68\"><a href=\"#Non-alcoholic_steatohepatitis\"><span class=\"tocnumber\">9.3</span> <span class=\"toctext\">Non-alcoholic steatohepatitis</span></a></li>\\n</ul>\\n</li>\\n<li class=\"toclevel-1 tocsection-69\"><a href=\"#History\"><span class=\"tocnumber\">10</span> <span class=\"toctext\">History</span></a>\\n<ul>\\n<li class=\"toclevel-2 tocsection-70\"><a href=\"#Early_observations\"><span class=\"tocnumber\">10.1</span> <span class=\"toctext\">Early observations</span></a></li>\\n<li class=\"toclevel-2 tocsection-71\"><a href=\"#Willowbrook_State_School_experiments\"><span class=\"tocnumber\">10.2</span> <span class=\"toctext\">Willowbrook State School experiments</span></a></li>\\n<li class=\"toclevel-2 tocsection-72\"><a href=\"#Australia_antigen\"><span class=\"tocnumber\">10.3</span> <span class=\"toctext\">Australia antigen</span></a></li>\\n</ul>\\n</li>\\n<li class=\"toclevel-1 tocsection-73\"><a href=\"#Society_and_culture\"><span class=\"tocnumber\">11</span> <span class=\"toctext\">Society and culture</span></a>\\n<ul>\\n<li class=\"toclevel-2 tocsection-74\"><a href=\"#Economic_burden\"><span class=\"tocnumber\">11.1</span> <span class=\"toctext\">Economic burden</span></a></li>\\n<li class=\"toclevel-2 tocsection-75\"><a href=\"#2003_Monaca_outbreak\"><span class=\"tocnumber\">11.2</span> <span class=\"toctext\">2003 Monaca outbreak</span></a></li>\\n</ul>\\n</li>\\n<li class=\"toclevel-1 tocsection-76\"><a href=\"#Special_populations\"><span class=\"tocnumber\">12</span> <span class=\"toctext\">Special populations</span></a>\\n<ul>\\n<li class=\"toclevel-2 tocsection-77\"><a href=\"#HIV_co-infection\"><span class=\"tocnumber\">12.1</span> <span class=\"toctext\">HIV co-infection</span></a></li>\\n<li class=\"toclevel-2 tocsection-78\"><a href=\"#Pregnancy\"><span class=\"tocnumber\">12.2</span> <span class=\"toctext\">Pregnancy</span></a>\\n<ul>\\n<li class=\"toclevel-3 tocsection-79\"><a href=\"#Hepatitis_B_6\"><span class=\"tocnumber\">12.2.1</span> <span class=\"toctext\">Hepatitis B</span></a></li>\\n<li class=\"toclevel-3 tocsection-80\"><a href=\"#Hepatitis_C_5\"><span class=\"tocnumber\">12.2.2</span> <span class=\"toctext\">Hepatitis C</span></a></li>\\n<li class=\"toclevel-3 tocsection-81\"><a href=\"#Hepatitis_E_4\"><span class=\"tocnumber\">12.2.3</span> <span class=\"toctext\">Hepatitis E</span></a></li>\\n</ul>\\n</li>\\n</ul>\\n</li>\\n<li class=\"toclevel-1 tocsection-82\"><a href=\"#See_also\"><span class=\"tocnumber\">13</span> <span class=\"toctext\">See also</span></a></li>\\n<li class=\"toclevel-1 tocsection-83\"><a href=\"#References\"><span class=\"tocnumber\">14</span> <span class=\"toctext\">References</span></a></li>\\n<li class=\"toclevel-1 tocsection-84\"><a href=\"#External_links\"><span class=\"tocnumber\">15</span> <span class=\"toctext\">External links</span></a></li>\\n</ul>\\n</div>\\n</div>\\n<h2><span class=\"mw-headline\" id=\"Signs_and_symptoms\">Signs and symptoms</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=1\" title=\"Edit section: Signs and symptoms\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\\n<figure class=\"mw-default-size\" typeof=\"mw:File/Thumb\"><a href=\"/wiki/File:Jaundice_eye.jpg\" class=\"mw-file-description\"><img src=\"//upload.wikimedia.org/wikipedia/commons/thumb/d/de/Jaundice_eye.jpg/290px-Jaundice_eye.jpg\" decoding=\"async\" width=\"290\" height=\"208\" class=\"mw-file-element\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/d/de/Jaundice_eye.jpg/435px-Jaundice_eye.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/d/de/Jaundice_eye.jpg/580px-Jaundice_eye.jpg 2x\" data-file-width=\"700\" data-file-height=\"501\" /></a><figcaption>Jaundiced eyes</figcaption></figure>\\n<p>Hepatitis has a broad spectrum of presentations that range from a complete lack of symptoms to severe&#160;<a href=\"/wiki/Liver_failure\" title=\"Liver failure\">liver failure</a>.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-0\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-CURRENT_Diagnosis_&amp;_Treatment_18-0\" class=\"reference\"><a href=\"#cite_note-CURRENT_Diagnosis_&amp;_Treatment-18\">&#91;18&#93;</a></sup><sup id=\"cite_ref-Khalili_&amp;_Burman_19-0\" class=\"reference\"><a href=\"#cite_note-Khalili_&amp;_Burman-19\">&#91;19&#93;</a></sup> The acute form of hepatitis, generally caused by viral infection, is characterized by&#160;<a href=\"/wiki/Constitutional_symptoms\" class=\"mw-redirect\" title=\"Constitutional symptoms\">constitutional symptoms</a>&#160;that are typically self-limiting.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-1\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-CURRENT_Diagnosis_&amp;_Treatment_18-1\" class=\"reference\"><a href=\"#cite_note-CURRENT_Diagnosis_&amp;_Treatment-18\">&#91;18&#93;</a></sup> Chronic hepatitis presents similarly, but can manifest <a href=\"/wiki/Medical_sign\" class=\"mw-redirect\" title=\"Medical sign\">signs</a> and symptoms specific to liver dysfunction with long-standing inflammation and damage to the organ.<sup id=\"cite_ref-Khalili_&amp;_Burman_19-1\" class=\"reference\"><a href=\"#cite_note-Khalili_&amp;_Burman-19\">&#91;19&#93;</a></sup><sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-0\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Acute_hepatitis\">Acute hepatitis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=2\" title=\"Edit section: Acute hepatitis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<p>Acute viral hepatitis follows three distinct phases:\\n</p>\\n<ol><li>The initial <a href=\"/wiki/Prodrome\" title=\"Prodrome\">prodromal phase</a> (preceding symptoms) involves <a href=\"/wiki/Non-specific\" class=\"mw-redirect\" title=\"Non-specific\">non-specific</a> and <a href=\"/wiki/Flu-like\" class=\"mw-redirect\" title=\"Flu-like\">flu-like</a> symptoms common to many acute viral infections. These include <a href=\"/wiki/Fatigue_(medical)\" class=\"mw-redirect\" title=\"Fatigue (medical)\">fatigue</a>, <a href=\"/wiki/Nausea\" title=\"Nausea\">nausea</a>, <a href=\"/wiki/Vomiting\" title=\"Vomiting\">vomiting</a>, poor appetite, joint pain, and headaches.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-2\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-CURRENT_Diagnosis_&amp;_Treatment_18-2\" class=\"reference\"><a href=\"#cite_note-CURRENT_Diagnosis_&amp;_Treatment-18\">&#91;18&#93;</a></sup> Fever, when present, is most common in cases of hepatitis A and E.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-3\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup> Late in this phase, people can experience liver-specific symptoms, including <a href=\"/wiki/Choluria\" title=\"Choluria\">choluria</a> (dark urine) and clay-colored stools.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-4\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-CURRENT_Diagnosis_&amp;_Treatment_18-3\" class=\"reference\"><a href=\"#cite_note-CURRENT_Diagnosis_&amp;_Treatment-18\">&#91;18&#93;</a></sup></li>\\n<li><a href=\"/wiki/Jaundice\" title=\"Jaundice\">Yellowing of the skin and whites of the eyes</a> follow the prodrome after about 1–2 weeks and can last for up to 4 weeks.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-5\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-CURRENT_Diagnosis_&amp;_Treatment_18-4\" class=\"reference\"><a href=\"#cite_note-CURRENT_Diagnosis_&amp;_Treatment-18\">&#91;18&#93;</a></sup> The non-specific symptoms seen in the prodromal typically resolve by this time, but people will develop an <a href=\"/wiki/Hepatomegaly\" title=\"Hepatomegaly\">enlarged liver</a> and right upper abdominal pain or discomfort.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-6\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup> 10–20% of people will also experience an <a href=\"/wiki/Splenomegaly\" title=\"Splenomegaly\">enlarged spleen</a>, while some people will also experience a mild unintentional weight loss.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-7\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-Khalili_&amp;_Burman_19-2\" class=\"reference\"><a href=\"#cite_note-Khalili_&amp;_Burman-19\">&#91;19&#93;</a></sup></li>\\n<li>The recovery phase is characterized by resolution of the clinical symptoms of hepatitis with persistent elevations in <a href=\"/wiki/Liver_function_tests\" title=\"Liver function tests\">liver lab values</a> and potentially a persistently enlarged liver.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-8\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup> All cases of hepatitis A and E are expected to fully resolve after 1–2 months.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-9\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup> Most hepatitis B cases are also self-limiting and will resolve in 3–4 months.  Few cases of hepatitis C will resolve completely.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-10\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup></li></ol>\\n<p>Both <a href=\"/wiki/Drug-induced_hepatitis\" class=\"mw-redirect\" title=\"Drug-induced hepatitis\">drug-induced hepatitis</a> and <a href=\"/wiki/Autoimmune_hepatitis\" title=\"Autoimmune hepatitis\">autoimmune hepatitis</a> can present very similarly to acute viral hepatitis, with slight variations in symptoms depending on the cause.<sup id=\"cite_ref-Fontana_&amp;_Hayashi_21-0\" class=\"reference\"><a href=\"#cite_note-Fontana_&amp;_Hayashi-21\">&#91;21&#93;</a></sup><sup id=\"cite_ref-Manns_Lohse_Vergani_22-0\" class=\"reference\"><a href=\"#cite_note-Manns_Lohse_Vergani-22\">&#91;22&#93;</a></sup> Cases of drug-induced hepatitis can manifest with systemic signs of an allergic reaction including rash, fever, <a href=\"/wiki/Serositis\" title=\"Serositis\">serositis</a> (inflammation of membranes lining certain organs), elevated <a href=\"/wiki/Eosinophil_granulocyte\" class=\"mw-redirect\" title=\"Eosinophil granulocyte\">eosinophils</a> (a type of white blood cell), and <a href=\"/wiki/Bone_marrow_suppression\" title=\"Bone marrow suppression\">suppression of bone marrow activity</a>.<sup id=\"cite_ref-Fontana_&amp;_Hayashi_21-1\" class=\"reference\"><a href=\"#cite_note-Fontana_&amp;_Hayashi-21\">&#91;21&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Fulminant_hepatitis\">Fulminant hepatitis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=3\" title=\"Edit section: Fulminant hepatitis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<p>Fulminant hepatitis, or massive hepatic <a href=\"/wiki/Necrosis\" title=\"Necrosis\">cell death</a>, is a rare and life-threatening complication of acute hepatitis that can occur in cases of hepatitis B, D, and E, in addition to drug-induced and autoimmune hepatitis.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-11\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-Fontana_&amp;_Hayashi_21-2\" class=\"reference\"><a href=\"#cite_note-Fontana_&amp;_Hayashi-21\">&#91;21&#93;</a></sup><sup id=\"cite_ref-Manns_Lohse_Vergani_22-1\" class=\"reference\"><a href=\"#cite_note-Manns_Lohse_Vergani-22\">&#91;22&#93;</a></sup> The complication more frequently occurs in instances of hepatitis B and D co-infection at a rate of 2–20% and in pregnant women with hepatitis E at rate of 15–20% of cases.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-12\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-CURRENT_Diagnosis_&amp;_Treatment_18-5\" class=\"reference\"><a href=\"#cite_note-CURRENT_Diagnosis_&amp;_Treatment-18\">&#91;18&#93;</a></sup> In addition to the signs of acute hepatitis, people can also demonstrate signs of <a href=\"/wiki/Coagulopathy\" title=\"Coagulopathy\">coagulopathy</a> (abnormal coagulation studies with easy bruising and bleeding) and <a href=\"/wiki/Encephalopathy\" title=\"Encephalopathy\">encephalopathy</a> (confusion, disorientation, and <a href=\"/wiki/Somnolence\" title=\"Somnolence\">sleepiness</a>).<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-13\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-CURRENT_Diagnosis_&amp;_Treatment_18-6\" class=\"reference\"><a href=\"#cite_note-CURRENT_Diagnosis_&amp;_Treatment-18\">&#91;18&#93;</a></sup> Mortality due to fulminant hepatitis is typically the result of various complications including <a href=\"/wiki/Cerebral_edema\" title=\"Cerebral edema\">cerebral edema</a>, <a href=\"/wiki/Gastrointestinal_bleeding\" title=\"Gastrointestinal bleeding\">gastrointestinal bleeding</a>, <a href=\"/wiki/Sepsis\" title=\"Sepsis\">sepsis</a>, <a href=\"/wiki/Respiratory_failure\" title=\"Respiratory failure\">respiratory failure</a>, or <a href=\"/wiki/Kidney_failure\" title=\"Kidney failure\">kidney failure</a>.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-14\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Chronic_hepatitis\">Chronic hepatitis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=4\" title=\"Edit section: Chronic hepatitis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<p>Acute cases of hepatitis are seen to be resolved well within a six-month period. When hepatitis is continued for more than six months it is termed chronic hepatitis.<sup id=\"cite_ref-23\" class=\"reference\"><a href=\"#cite_note-23\">&#91;23&#93;</a></sup> Chronic hepatitis is often asymptomatic early in its course and is detected only by liver laboratory studies for <a href=\"/wiki/Screening_(medicine)\" title=\"Screening (medicine)\">screening</a> purposes or to evaluate non-specific symptoms.<sup id=\"cite_ref-Khalili_&amp;_Burman_19-3\" class=\"reference\"><a href=\"#cite_note-Khalili_&amp;_Burman-19\">&#91;19&#93;</a></sup><sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-1\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup> As the inflammation progresses, patients can develop constitutional symptoms similar to acute hepatitis, including fatigue, nausea, vomiting, poor appetite, and joint pain.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-2\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup> Jaundice can occur as well, but much later in the disease process and is typically a sign of advanced disease.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-3\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup> Chronic hepatitis interferes with hormonal functions of the liver which can result in acne, <a href=\"/wiki/Hirsutism\" title=\"Hirsutism\">hirsutism</a> (abnormal hair growth), and <a href=\"/wiki/Amenorrhoea\" class=\"mw-redirect\" title=\"Amenorrhoea\">amenorrhea</a> (lack of menstrual period) in women.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-4\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup> Extensive damage and scarring of the liver over time defines <a href=\"/wiki/Cirrhosis\" title=\"Cirrhosis\">cirrhosis</a>, a condition in which the liver\\'s ability to function is permanently impeded.<sup id=\"cite_ref-Khalili_&amp;_Burman_19-4\" class=\"reference\"><a href=\"#cite_note-Khalili_&amp;_Burman-19\">&#91;19&#93;</a></sup> This results in jaundice, weight loss, coagulopathy, <a href=\"/wiki/Ascites\" title=\"Ascites\">ascites</a> (abdominal fluid collection), and <a href=\"/wiki/Peripheral_edema\" title=\"Peripheral edema\">peripheral edema</a> (leg swelling).<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-5\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup> Cirrhosis can lead to other life-threatening complications such as <a href=\"/wiki/Hepatic_encephalopathy\" title=\"Hepatic encephalopathy\">hepatic encephalopathy</a>, <a href=\"/wiki/Esophageal_varices\" title=\"Esophageal varices\">esophageal varices</a>,  <a href=\"/wiki/Hepatorenal_syndrome\" title=\"Hepatorenal syndrome\">hepatorenal syndrome</a>, and <a href=\"/wiki/Hepatocellular_carcinoma\" title=\"Hepatocellular carcinoma\">liver cancer</a>.<sup id=\"cite_ref-Khalili_&amp;_Burman_19-5\" class=\"reference\"><a href=\"#cite_note-Khalili_&amp;_Burman-19\">&#91;19&#93;</a></sup>\\n</p>\\n<h2><span class=\"mw-headline\" id=\"Causes\">Causes</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=5\" title=\"Edit section: Causes\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\\n<p>Causes of hepatitis can be divided into the following major categories: infectious, metabolic, ischemic, autoimmune, genetic, and other. Infectious agents include viruses, bacteria, and parasites. Metabolic causes include prescription medications, toxins (most notably <a href=\"/wiki/Alcoholic_liver_disease\" title=\"Alcoholic liver disease\">alcohol</a>), and <a href=\"/wiki/Non-alcoholic_fatty_liver_disease\" title=\"Non-alcoholic fatty liver disease\">non-alcoholic fatty liver disease</a>. <a href=\"/wiki/Autoimmune_hepatitis\" title=\"Autoimmune hepatitis\">Autoimmune</a> and genetic causes of hepatitis involve genetic predispositions and tend to affect characteristic populations.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (March 2022)\">citation needed</span></a></i>&#93;</sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Infectious\">Infectious</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=6\" title=\"Edit section: Infectious\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<h4><span class=\"mw-headline\" id=\"Viral_hepatitis\">Viral hepatitis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=7\" title=\"Edit section: Viral hepatitis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\\n<link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1033289096\"><div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Viral_hepatitis\" title=\"Viral hepatitis\">Viral hepatitis</a></div>\\n<p><a href=\"/wiki/Viral_hepatitis\" title=\"Viral hepatitis\">Viral hepatitis</a> is the most common type of hepatitis worldwide, especially in Asia and Africa.<sup id=\"cite_ref-24\" class=\"reference\"><a href=\"#cite_note-24\">&#91;24&#93;</a></sup> Viral hepatitis is caused by five different viruses (hepatitis A, B, C, D, and E).<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-15\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup> <a href=\"/wiki/Hepatitis_A\" title=\"Hepatitis A\">Hepatitis A</a> and <a href=\"/wiki/Hepatitis_E\" title=\"Hepatitis E\">hepatitis E</a> behave similarly: they are both transmitted by the <a href=\"/wiki/Fecal%E2%80%93oral_route\" title=\"Fecal–oral route\">fecal–oral route</a>, are more common in developing countries, and are self-limiting illnesses that do not lead to chronic hepatitis.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-16\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-25\" class=\"reference\"><a href=\"#cite_note-25\">&#91;25&#93;</a></sup><sup id=\"cite_ref-26\" class=\"reference\"><a href=\"#cite_note-26\">&#91;26&#93;</a></sup>\\n</p><p><a href=\"/wiki/Hepatitis_B\" title=\"Hepatitis B\">Hepatitis B</a>, <a href=\"/wiki/Hepatitis_C\" title=\"Hepatitis C\">hepatitis C</a>, and <a href=\"/wiki/Hepatitis_D\" title=\"Hepatitis D\">hepatitis D</a> are transmitted when blood or <a href=\"/wiki/Mucous_membrane\" title=\"Mucous membrane\">mucous membranes</a> are exposed to infected blood and body fluids, such as semen and vaginal secretions.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-17\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup> Viral particles have also been found in saliva and breastmilk. Kissing, sharing utensils, and breastfeeding do not lead to transmission unless these fluids are introduced into open sores or cuts.<sup id=\"cite_ref-27\" class=\"reference\"><a href=\"#cite_note-27\">&#91;27&#93;</a></sup> Many families who do not have safe drinking water or live in unhygienic homes have contracted hepatitis because saliva and blood droplets are often carried through the water and blood-borne illnesses spread quickly in unsanitary settings.<sup id=\"cite_ref-28\" class=\"reference\"><a href=\"#cite_note-28\">&#91;28&#93;</a></sup>\\n</p><p>Hepatitis B and C can present either acutely or chronically.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-18\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup> Hepatitis D is a defective virus that requires hepatitis B to replicate and is only found with hepatitis B co-infection.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-19\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup> In adults, hepatitis B infection is most commonly self-limiting, with less than 5% progressing to chronic state, and 20 to 30% of those chronically infected developing cirrhosis or liver cancer.<sup id=\"cite_ref-WHO_Hepatitis_B_29-0\" class=\"reference\"><a href=\"#cite_note-WHO_Hepatitis_B-29\">&#91;29&#93;</a></sup> Infection in infants and children frequently leads to chronic infection.<sup id=\"cite_ref-WHO_Hepatitis_B_29-1\" class=\"reference\"><a href=\"#cite_note-WHO_Hepatitis_B-29\">&#91;29&#93;</a></sup>\\n</p><p>Unlike hepatitis B, most cases of hepatitis C lead to chronic infection.<sup id=\"cite_ref-CDC_FAQ_on_Hepatitis_C_30-0\" class=\"reference\"><a href=\"#cite_note-CDC_FAQ_on_Hepatitis_C-30\">&#91;30&#93;</a></sup> Hepatitis C is the second most common cause of cirrhosis in the US (second to alcoholic hepatitis).<sup id=\"cite_ref-Friedman_55e_31-0\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup> In the 1970s and 1980s, blood transfusions were a major factor in spreading hepatitis C virus.<sup id=\"cite_ref-CDC_FAQ_on_Hepatitis_C_30-1\" class=\"reference\"><a href=\"#cite_note-CDC_FAQ_on_Hepatitis_C-30\">&#91;30&#93;</a></sup> Since widespread screening of blood products for hepatitis C began in 1992, the risk of acquiring hepatitis C from a blood transfusion has decreased from approximately 10% in the 1970s to 1 in 2 million currently.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-20\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup>\\n</p>\\n<h4><span class=\"mw-headline\" id=\"Parasitic_hepatitis\">Parasitic hepatitis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=8\" title=\"Edit section: Parasitic hepatitis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\\n<figure class=\"mw-default-size\" typeof=\"mw:File/Thumb\"><a href=\"/wiki/File:Echinococcus_granulosus.JPG\" class=\"mw-file-description\"><img src=\"//upload.wikimedia.org/wikipedia/commons/thumb/d/d9/Echinococcus_granulosus.JPG/220px-Echinococcus_granulosus.JPG\" decoding=\"async\" width=\"220\" height=\"165\" class=\"mw-file-element\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/d/d9/Echinococcus_granulosus.JPG/330px-Echinococcus_granulosus.JPG 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/d/d9/Echinococcus_granulosus.JPG/440px-Echinococcus_granulosus.JPG 2x\" data-file-width=\"3000\" data-file-height=\"2250\" /></a><figcaption>Echinococcus granulosus</figcaption></figure>\\n<p><a href=\"/wiki/Parasites_of_humans\" class=\"mw-redirect\" title=\"Parasites of humans\">Parasites</a> can also infect the liver and activate the immune response, resulting in symptoms of acute hepatitis with increased serum <a href=\"/wiki/Immunoglobulin_E\" title=\"Immunoglobulin E\">IgE</a> (though chronic hepatitis is possible with chronic infections).<sup id=\"cite_ref-Harder_&amp;_Mehlhorn_32-0\" class=\"reference\"><a href=\"#cite_note-Harder_&amp;_Mehlhorn-32\">&#91;32&#93;</a></sup> Of the <a href=\"/wiki/Protozoa\" title=\"Protozoa\">protozoans</a>, <a href=\"/wiki/Trypanosoma_cruzi\" title=\"Trypanosoma cruzi\">Trypanosoma cruzi</a>, <a href=\"/wiki/Leishmaniasis\" title=\"Leishmaniasis\">Leishmania</a> species, and the <a href=\"/wiki/Malaria\" title=\"Malaria\">malaria</a>-causing <a href=\"/wiki/Plasmodium\" title=\"Plasmodium\">Plasmodium</a> species all can cause liver inflammation.<sup id=\"cite_ref-Harder_&amp;_Mehlhorn_32-1\" class=\"reference\"><a href=\"#cite_note-Harder_&amp;_Mehlhorn-32\">&#91;32&#93;</a></sup> Another protozoan, <a href=\"/wiki/Entamoeba_histolytica\" title=\"Entamoeba histolytica\">Entamoeba histolytica</a>, causes hepatitis with distinct liver abscesses.<sup id=\"cite_ref-Harder_&amp;_Mehlhorn_32-2\" class=\"reference\"><a href=\"#cite_note-Harder_&amp;_Mehlhorn-32\">&#91;32&#93;</a></sup>\\n</p><p>Of the worms, the <a href=\"/wiki/Cestode_infection\" class=\"mw-redirect\" title=\"Cestode infection\">cestode</a> <a href=\"/wiki/Echinococcus_granulosus\" title=\"Echinococcus granulosus\">Echinococcus granulosus</a>, also known as the dog tapeworm, infects the liver and forms characteristic hepatic <a href=\"/wiki/Echinococcosis\" title=\"Echinococcosis\">hydatid cysts</a>.<sup id=\"cite_ref-Harder_&amp;_Mehlhorn_32-3\" class=\"reference\"><a href=\"#cite_note-Harder_&amp;_Mehlhorn-32\">&#91;32&#93;</a></sup> The liver <a href=\"/wiki/Fluke_(parasite)\" class=\"mw-redirect\" title=\"Fluke (parasite)\">flukes</a> <a href=\"/wiki/Fasciola_hepatica\" title=\"Fasciola hepatica\">Fasciola hepatica</a> and <a href=\"/wiki/Clonorchis_sinensis\" title=\"Clonorchis sinensis\">Clonorchis sinensis</a> live in the bile ducts and cause progressive hepatitis and liver fibrosis.<sup id=\"cite_ref-Harder_&amp;_Mehlhorn_32-4\" class=\"reference\"><a href=\"#cite_note-Harder_&amp;_Mehlhorn-32\">&#91;32&#93;</a></sup>\\n</p>\\n<h4><span class=\"mw-headline\" id=\"Bacterial_hepatitis\">Bacterial hepatitis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=9\" title=\"Edit section: Bacterial hepatitis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\\n<p>Bacterial infection of the liver commonly results in <a href=\"/wiki/Pyogenic_liver_abscess\" title=\"Pyogenic liver abscess\">pyogenic liver abscesses</a>, acute hepatitis, or <a href=\"/wiki/Granuloma\" title=\"Granuloma\">granulomatous</a> (or chronic) liver disease.<sup id=\"cite_ref-Wisplinghoff_&amp;_Appleton_33-0\" class=\"reference\"><a href=\"#cite_note-Wisplinghoff_&amp;_Appleton-33\">&#91;33&#93;</a></sup> Pyogenic abscesses commonly involve <a href=\"/wiki/Enteric\" class=\"mw-redirect\" title=\"Enteric\">enteric</a> bacteria such as <i><a href=\"/wiki/Escherichia_coli\" title=\"Escherichia coli\">Escherichia coli</a></i> and <i><a href=\"/wiki/Klebsiella_pneumoniae\" title=\"Klebsiella pneumoniae\">Klebsiella pneumoniae</a></i> and are composed of multiple bacteria up to 50% of the time.<sup id=\"cite_ref-Wisplinghoff_&amp;_Appleton_33-1\" class=\"reference\"><a href=\"#cite_note-Wisplinghoff_&amp;_Appleton-33\">&#91;33&#93;</a></sup> Acute hepatitis is caused by <i><a href=\"/wiki/Neisseria_meningitidis\" title=\"Neisseria meningitidis\">Neisseria meningitidis</a></i>, <i><a href=\"/wiki/Neisseria_gonorrhoeae\" title=\"Neisseria gonorrhoeae\">Neisseria gonorrhoeae</a></i>, <i><a href=\"/wiki/Bartonella_henselae\" title=\"Bartonella henselae\">Bartonella henselae</a></i>, <i><a href=\"/wiki/Borrelia_burgdorferi\" title=\"Borrelia burgdorferi\">Borrelia burgdorferi</a></i>, <a href=\"/wiki/Salmonella\" title=\"Salmonella\">salmonella</a> species, <a href=\"/wiki/Brucella\" title=\"Brucella\">brucella</a> species and <a href=\"/wiki/Campylobacter\" title=\"Campylobacter\">campylobacter</a> species.<sup id=\"cite_ref-Wisplinghoff_&amp;_Appleton_33-2\" class=\"reference\"><a href=\"#cite_note-Wisplinghoff_&amp;_Appleton-33\">&#91;33&#93;</a></sup> Chronic or granulomatous hepatitis is seen with infection from <a href=\"/wiki/Mycobacterium\" title=\"Mycobacterium\">mycobacteria</a> species, <i><a href=\"/wiki/Tropheryma_whipplei\" class=\"mw-redirect\" title=\"Tropheryma whipplei\">Tropheryma whipplei</a></i>, <i><a href=\"/wiki/Treponema_pallidum\" title=\"Treponema pallidum\">Treponema pallidum</a></i>, <i><a href=\"/wiki/Coxiella_burnetii\" title=\"Coxiella burnetii\">Coxiella burnetii</a></i>, and <a href=\"/wiki/Rickettsia\" title=\"Rickettsia\">rickettsia</a> species.<sup id=\"cite_ref-Wisplinghoff_&amp;_Appleton_33-3\" class=\"reference\"><a href=\"#cite_note-Wisplinghoff_&amp;_Appleton-33\">&#91;33&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Metabolic\">Metabolic</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=10\" title=\"Edit section: Metabolic\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<h4><span class=\"mw-headline\" id=\"Alcoholic_hepatitis\">Alcoholic hepatitis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=11\" title=\"Edit section: Alcoholic hepatitis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\\n<link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1033289096\"><div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Alcoholic_hepatitis\" title=\"Alcoholic hepatitis\">Alcoholic hepatitis</a></div>\\n<p>Excessive alcohol consumption is a significant cause of hepatitis and is the most common cause of cirrhosis in the U.S.<sup id=\"cite_ref-Friedman_55e_31-1\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup> Alcoholic hepatitis is within the spectrum of <a href=\"/wiki/Alcoholic_liver_disease\" title=\"Alcoholic liver disease\">alcoholic liver disease</a>. This ranges in order of severity and reversibility from <a href=\"/wiki/Alcoholic_fatty_liver\" class=\"mw-redirect\" title=\"Alcoholic fatty liver\">alcoholic steatosis</a> (least severe, most reversible), <a href=\"/wiki/Alcoholic_hepatitis\" title=\"Alcoholic hepatitis\">alcoholic hepatitis</a>, cirrhosis, and liver cancer (most severe, least reversible).<sup id=\"cite_ref-Friedman_55e_31-2\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup> Hepatitis usually develops over years-long exposure to alcohol, occurring in 10 to 20% of alcoholics.<sup id=\"cite_ref-Harrison&#39;s_Principles_chapter_363_(Alcohol)_34-0\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles_chapter_363_(Alcohol)-34\">&#91;34&#93;</a></sup> The most important risk factors for the development of alcoholic hepatitis are quantity and duration of alcohol intake.<sup id=\"cite_ref-Harrison&#39;s_Principles_chapter_363_(Alcohol)_34-1\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles_chapter_363_(Alcohol)-34\">&#91;34&#93;</a></sup> Long-term alcohol intake in excess of 80 grams of alcohol a day in men and 40 grams a day in women is associated with development of alcoholic hepatitis (1 beer or 4 ounces of wine is equivalent to 12g of alcohol).<sup id=\"cite_ref-Friedman_55e_31-3\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup> Alcoholic hepatitis can vary from asymptomatic <a href=\"/wiki/Hepatomegaly\" title=\"Hepatomegaly\">hepatomegaly</a> (enlarged liver) to symptoms of acute or chronic hepatitis to liver failure.<sup id=\"cite_ref-Friedman_55e_31-4\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup>\\n</p>\\n<h4><span class=\"mw-headline\" id=\"Toxic_and_drug-induced_hepatitis\">Toxic and drug-induced hepatitis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=12\" title=\"Edit section: Toxic and drug-induced hepatitis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\\n<p>Many chemical agents, including medications, industrial toxins, and herbal and dietary supplements, can cause hepatitis.<sup id=\"cite_ref-Harrison&#39;s_Principles_chapter_361_(Toxic_and_Drug-Induced)_35-0\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles_chapter_361_(Toxic_and_Drug-Induced)-35\">&#91;35&#93;</a></sup><sup id=\"cite_ref-Occupational_exposure_to_solvents_36-0\" class=\"reference\"><a href=\"#cite_note-Occupational_exposure_to_solvents-36\">&#91;36&#93;</a></sup> The spectrum of drug-induced liver injury varies from acute hepatitis to chronic hepatitis to acute liver failure.<sup id=\"cite_ref-Harrison&#39;s_Principles_chapter_361_(Toxic_and_Drug-Induced)_35-1\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles_chapter_361_(Toxic_and_Drug-Induced)-35\">&#91;35&#93;</a></sup> Toxins and medications can cause liver injury through a variety of mechanisms, including direct <a href=\"/wiki/Cell_damage\" title=\"Cell damage\">cell damage</a>, disruption of cell metabolism, and causing structural changes.<sup id=\"cite_ref-37\" class=\"reference\"><a href=\"#cite_note-37\">&#91;37&#93;</a></sup> Some drugs such as <a href=\"/wiki/Paracetamol\" title=\"Paracetamol\">paracetamol</a> exhibit predictable dose-dependent liver damage while others such as <a href=\"/wiki/Isoniazid\" title=\"Isoniazid\">isoniazid</a> cause idiosyncratic and unpredictable reactions that vary by person.<sup id=\"cite_ref-Harrison&#39;s_Principles_chapter_361_(Toxic_and_Drug-Induced)_35-2\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles_chapter_361_(Toxic_and_Drug-Induced)-35\">&#91;35&#93;</a></sup> There are wide variations in the mechanisms of liver injury and <a href=\"/wiki/Latency_period\" class=\"mw-redirect\" title=\"Latency period\">latency period</a> from exposure to development of clinical illness.<sup id=\"cite_ref-Friedman_55e_31-5\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup>\\n</p><p>Many types of drugs can cause liver injury, including the <a href=\"/wiki/Analgesic\" title=\"Analgesic\">analgesic</a> paracetamol; <a href=\"/wiki/Antibiotic\" title=\"Antibiotic\">antibiotics</a> such as isoniazid, <a href=\"/wiki/Nitrofurantoin\" title=\"Nitrofurantoin\">nitrofurantoin</a>, <a href=\"/wiki/Amoxicillin/clavulanic_acid\" title=\"Amoxicillin/clavulanic acid\">amoxicillin-clavulanate</a>, <a href=\"/wiki/Erythromycin\" title=\"Erythromycin\">erythromycin</a>, and <a href=\"/wiki/Trimethoprim/sulfamethoxazole\" title=\"Trimethoprim/sulfamethoxazole\">trimethoprim-sulfamethoxazole</a>; <a href=\"/wiki/Anticonvulsant\" title=\"Anticonvulsant\">anticonvulsants</a> such as <a href=\"/wiki/Valproate\" title=\"Valproate\">valproate</a> and <a href=\"/wiki/Phenytoin\" title=\"Phenytoin\">phenytoin</a>; cholesterol-lowering <a href=\"/wiki/Statin\" title=\"Statin\">statins</a>; <a href=\"/wiki/Steroid\" title=\"Steroid\">steroids</a> such as <a href=\"/wiki/Oral_contraceptive_pill\" title=\"Oral contraceptive pill\">oral contraceptives</a> and <a href=\"/wiki/Anabolic_steroid\" title=\"Anabolic steroid\">anabolic steroids</a>; and <a href=\"/wiki/Highly_Active_Anti-Retroviral_Therapy\" class=\"mw-redirect\" title=\"Highly Active Anti-Retroviral Therapy\">highly active anti-retroviral therapy</a> used in the treatment of <a href=\"/wiki/HIV/AIDS\" title=\"HIV/AIDS\">HIV/AIDS</a>.<sup id=\"cite_ref-Friedman_55e_31-6\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup> Of these, amoxicillin-clavulanate is the most common cause of drug-induced liver injury, and <a href=\"/wiki/Paracetamol_toxicity\" class=\"mw-redirect\" title=\"Paracetamol toxicity\">paracetamol toxicity</a>  the most common cause of acute liver failure in the United States and Europe.<sup id=\"cite_ref-Harrison&#39;s_Principles_chapter_361_(Toxic_and_Drug-Induced)_35-3\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles_chapter_361_(Toxic_and_Drug-Induced)-35\">&#91;35&#93;</a></sup>\\n</p><p><a href=\"/wiki/Herb\" title=\"Herb\">Herbal remedies</a> and <a href=\"/wiki/Dietary_supplement\" title=\"Dietary supplement\">dietary supplements</a> are another important cause of hepatitis; these are the most common causes of drug-induced hepatitis in Korea.<sup id=\"cite_ref-38\" class=\"reference\"><a href=\"#cite_note-38\">&#91;38&#93;</a></sup> The United-States-based <a rel=\"nofollow\" class=\"external text\" href=\"http://www.dilin.org/\">Drug Induced Liver Injury Network</a> linked more than 16% of cases of hepatotoxicity to herbal and dietary supplements.<sup id=\"cite_ref-NIH_-_herbal_supplements_39-0\" class=\"reference\"><a href=\"#cite_note-NIH_-_herbal_supplements-39\">&#91;39&#93;</a></sup> In the United States, herbal and dietary supplements – unlike <a href=\"/wiki/Pharmaceutical_drug\" class=\"mw-redirect\" title=\"Pharmaceutical drug\">pharmaceutical drugs</a> – are unregulated by the <a href=\"/wiki/Food_and_Drug_Administration\" title=\"Food and Drug Administration\">Food and Drug Administration</a>.<sup id=\"cite_ref-NIH_-_herbal_supplements_39-1\" class=\"reference\"><a href=\"#cite_note-NIH_-_herbal_supplements-39\">&#91;39&#93;</a></sup> The <a href=\"/wiki/National_Institutes_of_Health\" title=\"National Institutes of Health\">National Institutes of Health</a> maintains the <a rel=\"nofollow\" class=\"external text\" href=\"https://livertox.nlm.nih.gov\">LiverTox</a> <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20190724165846/https://livertox.nlm.nih.gov/\">Archived</a> 2019-07-24 at the <a href=\"/wiki/Wayback_Machine\" title=\"Wayback Machine\">Wayback Machine</a> database for consumers to track all known prescription and non-prescription compounds associated with liver injury.<sup id=\"cite_ref-40\" class=\"reference\"><a href=\"#cite_note-40\">&#91;40&#93;</a></sup>\\n</p><p>Exposure to other <a href=\"/wiki/Hepatotoxin\" title=\"Hepatotoxin\">hepatotoxins</a> can occur accidentally or intentionally through ingestion, inhalation, and skin absorption. The industrial toxin <a href=\"/wiki/Carbon_tetrachloride\" title=\"Carbon tetrachloride\">carbon tetrachloride</a> and the wild mushroom <a href=\"/wiki/Amanita_phalloides\" title=\"Amanita phalloides\">Amanita phalloides</a> are other known hepatotoxins.<sup id=\"cite_ref-Harrison&#39;s_Principles_chapter_361_(Toxic_and_Drug-Induced)_35-4\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles_chapter_361_(Toxic_and_Drug-Induced)-35\">&#91;35&#93;</a></sup><sup id=\"cite_ref-Occupational_exposure_to_solvents_36-1\" class=\"reference\"><a href=\"#cite_note-Occupational_exposure_to_solvents-36\">&#91;36&#93;</a></sup><sup id=\"cite_ref-41\" class=\"reference\"><a href=\"#cite_note-41\">&#91;41&#93;</a></sup>\\n</p>\\n<h4><span class=\"mw-headline\" id=\"Non-alcoholic_fatty_liver_disease\">Non-alcoholic fatty liver disease</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=13\" title=\"Edit section: Non-alcoholic fatty liver disease\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\\n<link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1033289096\"><div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Non-alcoholic_fatty_liver_disease\" title=\"Non-alcoholic fatty liver disease\">Non-alcoholic fatty liver disease</a></div>\\n<p>Non-alcoholic hepatitis is within the spectrum of non-alcoholic liver disease (NALD), which ranges in severity and reversibility from <a href=\"/wiki/Non-alcoholic_fatty_liver_disease\" title=\"Non-alcoholic fatty liver disease\">non-alcoholic fatty liver disease</a> (NAFLD) to non-alcoholic steatohepatitis (NASH) to cirrhosis to liver cancer, similar to the spectrum of alcoholic liver disease.<sup id=\"cite_ref-Harrison&#39;s_Principles_chapter_364_(Nonalcoholic)_42-0\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles_chapter_364_(Nonalcoholic)-42\">&#91;42&#93;</a></sup>\\n</p><p>Non-alcoholic liver disease occurs in people with little or no history of alcohol use, and is instead strongly associated with <a href=\"/wiki/Metabolic_syndrome\" title=\"Metabolic syndrome\">metabolic syndrome</a>, obesity, <a href=\"/wiki/Insulin_resistance\" title=\"Insulin resistance\">insulin resistance</a> and <a href=\"/wiki/Diabetes_mellitus_type_2\" class=\"mw-redirect\" title=\"Diabetes mellitus type 2\">diabetes</a>, and hypertriglyceridemia.<sup id=\"cite_ref-Friedman_55e_31-7\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup> Over time, non-alcoholic fatty liver disease can progress to non-alcoholic <a href=\"/wiki/Steatohepatitis\" title=\"Steatohepatitis\">steatohepatitis</a>, which additionally involves liver cell death, liver inflammation and possible fibrosis.<sup id=\"cite_ref-Friedman_55e_31-8\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup> Factors accelerating progression from NAFLD to NASH are obesity, older age, non-African American ethnicity, female gender, diabetes mellitus, hypertension, higher <a href=\"/wiki/Alanine_transaminase\" title=\"Alanine transaminase\">ALT</a> or <a href=\"/wiki/Aspartate_transaminase\" title=\"Aspartate transaminase\">AST</a> level, higher AST/ALT ratio, low platelet count, and an <a rel=\"nofollow\" class=\"external text\" href=\"http://www.nature.com/ijo/journal/v28/n10/fig_tab/0802734t1.html\">ultrasound steatosis score</a>.<sup id=\"cite_ref-Friedman_55e_31-9\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup>\\n</p><p>In the early stages (as with NAFLD and early NASH), most patients are asymptomatic or have mild <a href=\"/wiki/Quadrant_(abdomen)\" class=\"mw-redirect\" title=\"Quadrant (abdomen)\">right upper quadrant</a> pain, and diagnosis is suspected on the basis of abnormal <a href=\"/wiki/Liver_function_tests\" title=\"Liver function tests\">liver function tests</a>.<sup id=\"cite_ref-Friedman_55e_31-10\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup> As the disease progresses, symptoms typical of chronic hepatitis may develop.<sup id=\"cite_ref-National_Digestive_Diseases_Information_Clearinghouse_NDDIC_43-0\" class=\"reference\"><a href=\"#cite_note-National_Digestive_Diseases_Information_Clearinghouse_NDDIC-43\">&#91;43&#93;</a></sup> While imaging can show fatty liver, only <a href=\"/wiki/Liver_biopsy\" title=\"Liver biopsy\">liver biopsy</a> can demonstrate inflammation and fibrosis characteristic of NASH.<sup id=\"cite_ref-Masuoka_2013_106–122_44-0\" class=\"reference\"><a href=\"#cite_note-Masuoka_2013_106–122-44\">&#91;44&#93;</a></sup> 9 to 25% of patients with NASH develop cirrhosis.<sup id=\"cite_ref-Friedman_55e_31-11\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup> NASH is recognized as the third most common cause of liver disease in the United States.<sup id=\"cite_ref-National_Digestive_Diseases_Information_Clearinghouse_NDDIC_43-1\" class=\"reference\"><a href=\"#cite_note-National_Digestive_Diseases_Information_Clearinghouse_NDDIC-43\">&#91;43&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Autoimmune\">Autoimmune</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=14\" title=\"Edit section: Autoimmune\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1033289096\"><div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Autoimmune_hepatitis\" title=\"Autoimmune hepatitis\">Autoimmune hepatitis</a></div>\\n<p>Autoimmune hepatitis is a chronic disease caused by an abnormal immune response against liver cells.<sup id=\"cite_ref-45\" class=\"reference\"><a href=\"#cite_note-45\">&#91;45&#93;</a></sup> The disease is thought to have a genetic predisposition as it is associated with certain <a href=\"/wiki/Human_leukocyte_antigen\" title=\"Human leukocyte antigen\">human leukocyte antigens</a> involved in the immune response.<sup id=\"cite_ref-46\" class=\"reference\"><a href=\"#cite_note-46\">&#91;46&#93;</a></sup> As in other autoimmune diseases, circulating <a href=\"/wiki/Autoantibody\" title=\"Autoantibody\">auto-antibodies</a> may be present and are helpful in diagnosis.<sup id=\"cite_ref-Czaja_Autoimmune_47-0\" class=\"reference\"><a href=\"#cite_note-Czaja_Autoimmune-47\">&#91;47&#93;</a></sup> Auto-antibodies found in patients with autoimmune hepatitis include the <a href=\"/wiki/Sensitivity_and_specificity\" title=\"Sensitivity and specificity\">sensitive but less specific</a> <a href=\"/wiki/Anti-nuclear_antibody\" class=\"mw-redirect\" title=\"Anti-nuclear antibody\">anti-nuclear antibody (ANA)</a>, smooth muscle antibody (SMA), and <a href=\"/wiki/Anti-neutrophil_cytoplasmic_antibody\" title=\"Anti-neutrophil cytoplasmic antibody\">atypical perinuclear antineutrophil cytoplasmic antibody (p-ANCA)</a>.<sup id=\"cite_ref-Czaja_Autoimmune_47-1\" class=\"reference\"><a href=\"#cite_note-Czaja_Autoimmune-47\">&#91;47&#93;</a></sup> Other autoantibodies that are less common but more specific to autoimmune hepatitis are the antibodies against liver kidney microsome 1 (LKM1) and soluble liver antigen (SLA).<sup id=\"cite_ref-Czaja_Autoimmune_47-2\" class=\"reference\"><a href=\"#cite_note-Czaja_Autoimmune-47\">&#91;47&#93;</a></sup> Autoimmune hepatitis can also be triggered by drugs (such as <a href=\"/wiki/Nitrofurantoin\" title=\"Nitrofurantoin\">nitrofurantoin</a>, <a href=\"/wiki/Hydralazine\" title=\"Hydralazine\">hydralazine</a>, and <a href=\"/wiki/Methyldopa\" title=\"Methyldopa\">methyldopa</a>), after liver transplant, or by viruses (such as hepatitis A, <a href=\"/wiki/Epstein%E2%80%93Barr_virus\" title=\"Epstein–Barr virus\">Epstein-Barr virus</a>, or <a href=\"/wiki/Measles\" title=\"Measles\">measles</a>).<sup id=\"cite_ref-Friedman_55e_31-12\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup>\\n</p><p>Autoimmune hepatitis can present anywhere within the spectrum from asymptomatic to acute or chronic hepatitis to fulminant liver failure.<sup id=\"cite_ref-Friedman_55e_31-13\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup> Patients are asymptomatic 25–34% of the time, and the diagnosis is suspected on the basis of abnormal liver function tests.<sup id=\"cite_ref-Czaja_Autoimmune_47-3\" class=\"reference\"><a href=\"#cite_note-Czaja_Autoimmune-47\">&#91;47&#93;</a></sup> Some studies show between 25% and 75% of cases present with signs and symptoms of acute hepatitis.<sup id=\"cite_ref-Friedman_55e_31-14\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup><sup id=\"cite_ref-:0_48-0\" class=\"reference\"><a href=\"#cite_note-:0-48\">&#91;48&#93;</a></sup> As with other autoimmune diseases, autoimmune hepatitis usually affects young females (though it can affect patients of either sex of any age), and patients can exhibit classic signs and symptoms of autoimmunity such as fatigue, anemia, anorexia, <a href=\"/wiki/Amenorrhoea\" class=\"mw-redirect\" title=\"Amenorrhoea\">amenorrhea</a>, acne, arthritis, <a href=\"/wiki/Pleurisy\" title=\"Pleurisy\">pleurisy</a>, <a href=\"/wiki/Thyroiditis\" title=\"Thyroiditis\">thyroiditis</a>, <a href=\"/wiki/Ulcerative_colitis\" title=\"Ulcerative colitis\">ulcerative colitis</a>, <a href=\"/wiki/Nephritis\" title=\"Nephritis\">nephritis</a>, and <a href=\"/wiki/Maculopapular_rash\" title=\"Maculopapular rash\">maculopapular rash</a>.<sup id=\"cite_ref-Friedman_55e_31-15\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup> Autoimmune hepatitis increases the risk for cirrhosis, and the risk for liver cancer is increased by about 1% for each year of the disease.<sup id=\"cite_ref-Friedman_55e_31-16\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup>\\n</p><p>Many people with autoimmune hepatitis have other <a href=\"/wiki/Autoimmune_disease\" title=\"Autoimmune disease\">autoimmune diseases</a>.<sup id=\"cite_ref-49\" class=\"reference\"><a href=\"#cite_note-49\">&#91;49&#93;</a></sup> Autoimmune hepatitis is distinct from the other autoimmune diseases of the liver, <a href=\"/wiki/Primary_biliary_cirrhosis\" class=\"mw-redirect\" title=\"Primary biliary cirrhosis\">primary biliary cirrhosis</a> and <a href=\"/wiki/Primary_sclerosing_cholangitis\" title=\"Primary sclerosing cholangitis\">primary sclerosing cholangitis</a>, both of which can also lead to scarring, fibrosis, and cirrhosis of the liver.<sup id=\"cite_ref-Friedman_55e_31-17\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup><sup id=\"cite_ref-Czaja_Autoimmune_47-4\" class=\"reference\"><a href=\"#cite_note-Czaja_Autoimmune-47\">&#91;47&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Genetic\">Genetic</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=15\" title=\"Edit section: Genetic\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<p>Genetic causes of hepatitis include <a href=\"/wiki/Alpha_1-antitrypsin_deficiency\" class=\"mw-redirect\" title=\"Alpha 1-antitrypsin deficiency\">alpha-1-antitrypsin deficiency</a>, <a href=\"/wiki/HFE_hereditary_haemochromatosis\" class=\"mw-redirect\" title=\"HFE hereditary haemochromatosis\">hemochromatosis</a>, and <a href=\"/wiki/Wilson%27s_disease\" title=\"Wilson&#39;s disease\">Wilson\\'s disease</a>.<sup id=\"cite_ref-Friedman_55e_31-18\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup> In alpha-1-antitrypsin deficiency, a <a href=\"/wiki/Co-dominant_expression\" class=\"mw-redirect\" title=\"Co-dominant expression\">co-dominant</a> mutation in the gene for alpha-1-antitrypsin results in the abnormal accumulation of the mutant AAT protein within liver cells, leading to liver disease.<sup id=\"cite_ref-50\" class=\"reference\"><a href=\"#cite_note-50\">&#91;50&#93;</a></sup> Hemochromatosis and Wilson\\'s disease are both <a href=\"/wiki/Autosomal_recessive\" class=\"mw-redirect\" title=\"Autosomal recessive\">autosomal recessive</a> diseases involving abnormal storage of minerals.<sup id=\"cite_ref-Friedman_55e_31-19\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup> In hemochromatosis, excess amounts of iron accumulate in multiple body sites, including the liver, which can lead to cirrhosis.<sup id=\"cite_ref-Friedman_55e_31-20\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup> In Wilson\\'s disease, excess amounts of copper accumulate in the liver and brain, causing cirrhosis and dementia.<sup id=\"cite_ref-Friedman_55e_31-21\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup>\\n</p><p>When the liver is involved, alpha-1-antitrypsin deficiency and Wilson\\'s disease tend to present as hepatitis in the neonatal period or in childhood.<sup id=\"cite_ref-Friedman_55e_31-22\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup> Hemochromatosis typically presents in adulthood, with the onset of clinical disease usually after age 50.<sup id=\"cite_ref-Friedman_55e_31-23\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Ischemic_hepatitis\">Ischemic hepatitis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=16\" title=\"Edit section: Ischemic hepatitis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1033289096\"><div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Ischemic_hepatitis\" title=\"Ischemic hepatitis\">Ischemic hepatitis</a></div>\\n<p><a href=\"/wiki/Ischemic_hepatitis\" title=\"Ischemic hepatitis\">Ischemic hepatitis</a> (also known as shock liver) results from reduced blood flow to the liver as in shock, heart failure, or vascular insufficiency.<sup id=\"cite_ref-Hepatic_ischemia_51-0\" class=\"reference\"><a href=\"#cite_note-Hepatic_ischemia-51\">&#91;51&#93;</a></sup> The condition is most often associated with <a href=\"/wiki/Heart_failure\" title=\"Heart failure\">heart failure</a> but can also be caused by <a href=\"/wiki/Shock_(circulatory)\" title=\"Shock (circulatory)\">shock</a> or <a href=\"/wiki/Sepsis\" title=\"Sepsis\">sepsis</a>. <a href=\"/wiki/Blood_testing\" class=\"mw-redirect\" title=\"Blood testing\">Blood testing</a> of a person with ischemic hepatitis will show very high levels of <a href=\"/wiki/Elevated_transaminases\" title=\"Elevated transaminases\">transaminase enzymes</a> (<a href=\"/wiki/Aspartate_transaminase\" title=\"Aspartate transaminase\">AST</a> and <a href=\"/wiki/Alanine_transaminase\" title=\"Alanine transaminase\">ALT</a>). The condition usually resolves if the underlying cause is treated successfully. Ischemic hepatitis rarely causes permanent liver damage.<sup id=\"cite_ref-52\" class=\"reference\"><a href=\"#cite_note-52\">&#91;52&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Other\">Other</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=17\" title=\"Edit section: Other\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1033289096\"><div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Neonatal_hepatitis\" title=\"Neonatal hepatitis\">Neonatal hepatitis</a></div>\\n<p>Hepatitis can also occur in neonates and is attributable to a variety of causes, some of which are not typically seen in adults.<sup id=\"cite_ref-Biliary_disease_in_infancy_53-0\" class=\"reference\"><a href=\"#cite_note-Biliary_disease_in_infancy-53\">&#91;53&#93;</a></sup> Congenital or perinatal infection with the hepatitis viruses, <a href=\"/wiki/Toxoplasma_gondii\" title=\"Toxoplasma gondii\">toxoplasma</a>, <a href=\"/wiki/Rubella\" title=\"Rubella\">rubella</a>, <a href=\"/wiki/Cytomegalovirus\" title=\"Cytomegalovirus\">cytomegalovirus</a>, and <a href=\"/wiki/Syphilis\" title=\"Syphilis\">syphilis</a> can cause neonatal hepatitis.<sup id=\"cite_ref-Biliary_disease_in_infancy_53-1\" class=\"reference\"><a href=\"#cite_note-Biliary_disease_in_infancy-53\">&#91;53&#93;</a></sup> Structural abnormalities such as <a href=\"/wiki/Biliary_atresia\" title=\"Biliary atresia\">biliary atresia</a> and <a href=\"/wiki/Choledochal_cysts\" title=\"Choledochal cysts\">choledochal cysts</a> can lead to <a href=\"/wiki/Cholestasis\" title=\"Cholestasis\">cholestatic liver injury</a> leading to neonatal hepatitis.<sup id=\"cite_ref-Biliary_disease_in_infancy_53-2\" class=\"reference\"><a href=\"#cite_note-Biliary_disease_in_infancy-53\">&#91;53&#93;</a></sup> <a href=\"/wiki/Inborn_error_of_metabolism\" class=\"mw-redirect\" title=\"Inborn error of metabolism\">Metabolic diseases</a> such as <a href=\"/wiki/Glycogen_storage_disease\" title=\"Glycogen storage disease\">glycogen storage disorders</a> and <a href=\"/wiki/Lysosomal_storage_disease\" title=\"Lysosomal storage disease\">lysosomal storage disorders</a> are also implicated.<sup id=\"cite_ref-Biliary_disease_in_infancy_53-3\" class=\"reference\"><a href=\"#cite_note-Biliary_disease_in_infancy-53\">&#91;53&#93;</a></sup> Neonatal hepatitis can be <a href=\"/wiki/Idiopathy\" class=\"mw-redirect\" title=\"Idiopathy\">idiopathic</a>, and in such cases, biopsy often shows large multinucleated cells in the liver tissue.<sup id=\"cite_ref-54\" class=\"reference\"><a href=\"#cite_note-54\">&#91;54&#93;</a></sup> This disease is termed giant cell hepatitis and may be associated with viral infection, autoimmune disorders, and drug toxicity.<sup id=\"cite_ref-55\" class=\"reference\"><a href=\"#cite_note-55\">&#91;55&#93;</a></sup><sup id=\"cite_ref-56\" class=\"reference\"><a href=\"#cite_note-56\">&#91;56&#93;</a></sup>\\n</p>\\n<h2><span class=\"mw-headline\" id=\"Mechanism\">Mechanism</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=18\" title=\"Edit section: Mechanism\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\\n<p>The specific mechanism varies and depends on the underlying cause of the hepatitis. Generally, there is an initial insult that causes liver injury and activation of an inflammatory response, which can become chronic, leading to progressive <a href=\"/wiki/Fibrosis\" title=\"Fibrosis\">fibrosis</a> and <a href=\"/wiki/Cirrhosis\" title=\"Cirrhosis\">cirrhosis</a>.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-21\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Viral_hepatitis_2\">Viral hepatitis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=19\" title=\"Edit section: Viral hepatitis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<figure class=\"mw-default-size\" typeof=\"mw:File/Thumb\"><a href=\"/wiki/File:Stages_of_Liver_disease_NIDDK_NIH.gif\" class=\"mw-file-description\"><img src=\"//upload.wikimedia.org/wikipedia/commons/thumb/1/16/Stages_of_Liver_disease_NIDDK_NIH.gif/290px-Stages_of_Liver_disease_NIDDK_NIH.gif\" decoding=\"async\" width=\"290\" height=\"162\" class=\"mw-file-element\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/1/16/Stages_of_Liver_disease_NIDDK_NIH.gif/435px-Stages_of_Liver_disease_NIDDK_NIH.gif 1.5x, //upload.wikimedia.org/wikipedia/commons/1/16/Stages_of_Liver_disease_NIDDK_NIH.gif 2x\" data-file-width=\"446\" data-file-height=\"249\" /></a><figcaption>Stages of liver disease</figcaption></figure>\\n<p>The pathway by which hepatic viruses cause <a href=\"/wiki/Viral_hepatitis\" title=\"Viral hepatitis\">viral hepatitis</a> is best understood in the case of hepatitis B and C.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-22\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup> The viruses do not directly activate <a href=\"/wiki/Apoptosis\" title=\"Apoptosis\">apoptosis</a> (cell death).<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-23\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-Nakamoto_&amp;_Kaneko_57-0\" class=\"reference\"><a href=\"#cite_note-Nakamoto_&amp;_Kaneko-57\">&#91;57&#93;</a></sup> Rather, infection of liver cells activates the <a href=\"/wiki/Innate_immune_system\" title=\"Innate immune system\">innate</a> and <a href=\"/wiki/Adaptive_immune_system\" title=\"Adaptive immune system\">adaptive</a> arms of the <a href=\"/wiki/Immune_system\" title=\"Immune system\">immune system</a> leading to an inflammatory response which causes cellular damage and death, including viral-induced apoptosis via the induction of the death receptor-mediated signaling pathway.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-24\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-Nakamoto_&amp;_Kaneko_57-1\" class=\"reference\"><a href=\"#cite_note-Nakamoto_&amp;_Kaneko-57\">&#91;57&#93;</a></sup><sup id=\"cite_ref-58\" class=\"reference\"><a href=\"#cite_note-58\">&#91;58&#93;</a></sup><sup id=\"cite_ref-59\" class=\"reference\"><a href=\"#cite_note-59\">&#91;59&#93;</a></sup>  Depending on the strength of the immune response, the types of immune cells involved and the ability of the virus to evade the body\\'s defense, infection can either lead to clearance (acute disease) or persistence (chronic disease) of the virus.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-25\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup>  The chronic presence of the virus within liver cells results in multiple waves of <a href=\"/wiki/Inflammation\" title=\"Inflammation\">inflammation</a>, injury and <a href=\"/wiki/Wound_healing\" title=\"Wound healing\">wound healing</a> that over time lead to scarring or <a href=\"/wiki/Fibrosis\" title=\"Fibrosis\">fibrosis</a> and culminate in <a href=\"/wiki/Hepatocellular_carcinoma\" title=\"Hepatocellular carcinoma\">hepatocellular carcinoma</a>.<sup id=\"cite_ref-Nakamoto_&amp;_Kaneko_57-2\" class=\"reference\"><a href=\"#cite_note-Nakamoto_&amp;_Kaneko-57\">&#91;57&#93;</a></sup><sup id=\"cite_ref-60\" class=\"reference\"><a href=\"#cite_note-60\">&#91;60&#93;</a></sup> People with impaired immune response are at greater risk of developing chronic infection.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-26\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup> <a href=\"/wiki/Natural_killer_cell\" title=\"Natural killer cell\">Natural killer cells</a> are the primary drivers of the initial innate response and create a <a href=\"/wiki/Cytokine\" title=\"Cytokine\">cytokine</a> environment that results in the recruitment of <a href=\"/wiki/T_helper_cell\" title=\"T helper cell\">CD4 T-helper</a> and <a href=\"/wiki/Cytotoxic_T_cell\" title=\"Cytotoxic T cell\">CD8 cytotoxic T-cells</a>.<sup id=\"cite_ref-Rehermann_Killer_Cells_61-0\" class=\"reference\"><a href=\"#cite_note-Rehermann_Killer_Cells-61\">&#91;61&#93;</a></sup><sup id=\"cite_ref-Heim_&amp;_Thimme_62-0\" class=\"reference\"><a href=\"#cite_note-Heim_&amp;_Thimme-62\">&#91;62&#93;</a></sup>  <a href=\"/wiki/Interferon_type_I\" title=\"Interferon type I\">Type I interferons</a> are the cytokines that drive the antiviral response.<sup id=\"cite_ref-Heim_&amp;_Thimme_62-1\" class=\"reference\"><a href=\"#cite_note-Heim_&amp;_Thimme-62\">&#91;62&#93;</a></sup> In chronic Hepatitis B and C, natural killer cell function is impaired.<sup id=\"cite_ref-Rehermann_Killer_Cells_61-1\" class=\"reference\"><a href=\"#cite_note-Rehermann_Killer_Cells-61\">&#91;61&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Steatohepatitis\">Steatohepatitis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=20\" title=\"Edit section: Steatohepatitis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<p><a href=\"/wiki/Steatohepatitis\" title=\"Steatohepatitis\">Steatohepatitis</a> is seen in both alcoholic and non-alcoholic liver disease and is the culmination of a cascade of events that began with injury.  In the case of <a href=\"/wiki/Non-alcoholic_fatty_liver_disease\" title=\"Non-alcoholic fatty liver disease\">non-alcoholic steatohepatitis</a>, this cascade is initiated by changes in metabolism associated with obesity, insulin resistance, and lipid dysregulation.<sup id=\"cite_ref-Hardy_Oakley_Anstee_Day_63-0\" class=\"reference\"><a href=\"#cite_note-Hardy_Oakley_Anstee_Day-63\">&#91;63&#93;</a></sup><sup id=\"cite_ref-Yoon_&amp;_Cha_Pathogenesis_64-0\" class=\"reference\"><a href=\"#cite_note-Yoon_&amp;_Cha_Pathogenesis-64\">&#91;64&#93;</a></sup> In <a href=\"/wiki/Alcoholic_hepatitis\" title=\"Alcoholic hepatitis\">alcoholic hepatitis</a>, chronic excess alcohol use is the culprit.<sup id=\"cite_ref-Chayanupatkul_&amp;_Liangpunsakul_65-0\" class=\"reference\"><a href=\"#cite_note-Chayanupatkul_&amp;_Liangpunsakul-65\">&#91;65&#93;</a></sup>  Though the inciting event may differ, the progression of events is similar and begins with accumulation of free <a href=\"/wiki/Fatty_acid\" title=\"Fatty acid\">fatty acids</a> (FFA) and their breakdown products  in the liver cells in a process called <a href=\"/wiki/Steatosis\" title=\"Steatosis\">steatosis</a>.<sup id=\"cite_ref-Hardy_Oakley_Anstee_Day_63-1\" class=\"reference\"><a href=\"#cite_note-Hardy_Oakley_Anstee_Day-63\">&#91;63&#93;</a></sup><sup id=\"cite_ref-Yoon_&amp;_Cha_Pathogenesis_64-1\" class=\"reference\"><a href=\"#cite_note-Yoon_&amp;_Cha_Pathogenesis-64\">&#91;64&#93;</a></sup><sup id=\"cite_ref-Chayanupatkul_&amp;_Liangpunsakul_65-1\" class=\"reference\"><a href=\"#cite_note-Chayanupatkul_&amp;_Liangpunsakul-65\">&#91;65&#93;</a></sup> This initially reversible process overwhelms the <a href=\"/wiki/Hepatocyte\" title=\"Hepatocyte\">hepatocyte</a>\\'s ability to maintain lipid homeostasis leading to a toxic effect  as fat molecules accumulate and are broken down in the setting of an <a href=\"/wiki/Cellular_stress_response\" title=\"Cellular stress response\">oxidative stress response</a>.<sup id=\"cite_ref-Hardy_Oakley_Anstee_Day_63-2\" class=\"reference\"><a href=\"#cite_note-Hardy_Oakley_Anstee_Day-63\">&#91;63&#93;</a></sup><sup id=\"cite_ref-Yoon_&amp;_Cha_Pathogenesis_64-2\" class=\"reference\"><a href=\"#cite_note-Yoon_&amp;_Cha_Pathogenesis-64\">&#91;64&#93;</a></sup><sup id=\"cite_ref-Chayanupatkul_&amp;_Liangpunsakul_65-2\" class=\"reference\"><a href=\"#cite_note-Chayanupatkul_&amp;_Liangpunsakul-65\">&#91;65&#93;</a></sup>  Over time, this abnormal lipid deposition triggers the <a href=\"/wiki/Immune_system\" title=\"Immune system\">immune system</a> via <a href=\"/wiki/Toll-like_receptor\" title=\"Toll-like receptor\">toll-like receptor 4</a> (TLR4) resulting in the production of inflammatory <a href=\"/wiki/Cytokine\" title=\"Cytokine\">cytokines</a> such as TNF that cause liver cell injury and death.<sup id=\"cite_ref-Hardy_Oakley_Anstee_Day_63-3\" class=\"reference\"><a href=\"#cite_note-Hardy_Oakley_Anstee_Day-63\">&#91;63&#93;</a></sup><sup id=\"cite_ref-Yoon_&amp;_Cha_Pathogenesis_64-3\" class=\"reference\"><a href=\"#cite_note-Yoon_&amp;_Cha_Pathogenesis-64\">&#91;64&#93;</a></sup><sup id=\"cite_ref-Chayanupatkul_&amp;_Liangpunsakul_65-3\" class=\"reference\"><a href=\"#cite_note-Chayanupatkul_&amp;_Liangpunsakul-65\">&#91;65&#93;</a></sup>  These events mark the transition to <a href=\"/wiki/Steatohepatitis\" title=\"Steatohepatitis\">steatohepatitis</a> and in the setting of chronic injury, <a href=\"/wiki/Fibrosis\" title=\"Fibrosis\">fibrosis</a> eventually develops setting up events that lead to cirrhosis and hepatocellular carcinoma.<sup id=\"cite_ref-Hardy_Oakley_Anstee_Day_63-4\" class=\"reference\"><a href=\"#cite_note-Hardy_Oakley_Anstee_Day-63\">&#91;63&#93;</a></sup> Microscopically, changes that can be seen include steatosis with large and swollen hepatocytes (<a href=\"/wiki/Ballooning_degeneration\" title=\"Ballooning degeneration\">ballooning</a>), evidence of cellular injury and cell death (apoptosis, necrosis), evidence of inflammation in particular in <a href=\"/wiki/Liver\" title=\"Liver\">zone 3 of the liver</a>, variable degrees of fibrosis and <a href=\"/wiki/Mallory_body\" title=\"Mallory body\">Mallory bodies</a>.<sup id=\"cite_ref-Hardy_Oakley_Anstee_Day_63-5\" class=\"reference\"><a href=\"#cite_note-Hardy_Oakley_Anstee_Day-63\">&#91;63&#93;</a></sup><sup id=\"cite_ref-Definition,_epidemiology,_and_magnitude_66-0\" class=\"reference\"><a href=\"#cite_note-Definition,_epidemiology,_and_magnitude-66\">&#91;66&#93;</a></sup><sup id=\"cite_ref-67\" class=\"reference\"><a href=\"#cite_note-67\">&#91;67&#93;</a></sup>\\n</p>\\n<h2><span class=\"mw-headline\" id=\"Diagnosis\">Diagnosis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=21\" title=\"Edit section: Diagnosis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\\n<table class=\"wikitable\" style=\"float: right; margin-left:15px; text-align:center\">\\n<tbody><tr>\\n<th scope=\"col\">Most elevated aminotransferase\\n</th>\\n<th scope=\"col\">Cause\\n</th></tr>\\n<tr>\\n<td rowspan=\"9\">ALT\\n</td>\\n<td>Chronic hepatitis B, C, and D\\n</td></tr>\\n<tr>\\n<td>Nonalcoholic liver disease\\n</td></tr>\\n<tr>\\n<td>Acute viral hepatitis\\n</td></tr>\\n<tr>\\n<td>Medications/toxins\\n</td></tr>\\n<tr>\\n<td>Autoimmune hepatitis\\n</td></tr>\\n<tr>\\n<td>Wilson\\'s disease\\n</td></tr>\\n<tr>\\n<td>Alpha-1-antitrypsin deficiency\\n</td></tr>\\n<tr>\\n<td>Hemochromatosis\\n</td></tr>\\n<tr>\\n<td><i>Ischemic hepatitis (severe elevation up to thousands)</i>\\n</td></tr>\\n<tr>\\n<td rowspan=\"2\">AST\\n</td>\\n<td>Alcoholic liver disease\\n</td></tr>\\n<tr>\\n<td>Cirrhosis\\n</td></tr></tbody></table>\\n<figure class=\"mw-default-size\" typeof=\"mw:File/Thumb\"><a href=\"/wiki/File:Histopathology_of_acute_hepatitis.jpg\" class=\"mw-file-description\"><img src=\"//upload.wikimedia.org/wikipedia/commons/thumb/e/e6/Histopathology_of_acute_hepatitis.jpg/220px-Histopathology_of_acute_hepatitis.jpg\" decoding=\"async\" width=\"220\" height=\"164\" class=\"mw-file-element\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/e/e6/Histopathology_of_acute_hepatitis.jpg/330px-Histopathology_of_acute_hepatitis.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/e6/Histopathology_of_acute_hepatitis.jpg/440px-Histopathology_of_acute_hepatitis.jpg 2x\" data-file-width=\"635\" data-file-height=\"474\" /></a><figcaption>Histopathology of acute hepatitis with lobular disarray and associated lymphocytic inflammation, acidophil body formation (arrow) and bilirubinostasis.</figcaption></figure>\\n<p>Diagnosis of hepatitis is made on the basis of some or all of the following: a person\\'s signs and symptoms, medical history including sexual and substance use history, blood tests, <a href=\"/wiki/Medical_imaging\" title=\"Medical imaging\">imaging</a>, and <a href=\"/wiki/Liver_biopsy\" title=\"Liver biopsy\">liver biopsy</a>.<sup id=\"cite_ref-Friedman_55e_31-24\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup> In general, for viral hepatitis and other acute causes of hepatitis, the person\\'s blood tests and clinical picture are sufficient for diagnosis.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-27\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-Friedman_55e_31-25\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup> For other causes of hepatitis, especially chronic causes, blood tests may not be useful.<sup id=\"cite_ref-Friedman_55e_31-26\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup> In this case, liver biopsy is the <a href=\"/wiki/Gold_standard_(test)\" title=\"Gold standard (test)\">gold standard</a> for establishing the diagnosis: <a href=\"/wiki/Histopathology\" title=\"Histopathology\">histopathologic</a> analysis is able to reveal the precise extent and pattern of inflammation and <a href=\"/wiki/Fibrosis\" title=\"Fibrosis\">fibrosis</a>.<sup id=\"cite_ref-Friedman_55e_31-27\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup> Biopsy is typically not the initial diagnostic test because it is invasive and is associated with a small but significant risk of bleeding that is increased in people with liver injury and cirrhosis.<sup id=\"cite_ref-68\" class=\"reference\"><a href=\"#cite_note-68\">&#91;68&#93;</a></sup>\\n</p><p>Blood testing includes <a href=\"/wiki/Liver_function_tests\" title=\"Liver function tests\">liver enzymes</a>, <a href=\"/wiki/Serology\" title=\"Serology\">serology</a> (i.e. for autoantibodies), <a href=\"/wiki/Nucleic_acid_test\" title=\"Nucleic acid test\">nucleic acid testing</a> (i.e. for hepatitis virus DNA/RNA), <a href=\"/wiki/Blood_chemistry_study\" class=\"mw-redirect\" title=\"Blood chemistry study\">blood chemistry</a>, and <a href=\"/wiki/Complete_blood_count\" title=\"Complete blood count\">complete blood count</a>.<sup id=\"cite_ref-Friedman_55e_31-28\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup> Characteristic patterns of liver enzyme abnormalities can point to certain causes or stages of hepatitis.<sup id=\"cite_ref-69\" class=\"reference\"><a href=\"#cite_note-69\">&#91;69&#93;</a></sup><sup id=\"cite_ref-70\" class=\"reference\"><a href=\"#cite_note-70\">&#91;70&#93;</a></sup> Generally, <a href=\"/wiki/Aspartate_transaminase\" title=\"Aspartate transaminase\">AST</a> and <a href=\"/wiki/Alanine_transaminase\" title=\"Alanine transaminase\">ALT</a> are elevated in most cases of hepatitis regardless of whether the person shows any symptoms.<sup id=\"cite_ref-Friedman_55e_31-29\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup> The degree of elevation (i.e. levels in the hundreds vs. in the thousands), the predominance for AST vs. ALT elevation, and the ratio between AST and ALT are informative of the diagnosis.<sup id=\"cite_ref-Friedman_55e_31-30\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup>\\n</p><p><a href=\"/wiki/Medical_ultrasound\" title=\"Medical ultrasound\">Ultrasound</a>, <a href=\"/wiki/CT_scan\" title=\"CT scan\">CT</a>, and <a href=\"/wiki/Magnetic_resonance_imaging\" title=\"Magnetic resonance imaging\">MRI</a> can all identify steatosis (fatty changes) of the liver tissue and nodularity of the liver surface suggestive of cirrhosis.<sup id=\"cite_ref-71\" class=\"reference\"><a href=\"#cite_note-71\">&#91;71&#93;</a></sup><sup id=\"cite_ref-72\" class=\"reference\"><a href=\"#cite_note-72\">&#91;72&#93;</a></sup> CT and especially MRI are able to provide a higher level of detail, allowing visualization and characterize such structures as vessels and tumors within the liver.<sup id=\"cite_ref-73\" class=\"reference\"><a href=\"#cite_note-73\">&#91;73&#93;</a></sup> Unlike steatosis and cirrhosis, no imaging test is able to detect liver inflammation (i.e. hepatitis) or fibrosis.<sup id=\"cite_ref-Friedman_55e_31-31\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup> Liver biopsy is the only definitive diagnostic test that is able to assess inflammation and fibrosis of the liver.<sup id=\"cite_ref-Friedman_55e_31-32\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Viral_hepatitis_3\">Viral hepatitis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=22\" title=\"Edit section: Viral hepatitis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1033289096\"><div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Viral_hepatitis\" title=\"Viral hepatitis\">Viral hepatitis</a></div>\\n<p>Viral hepatitis is primarily diagnosed through blood tests for levels of viral <a href=\"/wiki/Antigen\" title=\"Antigen\">antigens</a> (such as the <a href=\"/wiki/HBsAg\" title=\"HBsAg\">hepatitis B surface</a> or <a href=\"/wiki/HBcAg\" title=\"HBcAg\">core</a> antigen), anti-viral antibodies (such as the anti-hepatitis B surface antibody or anti-hepatitis A antibody), or viral DNA/RNA.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-28\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-Friedman_55e_31-33\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup> In early infection (i.e. within 1 week), <a href=\"/wiki/Immunoglobulin_M\" title=\"Immunoglobulin M\">IgM</a> antibodies are found in the blood.<sup id=\"cite_ref-Friedman_55e_31-34\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup> In late infection and after recovery, <a href=\"/wiki/Immunoglobulin_G\" title=\"Immunoglobulin G\">IgG</a> antibodies are present and remain in the body for up to years.<sup id=\"cite_ref-Friedman_55e_31-35\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup> Therefore, when a patient is positive for IgG antibody but negative for IgM antibody, he is considered <a href=\"/wiki/Immunity_(medical)\" title=\"Immunity (medical)\">immune</a> from the virus via either prior infection and recovery or prior vaccination.<sup id=\"cite_ref-Friedman_55e_31-36\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup>\\n</p><p>In the case of hepatitis B, blood tests exist for multiple virus antigens (which are different components of the <a href=\"/wiki/File:HBV.png\" title=\"File:HBV.png\">virion particle</a>) and antibodies.<sup id=\"cite_ref-pmid26568915_74-0\" class=\"reference\"><a href=\"#cite_note-pmid26568915-74\">&#91;74&#93;</a></sup> The combination of antigen and antibody positivity can provide information about the stage of infection (acute or chronic), the degree of viral replication, and the infectivity of the virus.<sup id=\"cite_ref-pmid26568915_74-1\" class=\"reference\"><a href=\"#cite_note-pmid26568915-74\">&#91;74&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Alcoholic_versus_non-alcoholic\">Alcoholic versus non-alcoholic</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=23\" title=\"Edit section: Alcoholic versus non-alcoholic\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<p>The most apparent distinguishing factor between <a href=\"/wiki/Alcoholic_hepatitis\" title=\"Alcoholic hepatitis\">alcoholic steatohepatitis</a> (ASH) and <a href=\"/wiki/Nonalcoholic_Steatohepatitis\" class=\"mw-redirect\" title=\"Nonalcoholic Steatohepatitis\">nonalcoholic steatohepatitis</a> (NASH) is a history of excessive alcohol use.<sup id=\"cite_ref-Neuman,_French,_et_al_75-0\" class=\"reference\"><a href=\"#cite_note-Neuman,_French,_et_al-75\">&#91;75&#93;</a></sup> Thus, in patients who have no or negligible alcohol use, the diagnosis is unlikely to be alcoholic hepatitis. In those who drink alcohol, the diagnosis may just as likely be alcoholic or nonalcoholic hepatitis especially if there is concurrent obesity, diabetes, and metabolic syndrome. In this case, alcoholic and nonalcoholic hepatitis can be distinguished by the pattern of liver enzyme abnormalities; specifically, in alcoholic steatohepatitis AST&gt;ALT with ratio of AST:ALT&gt;2:1 while in nonalcoholic steatohepatitis ALT&gt;AST with ratio of ALT:AST&gt;1.5:1.<sup id=\"cite_ref-Neuman,_French,_et_al_75-1\" class=\"reference\"><a href=\"#cite_note-Neuman,_French,_et_al-75\">&#91;75&#93;</a></sup>\\n</p><p>Liver biopsies show identical findings in patients with ASH and NASH, specifically, the presence of <a href=\"/wiki/Granulocyte\" title=\"Granulocyte\">polymorphonuclear</a> infiltration, hepatocyte <a href=\"/wiki/Necrosis\" title=\"Necrosis\">necrosis</a> and <a href=\"/wiki/Apoptosis\" title=\"Apoptosis\">apoptosis</a> in the form of <a href=\"/wiki/Ballooning_degeneration\" title=\"Ballooning degeneration\">ballooning degeneration</a>, <a href=\"/wiki/Mallory_body\" title=\"Mallory body\">Mallory bodies</a>, and fibrosis around veins and sinuses.<sup id=\"cite_ref-Friedman_55e_31-37\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup>\\n</p>\\n<h2><span class=\"mw-headline\" id=\"Virus_screening\">Virus screening</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=24\" title=\"Edit section: Virus screening\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\\n<p>The purpose of screening for viral hepatitis is to identify people infected with the disease as early as possible, even before symptoms and transaminase elevations may be present. This allows for early treatment, which can both prevent disease progression and  decrease the likelihood of transmission to others.<sup id=\"cite_ref-76\" class=\"reference\"><a href=\"#cite_note-76\">&#91;76&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Hepatitis_A\">Hepatitis A</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=25\" title=\"Edit section: Hepatitis A\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<p>Hepatitis A causes an acute illness that does not progress to chronic liver disease. Therefore, the role of screening is to assess immune status in people who are at high risk of contracting the virus, as well as in people with known liver disease for whom hepatitis A infection could lead to liver failure.<sup id=\"cite_ref-77\" class=\"reference\"><a href=\"#cite_note-77\">&#91;77&#93;</a></sup><sup id=\"cite_ref-78\" class=\"reference\"><a href=\"#cite_note-78\">&#91;78&#93;</a></sup> People in these groups who are not already immune can receive the <a href=\"/wiki/Hepatitis_A_vaccine\" title=\"Hepatitis A vaccine\">hepatitis A vaccine</a>.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (March 2023)\">citation needed</span></a></i>&#93;</sup>\\n</p><p>Those at high risk and in need of screening include:<sup id=\"cite_ref-WHO_Hep_A_Fact_Sheet_July_2015_79-0\" class=\"reference\"><a href=\"#cite_note-WHO_Hep_A_Fact_Sheet_July_2015-79\">&#91;79&#93;</a></sup><sup id=\"cite_ref-Voise_2011_80-0\" class=\"reference\"><a href=\"#cite_note-Voise_2011-80\">&#91;80&#93;</a></sup><sup id=\"cite_ref-CDC_Adult_Vaccine_81-0\" class=\"reference\"><a href=\"#cite_note-CDC_Adult_Vaccine-81\">&#91;81&#93;</a></sup>\\n</p>\\n<ul><li>People in close contact (either living with or having sexual contact) with someone who has hepatitis A</li>\\n<li>People traveling to an area with endemic hepatitis A</li>\\n<li>People who do not have access to clean water</li>\\n<li>People who use illicit drugs</li>\\n<li>People with liver disease</li>\\n<li>People with poor sanitary habits such as not washing hands after using the restroom or changing diapers</li></ul>\\n<p>The presence of anti-hepatitis A <a href=\"/wiki/Immunoglobulin_G\" title=\"Immunoglobulin G\">IgG</a> in the blood indicates past infection with the virus or prior vaccination.<sup id=\"cite_ref-82\" class=\"reference\"><a href=\"#cite_note-82\">&#91;82&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Hepatitis_B\">Hepatitis B</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=26\" title=\"Edit section: Hepatitis B\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<figure class=\"mw-default-size\" typeof=\"mw:File/Thumb\"><a href=\"/wiki/File:Hepatitis_B_virus_v2.png\" class=\"mw-file-description\"><img src=\"//upload.wikimedia.org/wikipedia/commons/thumb/2/2c/Hepatitis_B_virus_v2.png/220px-Hepatitis_B_virus_v2.png\" decoding=\"async\" width=\"220\" height=\"151\" class=\"mw-file-element\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/2/2c/Hepatitis_B_virus_v2.png/330px-Hepatitis_B_virus_v2.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/2/2c/Hepatitis_B_virus_v2.png/440px-Hepatitis_B_virus_v2.png 2x\" data-file-width=\"843\" data-file-height=\"577\" /></a><figcaption>Hepatitis B virus v2</figcaption></figure>\\n<p>The <a href=\"/wiki/Centers_for_Disease_Control_and_Prevention\" title=\"Centers for Disease Control and Prevention\">CDC</a>, <a href=\"/wiki/World_Health_Organization\" title=\"World Health Organization\">WHO</a>, <a href=\"/wiki/United_States_Preventive_Services_Task_Force\" title=\"United States Preventive Services Task Force\">USPSTF</a>, and <a href=\"/wiki/American_Congress_of_Obstetricians_and_Gynecologists\" class=\"mw-redirect\" title=\"American Congress of Obstetricians and Gynecologists\">ACOG</a> recommend routine hepatitis B screening for certain high-risk populations.<sup id=\"cite_ref-CDC_recommendations_for_Hepatitis_B_83-0\" class=\"reference\"><a href=\"#cite_note-CDC_recommendations_for_Hepatitis_B-83\">&#91;83&#93;</a></sup><sup id=\"cite_ref-Screening_for_Hepatitis_B_84-0\" class=\"reference\"><a href=\"#cite_note-Screening_for_Hepatitis_B-84\">&#91;84&#93;</a></sup><sup id=\"cite_ref-WHO_guidelines_for_chronic_Hepatitis_B_85-0\" class=\"reference\"><a href=\"#cite_note-WHO_guidelines_for_chronic_Hepatitis_B-85\">&#91;85&#93;</a></sup><sup id=\"cite_ref-ACOG_Practice_Bulletin_86-0\" class=\"reference\"><a href=\"#cite_note-ACOG_Practice_Bulletin-86\">&#91;86&#93;</a></sup> Specifically, these populations include people who are:\\n</p>\\n<ul><li>Beginning <a href=\"/wiki/Immunosuppressive_drug\" title=\"Immunosuppressive drug\">immunosuppressive</a> or <a href=\"/wiki/Chemotherapy\" title=\"Chemotherapy\">cytotoxic therapy</a><sup id=\"cite_ref-CDC_recommendations_for_Hepatitis_B_83-1\" class=\"reference\"><a href=\"#cite_note-CDC_recommendations_for_Hepatitis_B-83\">&#91;83&#93;</a></sup></li>\\n<li>Blood, organ, or tissue donors<sup id=\"cite_ref-WHO_guidelines_for_chronic_Hepatitis_B_85-1\" class=\"reference\"><a href=\"#cite_note-WHO_guidelines_for_chronic_Hepatitis_B-85\">&#91;85&#93;</a></sup></li>\\n<li>Born in countries where the prevalence of hepatitis B is high (defined as ≥2% of the population), whether or not they have been vaccinated<sup id=\"cite_ref-CDC_recommendations_for_Hepatitis_B_83-2\" class=\"reference\"><a href=\"#cite_note-CDC_recommendations_for_Hepatitis_B-83\">&#91;83&#93;</a></sup><sup id=\"cite_ref-Screening_for_Hepatitis_B_84-1\" class=\"reference\"><a href=\"#cite_note-Screening_for_Hepatitis_B-84\">&#91;84&#93;</a></sup></li>\\n<li>Born in the United States whose parents are from countries where the prevalence of hepatitis B is very high (defined as ≥8% of the population), and who were not vaccinated<sup id=\"cite_ref-CDC_recommendations_for_Hepatitis_B_83-3\" class=\"reference\"><a href=\"#cite_note-CDC_recommendations_for_Hepatitis_B-83\">&#91;83&#93;</a></sup><sup id=\"cite_ref-Screening_for_Hepatitis_B_84-2\" class=\"reference\"><a href=\"#cite_note-Screening_for_Hepatitis_B-84\">&#91;84&#93;</a></sup></li>\\n<li>Found to have elevated <a href=\"/wiki/Liver_function_tests\" title=\"Liver function tests\">liver enzymes</a> without a known cause<sup id=\"cite_ref-CDC_recommendations_for_Hepatitis_B_83-4\" class=\"reference\"><a href=\"#cite_note-CDC_recommendations_for_Hepatitis_B-83\">&#91;83&#93;</a></sup></li>\\n<li><a href=\"/wiki/HIV/AIDS\" title=\"HIV/AIDS\">HIV</a> positive<sup id=\"cite_ref-CDC_recommendations_for_Hepatitis_B_83-5\" class=\"reference\"><a href=\"#cite_note-CDC_recommendations_for_Hepatitis_B-83\">&#91;83&#93;</a></sup><sup id=\"cite_ref-Screening_for_Hepatitis_B_84-3\" class=\"reference\"><a href=\"#cite_note-Screening_for_Hepatitis_B-84\">&#91;84&#93;</a></sup><sup id=\"cite_ref-WHO_guidelines_for_chronic_Hepatitis_B_85-2\" class=\"reference\"><a href=\"#cite_note-WHO_guidelines_for_chronic_Hepatitis_B-85\">&#91;85&#93;</a></sup></li>\\n<li>In close contact with (i.e. live or have sex with) people known to have hepatitis B<sup id=\"cite_ref-CDC_recommendations_for_Hepatitis_B_83-6\" class=\"reference\"><a href=\"#cite_note-CDC_recommendations_for_Hepatitis_B-83\">&#91;83&#93;</a></sup><sup id=\"cite_ref-Screening_for_Hepatitis_B_84-4\" class=\"reference\"><a href=\"#cite_note-Screening_for_Hepatitis_B-84\">&#91;84&#93;</a></sup><sup id=\"cite_ref-WHO_guidelines_for_chronic_Hepatitis_B_85-3\" class=\"reference\"><a href=\"#cite_note-WHO_guidelines_for_chronic_Hepatitis_B-85\">&#91;85&#93;</a></sup></li>\\n<li>Incarcerated<sup id=\"cite_ref-WHO_guidelines_for_chronic_Hepatitis_B_85-4\" class=\"reference\"><a href=\"#cite_note-WHO_guidelines_for_chronic_Hepatitis_B-85\">&#91;85&#93;</a></sup></li>\\n<li><a href=\"/wiki/Intravenous_drug_users\" class=\"mw-redirect\" title=\"Intravenous drug users\">Intravenous drug users</a><sup id=\"cite_ref-CDC_recommendations_for_Hepatitis_B_83-7\" class=\"reference\"><a href=\"#cite_note-CDC_recommendations_for_Hepatitis_B-83\">&#91;83&#93;</a></sup><sup id=\"cite_ref-Screening_for_Hepatitis_B_84-5\" class=\"reference\"><a href=\"#cite_note-Screening_for_Hepatitis_B-84\">&#91;84&#93;</a></sup><sup id=\"cite_ref-WHO_guidelines_for_chronic_Hepatitis_B_85-5\" class=\"reference\"><a href=\"#cite_note-WHO_guidelines_for_chronic_Hepatitis_B-85\">&#91;85&#93;</a></sup></li>\\n<li><a href=\"/wiki/Men_who_have_sex_with_men\" title=\"Men who have sex with men\">Men who have sex with men</a><sup id=\"cite_ref-CDC_recommendations_for_Hepatitis_B_83-8\" class=\"reference\"><a href=\"#cite_note-CDC_recommendations_for_Hepatitis_B-83\">&#91;83&#93;</a></sup><sup id=\"cite_ref-Screening_for_Hepatitis_B_84-6\" class=\"reference\"><a href=\"#cite_note-Screening_for_Hepatitis_B-84\">&#91;84&#93;</a></sup><sup id=\"cite_ref-WHO_guidelines_for_chronic_Hepatitis_B_85-6\" class=\"reference\"><a href=\"#cite_note-WHO_guidelines_for_chronic_Hepatitis_B-85\">&#91;85&#93;</a></sup></li>\\n<li>On <a href=\"/wiki/Hemodialysis\" title=\"Hemodialysis\">hemodialysis</a><sup id=\"cite_ref-CDC_recommendations_for_Hepatitis_B_83-9\" class=\"reference\"><a href=\"#cite_note-CDC_recommendations_for_Hepatitis_B-83\">&#91;83&#93;</a></sup></li>\\n<li>Pregnant<sup id=\"cite_ref-CDC_recommendations_for_Hepatitis_B_83-10\" class=\"reference\"><a href=\"#cite_note-CDC_recommendations_for_Hepatitis_B-83\">&#91;83&#93;</a></sup><sup id=\"cite_ref-Screening_for_Hepatitis_B_84-7\" class=\"reference\"><a href=\"#cite_note-Screening_for_Hepatitis_B-84\">&#91;84&#93;</a></sup><sup id=\"cite_ref-ACOG_Practice_Bulletin_86-1\" class=\"reference\"><a href=\"#cite_note-ACOG_Practice_Bulletin-86\">&#91;86&#93;</a></sup></li></ul>\\n<p>Screening consists of a blood test that detects hepatitis B surface antigen (<a href=\"/wiki/HBsAg\" title=\"HBsAg\">HBsAg</a>). If HBsAg is present, a second test – usually done on the same blood sample – that detects the antibody for the hepatitis B core antigen (anti-<a href=\"/wiki/HBcAg\" title=\"HBcAg\">HBcAg</a>) can differentiate between acute and chronic infection.<sup id=\"cite_ref-CDC_recommendations_for_Hepatitis_B_83-11\" class=\"reference\"><a href=\"#cite_note-CDC_recommendations_for_Hepatitis_B-83\">&#91;83&#93;</a></sup><sup id=\"cite_ref-87\" class=\"reference\"><a href=\"#cite_note-87\">&#91;87&#93;</a></sup> People who are high-risk whose blood tests negative for HBsAg can receive the <a href=\"/wiki/Hepatitis_B_vaccine\" title=\"Hepatitis B vaccine\">hepatitis B vaccine</a> to prevent future infection.<sup id=\"cite_ref-CDC_recommendations_for_Hepatitis_B_83-12\" class=\"reference\"><a href=\"#cite_note-CDC_recommendations_for_Hepatitis_B-83\">&#91;83&#93;</a></sup><sup id=\"cite_ref-Screening_for_Hepatitis_B_84-8\" class=\"reference\"><a href=\"#cite_note-Screening_for_Hepatitis_B-84\">&#91;84&#93;</a></sup><sup id=\"cite_ref-WHO_guidelines_for_chronic_Hepatitis_B_85-7\" class=\"reference\"><a href=\"#cite_note-WHO_guidelines_for_chronic_Hepatitis_B-85\">&#91;85&#93;</a></sup><sup id=\"cite_ref-ACOG_Practice_Bulletin_86-2\" class=\"reference\"><a href=\"#cite_note-ACOG_Practice_Bulletin-86\">&#91;86&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Hepatitis_C\">Hepatitis C</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=27\" title=\"Edit section: Hepatitis C\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<figure class=\"mw-default-size\" typeof=\"mw:File/Thumb\"><a href=\"/wiki/File:HCV_structure.png\" class=\"mw-file-description\"><img src=\"//upload.wikimedia.org/wikipedia/commons/thumb/9/96/HCV_structure.png/220px-HCV_structure.png\" decoding=\"async\" width=\"220\" height=\"181\" class=\"mw-file-element\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/9/96/HCV_structure.png/330px-HCV_structure.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/9/96/HCV_structure.png/440px-HCV_structure.png 2x\" data-file-width=\"638\" data-file-height=\"524\" /></a><figcaption>HCV structure</figcaption></figure>\\n<figure class=\"mw-default-size\" typeof=\"mw:File/Thumb\"><span><video id=\"mwe_player_0\" poster=\"//upload.wikimedia.org/wikipedia/commons/thumb/a/a4/ABHD5CGI-58-the-Chanarin-Dorfman-Syndrome-Protein-Mobilises-Lipid-Stores-for-Hepatitis-C-Virus-ppat.1005568.s014.ogv/220px--ABHD5CGI-58-the-Chanarin-Dorfman-Syndrome-Protein-Mobilises-Lipid-Stores-for-Hepatitis-C-Virus-ppat.1005568.s014.ogv.jpg\" controls=\"\" preload=\"none\" class=\"mw-file-element\" width=\"220\" height=\"59\" data-durationhint=\"39\" data-mwtitle=\"ABHD5CGI-58-the-Chanarin-Dorfman-Syndrome-Protein-Mobilises-Lipid-Stores-for-Hepatitis-C-Virus-ppat.1005568.s014.ogv\" data-mwprovider=\"wikimediacommons\" resource=\"/wiki/File:ABHD5CGI-58-the-Chanarin-Dorfman-Syndrome-Protein-Mobilises-Lipid-Stores-for-Hepatitis-C-Virus-ppat.1005568.s014.ogv\"><source src=\"//upload.wikimedia.org/wikipedia/commons/transcoded/a/a4/ABHD5CGI-58-the-Chanarin-Dorfman-Syndrome-Protein-Mobilises-Lipid-Stores-for-Hepatitis-C-Virus-ppat.1005568.s014.ogv/ABHD5CGI-58-the-Chanarin-Dorfman-Syndrome-Protein-Mobilises-Lipid-Stores-for-Hepatitis-C-Virus-ppat.1005568.s014.ogv.480p.webm\" type=\"video/webm; codecs=&quot;vp8, vorbis&quot;\" data-title=\"SD WebM (480P)\" data-shorttitle=\"WebM 480P\" data-transcodekey=\"480p.webm\" data-width=\"854\" data-height=\"228\" /><source src=\"//upload.wikimedia.org/wikipedia/commons/transcoded/a/a4/ABHD5CGI-58-the-Chanarin-Dorfman-Syndrome-Protein-Mobilises-Lipid-Stores-for-Hepatitis-C-Virus-ppat.1005568.s014.ogv/ABHD5CGI-58-the-Chanarin-Dorfman-Syndrome-Protein-Mobilises-Lipid-Stores-for-Hepatitis-C-Virus-ppat.1005568.s014.ogv.480p.vp9.webm\" type=\"video/webm; codecs=&quot;vp9, opus&quot;\" data-title=\"SD VP9 (480P)\" data-shorttitle=\"VP9 480P\" data-transcodekey=\"480p.vp9.webm\" data-width=\"854\" data-height=\"228\" /><source src=\"//upload.wikimedia.org/wikipedia/commons/a/a4/ABHD5CGI-58-the-Chanarin-Dorfman-Syndrome-Protein-Mobilises-Lipid-Stores-for-Hepatitis-C-Virus-ppat.1005568.s014.ogv\" type=\"video/ogg; codecs=&quot;theora&quot;\" data-title=\"Original Ogg file, 960 × 256 (1.16 Mbps)\" data-shorttitle=\"Ogg source\" data-width=\"960\" data-height=\"256\" /><source src=\"//upload.wikimedia.org/wikipedia/commons/transcoded/a/a4/ABHD5CGI-58-the-Chanarin-Dorfman-Syndrome-Protein-Mobilises-Lipid-Stores-for-Hepatitis-C-Virus-ppat.1005568.s014.ogv/ABHD5CGI-58-the-Chanarin-Dorfman-Syndrome-Protein-Mobilises-Lipid-Stores-for-Hepatitis-C-Virus-ppat.1005568.s014.ogv.120p.vp9.webm\" type=\"video/webm; codecs=&quot;vp9, opus&quot;\" data-title=\"Lowest bandwidth VP9 (120P)\" data-shorttitle=\"VP9 120P\" data-transcodekey=\"120p.vp9.webm\" data-width=\"214\" data-height=\"56\" /><source src=\"//upload.wikimedia.org/wikipedia/commons/transcoded/a/a4/ABHD5CGI-58-the-Chanarin-Dorfman-Syndrome-Protein-Mobilises-Lipid-Stores-for-Hepatitis-C-Virus-ppat.1005568.s014.ogv/ABHD5CGI-58-the-Chanarin-Dorfman-Syndrome-Protein-Mobilises-Lipid-Stores-for-Hepatitis-C-Virus-ppat.1005568.s014.ogv.160p.webm\" type=\"video/webm; codecs=&quot;vp8, vorbis&quot;\" data-title=\"Low bandwidth WebM (160P)\" data-shorttitle=\"WebM 160P\" data-transcodekey=\"160p.webm\" data-width=\"288\" data-height=\"76\" /><source src=\"//upload.wikimedia.org/wikipedia/commons/transcoded/a/a4/ABHD5CGI-58-the-Chanarin-Dorfman-Syndrome-Protein-Mobilises-Lipid-Stores-for-Hepatitis-C-Virus-ppat.1005568.s014.ogv/ABHD5CGI-58-the-Chanarin-Dorfman-Syndrome-Protein-Mobilises-Lipid-Stores-for-Hepatitis-C-Virus-ppat.1005568.s014.ogv.180p.vp9.webm\" type=\"video/webm; codecs=&quot;vp9, opus&quot;\" data-title=\"Low bandwidth VP9 (180P)\" data-shorttitle=\"VP9 180P\" data-transcodekey=\"180p.vp9.webm\" data-width=\"320\" data-height=\"86\" /><source src=\"//upload.wikimedia.org/wikipedia/commons/transcoded/a/a4/ABHD5CGI-58-the-Chanarin-Dorfman-Syndrome-Protein-Mobilises-Lipid-Stores-for-Hepatitis-C-Virus-ppat.1005568.s014.ogv/ABHD5CGI-58-the-Chanarin-Dorfman-Syndrome-Protein-Mobilises-Lipid-Stores-for-Hepatitis-C-Virus-ppat.1005568.s014.ogv.240p.webm\" type=\"video/webm; codecs=&quot;vp8, vorbis&quot;\" data-title=\"Small WebM (240P)\" data-shorttitle=\"WebM 240P\" data-transcodekey=\"240p.webm\" data-width=\"426\" data-height=\"114\" /><source src=\"//upload.wikimedia.org/wikipedia/commons/transcoded/a/a4/ABHD5CGI-58-the-Chanarin-Dorfman-Syndrome-Protein-Mobilises-Lipid-Stores-for-Hepatitis-C-Virus-ppat.1005568.s014.ogv/ABHD5CGI-58-the-Chanarin-Dorfman-Syndrome-Protein-Mobilises-Lipid-Stores-for-Hepatitis-C-Virus-ppat.1005568.s014.ogv.240p.vp9.webm\" type=\"video/webm; codecs=&quot;vp9, opus&quot;\" data-title=\"Small VP9 (240P)\" data-shorttitle=\"VP9 240P\" data-transcodekey=\"240p.vp9.webm\" data-width=\"426\" data-height=\"114\" /><source src=\"//upload.wikimedia.org/wikipedia/commons/transcoded/a/a4/ABHD5CGI-58-the-Chanarin-Dorfman-Syndrome-Protein-Mobilises-Lipid-Stores-for-Hepatitis-C-Virus-ppat.1005568.s014.ogv/ABHD5CGI-58-the-Chanarin-Dorfman-Syndrome-Protein-Mobilises-Lipid-Stores-for-Hepatitis-C-Virus-ppat.1005568.s014.ogv.360p.vp9.webm\" type=\"video/webm; codecs=&quot;vp9, opus&quot;\" data-title=\"VP9 (360P)\" data-shorttitle=\"VP9 360P\" data-transcodekey=\"360p.vp9.webm\" data-width=\"640\" data-height=\"170\" /><source src=\"//upload.wikimedia.org/wikipedia/commons/transcoded/a/a4/ABHD5CGI-58-the-Chanarin-Dorfman-Syndrome-Protein-Mobilises-Lipid-Stores-for-Hepatitis-C-Virus-ppat.1005568.s014.ogv/ABHD5CGI-58-the-Chanarin-Dorfman-Syndrome-Protein-Mobilises-Lipid-Stores-for-Hepatitis-C-Virus-ppat.1005568.s014.ogv.360p.webm\" type=\"video/webm; codecs=&quot;vp8, vorbis&quot;\" data-title=\"WebM (360P)\" data-shorttitle=\"WebM 360P\" data-transcodekey=\"360p.webm\" data-width=\"640\" data-height=\"170\" /></video></span><figcaption>ABHD5CGI-58-the-Chanarin-Dorfman-Syndrome-Protein-Mobilises-Lipid-Stores-for-Hepatitis-C-Virus-ppat.1005568.s014</figcaption></figure>\\n<p>The <a href=\"/wiki/Centers_for_Disease_Control_and_Prevention\" title=\"Centers for Disease Control and Prevention\">CDC</a>, <a href=\"/wiki/World_Health_Organization\" title=\"World Health Organization\">WHO</a>, <a href=\"/wiki/United_States_Preventive_Services_Task_Force\" title=\"United States Preventive Services Task Force\">USPSTF</a>, <a href=\"/wiki/AASLD\" class=\"mw-redirect\" title=\"AASLD\">AASLD</a>, and <a href=\"/wiki/American_Congress_of_Obstetricians_and_Gynecologists\" class=\"mw-redirect\" title=\"American Congress of Obstetricians and Gynecologists\">ACOG</a> recommend screening people at high risk for hepatitis C infection.<sup id=\"cite_ref-ACOG_Practice_Bulletin_86-3\" class=\"reference\"><a href=\"#cite_note-ACOG_Practice_Bulletin-86\">&#91;86&#93;</a></sup><sup id=\"cite_ref-CDC_-_HCV_prevention_88-0\" class=\"reference\"><a href=\"#cite_note-CDC_-_HCV_prevention-88\">&#91;88&#93;</a></sup><sup id=\"cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-0\" class=\"reference\"><a href=\"#cite_note-Final_Recommendation_Statement:_Hepatitis_C:_Screening-89\">&#91;89&#93;</a></sup><sup id=\"cite_ref-Task_Force_90-0\" class=\"reference\"><a href=\"#cite_note-Task_Force-90\">&#91;90&#93;</a></sup><sup id=\"cite_ref-AASLD-IDSA_10-1\" class=\"reference\"><a href=\"#cite_note-AASLD-IDSA-10\">&#91;10&#93;</a></sup> These populations include people who are:\\n</p>\\n<ul><li>Adults in the United States born between 1945 and 1965<sup id=\"cite_ref-Task_Force_90-1\" class=\"reference\"><a href=\"#cite_note-Task_Force-90\">&#91;90&#93;</a></sup><sup id=\"cite_ref-AASLD-IDSA_10-2\" class=\"reference\"><a href=\"#cite_note-AASLD-IDSA-10\">&#91;10&#93;</a></sup></li>\\n<li>Blood or organ donors.<sup id=\"cite_ref-AASLD-IDSA_10-3\" class=\"reference\"><a href=\"#cite_note-AASLD-IDSA-10\">&#91;10&#93;</a></sup></li>\\n<li>Born to HCV-positive mothers<sup id=\"cite_ref-AASLD-IDSA_10-4\" class=\"reference\"><a href=\"#cite_note-AASLD-IDSA-10\">&#91;10&#93;</a></sup></li>\\n<li>HIV-positive<sup id=\"cite_ref-CDC_-_HCV_prevention_88-1\" class=\"reference\"><a href=\"#cite_note-CDC_-_HCV_prevention-88\">&#91;88&#93;</a></sup><sup id=\"cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-1\" class=\"reference\"><a href=\"#cite_note-Final_Recommendation_Statement:_Hepatitis_C:_Screening-89\">&#91;89&#93;</a></sup><sup id=\"cite_ref-Task_Force_90-2\" class=\"reference\"><a href=\"#cite_note-Task_Force-90\">&#91;90&#93;</a></sup><sup id=\"cite_ref-AASLD-IDSA_10-5\" class=\"reference\"><a href=\"#cite_note-AASLD-IDSA-10\">&#91;10&#93;</a></sup></li>\\n<li>Incarcerated, or who have been in the past<sup id=\"cite_ref-CDC_-_HCV_prevention_88-2\" class=\"reference\"><a href=\"#cite_note-CDC_-_HCV_prevention-88\">&#91;88&#93;</a></sup><sup id=\"cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-2\" class=\"reference\"><a href=\"#cite_note-Final_Recommendation_Statement:_Hepatitis_C:_Screening-89\">&#91;89&#93;</a></sup><sup id=\"cite_ref-Task_Force_90-3\" class=\"reference\"><a href=\"#cite_note-Task_Force-90\">&#91;90&#93;</a></sup><sup id=\"cite_ref-AASLD-IDSA_10-6\" class=\"reference\"><a href=\"#cite_note-AASLD-IDSA-10\">&#91;10&#93;</a></sup></li>\\n<li>Intranasal illicit drug users<sup id=\"cite_ref-CDC_-_HCV_prevention_88-3\" class=\"reference\"><a href=\"#cite_note-CDC_-_HCV_prevention-88\">&#91;88&#93;</a></sup><sup id=\"cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-3\" class=\"reference\"><a href=\"#cite_note-Final_Recommendation_Statement:_Hepatitis_C:_Screening-89\">&#91;89&#93;</a></sup><sup id=\"cite_ref-Task_Force_90-4\" class=\"reference\"><a href=\"#cite_note-Task_Force-90\">&#91;90&#93;</a></sup><sup id=\"cite_ref-AASLD-IDSA_10-7\" class=\"reference\"><a href=\"#cite_note-AASLD-IDSA-10\">&#91;10&#93;</a></sup></li>\\n<li>Intravenous drug users (past or current)<sup id=\"cite_ref-CDC_-_HCV_prevention_88-4\" class=\"reference\"><a href=\"#cite_note-CDC_-_HCV_prevention-88\">&#91;88&#93;</a></sup><sup id=\"cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-4\" class=\"reference\"><a href=\"#cite_note-Final_Recommendation_Statement:_Hepatitis_C:_Screening-89\">&#91;89&#93;</a></sup><sup id=\"cite_ref-Task_Force_90-5\" class=\"reference\"><a href=\"#cite_note-Task_Force-90\">&#91;90&#93;</a></sup><sup id=\"cite_ref-AASLD-IDSA_10-8\" class=\"reference\"><a href=\"#cite_note-AASLD-IDSA-10\">&#91;10&#93;</a></sup></li>\\n<li>Men who have sex with men<sup id=\"cite_ref-AASLD-IDSA_10-9\" class=\"reference\"><a href=\"#cite_note-AASLD-IDSA-10\">&#91;10&#93;</a></sup></li>\\n<li>On long-term hemodialysis, or who have been in the past<sup id=\"cite_ref-CDC_-_HCV_prevention_88-5\" class=\"reference\"><a href=\"#cite_note-CDC_-_HCV_prevention-88\">&#91;88&#93;</a></sup><sup id=\"cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-5\" class=\"reference\"><a href=\"#cite_note-Final_Recommendation_Statement:_Hepatitis_C:_Screening-89\">&#91;89&#93;</a></sup><sup id=\"cite_ref-Task_Force_90-6\" class=\"reference\"><a href=\"#cite_note-Task_Force-90\">&#91;90&#93;</a></sup><sup id=\"cite_ref-AASLD-IDSA_10-10\" class=\"reference\"><a href=\"#cite_note-AASLD-IDSA-10\">&#91;10&#93;</a></sup></li>\\n<li>Pregnant, and engaging in high-risk behaviors<sup id=\"cite_ref-ACOG_Practice_Bulletin_86-4\" class=\"reference\"><a href=\"#cite_note-ACOG_Practice_Bulletin-86\">&#91;86&#93;</a></sup></li>\\n<li>Recipients of blood products or organs prior to 1992 in the United States<sup id=\"cite_ref-CDC_-_HCV_prevention_88-6\" class=\"reference\"><a href=\"#cite_note-CDC_-_HCV_prevention-88\">&#91;88&#93;</a></sup><sup id=\"cite_ref-Task_Force_90-7\" class=\"reference\"><a href=\"#cite_note-Task_Force-90\">&#91;90&#93;</a></sup><sup id=\"cite_ref-AASLD-IDSA_10-11\" class=\"reference\"><a href=\"#cite_note-AASLD-IDSA-10\">&#91;10&#93;</a></sup></li>\\n<li>Recipients of tattoos in an \"unregulated setting\"<sup id=\"cite_ref-Task_Force_90-8\" class=\"reference\"><a href=\"#cite_note-Task_Force-90\">&#91;90&#93;</a></sup><sup id=\"cite_ref-AASLD-IDSA_10-12\" class=\"reference\"><a href=\"#cite_note-AASLD-IDSA-10\">&#91;10&#93;</a></sup></li>\\n<li>Sex workers<sup id=\"cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-6\" class=\"reference\"><a href=\"#cite_note-Final_Recommendation_Statement:_Hepatitis_C:_Screening-89\">&#91;89&#93;</a></sup></li>\\n<li>Workers in a healthcare setting who have had a needlestick injury<sup id=\"cite_ref-AASLD-IDSA_10-13\" class=\"reference\"><a href=\"#cite_note-AASLD-IDSA-10\">&#91;10&#93;</a></sup></li></ul>\\n<p>For people in the groups above whose exposure is ongoing, screening should be periodic, though there is no set optimal screening interval.<sup id=\"cite_ref-Task_Force_90-9\" class=\"reference\"><a href=\"#cite_note-Task_Force-90\">&#91;90&#93;</a></sup> The AASLD recommends screening men who have sex with men who are HIV-positive annually.<sup id=\"cite_ref-AASLD-IDSA_10-14\" class=\"reference\"><a href=\"#cite_note-AASLD-IDSA-10\">&#91;10&#93;</a></sup> People born in the US between 1945 and 1965 should be screened once (unless they have other exposure risks).<sup id=\"cite_ref-CDC_-_HCV_prevention_88-7\" class=\"reference\"><a href=\"#cite_note-CDC_-_HCV_prevention-88\">&#91;88&#93;</a></sup><sup id=\"cite_ref-Task_Force_90-10\" class=\"reference\"><a href=\"#cite_note-Task_Force-90\">&#91;90&#93;</a></sup><sup id=\"cite_ref-AASLD-IDSA_10-15\" class=\"reference\"><a href=\"#cite_note-AASLD-IDSA-10\">&#91;10&#93;</a></sup>\\n</p><p>Screening consists of a blood test that detects anti-hepatitis C virus antibody. If anti-hepatitis C virus antibody is present, a confirmatory test to detect HCV RNA indicates chronic disease.<sup id=\"cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-7\" class=\"reference\"><a href=\"#cite_note-Final_Recommendation_Statement:_Hepatitis_C:_Screening-89\">&#91;89&#93;</a></sup><sup id=\"cite_ref-AASLD-IDSA_10-16\" class=\"reference\"><a href=\"#cite_note-AASLD-IDSA-10\">&#91;10&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Hepatitis_D\">Hepatitis D</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=28\" title=\"Edit section: Hepatitis D\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<p>The <a href=\"/wiki/Centers_for_Disease_Control_and_Prevention\" title=\"Centers for Disease Control and Prevention\">CDC</a>, <a href=\"/wiki/World_Health_Organization\" title=\"World Health Organization\">WHO</a>, <a href=\"/wiki/United_States_Preventive_Services_Task_Force\" title=\"United States Preventive Services Task Force\">USPSTF</a>, <a href=\"/wiki/AASLD\" class=\"mw-redirect\" title=\"AASLD\">AASLD</a>, and <a href=\"/wiki/American_Congress_of_Obstetricians_and_Gynecologists\" class=\"mw-redirect\" title=\"American Congress of Obstetricians and Gynecologists\">ACOG</a> recommend screening people at high risk for hepatitis D infection.<sup id=\"cite_ref-ACOG_Practice_Bulletin_86-5\" class=\"reference\"><a href=\"#cite_note-ACOG_Practice_Bulletin-86\">&#91;86&#93;</a></sup><sup id=\"cite_ref-CDC_-_HCV_prevention_88-8\" class=\"reference\"><a href=\"#cite_note-CDC_-_HCV_prevention-88\">&#91;88&#93;</a></sup><sup id=\"cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-8\" class=\"reference\"><a href=\"#cite_note-Final_Recommendation_Statement:_Hepatitis_C:_Screening-89\">&#91;89&#93;</a></sup><sup id=\"cite_ref-Task_Force_90-11\" class=\"reference\"><a href=\"#cite_note-Task_Force-90\">&#91;90&#93;</a></sup><sup id=\"cite_ref-AASLD-IDSA_10-17\" class=\"reference\"><a href=\"#cite_note-AASLD-IDSA-10\">&#91;10&#93;</a></sup> These populations include people who are:\\n</p>\\n<ul><li>Blood or organ donors.<sup id=\"cite_ref-AASLD-IDSA_10-18\" class=\"reference\"><a href=\"#cite_note-AASLD-IDSA-10\">&#91;10&#93;</a></sup></li>\\n<li>Incarcerated, or who have been in the past<sup id=\"cite_ref-CDC_-_HCV_prevention_88-9\" class=\"reference\"><a href=\"#cite_note-CDC_-_HCV_prevention-88\">&#91;88&#93;</a></sup><sup id=\"cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-9\" class=\"reference\"><a href=\"#cite_note-Final_Recommendation_Statement:_Hepatitis_C:_Screening-89\">&#91;89&#93;</a></sup><sup id=\"cite_ref-Task_Force_90-12\" class=\"reference\"><a href=\"#cite_note-Task_Force-90\">&#91;90&#93;</a></sup><sup id=\"cite_ref-AASLD-IDSA_10-19\" class=\"reference\"><a href=\"#cite_note-AASLD-IDSA-10\">&#91;10&#93;</a></sup></li>\\n<li>Intranasal illicit drug users<sup id=\"cite_ref-CDC_-_HCV_prevention_88-10\" class=\"reference\"><a href=\"#cite_note-CDC_-_HCV_prevention-88\">&#91;88&#93;</a></sup><sup id=\"cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-10\" class=\"reference\"><a href=\"#cite_note-Final_Recommendation_Statement:_Hepatitis_C:_Screening-89\">&#91;89&#93;</a></sup><sup id=\"cite_ref-Task_Force_90-13\" class=\"reference\"><a href=\"#cite_note-Task_Force-90\">&#91;90&#93;</a></sup><sup id=\"cite_ref-AASLD-IDSA_10-20\" class=\"reference\"><a href=\"#cite_note-AASLD-IDSA-10\">&#91;10&#93;</a></sup></li>\\n<li>Intravenous drug users (past or current)<sup id=\"cite_ref-CDC_-_HCV_prevention_88-11\" class=\"reference\"><a href=\"#cite_note-CDC_-_HCV_prevention-88\">&#91;88&#93;</a></sup><sup id=\"cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-11\" class=\"reference\"><a href=\"#cite_note-Final_Recommendation_Statement:_Hepatitis_C:_Screening-89\">&#91;89&#93;</a></sup><sup id=\"cite_ref-Task_Force_90-14\" class=\"reference\"><a href=\"#cite_note-Task_Force-90\">&#91;90&#93;</a></sup><sup id=\"cite_ref-AASLD-IDSA_10-21\" class=\"reference\"><a href=\"#cite_note-AASLD-IDSA-10\">&#91;10&#93;</a></sup></li>\\n<li>Sex workers<sup id=\"cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-12\" class=\"reference\"><a href=\"#cite_note-Final_Recommendation_Statement:_Hepatitis_C:_Screening-89\">&#91;89&#93;</a></sup></li>\\n<li>Workers in a healthcare setting who have had a needlestick injury<sup id=\"cite_ref-AASLD-IDSA_10-22\" class=\"reference\"><a href=\"#cite_note-AASLD-IDSA-10\">&#91;10&#93;</a></sup></li></ul>\\n<blockquote><p>Hepatitis D is extremely rare. Symptoms include chronic diarrhea, anal and intestinal blisters, purple urine, and burnt popcorn scented breath.<sup id=\"cite_ref-CDC_recommendations_for_Hepatitis_B_83-13\" class=\"reference\"><a href=\"#cite_note-CDC_recommendations_for_Hepatitis_B-83\">&#91;83&#93;</a></sup><sup id=\"cite_ref-Screening_for_Hepatitis_B_84-9\" class=\"reference\"><a href=\"#cite_note-Screening_for_Hepatitis_B-84\">&#91;84&#93;</a></sup><sup id=\"cite_ref-WHO_guidelines_for_chronic_Hepatitis_B_85-8\" class=\"reference\"><a href=\"#cite_note-WHO_guidelines_for_chronic_Hepatitis_B-85\">&#91;85&#93;</a></sup>\\nScreening consists of a blood test that detects the anti-hepitits D virus antibbody. If anti-hepitits D virus antibody is present, a confirmatory test to detect HDV RNA DNA inidicates chronic disease.<sup id=\"cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-13\" class=\"reference\"><a href=\"#cite_note-Final_Recommendation_Statement:_Hepatitis_C:_Screening-89\">&#91;89&#93;</a></sup><sup id=\"cite_ref-AASLD-IDSA_10-23\" class=\"reference\"><a href=\"#cite_note-AASLD-IDSA-10\">&#91;10&#93;</a></sup></p></blockquote>\\n<h2><span class=\"mw-headline\" id=\"Prevention\">Prevention</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=29\" title=\"Edit section: Prevention\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\\n<h3><span class=\"mw-headline\" id=\"Vaccines\">Vaccines</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=30\" title=\"Edit section: Vaccines\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<h4><span class=\"mw-headline\" id=\"Hepatitis_A_2\">Hepatitis A</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=31\" title=\"Edit section: Hepatitis A\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\\n<link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1033289096\"><div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Hepatitis_A_vaccine\" title=\"Hepatitis A vaccine\">Hepatitis A vaccine</a></div>\\n<figure class=\"mw-default-size\" typeof=\"mw:File/Thumb\"><a href=\"/wiki/File:Havrix-rokote.jpg\" class=\"mw-file-description\"><img src=\"//upload.wikimedia.org/wikipedia/commons/thumb/d/d7/Havrix-rokote.jpg/220px-Havrix-rokote.jpg\" decoding=\"async\" width=\"220\" height=\"91\" class=\"mw-file-element\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/d/d7/Havrix-rokote.jpg/330px-Havrix-rokote.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/d/d7/Havrix-rokote.jpg/440px-Havrix-rokote.jpg 2x\" data-file-width=\"3684\" data-file-height=\"1528\" /></a><figcaption>Havrix vaccine</figcaption></figure>\\n<p>The CDC recommends the <a href=\"/wiki/Hepatitis_A_vaccine\" title=\"Hepatitis A vaccine\">hepatitis A vaccine</a> for all children beginning at age one, as well as for those who have not been previously immunized and are at high risk for contracting the disease.<sup id=\"cite_ref-WHO_Hep_A_Fact_Sheet_July_2015_79-1\" class=\"reference\"><a href=\"#cite_note-WHO_Hep_A_Fact_Sheet_July_2015-79\">&#91;79&#93;</a></sup><sup id=\"cite_ref-Voise_2011_80-1\" class=\"reference\"><a href=\"#cite_note-Voise_2011-80\">&#91;80&#93;</a></sup>\\n</p><p>For children 12 months of age or older, the vaccination is given as a shot into the muscle in two doses 6–18 months apart and should be started before the age 24 months.<sup id=\"cite_ref-CDC_Birth-18Y_Immunizations_91-0\" class=\"reference\"><a href=\"#cite_note-CDC_Birth-18Y_Immunizations-91\">&#91;91&#93;</a></sup> &#160;The dosing is slightly different for adults depending on the type of the vaccine. &#160;If the vaccine is for hepatitis A only, two doses are given 6–18 months apart depending on the manufacturer.<sup id=\"cite_ref-CDC_Adult_Vaccine_81-1\" class=\"reference\"><a href=\"#cite_note-CDC_Adult_Vaccine-81\">&#91;81&#93;</a></sup> &#160;If the vaccine is <a href=\"/wiki/Hepatitis_A_vaccine\" title=\"Hepatitis A vaccine\">combined hepatitis A and hepatitis B</a>, up to 4 doses may be required.<sup id=\"cite_ref-CDC_Adult_Vaccine_81-2\" class=\"reference\"><a href=\"#cite_note-CDC_Adult_Vaccine-81\">&#91;81&#93;</a></sup>\\n</p>\\n<h4><span class=\"mw-headline\" id=\"Hepatitis_B_2\">Hepatitis B</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=32\" title=\"Edit section: Hepatitis B\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\\n<link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1033289096\"><div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Hepatitis_B_vaccine\" title=\"Hepatitis B vaccine\">Hepatitis B vaccine</a></div>\\n<figure class=\"mw-default-size\" typeof=\"mw:File/Thumb\"><a href=\"/wiki/File:WHO-UNICEF_estimates_of_hepatitis_B_vaccine_(HepB-BD)_coverage_in_countries_from_the_European_WHO_region_in_the_years_2000-2015.png\" class=\"mw-file-description\"><img src=\"//upload.wikimedia.org/wikipedia/commons/thumb/a/ac/WHO-UNICEF_estimates_of_hepatitis_B_vaccine_%28HepB-BD%29_coverage_in_countries_from_the_European_WHO_region_in_the_years_2000-2015.png/220px-WHO-UNICEF_estimates_of_hepatitis_B_vaccine_%28HepB-BD%29_coverage_in_countries_from_the_European_WHO_region_in_the_years_2000-2015.png\" decoding=\"async\" width=\"220\" height=\"214\" class=\"mw-file-element\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/a/ac/WHO-UNICEF_estimates_of_hepatitis_B_vaccine_%28HepB-BD%29_coverage_in_countries_from_the_European_WHO_region_in_the_years_2000-2015.png/330px-WHO-UNICEF_estimates_of_hepatitis_B_vaccine_%28HepB-BD%29_coverage_in_countries_from_the_European_WHO_region_in_the_years_2000-2015.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/a/ac/WHO-UNICEF_estimates_of_hepatitis_B_vaccine_%28HepB-BD%29_coverage_in_countries_from_the_European_WHO_region_in_the_years_2000-2015.png/440px-WHO-UNICEF_estimates_of_hepatitis_B_vaccine_%28HepB-BD%29_coverage_in_countries_from_the_European_WHO_region_in_the_years_2000-2015.png 2x\" data-file-width=\"724\" data-file-height=\"704\" /></a><figcaption>WHO-UNICEF estimates of hepatitis B vaccine (HepB-BD) coverage in countries from the European WHO region in the years 2000–2015</figcaption></figure>\\n<p>The CDC recommends the routine vaccination of all children under the age of 19 with the <a href=\"/wiki/Hepatitis_B_vaccine\" title=\"Hepatitis B vaccine\">hepatitis B vaccine</a>.<sup id=\"cite_ref-CDC_Update_1999_92-0\" class=\"reference\"><a href=\"#cite_note-CDC_Update_1999-92\">&#91;92&#93;</a></sup> They also recommend it for those who desire it or are at high risk.<sup id=\"cite_ref-Voise_2011_80-2\" class=\"reference\"><a href=\"#cite_note-Voise_2011-80\">&#91;80&#93;</a></sup>\\n</p><p>Routine vaccination for hepatitis B starts with the first dose administered as &#160;a shot into the muscle before the newborn is discharged from the hospital.  An additional two doses should be administered before the child is 18 months.<sup id=\"cite_ref-CDC_Birth-18Y_Immunizations_91-1\" class=\"reference\"><a href=\"#cite_note-CDC_Birth-18Y_Immunizations-91\">&#91;91&#93;</a></sup>\\n</p><p>For babies born to a mother with hepatitis B surface antigen positivity, the first dose is unique – in addition to the vaccine, the hepatitis immune globulin should also be administered, both within 12 hours of birth. &#160;These newborns should also be regularly tested for infection for at least the first year of life.<sup id=\"cite_ref-CDC_Birth-18Y_Immunizations_91-2\" class=\"reference\"><a href=\"#cite_note-CDC_Birth-18Y_Immunizations-91\">&#91;91&#93;</a></sup>\\n</p><p>There is also a combination formulation that includes <a href=\"/wiki/Hepatitis_A_vaccine\" title=\"Hepatitis A vaccine\">both hepatitis A and B vaccines</a>.<sup id=\"cite_ref-93\" class=\"reference\"><a href=\"#cite_note-93\">&#91;93&#93;</a></sup>\\n</p>\\n<h4><span class=\"mw-headline\" id=\"Other_2\">Other</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=33\" title=\"Edit section: Other\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\\n<p>There are currently no vaccines available in the United States for hepatitis C or E.<sup id=\"cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-14\" class=\"reference\"><a href=\"#cite_note-Final_Recommendation_Statement:_Hepatitis_C:_Screening-89\">&#91;89&#93;</a></sup><sup id=\"cite_ref-WHO_-_Hepatitis_E_94-0\" class=\"reference\"><a href=\"#cite_note-WHO_-_Hepatitis_E-94\">&#91;94&#93;</a></sup><sup id=\"cite_ref-WHO_Hepatitis_D_95-0\" class=\"reference\"><a href=\"#cite_note-WHO_Hepatitis_D-95\">&#91;95&#93;</a></sup> In 2015, a group in China published an article regarding the development of a <a href=\"/wiki/Vaccine_for_hepatitis_E\" class=\"mw-redirect\" title=\"Vaccine for hepatitis E\">vaccine for hepatitis E</a>.<sup id=\"cite_ref-96\" class=\"reference\"><a href=\"#cite_note-96\">&#91;96&#93;</a></sup> As of March 2016, the United States government was in the process of recruiting participants for the <a href=\"/wiki/Phases_of_clinical_research\" title=\"Phases of clinical research\">phase IV trial</a> of the hepatitis E vaccine.<sup id=\"cite_ref-97\" class=\"reference\"><a href=\"#cite_note-97\">&#91;97&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Behavioral_changes\">Behavioral changes</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=34\" title=\"Edit section: Behavioral changes\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<h4><span class=\"mw-headline\" id=\"Hepatitis_A_3\">Hepatitis A</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=35\" title=\"Edit section: Hepatitis A\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\\n<p>Because hepatitis A is transmitted primarily through the <a href=\"/wiki/Fecal-oral_route\" class=\"mw-redirect\" title=\"Fecal-oral route\">oral-fecal route</a>, the mainstay of prevention aside from vaccination is good hygiene, access to clean water and proper handling of sewage.<sup id=\"cite_ref-Voise_2011_80-3\" class=\"reference\"><a href=\"#cite_note-Voise_2011-80\">&#91;80&#93;</a></sup>\\n</p>\\n<h4><span class=\"mw-headline\" id=\"Hepatitis_B_and_C\">Hepatitis B and C</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=36\" title=\"Edit section: Hepatitis B and C\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\\n<p>As hepatitis B and C are transmitted through blood and multiple <a href=\"/wiki/Bodily_fluids\" class=\"mw-redirect\" title=\"Bodily fluids\">bodily fluids</a>, prevention is aimed at screening blood prior to <a href=\"/wiki/Blood_transfusion\" title=\"Blood transfusion\">transfusion</a>, abstaining from the use of injection drugs, safe needle and sharps practices in healthcare settings, and safe sex practices.<sup id=\"cite_ref-WHO_Hepatitis_B_29-2\" class=\"reference\"><a href=\"#cite_note-WHO_Hepatitis_B-29\">&#91;29&#93;</a></sup><sup id=\"cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-15\" class=\"reference\"><a href=\"#cite_note-Final_Recommendation_Statement:_Hepatitis_C:_Screening-89\">&#91;89&#93;</a></sup>\\n</p>\\n<h4><span class=\"mw-headline\" id=\"Hepatitis_D_2\">Hepatitis D</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=37\" title=\"Edit section: Hepatitis D\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\\n<figure typeof=\"mw:File/Thumb\"><a href=\"/wiki/File:Hep_D_Epidemiology_Figure_1.svg\" class=\"mw-file-description\"><img src=\"//upload.wikimedia.org/wikipedia/commons/thumb/5/54/Hep_D_Epidemiology_Figure_1.svg/350px-Hep_D_Epidemiology_Figure_1.svg.png\" decoding=\"async\" width=\"350\" height=\"236\" class=\"mw-file-element\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/5/54/Hep_D_Epidemiology_Figure_1.svg/525px-Hep_D_Epidemiology_Figure_1.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/5/54/Hep_D_Epidemiology_Figure_1.svg/700px-Hep_D_Epidemiology_Figure_1.svg.png 2x\" data-file-width=\"625\" data-file-height=\"421\" /></a><figcaption>Worldwide prevalence of HDV among HBV carriers in 2015. Eight genotypes have been identified worldwide by comparative phylogenetic analysis. Genotype 1 is the most frequent and has variable pathogenicity, Genotypes 2 and 4 are found in East Asia causing relatively mild disease. Genotype 3 is found in South America in association with severe hepatitis. Genotypes 5, 6, 7, 8 have been found only in Africa.<sup id=\"cite_ref-98\" class=\"reference\"><a href=\"#cite_note-98\">&#91;98&#93;</a></sup></figcaption></figure>\\n<p>The hepatitis D virus requires that a person first be infected with hepatitis B virus, so prevention efforts should focus on limiting the spread of hepatitis B. In people who have chronic hepatitis B infection and are at risk for <a href=\"/wiki/Superinfection\" title=\"Superinfection\">superinfection</a> with the hepatitis D virus, the preventive strategies are the same as for hepatitis B.<sup id=\"cite_ref-WHO_Hepatitis_D_95-1\" class=\"reference\"><a href=\"#cite_note-WHO_Hepatitis_D-95\">&#91;95&#93;</a></sup>\\n</p>\\n<h4><span class=\"mw-headline\" id=\"Hepatitis_E\">Hepatitis E</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=38\" title=\"Edit section: Hepatitis E\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\\n<p>Hepatitis E is spread primarily through the oral-fecal route but may also be spread by blood and from mother to fetus.  The mainstay of hepatitis E prevention is similar to that for hepatitis A (namely, good hygiene and clean water practices).<sup id=\"cite_ref-WHO_-_Hepatitis_E_94-1\" class=\"reference\"><a href=\"#cite_note-WHO_-_Hepatitis_E-94\">&#91;94&#93;</a></sup>\\n</p>\\n<h4><span class=\"mw-headline\" id=\"Alcoholic_and_metabolic_hepatitis\">Alcoholic and metabolic hepatitis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=39\" title=\"Edit section: Alcoholic and metabolic hepatitis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\\n<p>As excessive alcohol consumption can lead to hepatitis and cirrhosis, the following are maximal recommendations for alcohol consumption:<sup id=\"cite_ref-99\" class=\"reference\"><a href=\"#cite_note-99\">&#91;99&#93;</a></sup>\\n</p>\\n<ul><li>Men – ≤ 4 drinks on any given day and ≤ 14 drinks per week</li>\\n<li>Women – ≤ 3 drinks on any given day and ≤ 7 drinks per week</li></ul>\\n<p>To prevent MAFLD it is recommended to maintain a normal weight, eat a healthy diet, avoid <a href=\"/wiki/Added_sugar\" title=\"Added sugar\">added sugar</a>, and exercise regularly.<sup id=\"cite_ref-100\" class=\"reference\"><a href=\"#cite_note-100\">&#91;100&#93;</a></sup><sup id=\"cite_ref-101\" class=\"reference\"><a href=\"#cite_note-101\">&#91;101&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Successes\">Successes</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=40\" title=\"Edit section: Successes\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<h4><span class=\"mw-headline\" id=\"Hepatitis_A_4\">Hepatitis A</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=41\" title=\"Edit section: Hepatitis A\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\\n<p>In the United States, universal immunization has led to a two-thirds decrease in hospital admissions and medical expenses due to hepatitis A.<sup id=\"cite_ref-102\" class=\"reference\"><a href=\"#cite_note-102\">&#91;102&#93;</a></sup>\\n</p>\\n<h4><span class=\"mw-headline\" id=\"Hepatitis_B_3\">Hepatitis B</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=42\" title=\"Edit section: Hepatitis B\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\\n<p>In the United States new cases of hepatitis B decreased 75% from 1990 to 2004.<sup id=\"cite_ref-103\" class=\"reference\"><a href=\"#cite_note-103\">&#91;103&#93;</a></sup> &#160;The group that saw the greatest decrease was children and adolescents, likely reflecting the implementation of the 1999 guidelines.<sup id=\"cite_ref-Carroll_chapter_35_104-0\" class=\"reference\"><a href=\"#cite_note-Carroll_chapter_35-104\">&#91;104&#93;</a></sup>\\n</p>\\n<h4><span class=\"mw-headline\" id=\"Hepatitis_C_2\">Hepatitis C</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=43\" title=\"Edit section: Hepatitis C\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\\n<p>Hepatitis C infections each year had been declining since the 1980s, but began to increase again in 2006.<sup id=\"cite_ref-105\" class=\"reference\"><a href=\"#cite_note-105\">&#91;105&#93;</a></sup>  The data are unclear as to whether the decline can be attributed to <a href=\"/wiki/Needle_exchange_programme\" class=\"mw-redirect\" title=\"Needle exchange programme\">needle exchange programmes</a>.<sup id=\"cite_ref-106\" class=\"reference\"><a href=\"#cite_note-106\">&#91;106&#93;</a></sup>\\n</p>\\n<h4><span class=\"mw-headline\" id=\"Alcoholic_hepatitis_2\">Alcoholic hepatitis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=44\" title=\"Edit section: Alcoholic hepatitis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\\n<figure class=\"mw-default-size\" typeof=\"mw:File/Thumb\"><a href=\"/wiki/File:Depiction_of_a_liver_failure_patient.png\" class=\"mw-file-description\"><img src=\"//upload.wikimedia.org/wikipedia/commons/thumb/0/01/Depiction_of_a_liver_failure_patient.png/220px-Depiction_of_a_liver_failure_patient.png\" decoding=\"async\" width=\"220\" height=\"141\" class=\"mw-file-element\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/0/01/Depiction_of_a_liver_failure_patient.png/330px-Depiction_of_a_liver_failure_patient.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/0/01/Depiction_of_a_liver_failure_patient.png/440px-Depiction_of_a_liver_failure_patient.png 2x\" data-file-width=\"2605\" data-file-height=\"1667\" /></a><figcaption>Depiction of a liver failure patient</figcaption></figure>\\n<p>Because people with alcoholic hepatitis may have no symptoms, it can be difficult to diagnose and the number of people with the disease is probably higher than many estimates.<sup id=\"cite_ref-107\" class=\"reference\"><a href=\"#cite_note-107\">&#91;107&#93;</a></sup> Programs such as <a href=\"/wiki/Alcoholics_Anonymous\" title=\"Alcoholics Anonymous\">Alcoholics Anonymous</a> have been successful in decreasing death due to <a href=\"/wiki/Cirrhosis\" title=\"Cirrhosis\">cirrhosis</a>, but it is difficult to evaluate their success in decreasing the incidence of alcoholic hepatitis.<sup id=\"cite_ref-108\" class=\"reference\"><a href=\"#cite_note-108\">&#91;108&#93;</a></sup>\\n</p>\\n<h2><span class=\"mw-headline\" id=\"Treatment\">Treatment</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=45\" title=\"Edit section: Treatment\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\\n<p>The treatment of hepatitis varies according to the type, whether it is acute or chronic, and the severity of the disease.\\n</p>\\n<ul><li>Activity: Many people with hepatitis prefer bed rest, though it is not necessary to avoid all physical activity while recovering.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-29\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup></li>\\n<li>Diet: A high-calorie diet is recommended.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-30\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup> Many people develop nausea and cannot tolerate food later in the day, so the bulk of intake may be concentrated in the earlier part of the day.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-31\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup> In the acute phase of the disease, intravenous feeding may be needed if patients cannot tolerate food and have poor oral intake subsequent to nausea and vomiting.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-32\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup></li>\\n<li>Drugs: People with hepatitis should avoid taking drugs metabolized by the liver.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-33\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup> <a href=\"/wiki/Glucocorticoid\" title=\"Glucocorticoid\">Glucocorticoids</a> are not recommended as a treatment option for acute viral hepatitis and may even cause harm, such as development of chronic hepatitis.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-34\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup></li>\\n<li>Precautions: <a href=\"/wiki/Universal_precautions\" title=\"Universal precautions\">Universal precautions</a> should be observed. Isolation is usually not needed, except in cases of hepatitis A and E who have fecal incontinence, and  in cases of hepatitis B and C who have uncontrolled bleeding.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-35\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup></li></ul>\\n<h3><span class=\"mw-headline\" id=\"Hepatitis_A_5\">Hepatitis A</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=46\" title=\"Edit section: Hepatitis A\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1033289096\"><div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Hepatitis_A\" title=\"Hepatitis A\">Hepatitis A</a></div>\\n<p>Hepatitis A usually does not progress to a chronic state, and rarely requires hospitalization.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-36\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-WHO_Hep_A_Fact_Sheet_July_2015_79-2\" class=\"reference\"><a href=\"#cite_note-WHO_Hep_A_Fact_Sheet_July_2015-79\">&#91;79&#93;</a></sup> Treatment is supportive and includes such measures as providing intravenous (IV) hydration and maintaining adequate nutrition.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-37\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-WHO_Hep_A_Fact_Sheet_July_2015_79-3\" class=\"reference\"><a href=\"#cite_note-WHO_Hep_A_Fact_Sheet_July_2015-79\">&#91;79&#93;</a></sup>\\n</p><p>Rarely, people with the hepatitis A virus can rapidly develop liver failure, termed <i>fulminant hepatic failure</i>, especially the elderly and those who had a pre-existing liver disease, especially hepatitis C.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-38\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-WHO_Hep_A_Fact_Sheet_July_2015_79-4\" class=\"reference\"><a href=\"#cite_note-WHO_Hep_A_Fact_Sheet_July_2015-79\">&#91;79&#93;</a></sup> Mortality risk factors include greater age and chronic hepatitis C.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-39\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup> In these cases, more aggressive supportive therapy and liver transplant may be necessary.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-40\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Hepatitis_B_4\">Hepatitis B</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=47\" title=\"Edit section: Hepatitis B\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1033289096\"><div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Hepatitis_B\" title=\"Hepatitis B\">Hepatitis B</a></div>\\n<h4><span class=\"mw-headline\" id=\"Acute\">Acute</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=48\" title=\"Edit section: Acute\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\\n<p>In healthy patients, 95–99% recover with no long-lasting effects, and antiviral treatment is not warranted.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-41\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup> Age and comorbid conditions can result in a more prolonged and severe illness. Certain patients warrant hospitalization, especially those who present with clinical signs of ascites, peripheral edema, and hepatic encephalopathy, and laboratory signs of <a href=\"/wiki/Hypoglycemia\" title=\"Hypoglycemia\">hypoglycemia</a>, prolonged <a href=\"/wiki/Prothrombin_time\" title=\"Prothrombin time\">prothrombin time</a>, low serum <a href=\"/wiki/Albumin_human\" class=\"mw-redirect\" title=\"Albumin human\">albumin</a>, and very high serum <a href=\"/wiki/Bilirubin\" title=\"Bilirubin\">bilirubin</a>.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-42\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup>\\n</p><p>In these rare, more severe acute cases, patients have been successfully treated with antiviral therapy similar to that used in cases of chronic hepatitis B, with nucleoside analogues such as <a href=\"/wiki/Entecavir\" title=\"Entecavir\">entecavir</a> or <a href=\"/wiki/Tenofovir_disoproxil\" title=\"Tenofovir disoproxil\">tenofovir</a>. As there is a dearth of clinical trial data and the drugs used to treat are prone to developing <a href=\"/wiki/Drug_resistance\" title=\"Drug resistance\">resistance</a>, experts recommend reserving treatment for severe acute cases, not mild to moderate.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-43\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup>\\n</p>\\n<h4><span class=\"mw-headline\" id=\"Chronic\">Chronic</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=49\" title=\"Edit section: Chronic\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\\n<p>Chronic hepatitis B management aims to control viral replication, which is correlated with progression of disease.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-6\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup> Seven drugs are approved in the United States:<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-7\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup>\\n</p>\\n<ul><li><a href=\"/wiki/Adefovir_dipivoxil\" class=\"mw-redirect\" title=\"Adefovir dipivoxil\">Adefovir dipivoxil</a>, a nucleotide analogue, has been used to supplement lamivudine in patients who develop resistance, but is no longer recommended as first-line therapy.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-8\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup></li>\\n<li><a href=\"/wiki/Entecavir\" title=\"Entecavir\">Entecavir</a> is safe, well tolerated, less prone to developing resistance, and the most potent of the existing hepatitis B antivirals; it is thus a first-line treatment choice.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-9\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup> It is not recommended for lamivudine-resistant patients or as monotherapy in patients who are HIV positive.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-10\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup></li>\\n<li>Injectable <a href=\"/wiki/Interferon_alpha\" class=\"mw-redirect\" title=\"Interferon alpha\">interferon alpha</a> was the first therapy approved for chronic hepatitis B.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-11\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup> It has several side effects, most of which are reversible with removal of therapy, but it has been supplanted by newer treatments for this indication.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-12\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup> These include long-acting interferon bound to <a href=\"/wiki/Polyethylene_glycol\" title=\"Polyethylene glycol\">polyethylene glycol</a> (pegylated interferon) and the oral nucleoside analogues.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-13\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup></li>\\n<li><a href=\"/wiki/Lamivudine\" title=\"Lamivudine\">Lamivudine</a> was the first approved oral nucleoside analogue.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-14\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup> While effective and potent, lamivudine has been replaced by newer, more potent treatments in the Western world and is no longer recommended as first-line treatment.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-15\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup> It is still used in areas where newer agents either have not been approved or are too costly.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-16\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup> Generally, the course of treatment is a minimum of one year with a minimum of six additional months of \"consolidation therapy.\"<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-17\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup> Based on viral response, longer therapy may be required, and certain patients require indefinite long-term therapy.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-18\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup> Due to a less robust response in Asian patients, <a href=\"/wiki/Consolidation_therapy\" class=\"mw-redirect\" title=\"Consolidation therapy\">consolidation therapy</a> is recommended to be extended to at least a year.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-19\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup> All patients should be monitored for viral reactivation, which if identified, requires restarting treatment.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-20\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup> Lamivudine is generally safe and well tolerated.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-21\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup> Many patients develop resistance, which is correlated with longer treatment duration.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-22\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup> If this occurs, an additional antiviral is added.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-23\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup> Lamivudine as a single treatment is contraindicated in patients coinfected with HIV, as resistance develops rapidly, but it can be used as part of a multidrug regimen.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-24\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup></li>\\n<li><a href=\"/wiki/Pegylated_interferon\" title=\"Pegylated interferon\">Pegylated interferon</a> (PEG IFN) is dosed just once a week as a subcutaneous injection and is both more convenient and effective than standard interferon.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-25\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup> Although it does not develop resistance as do many of the oral antivirals, it is poorly tolerated and requires close monitoring.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-26\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup> PEG IFN is estimated to cost about $18,000 per year in the United States, compared to $2,500–8,700 for the oral medications. Its treatment duration is 48 weeks, unlike oral antivirals which require indefinite treatment for most patients (minimum one year).<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-27\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup> PEG IFN is not effective in patients with high levels of viral activity and cannot be used in immunosuppressed patients or those with cirrhosis.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-28\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup></li>\\n<li><a href=\"/wiki/Telbivudine\" title=\"Telbivudine\">Telbivudine</a> is effective but not recommended as first-line treatment; as compared to entecavir, it is both less potent and more resistance prone.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-29\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup></li>\\n<li><a href=\"/wiki/Tenofovir_disoproxil\" title=\"Tenofovir disoproxil\">Tenofovir</a> is a nucleotide analogue and an antiretroviral drug that is also used to treat HIV infection.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-30\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup> It is preferred to adefovir both in lamivudine-resistant patients and as initial treatment since it is both more potent and less likely to develop resistance.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-31\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup></li></ul>\\n<p>First-line treatments currently used include PEG IFN, entecavir, and tenofovir, subject to patient and physician preference.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-32\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup> Treatment initiation is guided by recommendations issued by The American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) and is based on detectable viral levels, <a href=\"/wiki/HBeAg\" title=\"HBeAg\">HBeAg</a> positive or negative status, <a href=\"/wiki/Alanine_transaminase\" title=\"Alanine transaminase\">ALT</a> levels, and in certain cases, family history of HCC and liver biopsy.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-33\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup> In patients with compensated cirrhosis, treatment is recommended regardless of HBeAg status or ALT level, but recommendations differ regarding HBV DNA levels; AASLD recommends treating at DNA levels detectable above 2x10<sup>3</sup> IU/mL; EASL and WHO recommend treating when HBV DNA levels are detectable at any level.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-34\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup><sup id=\"cite_ref-WHO_guidelines_for_chronic_Hepatitis_B_85-9\" class=\"reference\"><a href=\"#cite_note-WHO_guidelines_for_chronic_Hepatitis_B-85\">&#91;85&#93;</a></sup> In patients with decompensated cirrhosis, treatment and evaluation for liver transplantation are recommended in all cases if HBV DNA is detectable.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-35\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup><sup id=\"cite_ref-WHO_guidelines_for_chronic_Hepatitis_B_85-10\" class=\"reference\"><a href=\"#cite_note-WHO_guidelines_for_chronic_Hepatitis_B-85\">&#91;85&#93;</a></sup> Currently, multidrug treatment is not recommended in treatment of chronic HBV as it is no more effective in the long term than individual treatment with entecavir or tenofovir.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-36\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Hepatitis_C_3\">Hepatitis C</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=50\" title=\"Edit section: Hepatitis C\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1033289096\"><div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Hepatitis_C\" title=\"Hepatitis C\">Hepatitis C</a></div>\\n<p>The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America (AASLD-IDSA) recommend antiviral treatment for all patients with chronic hepatitis C infection except for those with additional chronic medical conditions that limit their life expectancy.<sup id=\"cite_ref-AASLD-IDSA_10-24\" class=\"reference\"><a href=\"#cite_note-AASLD-IDSA-10\">&#91;10&#93;</a></sup>\\n</p><p>Once it is acquired, persistence of the hepatitis C virus is the rule, resulting in chronic hepatitis C. The goal of treatment is prevention of hepatocellular carcinoma (HCC).<sup id=\"cite_ref-Messori_Badiani_Tripoli_109-0\" class=\"reference\"><a href=\"#cite_note-Messori_Badiani_Tripoli-109\">&#91;109&#93;</a></sup> The best way to reduce the long-term risk of HCC is to achieve sustained virological response (SVR).<sup id=\"cite_ref-Messori_Badiani_Tripoli_109-1\" class=\"reference\"><a href=\"#cite_note-Messori_Badiani_Tripoli-109\">&#91;109&#93;</a></sup> SVR is defined as an undetectable viral load at 12 weeks after treatment completion and indicates a cure.<sup id=\"cite_ref-Revolution_110-0\" class=\"reference\"><a href=\"#cite_note-Revolution-110\">&#91;110&#93;</a></sup><sup id=\"cite_ref-Enhancing_our_understanding_111-0\" class=\"reference\"><a href=\"#cite_note-Enhancing_our_understanding-111\">&#91;111&#93;</a></sup> Currently available treatments include indirect and direct acting antiviral drugs.<sup id=\"cite_ref-Revolution_110-1\" class=\"reference\"><a href=\"#cite_note-Revolution-110\">&#91;110&#93;</a></sup><sup id=\"cite_ref-Enhancing_our_understanding_111-1\" class=\"reference\"><a href=\"#cite_note-Enhancing_our_understanding-111\">&#91;111&#93;</a></sup> The indirect acting antivirals include <a href=\"/wiki/Pegylated_interferon\" title=\"Pegylated interferon\">pegylated interferon</a> (PEG IFN) and <a href=\"/wiki/Ribavirin\" title=\"Ribavirin\">ribavirin</a> (RBV), which in combination have historically been the basis of therapy for HCV.<sup id=\"cite_ref-Revolution_110-2\" class=\"reference\"><a href=\"#cite_note-Revolution-110\">&#91;110&#93;</a></sup><sup id=\"cite_ref-Enhancing_our_understanding_111-2\" class=\"reference\"><a href=\"#cite_note-Enhancing_our_understanding-111\">&#91;111&#93;</a></sup> Duration of and response to these treatments varies based on genotype.<sup id=\"cite_ref-Revolution_110-3\" class=\"reference\"><a href=\"#cite_note-Revolution-110\">&#91;110&#93;</a></sup><sup id=\"cite_ref-Enhancing_our_understanding_111-3\" class=\"reference\"><a href=\"#cite_note-Enhancing_our_understanding-111\">&#91;111&#93;</a></sup> These agents are poorly tolerated but are still used in some resource-poor areas.<sup id=\"cite_ref-Revolution_110-4\" class=\"reference\"><a href=\"#cite_note-Revolution-110\">&#91;110&#93;</a></sup><sup id=\"cite_ref-Enhancing_our_understanding_111-4\" class=\"reference\"><a href=\"#cite_note-Enhancing_our_understanding-111\">&#91;111&#93;</a></sup> In high-resource countries, they have been supplanted by direct acting antiviral agents, which first appeared in 2011; these agents target proteins responsible for viral replication and include the following three classes:<sup id=\"cite_ref-Revolution_110-5\" class=\"reference\"><a href=\"#cite_note-Revolution-110\">&#91;110&#93;</a></sup><sup id=\"cite_ref-Enhancing_our_understanding_111-5\" class=\"reference\"><a href=\"#cite_note-Enhancing_our_understanding-111\">&#91;111&#93;</a></sup>\\n</p>\\n<ul><li><a href=\"/wiki/NS3_(HCV)\" class=\"mw-redirect\" title=\"NS3 (HCV)\">NS3</a> and <a href=\"/wiki/NS4A_(Hepacivirus)\" class=\"mw-redirect\" title=\"NS4A (Hepacivirus)\">NS4A</a> <a href=\"/wiki/Protease_inhibitor_(pharmacology)\" title=\"Protease inhibitor (pharmacology)\">protease inhibitors</a>, including <a href=\"/wiki/Telaprevir\" title=\"Telaprevir\">telaprevir</a>, <a href=\"/wiki/Boceprevir\" title=\"Boceprevir\">boceprevir</a>, <a href=\"/wiki/Simeprevir\" title=\"Simeprevir\">simeprevir</a>, and others</li>\\n<li><a href=\"/wiki/NS5A_(hepacivirus)\" class=\"mw-redirect\" title=\"NS5A (hepacivirus)\">NS5A</a> inhibitors, including <a href=\"/wiki/Ledipasvir\" title=\"Ledipasvir\">ledipasvir</a>, <a href=\"/wiki/Daclatasvir\" title=\"Daclatasvir\">daclatasvir</a>, and others</li>\\n<li><a href=\"/wiki/NS5B_inhibitors\" class=\"mw-redirect\" title=\"NS5B inhibitors\">NS5B inhibitors</a>, including <a href=\"/wiki/Sofosbuvir\" title=\"Sofosbuvir\">sofosbuvir</a>, <a href=\"/wiki/Dasabuvir\" title=\"Dasabuvir\">dasabuvir</a>, and others</li></ul>\\n<p>These drugs are used in various combinations, sometimes combined with ribavirin, based on the patient\\'s <a href=\"/wiki/Genotype\" title=\"Genotype\">genotype</a>, delineated as genotypes 1–6.<sup id=\"cite_ref-Enhancing_our_understanding_111-6\" class=\"reference\"><a href=\"#cite_note-Enhancing_our_understanding-111\">&#91;111&#93;</a></sup> Genotype 1 (GT1), which is the most prevalent genotype in the United States and around the world, can now be cured with a direct acting antiviral regimen.<sup id=\"cite_ref-Enhancing_our_understanding_111-7\" class=\"reference\"><a href=\"#cite_note-Enhancing_our_understanding-111\">&#91;111&#93;</a></sup> First-line therapy for GT1 is a combination of sofosbuvir and ledipasvir (SOF/LDV) for 12 weeks for most patients, including those with advanced fibrosis or cirrhosis.<sup id=\"cite_ref-Enhancing_our_understanding_111-8\" class=\"reference\"><a href=\"#cite_note-Enhancing_our_understanding-111\">&#91;111&#93;</a></sup> Certain patients with early disease need only 8 weeks of treatment while those with advanced fibrosis or cirrhosis who have not responded to prior treatment require 24 weeks.<sup id=\"cite_ref-Enhancing_our_understanding_111-9\" class=\"reference\"><a href=\"#cite_note-Enhancing_our_understanding-111\">&#91;111&#93;</a></sup> Cost remains a major factor limiting access to these drugs, particularly in low-resource nations; the cost of the 12-week GT1 regimen (SOF/LDV)  has been estimated at US$94,500.<sup id=\"cite_ref-Revolution_110-6\" class=\"reference\"><a href=\"#cite_note-Revolution-110\">&#91;110&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Hepatitis_D_3\">Hepatitis D</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=51\" title=\"Edit section: Hepatitis D\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1033289096\"><div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Hepatitis_D\" title=\"Hepatitis D\">Hepatitis D</a></div>\\n<p>Hepatitis D is difficult to treat, and effective treatments are lacking. Interferon alpha has proven effective at inhibiting viral activity but only on a temporary basis.<sup id=\"cite_ref-Interferon_alpha_112-0\" class=\"reference\"><a href=\"#cite_note-Interferon_alpha-112\">&#91;112&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Hepatitis_E_2\">Hepatitis E</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=52\" title=\"Edit section: Hepatitis E\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1033289096\"><div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Hepatitis_E\" title=\"Hepatitis E\">Hepatitis E</a></div>\\n<figure class=\"mw-default-size\" typeof=\"mw:File/Thumb\"><a href=\"/wiki/File:Hepatitis_E_virus.jpg\" class=\"mw-file-description\"><img src=\"//upload.wikimedia.org/wikipedia/commons/thumb/3/33/Hepatitis_E_virus.jpg/220px-Hepatitis_E_virus.jpg\" decoding=\"async\" width=\"220\" height=\"146\" class=\"mw-file-element\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/3/33/Hepatitis_E_virus.jpg/330px-Hepatitis_E_virus.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/3/33/Hepatitis_E_virus.jpg/440px-Hepatitis_E_virus.jpg 2x\" data-file-width=\"1418\" data-file-height=\"940\" /></a><figcaption>Hepatitis E virus</figcaption></figure>\\n<p>Similar to hepatitis A, treatment of hepatitis E is supportive and includes rest and ensuring adequate nutrition and hydration.<sup id=\"cite_ref-CDC_-_HEV_FAQ_113-0\" class=\"reference\"><a href=\"#cite_note-CDC_-_HEV_FAQ-113\">&#91;113&#93;</a></sup> Hospitalization may be required for particularly severe cases or for pregnant women.<sup id=\"cite_ref-CDC_-_HEV_FAQ_113-1\" class=\"reference\"><a href=\"#cite_note-CDC_-_HEV_FAQ-113\">&#91;113&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Alcoholic_hepatitis_3\">Alcoholic hepatitis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=53\" title=\"Edit section: Alcoholic hepatitis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<p>First-line treatment of alcoholic hepatitis is treatment of alcoholism.<sup id=\"cite_ref-Harrison&#39;s_Principles_chapter_363_(Alcohol)_34-2\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles_chapter_363_(Alcohol)-34\">&#91;34&#93;</a></sup> For those who abstain completely from alcohol, reversal of liver disease and a longer life are possible; patients at every disease stage have been shown to benefit by prevention of additional liver injury.<sup id=\"cite_ref-Harrison&#39;s_Principles_chapter_363_(Alcohol)_34-3\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles_chapter_363_(Alcohol)-34\">&#91;34&#93;</a></sup><sup id=\"cite_ref-Chayanupatkul_&amp;_Liangpunsakul_65-4\" class=\"reference\"><a href=\"#cite_note-Chayanupatkul_&amp;_Liangpunsakul-65\">&#91;65&#93;</a></sup> In addition to referral to psychotherapy and other treatment programs, treatment should include nutritional and psychosocial evaluation and treatment.<sup id=\"cite_ref-Harrison&#39;s_Principles_chapter_363_(Alcohol)_34-4\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles_chapter_363_(Alcohol)-34\">&#91;34&#93;</a></sup><sup id=\"cite_ref-Chayanupatkul_&amp;_Liangpunsakul_65-5\" class=\"reference\"><a href=\"#cite_note-Chayanupatkul_&amp;_Liangpunsakul-65\">&#91;65&#93;</a></sup><sup id=\"cite_ref-Comparative_effectiveness_-_meta-analysis_114-0\" class=\"reference\"><a href=\"#cite_note-Comparative_effectiveness_-_meta-analysis-114\">&#91;114&#93;</a></sup> Patients should also be treated appropriately for related signs and symptoms, such as ascites, hepatic encephalopathy, and infection.<sup id=\"cite_ref-Chayanupatkul_&amp;_Liangpunsakul_65-6\" class=\"reference\"><a href=\"#cite_note-Chayanupatkul_&amp;_Liangpunsakul-65\">&#91;65&#93;</a></sup>\\n</p><p>Severe alcoholic hepatitis has a poor prognosis and is notoriously difficult to treat.<sup id=\"cite_ref-Harrison&#39;s_Principles_chapter_363_(Alcohol)_34-5\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles_chapter_363_(Alcohol)-34\">&#91;34&#93;</a></sup><sup id=\"cite_ref-Chayanupatkul_&amp;_Liangpunsakul_65-7\" class=\"reference\"><a href=\"#cite_note-Chayanupatkul_&amp;_Liangpunsakul-65\">&#91;65&#93;</a></sup><sup id=\"cite_ref-Comparative_effectiveness_-_meta-analysis_114-1\" class=\"reference\"><a href=\"#cite_note-Comparative_effectiveness_-_meta-analysis-114\">&#91;114&#93;</a></sup> Without any treatment, 20–50% of patients may die within a month, but evidence shows treatment may extend life beyond one month (i.e., reduce short-term mortality).<sup id=\"cite_ref-Harrison&#39;s_Principles_chapter_363_(Alcohol)_34-6\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles_chapter_363_(Alcohol)-34\">&#91;34&#93;</a></sup><sup id=\"cite_ref-Comparative_effectiveness_-_meta-analysis_114-2\" class=\"reference\"><a href=\"#cite_note-Comparative_effectiveness_-_meta-analysis-114\">&#91;114&#93;</a></sup><sup id=\"cite_ref-STOPAH_115-0\" class=\"reference\"><a href=\"#cite_note-STOPAH-115\">&#91;115&#93;</a></sup> Available treatment options include <a href=\"/wiki/Pentoxifylline\" title=\"Pentoxifylline\">pentoxifylline</a> (PTX), which is a nonspecific <a href=\"/wiki/TNF_inhibitor\" title=\"TNF inhibitor\">TNF inhibitor</a>, <a href=\"/wiki/Corticosteroid\" title=\"Corticosteroid\">corticosteroids</a>, such as <a href=\"/wiki/Prednisone\" title=\"Prednisone\">prednisone</a> or <a href=\"/wiki/Prednisolone\" title=\"Prednisolone\">prednisolone</a> (CS), corticosteroids with <i><a href=\"/wiki/N-Acetylcysteine\" class=\"mw-redirect\" title=\"N-Acetylcysteine\">N</a></i><a href=\"/wiki/N-Acetylcysteine\" class=\"mw-redirect\" title=\"N-Acetylcysteine\">-acetylcysteine</a> (CS with NAC), and corticosteroids with pentoxifylline (CS with PTX).<sup id=\"cite_ref-Comparative_effectiveness_-_meta-analysis_114-3\" class=\"reference\"><a href=\"#cite_note-Comparative_effectiveness_-_meta-analysis-114\">&#91;114&#93;</a></sup> Data suggest that CS alone or CS with NAC are most effective at reducing short-term mortality.<sup id=\"cite_ref-Comparative_effectiveness_-_meta-analysis_114-4\" class=\"reference\"><a href=\"#cite_note-Comparative_effectiveness_-_meta-analysis-114\">&#91;114&#93;</a></sup> Unfortunately, corticosteroids are contraindicated in some patients, such as those who have active gastrointestinal bleeding, infection, kidney failure, or pancreatitis.<sup id=\"cite_ref-Harrison&#39;s_Principles_chapter_363_(Alcohol)_34-7\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles_chapter_363_(Alcohol)-34\">&#91;34&#93;</a></sup><sup id=\"cite_ref-Chayanupatkul_&amp;_Liangpunsakul_65-8\" class=\"reference\"><a href=\"#cite_note-Chayanupatkul_&amp;_Liangpunsakul-65\">&#91;65&#93;</a></sup> In these cases PTX may be considered on a case-by-case basis in lieu of CS; some evidence shows PTX is better than no treatment at all and may be comparable to CS while other data show no evidence of benefit over placebo.<sup id=\"cite_ref-Comparative_effectiveness_-_meta-analysis_114-5\" class=\"reference\"><a href=\"#cite_note-Comparative_effectiveness_-_meta-analysis-114\">&#91;114&#93;</a></sup><sup id=\"cite_ref-STOPAH_115-1\" class=\"reference\"><a href=\"#cite_note-STOPAH-115\">&#91;115&#93;</a></sup> Unfortunately, there are currently no drug treatments that decrease these patients\\' risk of dying in the longer term, at 3–12 months and beyond.<sup id=\"cite_ref-Comparative_effectiveness_-_meta-analysis_114-6\" class=\"reference\"><a href=\"#cite_note-Comparative_effectiveness_-_meta-analysis-114\">&#91;114&#93;</a></sup>\\n</p><p>Weak evidence suggests <a href=\"/wiki/Milk_Thistle\" class=\"mw-redirect\" title=\"Milk Thistle\">milk thistle</a> extracts may improve survival in alcoholic liver disease and improve certain liver tests (serum bilirubin and <a href=\"/wiki/Gamma-glutamyl_transpeptidase\" class=\"mw-redirect\" title=\"Gamma-glutamyl transpeptidase\">GGT</a>) without causing side effects, but a firm recommendation cannot be made for or against milk thistle without further study.<sup id=\"cite_ref-116\" class=\"reference\"><a href=\"#cite_note-116\">&#91;116&#93;</a></sup>&#160;\\n</p><p>The <a href=\"/wiki/Modified_Maddrey%27s_discriminant_function\" title=\"Modified Maddrey&#39;s discriminant function\">modified Maddrey\\'s discriminant function</a> may be used to evaluate the severity and prognosis in alcoholic hepatitis and evaluates the efficacy of using alcoholic hepatitis corticosteroid treatment.\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Metabolic_hepatitis\">Metabolic hepatitis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=54\" title=\"Edit section: Metabolic hepatitis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1033289096\"><div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Non-alcoholic_fatty_liver_disease#Management\" title=\"Non-alcoholic fatty liver disease\">Non-alcoholic_fatty_liver_disease §&#160;Management</a></div>\\n<p>The main treatment of NASH  is gradual weight loss and increased physical activity. In the United States, no medications have been approved to treat this disease.<sup id=\"cite_ref-117\" class=\"reference\"><a href=\"#cite_note-117\">&#91;117&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Autoimmune_hepatitis\">Autoimmune hepatitis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=55\" title=\"Edit section: Autoimmune hepatitis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<p>Autoimmune hepatitis is commonly treated by immunosuppressants such as the corticosteroids prednisone or prednisolone, the active version of prednisolone that does not require liver synthesis, either alone or in combination with azathioprine, and some have suggested the combination therapy is preferred to allow for lower doses of corticosteroids to reduce associated side effects,<sup id=\"cite_ref-:0_48-1\" class=\"reference\"><a href=\"#cite_note-:0-48\">&#91;48&#93;</a></sup> although the result of treatment efficacy is comparative.<sup id=\"cite_ref-118\" class=\"reference\"><a href=\"#cite_note-118\">&#91;118&#93;</a></sup>\\n</p><p>Treatment of autoimmune hepatitis consists of two phases; an initial and maintenance phase. The initial phase consists of higher doses of corticosteroids which are tapered down over a number of weeks to a lower dose. If used in combination, azathioprine is given during the initial phase as well. Once the initial phase has been completed, a maintenance phase that consists of lower dose corticosteroids, and in combination therapy, azathioprine until liver blood markers are normalized. Treatment results in 66–91% of patients achieving normal liver test values in two years, with the average being 22 months.<sup id=\"cite_ref-:0_48-2\" class=\"reference\"><a href=\"#cite_note-:0-48\">&#91;48&#93;</a></sup>\\n</p>\\n<h2><span class=\"mw-headline\" id=\"Prognosis\">Prognosis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=56\" title=\"Edit section: Prognosis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\\n<h3><span class=\"mw-headline\" id=\"Acute_hepatitis_2\">Acute hepatitis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=57\" title=\"Edit section: Acute hepatitis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<p>Nearly all patients with hepatitis A infections recover completely without complications if they were healthy prior to the infection. Similarly, acute hepatitis B infections have a favorable course towards complete recovery in 95–99% of patients.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-44\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup> Certain factors may portend a poorer outcome, such as co-morbid medical conditions or initial presenting symptoms of ascites, edema, or encephalopathy.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-45\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup> Overall, the mortality rate for acute hepatitis is low: ~0.1% in total for cases of hepatitis A and B, but rates can be higher in certain populations (super infection with both hepatitis B and D, pregnant women, etc.).<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-46\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup>\\n</p><p>In contrast to hepatitis A &amp; B, hepatitis C carries a much higher risk of progressing to chronic hepatitis, approaching 85–90%.<sup id=\"cite_ref-119\" class=\"reference\"><a href=\"#cite_note-119\">&#91;119&#93;</a></sup>  Cirrhosis has been reported to develop in 20–50% of patients with chronic hepatitis C.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (March 2022)\">citation needed</span></a></i>&#93;</sup>\\n</p><p>Other rare complications of acute hepatitis include <a href=\"/wiki/Pancreatitis\" title=\"Pancreatitis\">pancreatitis</a>, <a href=\"/wiki/Aplastic_anemia\" title=\"Aplastic anemia\">aplastic anemia</a>, <a href=\"/wiki/Peripheral_neuropathy\" title=\"Peripheral neuropathy\">peripheral neuropathy</a>, and <a href=\"/wiki/Myocarditis\" title=\"Myocarditis\">myocarditis</a>.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-47\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup>\\n</p>\\n<h4><span class=\"mw-headline\" id=\"Fulminant_hepatitis_2\">Fulminant hepatitis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=58\" title=\"Edit section: Fulminant hepatitis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\\n<p>Despite the relatively benign course of most viral cases of hepatitis, fulminant hepatitis represents a rare but feared complication. Fulminant hepatitis most commonly occurs in hepatitis B, D, and E. About 1–2% of cases of hepatitis E can lead to fulminant hepatitis, but pregnant women are particularly susceptible, occurring in up to 20% of cases.<sup id=\"cite_ref-120\" class=\"reference\"><a href=\"#cite_note-120\">&#91;120&#93;</a></sup> Mortality rates in cases of fulminant hepatitis rise over 80%, but those patients that do survive often make a complete recovery. Liver transplantation can be life-saving in patients with fulminant liver failure.<sup id=\"cite_ref-121\" class=\"reference\"><a href=\"#cite_note-121\">&#91;121&#93;</a></sup>\\n</p><p>Hepatitis D infections can transform benign cases of hepatitis B into severe, progressive hepatitis, a phenomenon known as <a href=\"/wiki/Superinfection\" title=\"Superinfection\">superinfection</a>.<sup id=\"cite_ref-122\" class=\"reference\"><a href=\"#cite_note-122\">&#91;122&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Chronic_hepatitis_2\">Chronic hepatitis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=59\" title=\"Edit section: Chronic hepatitis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<p>Acute hepatitis B infections become less likely to progress to chronic forms as the age of the patient increases, with rates of progression approaching 90% in vertically transmitted cases of infants compared to 1% risk in young adults.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-37\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup> Overall, the five-year survival rate for chronic hepatitis B ranges from 97% in mild cases to 55% in severe cases with cirrhosis.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-38\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\">&#91;20&#93;</a></sup>\\n</p><p>Most patients who acquire hepatitis D at the same time as hepatitis B (co-infection) recover without developing a chronic infection. In people with hepatitis B who later acquire hepatitis D (superinfection), chronic infection is much more common at 80–90%, and liver disease progression is accelerated.<sup id=\"cite_ref-Interferon_alpha_112-1\" class=\"reference\"><a href=\"#cite_note-Interferon_alpha-112\">&#91;112&#93;</a></sup><sup id=\"cite_ref-123\" class=\"reference\"><a href=\"#cite_note-123\">&#91;123&#93;</a></sup>\\n</p><p>Chronic hepatitis C progresses towards cirrhosis, with estimates of cirrhosis prevalence of 16% at 20 years after infection.<sup id=\"cite_ref-124\" class=\"reference\"><a href=\"#cite_note-124\">&#91;124&#93;</a></sup> While the major causes of mortality in hepatitis C is end stage liver disease, hepatocellular carcinoma is an important additional long term complication and cause of death in chronic hepatitis.\\n</p><p>Rates of mortality increase with progression of the underlying liver disease. Series of patients with compensated cirrhosis due to HCV have shown 3,5, and 10-year survival rates of 96, 91, and 79% respectively.<sup id=\"cite_ref-125\" class=\"reference\"><a href=\"#cite_note-125\">&#91;125&#93;</a></sup>  The 5-year survival rate drops to 50% upon if the cirrhosis becomes decompensated.\\n</p>\\n<h2><span class=\"mw-headline\" id=\"Epidemiology\">Epidemiology</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=60\" title=\"Edit section: Epidemiology\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\\n<h3><span class=\"mw-headline\" id=\"Viral_hepatitis_4\">Viral hepatitis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=61\" title=\"Edit section: Viral hepatitis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<h4><span class=\"mw-headline\" id=\"Hepatitis_A_6\">Hepatitis A</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=62\" title=\"Edit section: Hepatitis A\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\\n<p>Hepatitis A is found throughout the world and manifests as large <a href=\"/wiki/Outbreak\" class=\"mw-redirect\" title=\"Outbreak\">outbreaks</a> and <a href=\"/wiki/Epidemic\" title=\"Epidemic\">epidemics</a> associated with fecal contamination of water and food sources.<sup id=\"cite_ref-Carroll_chapter_35_104-1\" class=\"reference\"><a href=\"#cite_note-Carroll_chapter_35-104\">&#91;104&#93;</a></sup> Hepatitis A viral infection is predominant in children ages 5–14 with rare infection of infants.<sup id=\"cite_ref-Carroll_chapter_35_104-2\" class=\"reference\"><a href=\"#cite_note-Carroll_chapter_35-104\">&#91;104&#93;</a></sup> Infected children have little to no apparent clinical illness, in contrast to adults in whom greater than 80% are symptomatic if infected.<sup id=\"cite_ref-126\" class=\"reference\"><a href=\"#cite_note-126\">&#91;126&#93;</a></sup> Infection rates are highest in low resource countries with inadequate public sanitation and large concentrated populations.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-48\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-Aggarwal_488–496_127-0\" class=\"reference\"><a href=\"#cite_note-Aggarwal_488–496-127\">&#91;127&#93;</a></sup>  In such regions, as much as 90% of children younger than 10 years old have been infected and are immune, corresponding both to lower rates of clinically symptomatic disease and outbreaks.<sup id=\"cite_ref-Carroll_chapter_35_104-3\" class=\"reference\"><a href=\"#cite_note-Carroll_chapter_35-104\">&#91;104&#93;</a></sup><sup id=\"cite_ref-Aggarwal_488–496_127-1\" class=\"reference\"><a href=\"#cite_note-Aggarwal_488–496-127\">&#91;127&#93;</a></sup><sup id=\"cite_ref-128\" class=\"reference\"><a href=\"#cite_note-128\">&#91;128&#93;</a></sup> The availability of a childhood <a href=\"/wiki/Vaccine\" title=\"Vaccine\">vaccine</a> has significantly reduced infections in the United States, with incidence declining by more than 95% as of 2013.<sup id=\"cite_ref-129\" class=\"reference\"><a href=\"#cite_note-129\">&#91;129&#93;</a></sup> Paradoxically, the highest rates of new infection now occur in young adults and adults who present with worse clinical illness.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-49\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup> Specific populations at greatest risk include: travelers to endemic regions, men who have sex with men, those with occupational exposure to non-human primates, people with <a href=\"/wiki/Clotting_disorder\" class=\"mw-redirect\" title=\"Clotting disorder\">clotting disorders</a> who have received <a href=\"/wiki/Clotting_factors\" class=\"mw-redirect\" title=\"Clotting factors\">clotting factors</a>, people with history of <a href=\"/wiki/Chronic_liver_disease\" title=\"Chronic liver disease\">chronic liver disease</a> in whom co-infection with hepatitis A can lead to fulminant hepatitis, and intravenous drug users (rare).<sup id=\"cite_ref-Carroll_chapter_35_104-4\" class=\"reference\"><a href=\"#cite_note-Carroll_chapter_35-104\">&#91;104&#93;</a></sup>\\n</p>\\n<h4><span class=\"mw-headline\" id=\"Hepatitis_B_5\">Hepatitis B</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=63\" title=\"Edit section: Hepatitis B\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\\n<link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1033289096\"><div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Hepatitis_B\" title=\"Hepatitis B\">Hepatitis B</a></div>\\n<figure class=\"mw-default-size\" typeof=\"mw:File/Thumb\"><a href=\"/wiki/File:HBV_replication.png\" class=\"mw-file-description\"><img src=\"//upload.wikimedia.org/wikipedia/commons/thumb/8/8c/HBV_replication.png/220px-HBV_replication.png\" decoding=\"async\" width=\"220\" height=\"165\" class=\"mw-file-element\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/8/8c/HBV_replication.png/330px-HBV_replication.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/8/8c/HBV_replication.png/440px-HBV_replication.png 2x\" data-file-width=\"960\" data-file-height=\"720\" /></a><figcaption>HBV replication</figcaption></figure>\\n<p><a href=\"/wiki/Hepatitis_B\" title=\"Hepatitis B\">Hepatitis B</a> is the most common cause of viral hepatitis in the world with more than 240 million chronic carriers of the virus, 1 million of whom are in the United States.<sup id=\"cite_ref-WHO_Hepatitis_B_29-3\" class=\"reference\"><a href=\"#cite_note-WHO_Hepatitis_B-29\">&#91;29&#93;</a></sup><sup id=\"cite_ref-Carroll_chapter_35_104-5\" class=\"reference\"><a href=\"#cite_note-Carroll_chapter_35-104\">&#91;104&#93;</a></sup> In approximately two-thirds of patients who develop acute hepatitis B infection, no identifiable exposure is evident.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-50\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup>  Of those acutely infected, 25% become lifetime carriers of the virus.<sup id=\"cite_ref-Carroll_chapter_35_104-6\" class=\"reference\"><a href=\"#cite_note-Carroll_chapter_35-104\">&#91;104&#93;</a></sup> Risk of infection is highest among intravenous drug users, people with high-risk sexual behaviors, healthcare workers, people who had multiple transfusions, organ transplant patients, dialysis patients and newborns infected during the birthing process.<sup id=\"cite_ref-Carroll_chapter_35_104-7\" class=\"reference\"><a href=\"#cite_note-Carroll_chapter_35-104\">&#91;104&#93;</a></sup> Close to 780,000 deaths in the world are attributed to hepatitis B.<sup id=\"cite_ref-WHO_Hepatitis_B_29-4\" class=\"reference\"><a href=\"#cite_note-WHO_Hepatitis_B-29\">&#91;29&#93;</a></sup> The most endemic regions are in sub-Saharan Africa and East Asia, where as many as 10% of adults are chronic carriers.<sup id=\"cite_ref-WHO_Hepatitis_B_29-5\" class=\"reference\"><a href=\"#cite_note-WHO_Hepatitis_B-29\">&#91;29&#93;</a></sup> Carrier rates in developed nations are significantly lower, encompassing less than 1% of the population.<sup id=\"cite_ref-WHO_Hepatitis_B_29-6\" class=\"reference\"><a href=\"#cite_note-WHO_Hepatitis_B-29\">&#91;29&#93;</a></sup> In endemic regions, transmission is thought to be associated with exposure during birth and close contact between young infants.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-51\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-WHO_Hepatitis_B_29-7\" class=\"reference\"><a href=\"#cite_note-WHO_Hepatitis_B-29\">&#91;29&#93;</a></sup>\\n</p>\\n<h4><span class=\"mw-headline\" id=\"Hepatitis_C_4\">Hepatitis C</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=64\" title=\"Edit section: Hepatitis C\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\\n<link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1033289096\"><div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Hepatitis_C\" title=\"Hepatitis C\">Hepatitis C</a></div>\\n<figure class=\"mw-default-size\" typeof=\"mw:File/Thumb\"><a href=\"/wiki/File:HepC_replication.png\" class=\"mw-file-description\"><img src=\"//upload.wikimedia.org/wikipedia/commons/thumb/d/da/HepC_replication.png/220px-HepC_replication.png\" decoding=\"async\" width=\"220\" height=\"165\" class=\"mw-file-element\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/d/da/HepC_replication.png/330px-HepC_replication.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/d/da/HepC_replication.png/440px-HepC_replication.png 2x\" data-file-width=\"960\" data-file-height=\"720\" /></a><figcaption>HepC replication</figcaption></figure>\\n<p>Chronic <a href=\"/wiki/Hepatitis_C\" title=\"Hepatitis C\">hepatitis C</a> is a major cause of liver cirrhosis and hepatocellular carcinoma.<sup id=\"cite_ref-Rosen_-_Clinical_Practice_130-0\" class=\"reference\"><a href=\"#cite_note-Rosen_-_Clinical_Practice-130\">&#91;130&#93;</a></sup> It is a common medical reason for liver transplantation due to its severe complications.<sup id=\"cite_ref-Rosen_-_Clinical_Practice_130-1\" class=\"reference\"><a href=\"#cite_note-Rosen_-_Clinical_Practice-130\">&#91;130&#93;</a></sup> It is estimated that 130–180 million people in the world are affected by this disease representing a little more than 3% of the world population.<sup id=\"cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-16\" class=\"reference\"><a href=\"#cite_note-Final_Recommendation_Statement:_Hepatitis_C:_Screening-89\">&#91;89&#93;</a></sup><sup id=\"cite_ref-Carroll_chapter_35_104-8\" class=\"reference\"><a href=\"#cite_note-Carroll_chapter_35-104\">&#91;104&#93;</a></sup><sup id=\"cite_ref-Rosen_-_Clinical_Practice_130-2\" class=\"reference\"><a href=\"#cite_note-Rosen_-_Clinical_Practice-130\">&#91;130&#93;</a></sup> In the developing regions of Africa, Asia and South America, prevalence can be as high as 10% of the population.<sup id=\"cite_ref-Carroll_chapter_35_104-9\" class=\"reference\"><a href=\"#cite_note-Carroll_chapter_35-104\">&#91;104&#93;</a></sup> In Egypt, rates of hepatitis C infection as high as 20%  have been documented and are associated with <a href=\"/wiki/Iatrogenesis\" title=\"Iatrogenesis\">iatrogenic</a> contamination related to <a href=\"/wiki/Schistosomiasis\" title=\"Schistosomiasis\">schistosomiasis</a> treatment in the 1950s–1980s.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-52\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-Carroll_chapter_35_104-10\" class=\"reference\"><a href=\"#cite_note-Carroll_chapter_35-104\">&#91;104&#93;</a></sup> Currently in the United States, approximately 3.5 million adults are estimated to be infected.<sup id=\"cite_ref-131\" class=\"reference\"><a href=\"#cite_note-131\">&#91;131&#93;</a></sup> Hepatitis C is particularly prevalent among people born between 1945 and 1965, a group of about 800,000 people, with prevalence as high as 3.2% versus 1.6% in the general U.S. population.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-53\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup> Most chronic carriers of hepatitis C are unaware of their infection status.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-54\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup> The most common mode of transmission of hepatitis C virus is exposure to blood products via blood transfusions (prior to 1992) and intravenous drug injection.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-55\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-Carroll_chapter_35_104-11\" class=\"reference\"><a href=\"#cite_note-Carroll_chapter_35-104\">&#91;104&#93;</a></sup> A history of intravenous drug injection is the most important risk factor for chronic hepatitis C.<sup id=\"cite_ref-Rosen_-_Clinical_Practice_130-3\" class=\"reference\"><a href=\"#cite_note-Rosen_-_Clinical_Practice-130\">&#91;130&#93;</a></sup> Other susceptible populations include those engaged in high-risk sexual behavior, infants of infected mothers, and healthcare workers.<sup id=\"cite_ref-Carroll_chapter_35_104-12\" class=\"reference\"><a href=\"#cite_note-Carroll_chapter_35-104\">&#91;104&#93;</a></sup>\\n</p>\\n<h4><span class=\"mw-headline\" id=\"Hepatitis_D_4\">Hepatitis D</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=65\" title=\"Edit section: Hepatitis D\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\\n<link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1033289096\"><div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Hepatitis_D\" title=\"Hepatitis D\">Hepatitis D</a></div>\\n<p>The <a href=\"/wiki/Hepatitis_D\" title=\"Hepatitis D\">hepatitis D</a> virus causes chronic and fulminant hepatitis in the context of co-infection with the hepatitis B virus.<sup id=\"cite_ref-Carroll_chapter_35_104-13\" class=\"reference\"><a href=\"#cite_note-Carroll_chapter_35-104\">&#91;104&#93;</a></sup> It is primarily transmitted via non-sexual contact and via needles.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-56\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-Carroll_chapter_35_104-14\" class=\"reference\"><a href=\"#cite_note-Carroll_chapter_35-104\">&#91;104&#93;</a></sup> Susceptibility to hepatitis D differs by geographic region.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-57\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-Carroll_chapter_35_104-15\" class=\"reference\"><a href=\"#cite_note-Carroll_chapter_35-104\">&#91;104&#93;</a></sup> In the United States and Northern Europe, populations at risk are intravenous drug users and people who receive multiple transfusions.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-58\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-Carroll_chapter_35_104-16\" class=\"reference\"><a href=\"#cite_note-Carroll_chapter_35-104\">&#91;104&#93;</a></sup> In the Mediterranean, hepatitis D is predominant among hepatitis B virus co-infected people.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-59\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-Carroll_chapter_35_104-17\" class=\"reference\"><a href=\"#cite_note-Carroll_chapter_35-104\">&#91;104&#93;</a></sup>\\n</p>\\n<h4><span class=\"mw-headline\" id=\"Hepatitis_E_3\">Hepatitis E</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=66\" title=\"Edit section: Hepatitis E\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\\n<link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1033289096\"><div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Hepatitis_E\" title=\"Hepatitis E\">Hepatitis E</a></div>\\n<p>Similar to Hepatitis A, <a href=\"/wiki/Hepatitis_E\" title=\"Hepatitis E\">hepatitis E</a> manifests as large outbreaks and epidemics associated with fecal contamination of water sources.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-60\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup> It accounts for more than 55,000 deaths annually with approximately 20 million people worldwide thought to be infected with the virus.<sup id=\"cite_ref-WHO_-_Hepatitis_E_94-2\" class=\"reference\"><a href=\"#cite_note-WHO_-_Hepatitis_E-94\">&#91;94&#93;</a></sup> It affects predominantly young adults, causing acute hepatitis.<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-61\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-HEV_FAQs_for_Health_Professionals_132-0\" class=\"reference\"><a href=\"#cite_note-HEV_FAQs_for_Health_Professionals-132\">&#91;132&#93;</a></sup> In infected pregnant women, Hepatitis E infection can lead to fulminant hepatitis with third trimester mortality rates as high as 30%.<sup id=\"cite_ref-Carroll_chapter_35_104-18\" class=\"reference\"><a href=\"#cite_note-Carroll_chapter_35-104\">&#91;104&#93;</a></sup><sup id=\"cite_ref-HEV_FAQs_for_Health_Professionals_132-1\" class=\"reference\"><a href=\"#cite_note-HEV_FAQs_for_Health_Professionals-132\">&#91;132&#93;</a></sup> Those with weakened immune systems, such as organ transplant recipients, are also susceptible.<sup id=\"cite_ref-HEV_FAQs_for_Health_Professionals_132-2\" class=\"reference\"><a href=\"#cite_note-HEV_FAQs_for_Health_Professionals-132\">&#91;132&#93;</a></sup> Infection is rare in the United States but rates are high in the developing world (Africa, Asia, Central America, Middle East).<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-62\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-HEV_FAQs_for_Health_Professionals_132-3\" class=\"reference\"><a href=\"#cite_note-HEV_FAQs_for_Health_Professionals-132\">&#91;132&#93;</a></sup> Many genotypes exist and are differentially distributed around the world.<sup id=\"cite_ref-WHO_-_Hepatitis_E_94-3\" class=\"reference\"><a href=\"#cite_note-WHO_-_Hepatitis_E-94\">&#91;94&#93;</a></sup> There is some evidence of hepatitis E infection of animals, serving as a reservoir for human infection.<sup id=\"cite_ref-Carroll_chapter_35_104-19\" class=\"reference\"><a href=\"#cite_note-Carroll_chapter_35-104\">&#91;104&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Alcoholic_hepatitis_4\">Alcoholic hepatitis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=67\" title=\"Edit section: Alcoholic hepatitis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<p><a href=\"/wiki/Alcoholic_hepatitis\" title=\"Alcoholic hepatitis\">Alcoholic hepatitis</a> (AH) in its severe form has a one-month mortality as high as 50%.<sup id=\"cite_ref-Chayanupatkul_&amp;_Liangpunsakul_65-9\" class=\"reference\"><a href=\"#cite_note-Chayanupatkul_&amp;_Liangpunsakul-65\">&#91;65&#93;</a></sup><sup id=\"cite_ref-Definition,_epidemiology,_and_magnitude_66-1\" class=\"reference\"><a href=\"#cite_note-Definition,_epidemiology,_and_magnitude-66\">&#91;66&#93;</a></sup><sup id=\"cite_ref-Singal_Kamath_Gores_Shah_133-0\" class=\"reference\"><a href=\"#cite_note-Singal_Kamath_Gores_Shah-133\">&#91;133&#93;</a></sup> Most people who develop AH are men but women are at higher risk of developing AH and its complications likely secondary to high body fat and differences in alcohol metabolism.<sup id=\"cite_ref-Definition,_epidemiology,_and_magnitude_66-2\" class=\"reference\"><a href=\"#cite_note-Definition,_epidemiology,_and_magnitude-66\">&#91;66&#93;</a></sup> Other contributing factors include younger age &lt;60, binge pattern drinking, poor nutritional status, obesity and hepatitis C co-infection.<sup id=\"cite_ref-Definition,_epidemiology,_and_magnitude_66-3\" class=\"reference\"><a href=\"#cite_note-Definition,_epidemiology,_and_magnitude-66\">&#91;66&#93;</a></sup> It is estimated that as much as 20% of people with AH are also infected with hepatitis C.<sup id=\"cite_ref-Shoreibah,_Bhupinderjit,_Singal_134-0\" class=\"reference\"><a href=\"#cite_note-Shoreibah,_Bhupinderjit,_Singal-134\">&#91;134&#93;</a></sup>  In this population, the presence of hepatitis C virus leads to more severe disease with faster progression to cirrhosis, hepatocellular carcinoma and increased mortality.<sup id=\"cite_ref-Definition,_epidemiology,_and_magnitude_66-4\" class=\"reference\"><a href=\"#cite_note-Definition,_epidemiology,_and_magnitude-66\">&#91;66&#93;</a></sup><sup id=\"cite_ref-Shoreibah,_Bhupinderjit,_Singal_134-1\" class=\"reference\"><a href=\"#cite_note-Shoreibah,_Bhupinderjit,_Singal-134\">&#91;134&#93;</a></sup><sup id=\"cite_ref-135\" class=\"reference\"><a href=\"#cite_note-135\">&#91;135&#93;</a></sup> Obesity increases the likelihood of progression to cirrhosis in cases of alcoholic hepatitis.<sup id=\"cite_ref-Definition,_epidemiology,_and_magnitude_66-5\" class=\"reference\"><a href=\"#cite_note-Definition,_epidemiology,_and_magnitude-66\">&#91;66&#93;</a></sup>  It is estimated that 70% of people who have AH will progress to cirrhosis.<sup id=\"cite_ref-Definition,_epidemiology,_and_magnitude_66-6\" class=\"reference\"><a href=\"#cite_note-Definition,_epidemiology,_and_magnitude-66\">&#91;66&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Non-alcoholic_steatohepatitis\">Non-alcoholic steatohepatitis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=68\" title=\"Edit section: Non-alcoholic steatohepatitis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<p>Non-alcoholic steatohepatitis (NASH) is projected to become the top reason for <a href=\"/wiki/Liver_transplantation\" title=\"Liver transplantation\">liver transplantation</a> in the United States by 2020, supplanting chronic liver disease due to hepatitis C.<sup id=\"cite_ref-From_NAFLD_to_NASH_136-0\" class=\"reference\"><a href=\"#cite_note-From_NAFLD_to_NASH-136\">&#91;136&#93;</a></sup>  About 20–45% of the U.S. population have NAFLD and 6% have NASH.<sup id=\"cite_ref-Friedman_55e_31-38\" class=\"reference\"><a href=\"#cite_note-Friedman_55e-31\">&#91;31&#93;</a></sup><sup id=\"cite_ref-Harrison&#39;s_Principles_chapter_364_(Nonalcoholic)_42-1\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles_chapter_364_(Nonalcoholic)-42\">&#91;42&#93;</a></sup> The estimated prevalence of NASH in the world is 3–5%.<sup id=\"cite_ref-Weiß,_Rau,_Geier_137-0\" class=\"reference\"><a href=\"#cite_note-Weiß,_Rau,_Geier-137\">&#91;137&#93;</a></sup>  Of NASH patients who develop <a href=\"/wiki/Cirrhosis\" title=\"Cirrhosis\">cirrhosis</a>, about 2% per year will likely progress to <a href=\"/wiki/Hepatocellular_carcinoma\" title=\"Hepatocellular carcinoma\">hepatocellular carcinoma</a>.<sup id=\"cite_ref-Weiß,_Rau,_Geier_137-1\" class=\"reference\"><a href=\"#cite_note-Weiß,_Rau,_Geier-137\">&#91;137&#93;</a></sup>   Worldwide, the estimated prevalence of hepatocellular carcinoma related to NAFLD is 15–30%.<sup id=\"cite_ref-NAFLD,_NASH_and_liver_cancer_138-0\" class=\"reference\"><a href=\"#cite_note-NAFLD,_NASH_and_liver_cancer-138\">&#91;138&#93;</a></sup> NASH is thought to be the primary cause of cirrhosis in approximately 25% of patients in the United States, representing 1–2% of the general population.<sup id=\"cite_ref-NAFLD,_NASH_and_liver_cancer_138-1\" class=\"reference\"><a href=\"#cite_note-NAFLD,_NASH_and_liver_cancer-138\">&#91;138&#93;</a></sup>\\n</p>\\n<h2><span class=\"mw-headline\" id=\"History\">History</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=69\" title=\"Edit section: History\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\\n<h3><span class=\"mw-headline\" id=\"Early_observations\">Early observations</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=70\" title=\"Edit section: Early observations\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<p>Initial accounts of a syndrome that we now think is likely to be hepatitis begin to occur around 3000 B.C.  Clay tablets that served as medical handbooks for the ancient Sumerians described the first observations of jaundice.  The Sumerians believed that the liver was the home of the soul, and attributed the findings of jaundice to the attack of the liver by a devil named <a href=\"/wiki/Akhkhazu\" title=\"Akhkhazu\">Ahhazu</a>.<sup id=\"cite_ref-139\" class=\"reference\"><a href=\"#cite_note-139\">&#91;139&#93;</a></sup>\\n</p><p>Around 400 B.C., <a href=\"/wiki/Hippocrates\" title=\"Hippocrates\">Hippocrates</a> recorded the first documentation of an epidemic jaundice, in particular noting the uniquely fulminant course of a cohort of patients who all died within two weeks.  He wrote, \"The bile contained in the liver is full of phlegm and blood, and erupts...After such an eruption, the patient soon raves, becomes angry, talks nonsense and barks like a dog.\"<sup id=\"cite_ref-140\" class=\"reference\"><a href=\"#cite_note-140\">&#91;140&#93;</a></sup>\\n</p><p>Given the poor sanitary conditions of war, infectious jaundice played a large role as a major cause of mortality among troops in the Napoleonic Wars, the American Revolutionary War, and both World Wars.<sup id=\"cite_ref-141\" class=\"reference\"><a href=\"#cite_note-141\">&#91;141&#93;</a></sup> During World War II, estimates of soldiers affected by hepatitis were upwards of 10 million.\\n</p><p>During World War II, soldiers received vaccines against diseases such as <a href=\"/wiki/Yellow_fever\" title=\"Yellow fever\">yellow fever</a>, but these vaccines were stabilized with human serum, presumably contaminated with hepatitis viruses, which often created epidemics of hepatitis.<sup id=\"cite_ref-142\" class=\"reference\"><a href=\"#cite_note-142\">&#91;142&#93;</a></sup> It was suspected these epidemics were due to a separate infectious agent, and not due to the yellow fever virus itself, after noting 89 cases of jaundice in the months after vaccination out of a total 3,100 patients that were vaccinated.  After changing the seed virus strain, no cases of jaundice were observed in the subsequent 8,000 vaccinations.<sup id=\"cite_ref-143\" class=\"reference\"><a href=\"#cite_note-143\">&#91;143&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Willowbrook_State_School_experiments\">Willowbrook State School experiments</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=71\" title=\"Edit section: Willowbrook State School experiments\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<p>A New York University researcher named <a href=\"/wiki/Saul_Krugman\" title=\"Saul Krugman\">Saul Krugman</a> continued this research into the 1950s and 1960s, most infamously with his experiments on mentally disabled children at the <a href=\"/wiki/Willowbrook_State_School\" title=\"Willowbrook State School\">Willowbrook State School</a> in New York, a crowded urban facility where hepatitis infections were highly endemic to the student body.  Krugman injected students with gamma globulin, a type of antibody.  After observing the temporary protection against infection this antibody provided, he then tried injected live hepatitis virus into students.  Krugman also controversially took feces from infected students, blended it into milkshakes, and fed it to newly admitted children.<sup id=\"cite_ref-144\" class=\"reference\"><a href=\"#cite_note-144\">&#91;144&#93;</a></sup>\\n</p><p>His research was received with much controversy, as people protested the questionable ethics surrounding the chosen target population.  <a href=\"/wiki/Henry_K._Beecher\" title=\"Henry K. Beecher\">Henry Beecher</a> was one of the foremost critics in an article in the <i>New England Journal of Medicine</i> in 1966, arguing that parents were unaware to the risks of consent and that the research was done to benefit others at the expense of children.<sup id=\"cite_ref-145\" class=\"reference\"><a href=\"#cite_note-145\">&#91;145&#93;</a></sup>  Moreover, he argued that poor families with mentally disabled children often felt pressured to join the research project to gain admission to the school, with all of the educational and support resources that would come along with it.<sup id=\"cite_ref-ReferenceA_146-0\" class=\"reference\"><a href=\"#cite_note-ReferenceA-146\">&#91;146&#93;</a></sup> Others in the medical community spoke out in support of Krugman\\'s research in terms of its widespread benefits and understanding of the hepatitis virus, and Willowbrook continues to be a commonly cited example in debates about medical ethics.<sup id=\"cite_ref-147\" class=\"reference\"><a href=\"#cite_note-147\">&#91;147&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Australia_antigen\">Australia antigen</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=72\" title=\"Edit section: Australia antigen\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<p>The next insight regarding hepatitis B was a serendipitous one by <a href=\"/wiki/Baruch_Samuel_Blumberg\" title=\"Baruch Samuel Blumberg\">Dr. Baruch Blumberg</a>, a researcher at the NIH who did not set out to research hepatitis, but rather studied lipoprotein genetics.  He travelled across the globe collecting blood samples, investigating the interplay between disease, environment, and genetics with the goal of designing  targeted interventions for at-risk people that could prevent them from getting sick.<sup id=\"cite_ref-148\" class=\"reference\"><a href=\"#cite_note-148\">&#91;148&#93;</a></sup>  He noticed an unexpected interaction between the blood of a patient with <a href=\"/wiki/Haemophilia\" title=\"Haemophilia\">hemophilia</a> that had received multiple transfusions and a protein found in the blood of an indigenous Australian person.<sup id=\"cite_ref-149\" class=\"reference\"><a href=\"#cite_note-149\">&#91;149&#93;</a></sup>  He named the protein the \"Australia antigen\" and made it the focus of his research.  He found a higher prevalence of the protein in the blood of patients from developing countries, compared to those from developed ones, and noted associations of the antigen with other diseases like leukemia and Down Syndrome.<sup id=\"cite_ref-150\" class=\"reference\"><a href=\"#cite_note-150\">&#91;150&#93;</a></sup>  Eventually, he came to the unifying conclusion that the Australia antigen was associated with viral hepatitis.\\n</p><p>In 1970, <a href=\"/wiki/David_Dane\" title=\"David Dane\">David Dane</a> first isolated the hepatitis B <a href=\"/wiki/Virion\" class=\"mw-redirect\" title=\"Virion\">virion</a> at London\\'s Middlesex Hospital, and named the virion the 42-nm \"Dane particle\".<sup id=\"cite_ref-ReferenceA_146-1\" class=\"reference\"><a href=\"#cite_note-ReferenceA-146\">&#91;146&#93;</a></sup>  Based on its association with the surface of the hepatitis B virus, the Australia antigen was renamed to \"hepatitis B surface antigen\" or <a href=\"/wiki/HBsAg\" title=\"HBsAg\">HBsAg</a>.\\n</p><p>Blumberg continued to study the antigen, and eventually developed the first hepatitis B vaccine using plasma rich in HBsAg, for which he received the <a href=\"/wiki/Nobel_Prize_in_Physiology_or_Medicine\" title=\"Nobel Prize in Physiology or Medicine\">Nobel Prize in Medicine</a> in 1976.<sup id=\"cite_ref-151\" class=\"reference\"><a href=\"#cite_note-151\">&#91;151&#93;</a></sup>\\n</p>\\n<h2><span class=\"mw-headline\" id=\"Society_and_culture\">Society and culture</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=73\" title=\"Edit section: Society and culture\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\\n<h3><span class=\"mw-headline\" id=\"Economic_burden\">Economic burden</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=74\" title=\"Edit section: Economic burden\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<p>Overall, hepatitis accounts for a significant portion of healthcare expenditures in both developing and developed nations, and is expected to rise in several developing countries.<sup id=\"cite_ref-Udompap,_Kim_&amp;_Kim_152-0\" class=\"reference\"><a href=\"#cite_note-Udompap,_Kim_&amp;_Kim-152\">&#91;152&#93;</a></sup><sup id=\"cite_ref-Reducing_the_neglected_burden_153-0\" class=\"reference\"><a href=\"#cite_note-Reducing_the_neglected_burden-153\">&#91;153&#93;</a></sup> While hepatitis A infections are self-limited events, they are associated with significant costs in the United States.<sup id=\"cite_ref-Current_Childhood_Vaccination_Strategies_154-0\" class=\"reference\"><a href=\"#cite_note-Current_Childhood_Vaccination_Strategies-154\">&#91;154&#93;</a></sup> It has been estimated that <a href=\"/wiki/Direct_cost\" class=\"mw-redirect\" title=\"Direct cost\">direct and indirect costs</a> are approximately $1817 and $2459 respectively per case, and that an average of 27 work days is lost per infected adult.<sup id=\"cite_ref-Current_Childhood_Vaccination_Strategies_154-1\" class=\"reference\"><a href=\"#cite_note-Current_Childhood_Vaccination_Strategies-154\">&#91;154&#93;</a></sup> A 1997 report demonstrated that a single hospitalization related to hepatitis A cost an average of $6,900 and resulted in around $500 million in total annual healthcare costs.<sup id=\"cite_ref-155\" class=\"reference\"><a href=\"#cite_note-155\">&#91;155&#93;</a></sup> Cost effectiveness studies have found widespread vaccination of adults to not be feasible, but have stated that a combination hepatitis A and B vaccination of children and at risk groups (people from endemic areas, healthcare workers) may be.<sup id=\"cite_ref-156\" class=\"reference\"><a href=\"#cite_note-156\">&#91;156&#93;</a></sup>\\n</p><p>Hepatitis B accounts for a much larger percentage of health care spending in endemic regions like Asia.<sup id=\"cite_ref-157\" class=\"reference\"><a href=\"#cite_note-157\">&#91;157&#93;</a></sup><sup id=\"cite_ref-Economics_of_treating_in_Asia_158-0\" class=\"reference\"><a href=\"#cite_note-Economics_of_treating_in_Asia-158\">&#91;158&#93;</a></sup> In 1997 it accounted for 3.2% of South Korea\\'s total health care expenditures and resulted in $696 million in direct costs.<sup id=\"cite_ref-Economics_of_treating_in_Asia_158-1\" class=\"reference\"><a href=\"#cite_note-Economics_of_treating_in_Asia-158\">&#91;158&#93;</a></sup> A large majority of that sum was spent on treating disease symptoms and complications.<sup id=\"cite_ref-159\" class=\"reference\"><a href=\"#cite_note-159\">&#91;159&#93;</a></sup> Chronic hepatitis B infections are not as endemic in the United States, but accounted for $357 million in hospitalization costs in the year 1990.<sup id=\"cite_ref-Udompap,_Kim_&amp;_Kim_152-1\" class=\"reference\"><a href=\"#cite_note-Udompap,_Kim_&amp;_Kim-152\">&#91;152&#93;</a></sup> That number grew to $1.5 billion in 2003, but remained stable as of 2006, which may be attributable to the introduction of effective drug therapies and vaccination campaigns.<sup id=\"cite_ref-Udompap,_Kim_&amp;_Kim_152-2\" class=\"reference\"><a href=\"#cite_note-Udompap,_Kim_&amp;_Kim-152\">&#91;152&#93;</a></sup><sup id=\"cite_ref-Reducing_the_neglected_burden_153-1\" class=\"reference\"><a href=\"#cite_note-Reducing_the_neglected_burden-153\">&#91;153&#93;</a></sup>\\n</p><p>People infected with chronic hepatitis C tend to be frequent users of the health care system globally.<sup id=\"cite_ref-Younossi,_Kanwal,_Saab,_et_al_160-0\" class=\"reference\"><a href=\"#cite_note-Younossi,_Kanwal,_Saab,_et_al-160\">&#91;160&#93;</a></sup> It has been estimated that a person infected with hepatitis C in the United States will result in a monthly cost of $691.<sup id=\"cite_ref-Younossi,_Kanwal,_Saab,_et_al_160-1\" class=\"reference\"><a href=\"#cite_note-Younossi,_Kanwal,_Saab,_et_al-160\">&#91;160&#93;</a></sup> That number nearly doubles to $1,227 for people with compensated (stable) cirrhosis, while the monthly cost of people with decompensated (worsening) cirrhosis is almost five times as large at $3,682.<sup id=\"cite_ref-Younossi,_Kanwal,_Saab,_et_al_160-2\" class=\"reference\"><a href=\"#cite_note-Younossi,_Kanwal,_Saab,_et_al-160\">&#91;160&#93;</a></sup> The wide-ranging effects of hepatitis make it difficult to estimate indirect costs, but studies have speculated that the total cost is $6.5 billion annually in the United States.<sup id=\"cite_ref-Udompap,_Kim_&amp;_Kim_152-3\" class=\"reference\"><a href=\"#cite_note-Udompap,_Kim_&amp;_Kim-152\">&#91;152&#93;</a></sup> In Canada, 56% of HCV related costs are attributable to cirrhosis and total expenditures related to the virus are expected to peak at CAD$396 million in the year 2032.<sup id=\"cite_ref-161\" class=\"reference\"><a href=\"#cite_note-161\">&#91;161&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"2003_Monaca_outbreak\">2003 Monaca outbreak</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=75\" title=\"Edit section: 2003 Monaca outbreak\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<p>The largest outbreak of hepatitis A virus in United States history occurred among people who ate at a now-defunct Mexican food restaurant located in Monaca, Pennsylvania in late 2003.<sup id=\"cite_ref-green_onions_162-0\" class=\"reference\"><a href=\"#cite_note-green_onions-162\">&#91;162&#93;</a></sup> Over 550 people who visited the restaurant between September and October 2003 were infected with the virus, three of whom died as a direct result.<sup id=\"cite_ref-green_onions_162-1\" class=\"reference\"><a href=\"#cite_note-green_onions-162\">&#91;162&#93;</a></sup> The outbreak was brought to the attention of health officials when local <a href=\"/wiki/Emergency_medicine\" title=\"Emergency medicine\">emergency medicine</a> physicians noticed a significant increase in  cases of hepatitis A in the county.<sup id=\"cite_ref-163\" class=\"reference\"><a href=\"#cite_note-163\">&#91;163&#93;</a></sup> After conducting its investigation, the <a href=\"/wiki/Centers_for_Disease_Control_and_Prevention\" title=\"Centers for Disease Control and Prevention\">CDC</a> attributed the source of the outbreak to the use of contaminated raw <a href=\"/wiki/Scallion\" title=\"Scallion\">green onion</a>. The restaurant was purchasing its green onion stock from farms in Mexico at the time.<sup id=\"cite_ref-green_onions_162-2\" class=\"reference\"><a href=\"#cite_note-green_onions-162\">&#91;162&#93;</a></sup> It is believed that the green onions may have been contaminated through the use of contaminated water for crop irrigation, rinsing, or icing or by handling of the vegetables by infected people.<sup id=\"cite_ref-green_onions_162-3\" class=\"reference\"><a href=\"#cite_note-green_onions-162\">&#91;162&#93;</a></sup> Green onion had caused similar outbreaks of hepatitis A in the southern United States prior to this, but not to the same magnitude.<sup id=\"cite_ref-green_onions_162-4\" class=\"reference\"><a href=\"#cite_note-green_onions-162\">&#91;162&#93;</a></sup> The CDC believes that the restaurant\\'s use of a large communal bucket for chopped raw green onion allowed non-contaminated plants to be mixed with contaminated ones, increasing the number of vectors of infection and amplifying the outbreak.<sup id=\"cite_ref-green_onions_162-5\" class=\"reference\"><a href=\"#cite_note-green_onions-162\">&#91;162&#93;</a></sup> The restaurant was closed once it was discovered to be the source, and over 9,000 people were given hepatitis A <a href=\"/wiki/Antibody\" title=\"Antibody\">immune globulin</a> because they had either eaten at the restaurant or had been in close contact with someone who had.<sup id=\"cite_ref-green_onions_162-6\" class=\"reference\"><a href=\"#cite_note-green_onions-162\">&#91;162&#93;</a></sup>\\n</p>\\n<h2><span class=\"mw-headline\" id=\"Special_populations\">Special populations</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=76\" title=\"Edit section: Special populations\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\\n<h3><span class=\"mw-headline\" id=\"HIV_co-infection\">HIV co-infection</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=77\" title=\"Edit section: HIV co-infection\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<p>Persons infected with HIV have a particularly high burden of <a href=\"/wiki/Hepatitis_C_and_HIV_coinfection\" title=\"Hepatitis C and HIV coinfection\">HIV-HCV co-infection</a>.<sup id=\"cite_ref-HIV_co-infection_164-0\" class=\"reference\"><a href=\"#cite_note-HIV_co-infection-164\">&#91;164&#93;</a></sup><sup id=\"cite_ref-Platt,_Easterbrook_et_al_165-0\" class=\"reference\"><a href=\"#cite_note-Platt,_Easterbrook_et_al-165\">&#91;165&#93;</a></sup>  In a recent study by the <a href=\"/wiki/World_Health_Organization\" title=\"World Health Organization\">WHO</a>, the likelihood of being infected with hepatitis C virus was six times greater in those who also had HIV.<sup id=\"cite_ref-Platt,_Easterbrook_et_al_165-1\" class=\"reference\"><a href=\"#cite_note-Platt,_Easterbrook_et_al-165\">&#91;165&#93;</a></sup>  The prevalence of HIV-HCV co-infection worldwide was estimated to be 6.2% representing more than 2.2 million people.<sup id=\"cite_ref-Platt,_Easterbrook_et_al_165-2\" class=\"reference\"><a href=\"#cite_note-Platt,_Easterbrook_et_al-165\">&#91;165&#93;</a></sup>  Intravenous drug use was an independent risk factor for HCV infection.<sup id=\"cite_ref-Rosen_-_Clinical_Practice_130-4\" class=\"reference\"><a href=\"#cite_note-Rosen_-_Clinical_Practice-130\">&#91;130&#93;</a></sup> In the WHO study, the prevalence of HIV-HCV co-infection was markedly higher at 82.4% in those who injected drugs compared to the general population (2.4%).<sup id=\"cite_ref-Platt,_Easterbrook_et_al_165-3\" class=\"reference\"><a href=\"#cite_note-Platt,_Easterbrook_et_al-165\">&#91;165&#93;</a></sup> In a study of HIV-HCV co-infection among HIV positive men who have sex with men (MSM), the overall prevalence of anti-hepatitis C antibodies was estimated to be 8.1% and increased to 40% among HIV positive MSM who also injected drugs.<sup id=\"cite_ref-HIV_co-infection_164-1\" class=\"reference\"><a href=\"#cite_note-HIV_co-infection-164\">&#91;164&#93;</a></sup>\\n</p>\\n<h3><span class=\"mw-headline\" id=\"Pregnancy\">Pregnancy</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=78\" title=\"Edit section: Pregnancy\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\\n<h4><span class=\"mw-headline\" id=\"Hepatitis_B_6\">Hepatitis B</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=79\" title=\"Edit section: Hepatitis B\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\\n<p><a href=\"/wiki/Vertically_transmitted_infection\" title=\"Vertically transmitted infection\">Vertical transmission</a> is a significant contributor of new <a href=\"/wiki/Hepatitis_B_virus\" title=\"Hepatitis B virus\">HBV</a> cases each year, with 35–50% of transmission from mother to neonate in endemic countries.<sup id=\"cite_ref-ACOG_Practice_Bulletin_86-6\" class=\"reference\"><a href=\"#cite_note-ACOG_Practice_Bulletin-86\">&#91;86&#93;</a></sup><sup id=\"cite_ref-mother-to-neonate_166-0\" class=\"reference\"><a href=\"#cite_note-mother-to-neonate-166\">&#91;166&#93;</a></sup> Vertical transmission occurs largely via a neonate\\'s exposure to maternal blood and vaginal secretions during birth.<sup id=\"cite_ref-mother-to-neonate_166-1\" class=\"reference\"><a href=\"#cite_note-mother-to-neonate-166\">&#91;166&#93;</a></sup> While the risk of progression to chronic infection is approximately 5% among adults who contract the virus, it is as high as 95% among neonates subject to vertical transmission.<sup id=\"cite_ref-ACOG_Practice_Bulletin_86-7\" class=\"reference\"><a href=\"#cite_note-ACOG_Practice_Bulletin-86\">&#91;86&#93;</a></sup><sup id=\"cite_ref-167\" class=\"reference\"><a href=\"#cite_note-167\">&#91;167&#93;</a></sup> The risk of viral transmission is approximately 10–20% when maternal blood is positive for HBsAg, and up to 90% when also positive for <a href=\"/wiki/HBeAg\" title=\"HBeAg\">HBeAg</a>.<sup id=\"cite_ref-ACOG_Practice_Bulletin_86-8\" class=\"reference\"><a href=\"#cite_note-ACOG_Practice_Bulletin-86\">&#91;86&#93;</a></sup>\\n</p><p>Given the high risk of perinatal transmission, the <a href=\"/wiki/Centre_for_Disease_Control\" class=\"mw-redirect\" title=\"Centre for Disease Control\">CDC</a> recommends screening all pregnant women for HBV at their first prenatal visit.<sup id=\"cite_ref-ACOG_Practice_Bulletin_86-9\" class=\"reference\"><a href=\"#cite_note-ACOG_Practice_Bulletin-86\">&#91;86&#93;</a></sup><sup id=\"cite_ref-168\" class=\"reference\"><a href=\"#cite_note-168\">&#91;168&#93;</a></sup> It is safe for non-immune pregnant women to receive the HBV vaccine.<sup id=\"cite_ref-ACOG_Practice_Bulletin_86-10\" class=\"reference\"><a href=\"#cite_note-ACOG_Practice_Bulletin-86\">&#91;86&#93;</a></sup><sup id=\"cite_ref-mother-to-neonate_166-2\" class=\"reference\"><a href=\"#cite_note-mother-to-neonate-166\">&#91;166&#93;</a></sup> Based on the limited available evidence, the <a href=\"/wiki/American_Association_for_the_Study_of_Liver_Diseases\" title=\"American Association for the Study of Liver Diseases\">American Association for the Study of Liver Diseases</a> (AASLD) recommends antiviral therapy in pregnant women whose viral load exceeds 200,000 IU/mL.<sup id=\"cite_ref-AASLD_guidelines_for_chronic_B_169-0\" class=\"reference\"><a href=\"#cite_note-AASLD_guidelines_for_chronic_B-169\">&#91;169&#93;</a></sup> A growing body of evidence shows that antiviral therapy initiated in the third trimester significantly reduces transmission to the neonate.<sup id=\"cite_ref-mother-to-neonate_166-3\" class=\"reference\"><a href=\"#cite_note-mother-to-neonate-166\">&#91;166&#93;</a></sup><sup id=\"cite_ref-AASLD_guidelines_for_chronic_B_169-1\" class=\"reference\"><a href=\"#cite_note-AASLD_guidelines_for_chronic_B-169\">&#91;169&#93;</a></sup> A systematic review of the Antiretroviral Pregnancy Registry database found that there was no increased risk of congenital anomalies with <a href=\"/wiki/Tenofovir_disoproxil\" title=\"Tenofovir disoproxil\">Tenofovir</a>; for this reason, along with its potency and low risk of resistance, the AASLD recommends this drug.<sup id=\"cite_ref-AASLD_guidelines_for_chronic_B_169-2\" class=\"reference\"><a href=\"#cite_note-AASLD_guidelines_for_chronic_B-169\">&#91;169&#93;</a></sup><sup id=\"cite_ref-170\" class=\"reference\"><a href=\"#cite_note-170\">&#91;170&#93;</a></sup> A 2010 systematic review and meta-analysis found that <a href=\"/wiki/Lamivudine\" title=\"Lamivudine\">Lamivudine</a> initiated early in the third trimester also significantly reduced mother-to-child transmission of HBV, without any known adverse effects.<sup id=\"cite_ref-171\" class=\"reference\"><a href=\"#cite_note-171\">&#91;171&#93;</a></sup>\\n</p><p>The <a href=\"/wiki/American_Congress_of_Obstetricians_and_Gynecologists\" class=\"mw-redirect\" title=\"American Congress of Obstetricians and Gynecologists\">ACOG</a> states that the evidence available does not suggest any particular mode of delivery (i.e. <a href=\"/wiki/Vaginal_delivery\" title=\"Vaginal delivery\">vaginal</a> vs. <a href=\"/wiki/Caesarean_section\" title=\"Caesarean section\">cesarean</a>) is better at reducing vertical transmission in mothers with HBV.<sup id=\"cite_ref-ACOG_Practice_Bulletin_86-11\" class=\"reference\"><a href=\"#cite_note-ACOG_Practice_Bulletin-86\">&#91;86&#93;</a></sup>\\n</p><p>The <a href=\"/wiki/World_Health_Organization\" title=\"World Health Organization\">WHO</a> and CDC recommend that neonates born to mothers with HBV should receive hepatitis B immune globulin (<a href=\"/wiki/Hepatitis_B_immune_globulin\" title=\"Hepatitis B immune globulin\">HBIG</a>) as well as the <a href=\"/wiki/Hepatitis_B_vaccine\" title=\"Hepatitis B vaccine\">HBV vaccine</a> within 12 hours of birth.<sup id=\"cite_ref-CDC_recommendations_for_Hepatitis_B_83-14\" class=\"reference\"><a href=\"#cite_note-CDC_recommendations_for_Hepatitis_B-83\">&#91;83&#93;</a></sup><sup id=\"cite_ref-WHO_guidelines_for_chronic_Hepatitis_B_85-11\" class=\"reference\"><a href=\"#cite_note-WHO_guidelines_for_chronic_Hepatitis_B-85\">&#91;85&#93;</a></sup> For infants who have received HBIG and the HBV vaccine, breastfeeding is safe.<sup id=\"cite_ref-ACOG_Practice_Bulletin_86-12\" class=\"reference\"><a href=\"#cite_note-ACOG_Practice_Bulletin-86\">&#91;86&#93;</a></sup><sup id=\"cite_ref-mother-to-neonate_166-4\" class=\"reference\"><a href=\"#cite_note-mother-to-neonate-166\">&#91;166&#93;</a></sup>\\n</p>\\n<h4><span class=\"mw-headline\" id=\"Hepatitis_C_5\">Hepatitis C</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=80\" title=\"Edit section: Hepatitis C\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\\n<p>Estimates of the rate of <a href=\"/wiki/Hepatitis_C_virus\" title=\"Hepatitis C virus\">HCV</a> vertical transmission range from 2–8%; a 2014 systematic review and meta-analysis found the risk to be 5.8% in HCV-positive, HIV-negative women.<sup id=\"cite_ref-ACOG_Practice_Bulletin_86-13\" class=\"reference\"><a href=\"#cite_note-ACOG_Practice_Bulletin-86\">&#91;86&#93;</a></sup><sup id=\"cite_ref-Benova_-_vertical_transmission_172-0\" class=\"reference\"><a href=\"#cite_note-Benova_-_vertical_transmission-172\">&#91;172&#93;</a></sup> The same study found the risk of vertical transmission to be 10.8% in HCV-positive, HIV-positive women.<sup id=\"cite_ref-Benova_-_vertical_transmission_172-1\" class=\"reference\"><a href=\"#cite_note-Benova_-_vertical_transmission-172\">&#91;172&#93;</a></sup> Other studies have found the risk of vertical transmission to be as high as 44% among HIV-positive women.<sup id=\"cite_ref-ACOG_Practice_Bulletin_86-14\" class=\"reference\"><a href=\"#cite_note-ACOG_Practice_Bulletin-86\">&#91;86&#93;</a></sup> The risk of vertical transmission is higher when the virus is detectable in the mother\\'s blood.<sup id=\"cite_ref-Benova_-_vertical_transmission_172-2\" class=\"reference\"><a href=\"#cite_note-Benova_-_vertical_transmission-172\">&#91;172&#93;</a></sup>\\n</p><p>Evidence does not indicate that mode of delivery (i.e. vaginal vs. cesarean) has an effect on vertical transmission.<sup id=\"cite_ref-ACOG_Practice_Bulletin_86-15\" class=\"reference\"><a href=\"#cite_note-ACOG_Practice_Bulletin-86\">&#91;86&#93;</a></sup>\\n</p><p>For women who are HCV-positive and HIV-negative, breastfeeding is safe. CDC guidelines suggest avoiding it if a woman\\'s nipples are cracked or bleeding to reduce the risk of transmission.<sup id=\"cite_ref-ACOG_Practice_Bulletin_86-16\" class=\"reference\"><a href=\"#cite_note-ACOG_Practice_Bulletin-86\">&#91;86&#93;</a></sup><sup id=\"cite_ref-CDC_-_HCV_prevention_88-12\" class=\"reference\"><a href=\"#cite_note-CDC_-_HCV_prevention-88\">&#91;88&#93;</a></sup>\\n</p>\\n<h4><span class=\"mw-headline\" id=\"Hepatitis_E_4\">Hepatitis E</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=81\" title=\"Edit section: Hepatitis E\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\\n<p>Pregnant women who contract <a href=\"/wiki/Hepatitis_E_virus\" class=\"mw-redirect\" title=\"Hepatitis E virus\">HEV</a> are at significant risk of developing fulminant hepatitis with maternal mortality rates as high as 20–30%, most commonly in the third trimester .<sup id=\"cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-63\" class=\"reference\"><a href=\"#cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-ACOG_Practice_Bulletin_86-17\" class=\"reference\"><a href=\"#cite_note-ACOG_Practice_Bulletin-86\">&#91;86&#93;</a></sup><sup id=\"cite_ref-mother-to-neonate_166-5\" class=\"reference\"><a href=\"#cite_note-mother-to-neonate-166\">&#91;166&#93;</a></sup> A 2016 systematic review and meta-analysis of 47 studies that included 3968 people found maternal <a href=\"/wiki/Case_fatality_rate\" title=\"Case fatality rate\">case-fatality rates</a> (CFR) of 20.8% and fetal CFR of 34.2%; among women who developed fulminant hepatic failure, CFR was 61.2%.<sup id=\"cite_ref-173\" class=\"reference\"><a href=\"#cite_note-173\">&#91;173&#93;</a></sup>\\n</p>\\n<h2><span class=\"mw-headline\" id=\"See_also\">See also</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=82\" title=\"Edit section: See also\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\\n<ul><li><a href=\"/wiki/Idiopathic_granulomatous_hepatitis\" title=\"Idiopathic granulomatous hepatitis\">Idiopathic granulomatous hepatitis</a></li>\\n<li><a href=\"/wiki/World_Hepatitis_Day\" title=\"World Hepatitis Day\">World Hepatitis Day</a></li></ul>\\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=83\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\\n<style data-mw-deduplicate=\"TemplateStyles:r1011085734\">.mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}</style><div class=\"reflist\">\\n<div class=\"mw-references-wrap mw-references-columns\"><ol class=\"references\">\\n<li id=\"cite_note-MedLine2016-1\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-MedLine2016_1-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-MedLine2016_1-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-MedLine2016_1-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-MedLine2016_1-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-MedLine2016_1-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-MedLine2016_1-5\"><sup><i><b>f</b></i></sup></a></span> <span class=\"reference-text\"><style data-mw-deduplicate=\"TemplateStyles:r1133582631\">.mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:\"\\\\\"\"\"\\\\\"\"\"\\'\"\"\\'\"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:url(\"//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg\")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:url(\"//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg\")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:url(\"//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg\")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:url(\"//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg\")right 0.1em center/12px no-repeat}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:#d33}.mw-parser-output .cs1-visible-error{color:#d33}.mw-parser-output .cs1-maint{display:none;color:#3a3;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://medlineplus.gov/hepatitis.html\">\"Hepatitis\"</a>. <i>MedlinePlus</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20161111061624/https://medlineplus.gov/hepatitis.html\">Archived</a> from the original on 11 November 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">10 November</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=MedlinePlus&amp;rft.atitle=Hepatitis&amp;rft_id=https%3A%2F%2Fmedlineplus.gov%2Fhepatitis.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-WHO2016QA-2\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-WHO2016QA_2-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-WHO2016QA_2-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-WHO2016QA_2-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-WHO2016QA_2-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-WHO2016QA_2-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-WHO2016QA_2-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-WHO2016QA_2-6\"><sup><i><b>g</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.who.int/features/qa/76/en/\">\"What is hepatitis?\"</a>. <i>WHO</i>. July 2016. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20161107003115/http://www.who.int/features/qa/76/en/\">Archived</a> from the original on 7 November 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">10 November</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=WHO&amp;rft.atitle=What+is+hepatitis%3F&amp;rft.date=2016-07&amp;rft_id=https%3A%2F%2Fwww.who.int%2Ffeatures%2Fqa%2F76%2Fen%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-NIH2016-3\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-NIH2016_3-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-NIH2016_3-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-NIH2016_3-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-NIH2016_3-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-NIH2016_3-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-NIH2016_3-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-NIH2016_3-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-NIH2016_3-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-NIH2016_3-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-NIH2016_3-9\"><sup><i><b>j</b></i></sup></a> <a href=\"#cite_ref-NIH2016_3-10\"><sup><i><b>k</b></i></sup></a> <a href=\"#cite_ref-NIH2016_3-11\"><sup><i><b>l</b></i></sup></a> <a href=\"#cite_ref-NIH2016_3-12\"><sup><i><b>m</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.niaid.nih.gov/diseases-conditions/hepatitis\">\"Hepatitis\"</a>. <i>NIAID</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20161104002228/https://www.niaid.nih.gov/diseases-conditions/hepatitis\">Archived</a> from the original on 4 November 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2 November</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=NIAID&amp;rft.atitle=Hepatitis&amp;rft_id=https%3A%2F%2Fwww.niaid.nih.gov%2Fdiseases-conditions%2Fhepatitis&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Trans2012-4\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Trans2012_4-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Trans2012_4-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20161111061924/https://www.niddk.nih.gov/health-information/health-topics/liver-disease/liver-transplant/Pages/facts.aspx\">\"Liver Transplant\"</a>. <i>NIDDK</i>. April 2012. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"https://www.niddk.nih.gov/health-information/health-topics/liver-disease/liver-transplant/Pages/facts.aspx\">the original</a> on 11 November 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">10 November</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=NIDDK&amp;rft.atitle=Liver+Transplant&amp;rft.date=2012-04&amp;rft_id=https%3A%2F%2Fwww.niddk.nih.gov%2Fhealth-information%2Fhealth-topics%2Fliver-disease%2Fliver-transplant%2FPages%2Ffacts.aspx&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-MedlinePlus_2020-5\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-MedlinePlus_2020_5-0\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://medlineplus.gov/hepatitis.html\">\"Hepatitis\"</a>. <i>MedlinePlus</i>. 2020-05-20<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2020-07-19</span></span>. <q>Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Hepatitis is an inflammation of the liver.</q></cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=MedlinePlus&amp;rft.atitle=Hepatitis&amp;rft.date=2020-05-20&amp;rft_id=https%3A%2F%2Fmedlineplus.gov%2Fhepatitis.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-6\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-6\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"http://patients.gi.org/topics/viral-hepatitis/\">\"Hepatitis (Hepatitis A, B, and C) | ACG Patients\"</a>. <i>patients.gi.org</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20170223163352/http://patients.gi.org/topics/viral-hepatitis/\">Archived</a> from the original on 2017-02-23.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=patients.gi.org&amp;rft.atitle=Hepatitis+%28Hepatitis+A%2C+B%2C+and+C%29+%7C+ACG+Patients&amp;rft_id=http%3A%2F%2Fpatients.gi.org%2Ftopics%2Fviral-hepatitis%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-7\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-7\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFBernal_W.Wendon_J.2013\" class=\"citation journal cs1\">Bernal W.; Wendon J. (2013). <a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1056%2Fnejmra1208937\">\"Acute Liver Failure\"</a>. <i>New England Journal of Medicine</i>. <b>369</b> (26): 2525–2534. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1056%2Fnejmra1208937\">10.1056/nejmra1208937</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/24369077\">24369077</a>. <a href=\"/wiki/S2CID_(identifier)\" class=\"mw-redirect\" title=\"S2CID (identifier)\">S2CID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://api.semanticscholar.org/CorpusID:205116503\">205116503</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=New+England+Journal+of+Medicine&amp;rft.atitle=Acute+Liver+Failure&amp;rft.volume=369&amp;rft.issue=26&amp;rft.pages=2525-2534&amp;rft.date=2013&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A205116503%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F24369077&amp;rft_id=info%3Adoi%2F10.1056%2Fnejmra1208937&amp;rft.au=Bernal+W.&amp;rft.au=Wendon+J.&amp;rft_id=https%3A%2F%2Fdoi.org%2F10.1056%252Fnejmra1208937&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-8\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-8\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1 cs1-prop-foreign-lang-source\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.infoterio.com/2022/08/Esto-es-la-hepatitis-Conocela-enfrentate-a-ella.html\">\"Esto es la hepatitis: Conócela, enfréntate a ella\"</a>. <i>Infoterio Noticias | Ciencia y Tecnología</i> (in Spanish). 8 August 2022<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2023-02-12</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Infoterio+Noticias+%7C+Ciencia+y+Tecnolog%C3%ADa&amp;rft.atitle=Esto+es+la+hepatitis%3A+Con%C3%B3cela%2C+enfr%C3%A9ntate+a+ella&amp;rft.date=2022-08-08&amp;rft_id=https%3A%2F%2Fwww.infoterio.com%2F2022%2F08%2FEsto-es-la-hepatitis-Conocela-enfrentate-a-ella.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-NASH2014-9\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-NASH2014_9-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-NASH2014_9-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-NASH2014_9-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20161111061658/https://www.niddk.nih.gov/health-information/health-topics/liver-disease/nonalcoholic-steatohepatitis/pages/facts.aspx\">\"Fatty Liver Disease (Nonalcoholic Steatohepatitis)\"</a>. <i>NIDDK</i>. May 2014. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"https://www.niddk.nih.gov/health-information/health-topics/liver-disease/nonalcoholic-steatohepatitis/pages/facts.aspx\">the original</a> on 11 November 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">10 November</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=NIDDK&amp;rft.atitle=Fatty+Liver+Disease+%28Nonalcoholic+Steatohepatitis%29&amp;rft.date=2014-05&amp;rft_id=https%3A%2F%2Fwww.niddk.nih.gov%2Fhealth-information%2Fhealth-topics%2Fliver-disease%2Fnonalcoholic-steatohepatitis%2Fpages%2Ffacts.aspx&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-AASLD-IDSA-10\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-AASLD-IDSA_10-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-AASLD-IDSA_10-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-AASLD-IDSA_10-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-AASLD-IDSA_10-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-AASLD-IDSA_10-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-AASLD-IDSA_10-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-AASLD-IDSA_10-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-AASLD-IDSA_10-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-AASLD-IDSA_10-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-AASLD-IDSA_10-9\"><sup><i><b>j</b></i></sup></a> <a href=\"#cite_ref-AASLD-IDSA_10-10\"><sup><i><b>k</b></i></sup></a> <a href=\"#cite_ref-AASLD-IDSA_10-11\"><sup><i><b>l</b></i></sup></a> <a href=\"#cite_ref-AASLD-IDSA_10-12\"><sup><i><b>m</b></i></sup></a> <a href=\"#cite_ref-AASLD-IDSA_10-13\"><sup><i><b>n</b></i></sup></a> <a href=\"#cite_ref-AASLD-IDSA_10-14\"><sup><i><b>o</b></i></sup></a> <a href=\"#cite_ref-AASLD-IDSA_10-15\"><sup><i><b>p</b></i></sup></a> <a href=\"#cite_ref-AASLD-IDSA_10-16\"><sup><i><b>q</b></i></sup></a> <a href=\"#cite_ref-AASLD-IDSA_10-17\"><sup><i><b>r</b></i></sup></a> <a href=\"#cite_ref-AASLD-IDSA_10-18\"><sup><i><b>s</b></i></sup></a> <a href=\"#cite_ref-AASLD-IDSA_10-19\"><sup><i><b>t</b></i></sup></a> <a href=\"#cite_ref-AASLD-IDSA_10-20\"><sup><i><b>u</b></i></sup></a> <a href=\"#cite_ref-AASLD-IDSA_10-21\"><sup><i><b>v</b></i></sup></a> <a href=\"#cite_ref-AASLD-IDSA_10-22\"><sup><i><b>w</b></i></sup></a> <a href=\"#cite_ref-AASLD-IDSA_10-23\"><sup><i><b>x</b></i></sup></a> <a href=\"#cite_ref-AASLD-IDSA_10-24\"><sup><i><b>y</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFAASLD/IDSA_HCV_Guidance_Panel2015\" class=\"citation journal cs1\">AASLD/IDSA HCV Guidance Panel (2015-09-01). <a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1002%2Fhep.27950\">\"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus\"</a>. <i>Hepatology</i>. <b>62</b> (3): 932–954. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1002%2Fhep.27950\">10.1002/hep.27950</a></span>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1527-3350\">1527-3350</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/26111063\">26111063</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Hepatology&amp;rft.atitle=Hepatitis+C+guidance%3A+AASLD-IDSA+recommendations+for+testing%2C+managing%2C+and+treating+adults+infected+with+hepatitis+C+virus&amp;rft.volume=62&amp;rft.issue=3&amp;rft.pages=932-954&amp;rft.date=2015-09-01&amp;rft.issn=1527-3350&amp;rft_id=info%3Apmid%2F26111063&amp;rft_id=info%3Adoi%2F10.1002%2Fhep.27950&amp;rft.au=AASLD%2FIDSA+HCV+Guidance+Panel&amp;rft_id=https%3A%2F%2Fdoi.org%2F10.1002%252Fhep.27950&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-11\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-11\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20161111061856/https://www.niddk.nih.gov/health-information/health-topics/liver-disease/autoimmune-hepatitis/Pages/facts.aspx\">\"Autoimmune Hepatitis\"</a>. <i>NIDDK</i>. March 2014. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"https://www.niddk.nih.gov/health-information/health-topics/liver-disease/autoimmune-hepatitis/Pages/facts.aspx\">the original</a> on 11 November 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">10 November</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=NIDDK&amp;rft.atitle=Autoimmune+Hepatitis&amp;rft.date=2014-03&amp;rft_id=https%3A%2F%2Fwww.niddk.nih.gov%2Fhealth-information%2Fhealth-topics%2Fliver-disease%2Fautoimmune-hepatitis%2FPages%2Ffacts.aspx&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-12\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-12\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFVosAllenAroraBarber2016\" class=\"citation journal cs1\">Vos, Theo; Allen, Christine; Arora, Megha; Barber, Ryan M.; Bhutta, Zulfiqar A.; Brown, Alexandria; Carter, Austin; Casey, Daniel C.; Charlson, Fiona J.; Chen, Alan Z.; Coggeshall, Megan; Cornaby, Leslie; Dandona, Lalit; Dicker, Daniel J.; Dilegge, Tina; Erskine, Holly E.; Ferrari, Alize J.; Fitzmaurice, Christina; Fleming, Tom; Forouzanfar, Mohammad H.; Fullman, Nancy; Gething, Peter W.; Goldberg, Ellen M.; Graetz, Nicholas; Haagsma, Juanita A.; Hay, Simon I.; Johnson, Catherine O.; Kassebaum, Nicholas J.; Kawashima, Toana; et&#160;al. (October 2016). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055577\">\"Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015\"</a>. <i>The Lancet</i>. <b>388</b> (10053): 1545–1602. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1016%2FS0140-6736%2816%2931678-6\">10.1016/S0140-6736(16)31678-6</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055577\">5055577</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/27733282\">27733282</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Lancet&amp;rft.atitle=Global%2C+regional%2C+and+national+incidence%2C+prevalence%2C+and+years+lived+with+disability+for+310+diseases+and+injuries%2C+1990%E2%80%932015%3A+a+systematic+analysis+for+the+Global+Burden+of+Disease+Study+2015&amp;rft.volume=388&amp;rft.issue=10053&amp;rft.pages=1545-1602&amp;rft.date=2016-10&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5055577%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F27733282&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2816%2931678-6&amp;rft.aulast=Vos&amp;rft.aufirst=Theo&amp;rft.au=Allen%2C+Christine&amp;rft.au=Arora%2C+Megha&amp;rft.au=Barber%2C+Ryan+M.&amp;rft.au=Bhutta%2C+Zulfiqar+A.&amp;rft.au=Brown%2C+Alexandria&amp;rft.au=Carter%2C+Austin&amp;rft.au=Casey%2C+Daniel+C.&amp;rft.au=Charlson%2C+Fiona+J.&amp;rft.au=Chen%2C+Alan+Z.&amp;rft.au=Coggeshall%2C+Megan&amp;rft.au=Cornaby%2C+Leslie&amp;rft.au=Dandona%2C+Lalit&amp;rft.au=Dicker%2C+Daniel+J.&amp;rft.au=Dilegge%2C+Tina&amp;rft.au=Erskine%2C+Holly+E.&amp;rft.au=Ferrari%2C+Alize+J.&amp;rft.au=Fitzmaurice%2C+Christina&amp;rft.au=Fleming%2C+Tom&amp;rft.au=Forouzanfar%2C+Mohammad+H.&amp;rft.au=Fullman%2C+Nancy&amp;rft.au=Gething%2C+Peter+W.&amp;rft.au=Goldberg%2C+Ellen+M.&amp;rft.au=Graetz%2C+Nicholas&amp;rft.au=Haagsma%2C+Juanita+A.&amp;rft.au=Hay%2C+Simon+I.&amp;rft.au=Johnson%2C+Catherine+O.&amp;rft.au=Kassebaum%2C+Nicholas+J.&amp;rft.au=Kawashima%2C+Toana&amp;rft.au=Kemmer%2C+Laura&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5055577&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-13\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-13\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFBasra2011\" class=\"citation journal cs1\">Basra, Sarpreet (2011). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3124876\">\"Definition, epidemiology and magnitude of alcoholic hepatitis\"</a>. <i>World Journal of Hepatology</i>. <b>3</b> (5): 108–13. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.4254%2Fwjh.v3.i5.108\">10.4254/wjh.v3.i5.108</a></span>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3124876\">3124876</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/21731902\">21731902</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=World+Journal+of+Hepatology&amp;rft.atitle=Definition%2C+epidemiology+and+magnitude+of+alcoholic+hepatitis&amp;rft.volume=3&amp;rft.issue=5&amp;rft.pages=108-13&amp;rft.date=2011&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3124876%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F21731902&amp;rft_id=info%3Adoi%2F10.4254%2Fwjh.v3.i5.108&amp;rft.aulast=Basra&amp;rft.aufirst=Sarpreet&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3124876&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-14\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-14\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFWangNaghaviAllenBarber2016\" class=\"citation journal cs1\">Wang, Haidong; Naghavi, Mohsen; Allen, Christine; Barber, Ryan M.; Bhutta, Zulfiqar A.; Carter, Austin; Casey, Daniel C.; Charlson, Fiona J.; Chen, Alan Zian; Coates, Matthew M.; Coggeshall, Megan; Dandona, Lalit; Dicker, Daniel J.; Erskine, Holly E.; Ferrari, Alize J.; Fitzmaurice, Christina; Foreman, Kyle; Forouzanfar, Mohammad H.; Fraser, Maya S.; Fullman, Nancy; Gething, Peter W.; Goldberg, Ellen M.; Graetz, Nicholas; Haagsma, Juanita A.; Hay, Simon I.; Huynh, Chantal; Johnson, Catherine O.; Kassebaum, Nicholas J.; Kinfu, Yohannes; et&#160;al. (October 2016). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388903\">\"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015\"</a>. <i>The Lancet</i>. <b>388</b> (10053): 1459–1544. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1016%2FS0140-6736%2816%2931012-1\">10.1016/S0140-6736(16)31012-1</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388903\">5388903</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/27733281\">27733281</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Lancet&amp;rft.atitle=Global%2C+regional%2C+and+national+life+expectancy%2C+all-cause+mortality%2C+and+cause-specific+mortality+for+249+causes+of+death%2C+1980%E2%80%932015%3A+a+systematic+analysis+for+the+Global+Burden+of+Disease+Study+2015&amp;rft.volume=388&amp;rft.issue=10053&amp;rft.pages=1459-1544&amp;rft.date=2016-10&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5388903%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F27733281&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2816%2931012-1&amp;rft.aulast=Wang&amp;rft.aufirst=Haidong&amp;rft.au=Naghavi%2C+Mohsen&amp;rft.au=Allen%2C+Christine&amp;rft.au=Barber%2C+Ryan+M.&amp;rft.au=Bhutta%2C+Zulfiqar+A.&amp;rft.au=Carter%2C+Austin&amp;rft.au=Casey%2C+Daniel+C.&amp;rft.au=Charlson%2C+Fiona+J.&amp;rft.au=Chen%2C+Alan+Zian&amp;rft.au=Coates%2C+Matthew+M.&amp;rft.au=Coggeshall%2C+Megan&amp;rft.au=Dandona%2C+Lalit&amp;rft.au=Dicker%2C+Daniel+J.&amp;rft.au=Erskine%2C+Holly+E.&amp;rft.au=Ferrari%2C+Alize+J.&amp;rft.au=Fitzmaurice%2C+Christina&amp;rft.au=Foreman%2C+Kyle&amp;rft.au=Forouzanfar%2C+Mohammad+H.&amp;rft.au=Fraser%2C+Maya+S.&amp;rft.au=Fullman%2C+Nancy&amp;rft.au=Gething%2C+Peter+W.&amp;rft.au=Goldberg%2C+Ellen+M.&amp;rft.au=Graetz%2C+Nicholas&amp;rft.au=Haagsma%2C+Juanita+A.&amp;rft.au=Hay%2C+Simon+I.&amp;rft.au=Huynh%2C+Chantal&amp;rft.au=Johnson%2C+Catherine+O.&amp;rft.au=Kassebaum%2C+Nicholas+J.&amp;rft.au=Kinfu%2C+Yohannes&amp;rft.au=Kulikoff%2C+Xie+Rachel&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5388903&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-15\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-15\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.cdc.gov/hepatitis/statistics/index.htm\">\"Statistics &amp; Surveillance Division of Viral Hepatitis CDC\"</a>. <i>CDC</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20161111012229/http://www.cdc.gov/hepatitis/Statistics/index.htm\">Archived</a> from the original on 11 November 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">10 November</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=CDC&amp;rft.atitle=Statistics+%26+Surveillance+Division+of+Viral+Hepatitis+CDC&amp;rft_id=https%3A%2F%2Fwww.cdc.gov%2Fhepatitis%2Fstatistics%2Findex.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-16\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-16\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.etymonline.com/index.php?search=hepatitis&amp;searchmode=none\">\"Online Etymology Dictionary\"</a>. Etymonline.com. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20121020195733/http://www.etymonline.com/index.php?search=hepatitis&amp;searchmode=none\">Archived</a> from the original on 2012-10-20<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2012-08-26</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Online+Etymology+Dictionary&amp;rft.pub=Etymonline.com&amp;rft_id=http%3A%2F%2Fwww.etymonline.com%2Findex.php%3Fsearch%3Dhepatitis%26searchmode%3Dnone&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)-17\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-9\"><sup><i><b>j</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-10\"><sup><i><b>k</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-11\"><sup><i><b>l</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-12\"><sup><i><b>m</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-13\"><sup><i><b>n</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-14\"><sup><i><b>o</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-15\"><sup><i><b>p</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-16\"><sup><i><b>q</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-17\"><sup><i><b>r</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-18\"><sup><i><b>s</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-19\"><sup><i><b>t</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-20\"><sup><i><b>u</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-21\"><sup><i><b>v</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-22\"><sup><i><b>w</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-23\"><sup><i><b>x</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-24\"><sup><i><b>y</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-25\"><sup><i><b>z</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-26\"><sup><i><b>aa</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-27\"><sup><i><b>ab</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-28\"><sup><i><b>ac</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-29\"><sup><i><b>ad</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-30\"><sup><i><b>ae</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-31\"><sup><i><b>af</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-32\"><sup><i><b>ag</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-33\"><sup><i><b>ah</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-34\"><sup><i><b>ai</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-35\"><sup><i><b>aj</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-36\"><sup><i><b>ak</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-37\"><sup><i><b>al</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-38\"><sup><i><b>am</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-39\"><sup><i><b>an</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-40\"><sup><i><b>ao</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-41\"><sup><i><b>ap</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-42\"><sup><i><b>aq</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-43\"><sup><i><b>ar</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-44\"><sup><i><b>as</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-45\"><sup><i><b>at</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-46\"><sup><i><b>au</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-47\"><sup><i><b>av</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-48\"><sup><i><b>aw</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-49\"><sup><i><b>ax</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-50\"><sup><i><b>ay</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-51\"><sup><i><b>az</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-52\"><sup><i><b>ba</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-53\"><sup><i><b>bb</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-54\"><sup><i><b>bc</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-55\"><sup><i><b>bd</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-56\"><sup><i><b>be</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-57\"><sup><i><b>bf</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-58\"><sup><i><b>bg</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-59\"><sup><i><b>bh</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-60\"><sup><i><b>bi</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-61\"><sup><i><b>bj</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-62\"><sup><i><b>bk</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_360_(Acute_Viral)_17-63\"><sup><i><b>bl</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFDienstag2015\" class=\"citation book cs1\">Dienstag, JL (2015). \"Chapter 360: Acute Viral Hepatitis\". In Kasper, D; Fauci, A; Hauser, S; Longo, D; Jameson, J; Loscalzo, J (eds.). <i>Harrison\\'s Principles of Internal Medicine, 19e</i>. New York, NY: McGraw-Hill. <a href=\"/wiki/ISBN_(identifier)\" class=\"mw-redirect\" title=\"ISBN (identifier)\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-0-07-180215-4\" title=\"Special:BookSources/978-0-07-180215-4\"><bdi>978-0-07-180215-4</bdi></a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Chapter+360%3A+Acute+Viral+Hepatitis&amp;rft.btitle=Harrison%27s+Principles+of+Internal+Medicine%2C+19e&amp;rft.place=New+York%2C+NY&amp;rft.pub=McGraw-Hill&amp;rft.date=2015&amp;rft.isbn=978-0-07-180215-4&amp;rft.aulast=Dienstag&amp;rft.aufirst=JL&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-CURRENT_Diagnosis_&amp;_Treatment-18\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-CURRENT_Diagnosis_&amp;_Treatment_18-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-CURRENT_Diagnosis_&amp;_Treatment_18-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-CURRENT_Diagnosis_&amp;_Treatment_18-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-CURRENT_Diagnosis_&amp;_Treatment_18-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-CURRENT_Diagnosis_&amp;_Treatment_18-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-CURRENT_Diagnosis_&amp;_Treatment_18-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-CURRENT_Diagnosis_&amp;_Treatment_18-6\"><sup><i><b>g</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFRutherfordDienstag2016\" class=\"citation book cs1\">Rutherford, A; Dienstag, JL (2016). \"Chapter 40: Viral Hepatitis\". In Greenberger, NJ; Blumberg, RS; Burakoff, R (eds.). <i>CURRENT Diagnosis &amp; Treatment: Gastroenterology, Hepatology, &amp; Endoscopy, 3e</i>. New York, NY: McGraw-Hill. <a href=\"/wiki/ISBN_(identifier)\" class=\"mw-redirect\" title=\"ISBN (identifier)\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-0-07-183772-9\" title=\"Special:BookSources/978-0-07-183772-9\"><bdi>978-0-07-183772-9</bdi></a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Chapter+40%3A+Viral+Hepatitis&amp;rft.btitle=CURRENT+Diagnosis+%26+Treatment%3A+Gastroenterology%2C+Hepatology%2C+%26+Endoscopy%2C+3e&amp;rft.place=New+York%2C+NY&amp;rft.pub=McGraw-Hill&amp;rft.date=2016&amp;rft.isbn=978-0-07-183772-9&amp;rft.aulast=Rutherford&amp;rft.aufirst=A&amp;rft.au=Dienstag%2C+JL&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Khalili_&amp;_Burman-19\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Khalili_&amp;_Burman_19-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Khalili_&amp;_Burman_19-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Khalili_&amp;_Burman_19-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Khalili_&amp;_Burman_19-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Khalili_&amp;_Burman_19-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-Khalili_&amp;_Burman_19-5\"><sup><i><b>f</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFKhaliliBurman2013\" class=\"citation book cs1\">Khalili, M; Burman, B (2013). \"Chapter 14: Liver Disease\". In Hammer, GD; McPhee, SJ (eds.). <i>Pathophysiology of Disease: An Introduction to Clinical Medicine, 7e</i>. McGraw-Hill. <a href=\"/wiki/ISBN_(identifier)\" class=\"mw-redirect\" title=\"ISBN (identifier)\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-1-25-925144-3\" title=\"Special:BookSources/978-1-25-925144-3\"><bdi>978-1-25-925144-3</bdi></a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Chapter+14%3A+Liver+Disease&amp;rft.btitle=Pathophysiology+of+Disease%3A+An+Introduction+to+Clinical+Medicine%2C+7e&amp;rft.pub=McGraw-Hill&amp;rft.date=2013&amp;rft.isbn=978-1-25-925144-3&amp;rft.aulast=Khalili&amp;rft.aufirst=M&amp;rft.au=Burman%2C+B&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Harrison&#39;s_Principles,_chapter_362_(Chronic)-20\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-9\"><sup><i><b>j</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-10\"><sup><i><b>k</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-11\"><sup><i><b>l</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-12\"><sup><i><b>m</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-13\"><sup><i><b>n</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-14\"><sup><i><b>o</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-15\"><sup><i><b>p</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-16\"><sup><i><b>q</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-17\"><sup><i><b>r</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-18\"><sup><i><b>s</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-19\"><sup><i><b>t</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-20\"><sup><i><b>u</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-21\"><sup><i><b>v</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-22\"><sup><i><b>w</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-23\"><sup><i><b>x</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-24\"><sup><i><b>y</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-25\"><sup><i><b>z</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-26\"><sup><i><b>aa</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-27\"><sup><i><b>ab</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-28\"><sup><i><b>ac</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-29\"><sup><i><b>ad</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-30\"><sup><i><b>ae</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-31\"><sup><i><b>af</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-32\"><sup><i><b>ag</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-33\"><sup><i><b>ah</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-34\"><sup><i><b>ai</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-35\"><sup><i><b>aj</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-36\"><sup><i><b>ak</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-37\"><sup><i><b>al</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles,_chapter_362_(Chronic)_20-38\"><sup><i><b>am</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFDienstag2015\" class=\"citation book cs1\">Dienstag, JL (2015). \"Chapter 362: Chronic Hepatitis\". In Kasper, D; Fauci, A; Hauser, S; Longo, D; Jameson, J; Loscalzo, J (eds.). <i>Harrison\\'s Principles of Internal Medicine, 19e</i>. New York, NY: McGraw-Hill. <a href=\"/wiki/ISBN_(identifier)\" class=\"mw-redirect\" title=\"ISBN (identifier)\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-0-07-180215-4\" title=\"Special:BookSources/978-0-07-180215-4\"><bdi>978-0-07-180215-4</bdi></a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Chapter+362%3A+Chronic+Hepatitis&amp;rft.btitle=Harrison%27s+Principles+of+Internal+Medicine%2C+19e&amp;rft.place=New+York%2C+NY&amp;rft.pub=McGraw-Hill&amp;rft.date=2015&amp;rft.isbn=978-0-07-180215-4&amp;rft.aulast=Dienstag&amp;rft.aufirst=JL&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Fontana_&amp;_Hayashi-21\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Fontana_&amp;_Hayashi_21-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Fontana_&amp;_Hayashi_21-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Fontana_&amp;_Hayashi_21-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFFontanaHayashi2014\" class=\"citation journal cs1\">Fontana, Robert; Hayashi, Paul (2014-05-01). <a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1055%2Fs-0034-1375955\">\"Clinical Features, Diagnosis, and Natural History of Drug-Induced Liver Injury\"</a>. <i>Seminars in Liver Disease</i>. <b>34</b> (2): 134–144. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1055%2Fs-0034-1375955\">10.1055/s-0034-1375955</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/24879979\">24879979</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Seminars+in+Liver+Disease&amp;rft.atitle=Clinical+Features%2C+Diagnosis%2C+and+Natural+History+of+Drug-Induced+Liver+Injury&amp;rft.volume=34&amp;rft.issue=2&amp;rft.pages=134-144&amp;rft.date=2014-05-01&amp;rft_id=info%3Adoi%2F10.1055%2Fs-0034-1375955&amp;rft_id=info%3Apmid%2F24879979&amp;rft.aulast=Fontana&amp;rft.aufirst=Robert&amp;rft.au=Hayashi%2C+Paul&amp;rft_id=https%3A%2F%2Fdoi.org%2F10.1055%252Fs-0034-1375955&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Manns_Lohse_Vergani-22\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Manns_Lohse_Vergani_22-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Manns_Lohse_Vergani_22-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFMannsLohseVergani2015\" class=\"citation journal cs1\">Manns, Michael P.; Lohse, Ansgar W.; Vergani, Diego (2015). <a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1016%2Fj.jhep.2015.03.005\">\"Autoimmune hepatitis – Update 2015\"</a>. <i>Journal of Hepatology</i>. <b>62</b> (1): S100–S111. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1016%2Fj.jhep.2015.03.005\">10.1016/j.jhep.2015.03.005</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/25920079\">25920079</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Hepatology&amp;rft.atitle=Autoimmune+hepatitis+%E2%80%93+Update+2015&amp;rft.volume=62&amp;rft.issue=1&amp;rft.pages=S100-S111&amp;rft.date=2015&amp;rft_id=info%3Adoi%2F10.1016%2Fj.jhep.2015.03.005&amp;rft_id=info%3Apmid%2F25920079&amp;rft.aulast=Manns&amp;rft.aufirst=Michael+P.&amp;rft.au=Lohse%2C+Ansgar+W.&amp;rft.au=Vergani%2C+Diego&amp;rft_id=https%3A%2F%2Fdoi.org%2F10.1016%252Fj.jhep.2015.03.005&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-23\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-23\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFMunjalSharm2012\" class=\"citation book cs1\">Munjal, Y. P.; Sharm, Surendra K. (2012). <a rel=\"nofollow\" class=\"external text\" href=\"https://books.google.com/books?id=L7pW3yGjj7kC&amp;pg=PA870\"><i>API Textbook of Medicine, Ninth Edition, Two Volume Set</i></a>. JP Medical Ltd. p.&#160;870. <a href=\"/wiki/ISBN_(identifier)\" class=\"mw-redirect\" title=\"ISBN (identifier)\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/9789350250747\" title=\"Special:BookSources/9789350250747\"><bdi>9789350250747</bdi></a>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20170910162730/https://books.google.com/books?id=L7pW3yGjj7kC&amp;pg=PA870\">Archived</a> from the original on 2017-09-10.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=API+Textbook+of+Medicine%2C+Ninth+Edition%2C+Two+Volume+Set&amp;rft.pages=870&amp;rft.pub=JP+Medical+Ltd&amp;rft.date=2012&amp;rft.isbn=9789350250747&amp;rft.aulast=Munjal&amp;rft.aufirst=Y.+P.&amp;rft.au=Sharm%2C+Surendra+K.&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3DL7pW3yGjj7kC%26pg%3DPA870&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-24\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-24\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFWorld_Health_Organization\" class=\"citation web cs1\">World Health Organization. <a rel=\"nofollow\" class=\"external text\" href=\"https://www.who.int/topics/hepatitis/en/\">\"Hepatitis\"</a>. World Health Organization. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20131202223841/http://www.who.int/topics/hepatitis/en/\">Archived</a> from the original on 2 December 2013<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">25 November</span> 2013</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Hepatitis&amp;rft.pub=World+Health+Organization&amp;rft.au=World+Health+Organization&amp;rft_id=https%3A%2F%2Fwww.who.int%2Ftopics%2Fhepatitis%2Fen%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-25\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-25\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.cdc.gov/hepatitis/hav/afaq.htm\">\"Hepatitis A Questions and Answers for the Public | Division of Viral Hepatitis | CDC\"</a>. <i>www.cdc.gov</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20160312094721/http://www.cdc.gov/hepatitis/hav/afaq.htm\">Archived</a> from the original on 2016-03-12<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-03-14</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cdc.gov&amp;rft.atitle=Hepatitis+A+Questions+and+Answers+for+the+Public+%7C+Division+of+Viral+Hepatitis+%7C+CDC&amp;rft_id=https%3A%2F%2Fwww.cdc.gov%2Fhepatitis%2Fhav%2Fafaq.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-26\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-26\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.who.int/mediacentre/factsheets/fs280/en/\">\"Hepatitis E\"</a>. <i>World Health Organization</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20160312074914/http://www.who.int/mediacentre/factsheets/fs280/en/\">Archived</a> from the original on 2016-03-12<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-03-14</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=World+Health+Organization&amp;rft.atitle=Hepatitis+E&amp;rft_id=https%3A%2F%2Fwww.who.int%2Fmediacentre%2Ffactsheets%2Ffs280%2Fen%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-27\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-27\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFCenters_for_Disease_Control_&amp;_Prevention2010\" class=\"citation web cs1\">Centers for Disease Control &amp; Prevention (June 2010). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.cdc.gov/hepatitis/HBV/PDFs/HepBWhenSomeoneClose.pdf\">\"When Someone Close to You Has Hepatitis\"</a> <span class=\"cs1-format\">(PDF)</span>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20160306084204/http://www.cdc.gov/hepatitis/HBV/PDFs/HepBWhenSomeoneClose.pdf\">Archived</a> <span class=\"cs1-format\">(PDF)</span> from the original on March 6, 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">March 14,</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=When+Someone+Close+to+You+Has+Hepatitis&amp;rft.date=2010-06&amp;rft.au=Centers+for+Disease+Control+%26+Prevention&amp;rft_id=https%3A%2F%2Fwww.cdc.gov%2Fhepatitis%2FHBV%2FPDFs%2FHepBWhenSomeoneClose.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-28\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-28\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.who.int/news-room/fact-sheets/detail/hepatitis-a\">\"Hepatitis A\"</a>. <i>www.who.int</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2023-05-07</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.who.int&amp;rft.atitle=Hepatitis+A&amp;rft_id=https%3A%2F%2Fwww.who.int%2Fnews-room%2Ffact-sheets%2Fdetail%2Fhepatitis-a&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-WHO_Hepatitis_B-29\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-WHO_Hepatitis_B_29-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-WHO_Hepatitis_B_29-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-WHO_Hepatitis_B_29-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-WHO_Hepatitis_B_29-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-WHO_Hepatitis_B_29-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-WHO_Hepatitis_B_29-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-WHO_Hepatitis_B_29-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-WHO_Hepatitis_B_29-7\"><sup><i><b>h</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.who.int/mediacentre/factsheets/fs204/en/\">\"Hepatitis B\"</a>. <i>World Health Organization</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20141109161444/http://www.who.int/mediacentre/factsheets/fs204/en/\">Archived</a> from the original on 2014-11-09<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-03-09</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=World+Health+Organization&amp;rft.atitle=Hepatitis+B&amp;rft_id=https%3A%2F%2Fwww.who.int%2Fmediacentre%2Ffactsheets%2Ffs204%2Fen%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-CDC_FAQ_on_Hepatitis_C-30\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-CDC_FAQ_on_Hepatitis_C_30-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-CDC_FAQ_on_Hepatitis_C_30-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.cdc.gov/hepatitis/hcv/cfaq.htm\">\"Hepatitis C FAQs for the Public | Division of Viral Hepatitis | CDC\"</a>. <i>www.cdc.gov</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20160315151117/http://www.cdc.gov/hepatitis/hcv/cfaq.htm\">Archived</a> from the original on 2016-03-15<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-03-14</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cdc.gov&amp;rft.atitle=Hepatitis+C+FAQs+for+the+Public+%7C+Division+of+Viral+Hepatitis+%7C+CDC&amp;rft_id=https%3A%2F%2Fwww.cdc.gov%2Fhepatitis%2Fhcv%2Fcfaq.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Friedman_55e-31\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Friedman_55e_31-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-9\"><sup><i><b>j</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-10\"><sup><i><b>k</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-11\"><sup><i><b>l</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-12\"><sup><i><b>m</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-13\"><sup><i><b>n</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-14\"><sup><i><b>o</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-15\"><sup><i><b>p</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-16\"><sup><i><b>q</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-17\"><sup><i><b>r</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-18\"><sup><i><b>s</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-19\"><sup><i><b>t</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-20\"><sup><i><b>u</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-21\"><sup><i><b>v</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-22\"><sup><i><b>w</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-23\"><sup><i><b>x</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-24\"><sup><i><b>y</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-25\"><sup><i><b>z</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-26\"><sup><i><b>aa</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-27\"><sup><i><b>ab</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-28\"><sup><i><b>ac</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-29\"><sup><i><b>ad</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-30\"><sup><i><b>ae</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-31\"><sup><i><b>af</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-32\"><sup><i><b>ag</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-33\"><sup><i><b>ah</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-34\"><sup><i><b>ai</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-35\"><sup><i><b>aj</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-36\"><sup><i><b>ak</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-37\"><sup><i><b>al</b></i></sup></a> <a href=\"#cite_ref-Friedman_55e_31-38\"><sup><i><b>am</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFFriedman2015\" class=\"citation book cs1\">Friedman, Lawrence S. (2015). \"Chapter 16: Liver, Biliary Tract, &amp; Pancreas Disorders\". In Papadakis, M; McPhee, SJ; Rabow, MW (eds.). <i>Current Medical Diagnosis &amp; Treatment 2016 55e</i>. McGraw Hill. <a href=\"/wiki/ISBN_(identifier)\" class=\"mw-redirect\" title=\"ISBN (identifier)\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-0071845090\" title=\"Special:BookSources/978-0071845090\"><bdi>978-0071845090</bdi></a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Chapter+16%3A+Liver%2C+Biliary+Tract%2C+%26+Pancreas+Disorders&amp;rft.btitle=Current+Medical+Diagnosis+%26+Treatment+2016+55e&amp;rft.pub=McGraw+Hill&amp;rft.date=2015&amp;rft.isbn=978-0071845090&amp;rft.aulast=Friedman&amp;rft.aufirst=Lawrence+S.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Harder_&amp;_Mehlhorn-32\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Harder_&amp;_Mehlhorn_32-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Harder_&amp;_Mehlhorn_32-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Harder_&amp;_Mehlhorn_32-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Harder_&amp;_Mehlhorn_32-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Harder_&amp;_Mehlhorn_32-4\"><sup><i><b>e</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFHarder,_AMehlhorn,_H2008\" class=\"citation book cs1\">Harder, A; Mehlhorn, H (2008). \"Diseases Caused by Adult Parasites or Their Distinct Life Cycle Stages\". In Weber, O; Protzer, U (eds.). <span class=\"cs1-lock-limited\" title=\"Free access subject to limited trial, subscription normally required\"><a rel=\"nofollow\" class=\"external text\" href=\"https://archive.org/details/comparativehepat00webe\"><i>Comparative Hepatitis</i></a></span>. Birkhauser. pp.&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://archive.org/details/comparativehepat00webe/page/n171\">161</a>–216. <a href=\"/wiki/ISBN_(identifier)\" class=\"mw-redirect\" title=\"ISBN (identifier)\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-3764385576\" title=\"Special:BookSources/978-3764385576\"><bdi>978-3764385576</bdi></a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Diseases+Caused+by+Adult+Parasites+or+Their+Distinct+Life+Cycle+Stages&amp;rft.btitle=Comparative+Hepatitis&amp;rft.pages=161-216&amp;rft.pub=Birkhauser&amp;rft.date=2008&amp;rft.isbn=978-3764385576&amp;rft.au=Harder%2C+A&amp;rft.au=Mehlhorn%2C+H&amp;rft_id=https%3A%2F%2Farchive.org%2Fdetails%2Fcomparativehepat00webe&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Wisplinghoff_&amp;_Appleton-33\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Wisplinghoff_&amp;_Appleton_33-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Wisplinghoff_&amp;_Appleton_33-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Wisplinghoff_&amp;_Appleton_33-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Wisplinghoff_&amp;_Appleton_33-3\"><sup><i><b>d</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFWisplinghoff,_HAppleton,_DL2008\" class=\"citation book cs1\">Wisplinghoff, H; Appleton, DL (2008). \"Bacterial Infections of the Liver\". In Weber, O; Protzer, U (eds.). <span class=\"cs1-lock-limited\" title=\"Free access subject to limited trial, subscription normally required\"><a rel=\"nofollow\" class=\"external text\" href=\"https://archive.org/details/comparativehepat00webe\"><i>Comparative Hepatitis</i></a></span>. Birkhauser. pp.&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://archive.org/details/comparativehepat00webe/page/n153\">143</a>–160. <a href=\"/wiki/ISBN_(identifier)\" class=\"mw-redirect\" title=\"ISBN (identifier)\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-3764385576\" title=\"Special:BookSources/978-3764385576\"><bdi>978-3764385576</bdi></a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Bacterial+Infections+of+the+Liver&amp;rft.btitle=Comparative+Hepatitis&amp;rft.pages=143-160&amp;rft.pub=Birkhauser&amp;rft.date=2008&amp;rft.isbn=978-3764385576&amp;rft.au=Wisplinghoff%2C+H&amp;rft.au=Appleton%2C+DL&amp;rft_id=https%3A%2F%2Farchive.org%2Fdetails%2Fcomparativehepat00webe&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Harrison&#39;s_Principles_chapter_363_(Alcohol)-34\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Harrison&#39;s_Principles_chapter_363_(Alcohol)_34-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles_chapter_363_(Alcohol)_34-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles_chapter_363_(Alcohol)_34-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles_chapter_363_(Alcohol)_34-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles_chapter_363_(Alcohol)_34-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles_chapter_363_(Alcohol)_34-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles_chapter_363_(Alcohol)_34-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles_chapter_363_(Alcohol)_34-7\"><sup><i><b>h</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFMailliard,_MESorrell,_MF2015\" class=\"citation book cs1\">Mailliard, ME; Sorrell, MF (2015). \"Chapter 363: Alcoholic Liver Disease\". In Kasper, D; Fauci, A; Hauser, S; Longo, D; Jameson, J; Loscalzo, J (eds.). <i>Harrison\\'s Principles of Internal Medicine 19e</i>. McGraw-Hill. <a href=\"/wiki/ISBN_(identifier)\" class=\"mw-redirect\" title=\"ISBN (identifier)\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-0-07-180215-4\" title=\"Special:BookSources/978-0-07-180215-4\"><bdi>978-0-07-180215-4</bdi></a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Chapter+363%3A+Alcoholic+Liver+Disease&amp;rft.btitle=Harrison%27s+Principles+of+Internal+Medicine+19e&amp;rft.pub=McGraw-Hill&amp;rft.date=2015&amp;rft.isbn=978-0-07-180215-4&amp;rft.au=Mailliard%2C+ME&amp;rft.au=Sorrell%2C+MF&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Harrison&#39;s_Principles_chapter_361_(Toxic_and_Drug-Induced)-35\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Harrison&#39;s_Principles_chapter_361_(Toxic_and_Drug-Induced)_35-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles_chapter_361_(Toxic_and_Drug-Induced)_35-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles_chapter_361_(Toxic_and_Drug-Induced)_35-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles_chapter_361_(Toxic_and_Drug-Induced)_35-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles_chapter_361_(Toxic_and_Drug-Induced)_35-4\"><sup><i><b>e</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFLee,_WMDienstag,_JL2015\" class=\"citation book cs1\">Lee, WM; Dienstag, JL (2015). \"Chapter 361: Toxic and Drug-Induced Hepatitis\". In Kasper, D; Fauci, A; Hauser, S; Longo, D; Jameson, J; Loscalzo, J (eds.). <i>Harrison\\'s Principles of Internal Medicine 19e</i>. McGraw-Hill. <a href=\"/wiki/ISBN_(identifier)\" class=\"mw-redirect\" title=\"ISBN (identifier)\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-0-07-180215-4\" title=\"Special:BookSources/978-0-07-180215-4\"><bdi>978-0-07-180215-4</bdi></a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Chapter+361%3A+Toxic+and+Drug-Induced+Hepatitis&amp;rft.btitle=Harrison%27s+Principles+of+Internal+Medicine+19e&amp;rft.pub=McGraw-Hill&amp;rft.date=2015&amp;rft.isbn=978-0-07-180215-4&amp;rft.au=Lee%2C+WM&amp;rft.au=Dienstag%2C+JL&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Occupational_exposure_to_solvents-36\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Occupational_exposure_to_solvents_36-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Occupational_exposure_to_solvents_36-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFMalaguarneraCataudellaGiordanoNunnari2012\" class=\"citation journal cs1\">Malaguarnera, Giulia; Cataudella, E; Giordano, M; Nunnari, G; Chisari, G; Malaguarnera, M (2012). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3374978\">\"Toxic hepatitis in occupational exposure to solvents\"</a>. <i>World Journal of Gastroenterology</i>. <b>18</b> (22): 2756–66. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.3748%2Fwjg.v18.i22.2756\">10.3748/wjg.v18.i22.2756</a></span>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3374978\">3374978</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/22719183\">22719183</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=World+Journal+of+Gastroenterology&amp;rft.atitle=Toxic+hepatitis+in+occupational+exposure+to+solvents&amp;rft.volume=18&amp;rft.issue=22&amp;rft.pages=2756-66&amp;rft.date=2012&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3374978%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F22719183&amp;rft_id=info%3Adoi%2F10.3748%2Fwjg.v18.i22.2756&amp;rft.aulast=Malaguarnera&amp;rft.aufirst=Giulia&amp;rft.au=Cataudella%2C+E&amp;rft.au=Giordano%2C+M&amp;rft.au=Nunnari%2C+G&amp;rft.au=Chisari%2C+G&amp;rft.au=Malaguarnera%2C+M&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3374978&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-37\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-37\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFLee2003\" class=\"citation journal cs1\">Lee, William M. (31 July 2003). \"Drug-Induced Hepatotoxicity\". <i>New England Journal of Medicine</i>. <b>349</b> (5): 474–485. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1056%2FNEJMra021844\">10.1056/NEJMra021844</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/12890847\">12890847</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=New+England+Journal+of+Medicine&amp;rft.atitle=Drug-Induced+Hepatotoxicity&amp;rft.volume=349&amp;rft.issue=5&amp;rft.pages=474-485&amp;rft.date=2003-07-31&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMra021844&amp;rft_id=info%3Apmid%2F12890847&amp;rft.aulast=Lee&amp;rft.aufirst=William+M.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-38\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-38\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFSukKim,_Dong_Joon2012\" class=\"citation journal cs1\">Suk, Ki Tae; Kim, Dong Joon (2012). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467427\">\"Drug-induced liver injury: present and future\"</a>. <i>Clinical and Molecular Hepatology</i>. <b>18</b> (3): 249–57. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.3350%2Fcmh.2012.18.3.249\">10.3350/cmh.2012.18.3.249</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467427\">3467427</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/23091804\">23091804</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clinical+and+Molecular+Hepatology&amp;rft.atitle=Drug-induced+liver+injury%3A+present+and+future&amp;rft.volume=18&amp;rft.issue=3&amp;rft.pages=249-57&amp;rft.date=2012&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3467427%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F23091804&amp;rft_id=info%3Adoi%2F10.3350%2Fcmh.2012.18.3.249&amp;rft.aulast=Suk&amp;rft.aufirst=Ki+Tae&amp;rft.au=Kim%2C+Dong+Joon&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3467427&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-NIH_-_herbal_supplements-39\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-NIH_-_herbal_supplements_39-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-NIH_-_herbal_supplements_39-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"http://livertox.nih.gov/Herbals_and_Dietary_Supplements.htm\">\"Herbals_and_Dietary_Supplements\"</a>. <i>livertox.nih.gov</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20160508234736/http://livertox.nih.gov/Herbals_and_Dietary_Supplements.htm\">Archived</a> from the original on 2016-05-08<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-03-14</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=livertox.nih.gov&amp;rft.atitle=Herbals_and_Dietary_Supplements&amp;rft_id=http%3A%2F%2Flivertox.nih.gov%2FHerbals_and_Dietary_Supplements.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-40\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-40\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation news cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.nih.gov/news-events/news-releases/nih-launches-free-database-drugs-associated-liver-injury\">\"NIH launches free database of drugs associated with liver injury\"</a>. <i>National Institutes of Health (NIH)</i>. 2015-09-30<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2018-09-18</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=National+Institutes+of+Health+%28NIH%29&amp;rft.atitle=NIH+launches+free+database+of+drugs+associated+with+liver+injury&amp;rft.date=2015-09-30&amp;rft_id=https%3A%2F%2Fwww.nih.gov%2Fnews-events%2Fnews-releases%2Fnih-launches-free-database-drugs-associated-liver-injury&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-41\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-41\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFO&#39;MaraGebreyes2011\" class=\"citation book cs1\">O\\'Mara SR, Gebreyes K (2011). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.accessmedicine.com/content.aspx?aID=6361074\">\"Chapter 83. Hepatic Disorders, Jaundice, and Hepatic Failure\"</a> <span class=\"cs1-format\">(Online)</span>. In Cydulka RK, Meckler GD (eds.). <i>Tintinalli\\'s Emergency Medicine: A Comprehensive Study Guide</i> (7th&#160;ed.). New York: McGraw-Hill. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20131202233459/http://www.accessmedicine.com/content.aspx?aID=6361074\">Archived</a> from the original on 2 December 2013<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">26 November</span> 2013</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Chapter+83.+Hepatic+Disorders%2C+Jaundice%2C+and+Hepatic+Failure&amp;rft.btitle=Tintinalli%27s+Emergency+Medicine%3A+A+Comprehensive+Study+Guide.&amp;rft.place=New+York&amp;rft.edition=7th&amp;rft.pub=McGraw-Hill&amp;rft.date=2011&amp;rft.aulast=O%27Mara&amp;rft.aufirst=SR&amp;rft.au=Gebreyes%2C+K&amp;rft_id=http%3A%2F%2Fwww.accessmedicine.com%2Fcontent.aspx%3FaID%3D6361074&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Harrison&#39;s_Principles_chapter_364_(Nonalcoholic)-42\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Harrison&#39;s_Principles_chapter_364_(Nonalcoholic)_42-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Harrison&#39;s_Principles_chapter_364_(Nonalcoholic)_42-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFAbdelmalek,_MFDiehl_AM2015\" class=\"citation book cs1\">Abdelmalek, MF; Diehl AM (2015). \"Chapter 364: Nonalcoholic Liver Diseases and Nonalcoholic Steatohepatitis\". In Kasper, D; Fauci, A; Hauser, S; Longo, D; Jameson, J; Loscalzo, J (eds.). <i>Harrison\\'s Principles of Internal Medicine 19e</i>. McGraw-Hill. <a href=\"/wiki/ISBN_(identifier)\" class=\"mw-redirect\" title=\"ISBN (identifier)\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-0-07-180215-4\" title=\"Special:BookSources/978-0-07-180215-4\"><bdi>978-0-07-180215-4</bdi></a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Chapter+364%3A+Nonalcoholic+Liver+Diseases+and+Nonalcoholic+Steatohepatitis&amp;rft.btitle=Harrison%27s+Principles+of+Internal+Medicine+19e&amp;rft.pub=McGraw-Hill&amp;rft.date=2015&amp;rft.isbn=978-0-07-180215-4&amp;rft.au=Abdelmalek%2C+MF&amp;rft.au=Diehl+AM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-National_Digestive_Diseases_Information_Clearinghouse_NDDIC-43\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-National_Digestive_Diseases_Information_Clearinghouse_NDDIC_43-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-National_Digestive_Diseases_Information_Clearinghouse_NDDIC_43-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFNational_Digestive_Diseases_Information_Clearinghouse_(NDDIC)\" class=\"citation web cs1\">National Digestive Diseases Information Clearinghouse (NDDIC). <a rel=\"nofollow\" class=\"external text\" href=\"http://digestive.niddk.nih.gov/ddiseases/pubs/nash/index.aspx\">\"Nonalcoholic Steatohepatitis\"</a>. National Digestive Diseases Information Clearinghouse (NDDIC). <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20131202231555/http://digestive.niddk.nih.gov/ddiseases/pubs/nash/index.aspx\">Archived</a> from the original on 2 December 2013<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">27 November</span> 2013</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Nonalcoholic+Steatohepatitis&amp;rft.pub=National+Digestive+Diseases+Information+Clearinghouse+%28NDDIC%29&amp;rft.au=National+Digestive+Diseases+Information+Clearinghouse+%28NDDIC%29&amp;rft_id=http%3A%2F%2Fdigestive.niddk.nih.gov%2Fddiseases%2Fpubs%2Fnash%2Findex.aspx&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Masuoka_2013_106–122-44\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Masuoka_2013_106–122_44-0\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFMasuokaChalasani,_Naga2013\" class=\"citation journal cs1\">Masuoka, Howard C.; Chalasani, Naga (April 2013). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646408\">\"Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals\"</a>. <i>Annals of the New York Academy of Sciences</i>. <b>1281</b> (1): 106–122. <a href=\"/wiki/Bibcode_(identifier)\" class=\"mw-redirect\" title=\"Bibcode (identifier)\">Bibcode</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://ui.adsabs.harvard.edu/abs/2013NYASA1281..106M\">2013NYASA1281..106M</a>. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1111%2Fnyas.12016\">10.1111/nyas.12016</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646408\">3646408</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/23363012\">23363012</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Annals+of+the+New+York+Academy+of+Sciences&amp;rft.atitle=Nonalcoholic+fatty+liver+disease%3A+an+emerging+threat+to+obese+and+diabetic+individuals&amp;rft.volume=1281&amp;rft.issue=1&amp;rft.pages=106-122&amp;rft.date=2013-04&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3646408%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F23363012&amp;rft_id=info%3Adoi%2F10.1111%2Fnyas.12016&amp;rft_id=info%3Abibcode%2F2013NYASA1281..106M&amp;rft.aulast=Masuoka&amp;rft.aufirst=Howard+C.&amp;rft.au=Chalasani%2C+Naga&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3646408&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-45\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-45\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFNational_Digestive_Diseases_Information_Clearinghouse_(NDDIC)\" class=\"citation web cs1\">National Digestive Diseases Information Clearinghouse (NDDIC). <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20100915033205/http://digestive.niddk.nih.gov/ddiseases/pubs/autoimmunehep/\">\"Autoimmune Hepatitis\"</a>. National Digestive Diseases Information Clearinghouse (NDDIC). Archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://digestive.niddk.nih.gov/ddiseases/pubs/autoimmunehep/\">the original</a> on 15 September 2010<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">27 November</span> 2013</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Autoimmune+Hepatitis&amp;rft.pub=National+Digestive+Diseases+Information+Clearinghouse+%28NDDIC%29&amp;rft.au=National+Digestive+Diseases+Information+Clearinghouse+%28NDDIC%29&amp;rft_id=http%3A%2F%2Fdigestive.niddk.nih.gov%2Fddiseases%2Fpubs%2Fautoimmunehep%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-46\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-46\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFTeufelGalleKanzler2009\" class=\"citation journal cs1\">Teufel, Andreas; Galle, PR; Kanzler, S (2009). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2655176\">\"Update on autoimmune hepatitis\"</a>. <i>World Journal of Gastroenterology</i>. <b>15</b> (9): 1035–41. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.3748%2Fwjg.15.1035\">10.3748/wjg.15.1035</a></span>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2655176\">2655176</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/19266594\">19266594</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=World+Journal+of+Gastroenterology&amp;rft.atitle=Update+on+autoimmune+hepatitis&amp;rft.volume=15&amp;rft.issue=9&amp;rft.pages=1035-41&amp;rft.date=2009&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2655176%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F19266594&amp;rft_id=info%3Adoi%2F10.3748%2Fwjg.15.1035&amp;rft.aulast=Teufel&amp;rft.aufirst=Andreas&amp;rft.au=Galle%2C+PR&amp;rft.au=Kanzler%2C+S&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2655176&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Czaja_Autoimmune-47\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Czaja_Autoimmune_47-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Czaja_Autoimmune_47-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Czaja_Autoimmune_47-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Czaja_Autoimmune_47-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Czaja_Autoimmune_47-4\"><sup><i><b>e</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFCzaja2016\" class=\"citation journal cs1\">Czaja, Albert J (2016). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780448\">\"Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions\"</a>. <i>Gut and Liver</i>. <b>10</b> (2): 177–203. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.5009%2Fgnl15352\">10.5009/gnl15352</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780448\">4780448</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/26934884\">26934884</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Gut+and+Liver&amp;rft.atitle=Diagnosis+and+Management+of+Autoimmune+Hepatitis%3A+Current+Status+and+Future+Directions&amp;rft.volume=10&amp;rft.issue=2&amp;rft.pages=177-203&amp;rft.date=2016&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4780448%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F26934884&amp;rft_id=info%3Adoi%2F10.5009%2Fgnl15352&amp;rft.aulast=Czaja&amp;rft.aufirst=Albert+J&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4780448&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-:0-48\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:0_48-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:0_48-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-:0_48-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFCzaja2016\" class=\"citation journal cs1\">Czaja, Albert J. (2016-03-15). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780448\">\"Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions\"</a>. <i>Gut and Liver</i>. <b>10</b> (2): 177–203. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.5009%2Fgnl15352\">10.5009/gnl15352</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1976-2283\">1976-2283</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780448\">4780448</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/26934884\">26934884</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Gut+and+Liver&amp;rft.atitle=Diagnosis+and+Management+of+Autoimmune+Hepatitis%3A+Current+Status+and+Future+Directions&amp;rft.volume=10&amp;rft.issue=2&amp;rft.pages=177-203&amp;rft.date=2016-03-15&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4780448%23id-name%3DPMC&amp;rft.issn=1976-2283&amp;rft_id=info%3Apmid%2F26934884&amp;rft_id=info%3Adoi%2F10.5009%2Fgnl15352&amp;rft.aulast=Czaja&amp;rft.aufirst=Albert+J.&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4780448&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-49\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-49\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFKrawitt2008\" class=\"citation journal cs1\">Krawitt, Edward-L (2008). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2716584\">\"Clinical features and management of autoimmune hepatitis\"</a>. <i>World Journal of Gastroenterology</i>. <b>14</b> (21): 3301–5. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.3748%2Fwjg.14.3301\">10.3748/wjg.14.3301</a></span>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2716584\">2716584</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/18528927\">18528927</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=World+Journal+of+Gastroenterology&amp;rft.atitle=Clinical+features+and+management+of+autoimmune+hepatitis&amp;rft.volume=14&amp;rft.issue=21&amp;rft.pages=3301-5&amp;rft.date=2008&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2716584%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F18528927&amp;rft_id=info%3Adoi%2F10.3748%2Fwjg.14.3301&amp;rft.aulast=Krawitt&amp;rft.aufirst=Edward-L&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2716584&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-50\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-50\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFTeckman2013\" class=\"citation journal cs1\">Teckman, Jeffrey H. (2013-03-07). \"Liver Disease in Alpha-1 Antitrypsin Deficiency: Current Understanding and Future Therapy\". <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i>. <b>10</b> (sup1): 35–43. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.3109%2F15412555.2013.765839\">10.3109/15412555.2013.765839</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1541-2555\">1541-2555</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/23527737\">23527737</a>. <a href=\"/wiki/S2CID_(identifier)\" class=\"mw-redirect\" title=\"S2CID (identifier)\">S2CID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://api.semanticscholar.org/CorpusID:35451941\">35451941</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=COPD%3A+Journal+of+Chronic+Obstructive+Pulmonary+Disease&amp;rft.atitle=Liver+Disease+in+Alpha-1+Antitrypsin+Deficiency%3A+Current+Understanding+and+Future+Therapy&amp;rft.volume=10&amp;rft.issue=sup1&amp;rft.pages=35-43&amp;rft.date=2013-03-07&amp;rft.issn=1541-2555&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A35451941%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F23527737&amp;rft_id=info%3Adoi%2F10.3109%2F15412555.2013.765839&amp;rft.aulast=Teckman&amp;rft.aufirst=Jeffrey+H.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Hepatic_ischemia-51\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Hepatic_ischemia_51-0\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFMedline_Plus2012\" class=\"citation web cs1\">Medline Plus (2012-08-10). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.nlm.nih.gov/medlineplus/ency/article/000214.htm\">\"Hepatic ischemia\"</a>. National Library of Medicine. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20131208021441/http://www.nlm.nih.gov/medlineplus/ency/article/000214.htm\">Archived</a> from the original on 8 December 2013<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">4 December</span> 2013</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Hepatic+ischemia&amp;rft.pub=National+Library+of+Medicine&amp;rft.date=2012-08-10&amp;rft.au=Medline+Plus&amp;rft_id=https%3A%2F%2Fwww.nlm.nih.gov%2Fmedlineplus%2Fency%2Farticle%2F000214.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-52\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-52\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFFeldman,_FriedmanFeldman,_Brandt2010\" class=\"citation book cs1\">Feldman, Friedman; Feldman, Brandt, eds. (2010). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.mdconsult.com/books/page.do?eid=4-u1.0-B978-1-4160-6189-2..00083-4--s0085&amp;isbn=978-1-4160-6189-2&amp;type=bookPage&amp;from=content&amp;uniqId=431734887-1227\">\"Chapter 83 Vascular Diseases of the Liver\"</a> <span class=\"cs1-format\">(Online)</span>. <i>Sleisenger and Fordtran\\'s Gastrointestinal and Liver Disease</i>. Saunders. <a href=\"/wiki/ISBN_(identifier)\" class=\"mw-redirect\" title=\"ISBN (identifier)\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-1416061892\" title=\"Special:BookSources/978-1416061892\"><bdi>978-1416061892</bdi></a>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20160304110546/http://www.mdconsult.com/books/page.do?eid=4-u1.0-B978-1-4160-6189-2..00083-4--s0085&amp;isbn=978-1-4160-6189-2&amp;type=bookPage&amp;from=content&amp;uniqId=431734887-1227\">Archived</a> from the original on 4 March 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">4 December</span> 2013</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Chapter+83+Vascular+Diseases+of+the+Liver&amp;rft.btitle=Sleisenger+and+Fordtran%27s+Gastrointestinal+and+Liver+Disease&amp;rft.pub=Saunders&amp;rft.date=2010&amp;rft.isbn=978-1416061892&amp;rft_id=http%3A%2F%2Fwww.mdconsult.com%2Fbooks%2Fpage.do%3Feid%3D4-u1.0-B978-1-4160-6189-2..00083-4--s0085%26isbn%3D978-1-4160-6189-2%26type%3DbookPage%26from%3Dcontent%26uniqId%3D431734887-1227&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Biliary_disease_in_infancy-53\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Biliary_disease_in_infancy_53-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Biliary_disease_in_infancy_53-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Biliary_disease_in_infancy_53-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Biliary_disease_in_infancy_53-3\"><sup><i><b>d</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFSamyn,_MMieli-Vergani,_G2015\" class=\"citation journal cs1\">Samyn, M; Mieli-Vergani, G (November 2015). \"Liver and Biliary Disease in Infancy\". <i>Medicine</i>. <b>43</b> (11): 625–630. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1016%2Fj.mpmed.2015.08.008\">10.1016/j.mpmed.2015.08.008</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Medicine&amp;rft.atitle=Liver+and+Biliary+Disease+in+Infancy&amp;rft.volume=43&amp;rft.issue=11&amp;rft.pages=625-630&amp;rft.date=2015-11&amp;rft_id=info%3Adoi%2F10.1016%2Fj.mpmed.2015.08.008&amp;rft.au=Samyn%2C+M&amp;rft.au=Mieli-Vergani%2C+G&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-54\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-54\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFRoberts2003\" class=\"citation journal cs1\">Roberts, Eve A. (2003-10-01). \"Neonatal hepatitis syndrome\". <i>Seminars in Neonatology</i>. <b>8</b> (5): 357–374. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1016%2FS1084-2756%2803%2900093-9\">10.1016/S1084-2756(03)00093-9</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1084-2756\">1084-2756</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/15001124\">15001124</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Seminars+in+Neonatology&amp;rft.atitle=Neonatal+hepatitis+syndrome&amp;rft.volume=8&amp;rft.issue=5&amp;rft.pages=357-374&amp;rft.date=2003-10-01&amp;rft.issn=1084-2756&amp;rft_id=info%3Apmid%2F15001124&amp;rft_id=info%3Adoi%2F10.1016%2FS1084-2756%2803%2900093-9&amp;rft.aulast=Roberts&amp;rft.aufirst=Eve+A.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-55\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-55\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFSokolNarkewicz2012\" class=\"citation book cs1\">Sokol, Ronald J.; Narkewicz, Michael R. (2012-06-21). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.accessmedicine.com/content.aspx?aID=56821699\">\"Chapter 22: Liver &amp; Pancreas\"</a>. In Hay, William W.; et&#160;al. (eds.). <i>Current diagnosis &amp; treatment: pediatrics</i> (21st&#160;ed.). New York: McGraw-Hill Medical. <a href=\"/wiki/ISBN_(identifier)\" class=\"mw-redirect\" title=\"ISBN (identifier)\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-0-07-177970-8\" title=\"Special:BookSources/978-0-07-177970-8\"><bdi>978-0-07-177970-8</bdi></a>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20131210093945/http://www.accessmedicine.com/content.aspx?aID=56821699\">Archived</a> from the original on 10 December 2013<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2 December</span> 2013</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Chapter+22%3A+Liver+%26+Pancreas&amp;rft.btitle=Current+diagnosis+%26+treatment%3A+pediatrics&amp;rft.place=New+York&amp;rft.edition=21st&amp;rft.pub=McGraw-Hill+Medical&amp;rft.date=2012-06-21&amp;rft.isbn=978-0-07-177970-8&amp;rft.aulast=Sokol&amp;rft.aufirst=Ronald+J.&amp;rft.au=Narkewicz%2C+Michael+R.&amp;rft_id=http%3A%2F%2Fwww.accessmedicine.com%2Fcontent.aspx%3FaID%3D56821699&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-56\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-56\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFAlexopoulouDeutsch,_MelanieAgeletopoulou,_JohannaDelladetsima,_Johanna_K.2003\" class=\"citation journal cs1\">Alexopoulou, Alexandra; Deutsch, Melanie; Ageletopoulou, Johanna; Delladetsima, Johanna K.; Marinos, Evangelos; Kapranos, Nikiforos; Dourakis, Spyros P. (May 2003). \"A fatal case of postinfantile giant cell hepatitis in a patient with chronic lymphocytic leukaemia\". <i>European Journal of Gastroenterology &amp; Hepatology</i>. <b>15</b> (5): 551–555. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1097%2F01.meg.0000050026.34359.7c\">10.1097/01.meg.0000050026.34359.7c</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/12702915\">12702915</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=European+Journal+of+Gastroenterology+%26+Hepatology&amp;rft.atitle=A+fatal+case+of+postinfantile+giant+cell+hepatitis+in+a+patient+with+chronic+lymphocytic+leukaemia&amp;rft.volume=15&amp;rft.issue=5&amp;rft.pages=551-555&amp;rft.date=2003-05&amp;rft_id=info%3Adoi%2F10.1097%2F01.meg.0000050026.34359.7c&amp;rft_id=info%3Apmid%2F12702915&amp;rft.aulast=Alexopoulou&amp;rft.aufirst=Alexandra&amp;rft.au=Deutsch%2C+Melanie&amp;rft.au=Ageletopoulou%2C+Johanna&amp;rft.au=Delladetsima%2C+Johanna+K.&amp;rft.au=Marinos%2C+Evangelos&amp;rft.au=Kapranos%2C+Nikiforos&amp;rft.au=Dourakis%2C+Spyros+P.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Nakamoto_&amp;_Kaneko-57\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Nakamoto_&amp;_Kaneko_57-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Nakamoto_&amp;_Kaneko_57-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Nakamoto_&amp;_Kaneko_57-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFNakamotoKaneko2003\" class=\"citation journal cs1\">Nakamoto, Yasunari; Kaneko, Shuichi (2003-09-01). \"Mechanisms of viral hepatitis induced liver injury\". <i>Current Molecular Medicine</i>. <b>3</b> (6): 537–544. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.2174%2F1566524033479591\">10.2174/1566524033479591</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1566-5240\">1566-5240</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/14527085\">14527085</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Current+Molecular+Medicine&amp;rft.atitle=Mechanisms+of+viral+hepatitis+induced+liver+injury&amp;rft.volume=3&amp;rft.issue=6&amp;rft.pages=537-544&amp;rft.date=2003-09-01&amp;rft.issn=1566-5240&amp;rft_id=info%3Apmid%2F14527085&amp;rft_id=info%3Adoi%2F10.2174%2F1566524033479591&amp;rft.aulast=Nakamoto&amp;rft.aufirst=Yasunari&amp;rft.au=Kaneko%2C+Shuichi&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-58\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-58\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFLinZhang2017\" class=\"citation journal cs1\">Lin, Shaoli; Zhang, Yan-Jin (August 2017). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5580487\">\"Interference of Apoptosis by Hepatitis B Virus\"</a>. <i>Viruses</i>. <b>9</b> (8): 230. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.3390%2Fv9080230\">10.3390/v9080230</a></span>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5580487\">5580487</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/28820498\">28820498</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Viruses&amp;rft.atitle=Interference+of+Apoptosis+by+Hepatitis+B+Virus&amp;rft.volume=9&amp;rft.issue=8&amp;rft.pages=230&amp;rft.date=2017-08&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5580487%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F28820498&amp;rft_id=info%3Adoi%2F10.3390%2Fv9080230&amp;rft.aulast=Lin&amp;rft.aufirst=Shaoli&amp;rft.au=Zhang%2C+Yan-Jin&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5580487&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-59\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-59\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFCaoQuanZengYang2016\" class=\"citation journal cs1\">Cao, Lei; Quan, Xi-Bing; Zeng, Wen-Jiao; Yang, Xiao-Ou; Wang, Ming-Jie (2016). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5201115\">\"Mechanism of Hepatocyte Apoptosis\"</a>. <i>Journal of Cell Death</i>. <b>9</b>: 19–29. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.4137%2FJCD.S39824\">10.4137/JCD.S39824</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5201115\">5201115</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/28058033\">28058033</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Cell+Death&amp;rft.atitle=Mechanism+of+Hepatocyte+Apoptosis&amp;rft.volume=9&amp;rft.pages=19-29&amp;rft.date=2016&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5201115%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F28058033&amp;rft_id=info%3Adoi%2F10.4137%2FJCD.S39824&amp;rft.aulast=Cao&amp;rft.aufirst=Lei&amp;rft.au=Quan%2C+Xi-Bing&amp;rft.au=Zeng%2C+Wen-Jiao&amp;rft.au=Yang%2C+Xiao-Ou&amp;rft.au=Wang%2C+Ming-Jie&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5201115&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-60\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-60\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFWong2014\" class=\"citation journal cs1\">Wong, Grace Lai-Hung (2014-09-01). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4197170\">\"Prediction of fibrosis progression in chronic viral hepatitis\"</a>. <i>Clinical and Molecular Hepatology</i>. <b>20</b> (3): 228–236. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.3350%2Fcmh.2014.20.3.228\">10.3350/cmh.2014.20.3.228</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/2287-285X\">2287-285X</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4197170\">4197170</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/25320725\">25320725</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clinical+and+Molecular+Hepatology&amp;rft.atitle=Prediction+of+fibrosis+progression+in+chronic+viral+hepatitis&amp;rft.volume=20&amp;rft.issue=3&amp;rft.pages=228-236&amp;rft.date=2014-09-01&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4197170%23id-name%3DPMC&amp;rft.issn=2287-285X&amp;rft_id=info%3Apmid%2F25320725&amp;rft_id=info%3Adoi%2F10.3350%2Fcmh.2014.20.3.228&amp;rft.aulast=Wong&amp;rft.aufirst=Grace+Lai-Hung&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4197170&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Rehermann_Killer_Cells-61\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Rehermann_Killer_Cells_61-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Rehermann_Killer_Cells_61-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFRehermann2015\" class=\"citation journal cs1\">Rehermann, Barbara (2015-11-01). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678927\">\"Natural Killer Cells in Viral Hepatitis\"</a>. <i>Cellular and Molecular Gastroenterology and Hepatology</i>. <b>1</b> (6): 578–588. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1016%2Fj.jcmgh.2015.09.004\">10.1016/j.jcmgh.2015.09.004</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/2352-345X\">2352-345X</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678927\">4678927</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/26682281\">26682281</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cellular+and+Molecular+Gastroenterology+and+Hepatology&amp;rft.atitle=Natural+Killer+Cells+in+Viral+Hepatitis&amp;rft.volume=1&amp;rft.issue=6&amp;rft.pages=578-588&amp;rft.date=2015-11-01&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4678927%23id-name%3DPMC&amp;rft.issn=2352-345X&amp;rft_id=info%3Apmid%2F26682281&amp;rft_id=info%3Adoi%2F10.1016%2Fj.jcmgh.2015.09.004&amp;rft.aulast=Rehermann&amp;rft.aufirst=Barbara&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4678927&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Heim_&amp;_Thimme-62\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Heim_&amp;_Thimme_62-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Heim_&amp;_Thimme_62-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFHeimThimme2014\" class=\"citation journal cs1\">Heim, Markus H.; Thimme, Robert (2014-11-01). <a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1016%2Fj.jhep.2014.06.035\">\"Innate and adaptive immune responses in HCV infections\"</a>. <i>Journal of Hepatology</i>. <b>61</b> (1 Suppl): S14–25. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1016%2Fj.jhep.2014.06.035\">10.1016/j.jhep.2014.06.035</a></span>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1600-0641\">1600-0641</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/25443342\">25443342</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Hepatology&amp;rft.atitle=Innate+and+adaptive+immune+responses+in+HCV+infections&amp;rft.volume=61&amp;rft.issue=1+Suppl&amp;rft.pages=S14-25&amp;rft.date=2014-11-01&amp;rft.issn=1600-0641&amp;rft_id=info%3Apmid%2F25443342&amp;rft_id=info%3Adoi%2F10.1016%2Fj.jhep.2014.06.035&amp;rft.aulast=Heim&amp;rft.aufirst=Markus+H.&amp;rft.au=Thimme%2C+Robert&amp;rft_id=https%3A%2F%2Fdoi.org%2F10.1016%252Fj.jhep.2014.06.035&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Hardy_Oakley_Anstee_Day-63\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Hardy_Oakley_Anstee_Day_63-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Hardy_Oakley_Anstee_Day_63-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Hardy_Oakley_Anstee_Day_63-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Hardy_Oakley_Anstee_Day_63-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Hardy_Oakley_Anstee_Day_63-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-Hardy_Oakley_Anstee_Day_63-5\"><sup><i><b>f</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFHardyOakleyAnsteeDay2016\" class=\"citation journal cs1\">Hardy, Timothy; Oakley, Fiona; Anstee, Quentin M.; Day, Christopher P. (2016-03-03). <a rel=\"nofollow\" class=\"external text\" href=\"https://zenodo.org/record/3452754\">\"Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum\"</a>. <i>Annual Review of Pathology</i>. <b>11</b>: 451–96. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1146%2Fannurev-pathol-012615-044224\">10.1146/annurev-pathol-012615-044224</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1553-4014\">1553-4014</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/26980160\">26980160</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Annual+Review+of+Pathology&amp;rft.atitle=Nonalcoholic+Fatty+Liver+Disease%3A+Pathogenesis+and+Disease+Spectrum&amp;rft.volume=11&amp;rft.pages=451-96&amp;rft.date=2016-03-03&amp;rft.issn=1553-4014&amp;rft_id=info%3Apmid%2F26980160&amp;rft_id=info%3Adoi%2F10.1146%2Fannurev-pathol-012615-044224&amp;rft.aulast=Hardy&amp;rft.aufirst=Timothy&amp;rft.au=Oakley%2C+Fiona&amp;rft.au=Anstee%2C+Quentin+M.&amp;rft.au=Day%2C+Christopher+P.&amp;rft_id=https%3A%2F%2Fzenodo.org%2Frecord%2F3452754&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span><sup class=\"noprint Inline-Template\"><span style=\"white-space: nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Link_rot\" title=\"Wikipedia:Link rot\"><span title=\"&#160;Dead link tagged February 2022\">permanent dead link</span></a></i>&#93;</span></sup></span>\\n</li>\\n<li id=\"cite_note-Yoon_&amp;_Cha_Pathogenesis-64\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Yoon_&amp;_Cha_Pathogenesis_64-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Yoon_&amp;_Cha_Pathogenesis_64-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Yoon_&amp;_Cha_Pathogenesis_64-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Yoon_&amp;_Cha_Pathogenesis_64-3\"><sup><i><b>d</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFYoonCha2014\" class=\"citation journal cs1\">Yoon, Hye-Jin; Cha, Bong Soo (2014-11-27). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243154\">\"Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease\"</a>. <i>World Journal of Hepatology</i>. <b>6</b> (11): 800–811. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.4254%2Fwjh.v6.i11.800\">10.4254/wjh.v6.i11.800</a></span>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1948-5182\">1948-5182</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243154\">4243154</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/25429318\">25429318</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=World+Journal+of+Hepatology&amp;rft.atitle=Pathogenesis+and+therapeutic+approaches+for+non-alcoholic+fatty+liver+disease&amp;rft.volume=6&amp;rft.issue=11&amp;rft.pages=800-811&amp;rft.date=2014-11-27&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4243154%23id-name%3DPMC&amp;rft.issn=1948-5182&amp;rft_id=info%3Apmid%2F25429318&amp;rft_id=info%3Adoi%2F10.4254%2Fwjh.v6.i11.800&amp;rft.aulast=Yoon&amp;rft.aufirst=Hye-Jin&amp;rft.au=Cha%2C+Bong+Soo&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4243154&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Chayanupatkul_&amp;_Liangpunsakul-65\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Chayanupatkul_&amp;_Liangpunsakul_65-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Chayanupatkul_&amp;_Liangpunsakul_65-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Chayanupatkul_&amp;_Liangpunsakul_65-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Chayanupatkul_&amp;_Liangpunsakul_65-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Chayanupatkul_&amp;_Liangpunsakul_65-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-Chayanupatkul_&amp;_Liangpunsakul_65-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-Chayanupatkul_&amp;_Liangpunsakul_65-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-Chayanupatkul_&amp;_Liangpunsakul_65-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-Chayanupatkul_&amp;_Liangpunsakul_65-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-Chayanupatkul_&amp;_Liangpunsakul_65-9\"><sup><i><b>j</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFChayanupatkulLiangpunsakul2014\" class=\"citation journal cs1\">Chayanupatkul, Maneerat; Liangpunsakul, Suthat (2014-05-28). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033465\">\"Alcoholic hepatitis: a comprehensive review of pathogenesis and treatment\"</a>. <i>World Journal of Gastroenterology</i>. <b>20</b> (20): 6279–6286. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.3748%2Fwjg.v20.i20.6279\">10.3748/wjg.v20.i20.6279</a></span>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/2219-2840\">2219-2840</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033465\">4033465</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/24876748\">24876748</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=World+Journal+of+Gastroenterology&amp;rft.atitle=Alcoholic+hepatitis%3A+a+comprehensive+review+of+pathogenesis+and+treatment&amp;rft.volume=20&amp;rft.issue=20&amp;rft.pages=6279-6286&amp;rft.date=2014-05-28&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4033465%23id-name%3DPMC&amp;rft.issn=2219-2840&amp;rft_id=info%3Apmid%2F24876748&amp;rft_id=info%3Adoi%2F10.3748%2Fwjg.v20.i20.6279&amp;rft.aulast=Chayanupatkul&amp;rft.aufirst=Maneerat&amp;rft.au=Liangpunsakul%2C+Suthat&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4033465&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Definition,_epidemiology,_and_magnitude-66\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Definition,_epidemiology,_and_magnitude_66-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Definition,_epidemiology,_and_magnitude_66-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Definition,_epidemiology,_and_magnitude_66-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Definition,_epidemiology,_and_magnitude_66-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Definition,_epidemiology,_and_magnitude_66-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-Definition,_epidemiology,_and_magnitude_66-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-Definition,_epidemiology,_and_magnitude_66-6\"><sup><i><b>g</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFBasraAnand2011\" class=\"citation journal cs1\">Basra, Sarpreet; Anand, Bhupinderjit S. (2011-05-27). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3124876\">\"Definition, epidemiology and magnitude of alcoholic hepatitis\"</a>. <i>World Journal of Hepatology</i>. <b>3</b> (5): 108–113. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.4254%2Fwjh.v3.i5.108\">10.4254/wjh.v3.i5.108</a></span>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1948-5182\">1948-5182</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3124876\">3124876</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/21731902\">21731902</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=World+Journal+of+Hepatology&amp;rft.atitle=Definition%2C+epidemiology+and+magnitude+of+alcoholic+hepatitis&amp;rft.volume=3&amp;rft.issue=5&amp;rft.pages=108-113&amp;rft.date=2011-05-27&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3124876%23id-name%3DPMC&amp;rft.issn=1948-5182&amp;rft_id=info%3Apmid%2F21731902&amp;rft_id=info%3Adoi%2F10.4254%2Fwjh.v3.i5.108&amp;rft.aulast=Basra&amp;rft.aufirst=Sarpreet&amp;rft.au=Anand%2C+Bhupinderjit+S.&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3124876&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-67\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-67\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFHagaKandaSasakiNakamura2015\" class=\"citation journal cs1\">Haga, Yuki; Kanda, Tatsuo; Sasaki, Reina; Nakamura, Masato; Nakamoto, Shingo; Yokosuka, Osamu (2015-12-14). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674717\">\"Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis\"</a>. <i>World Journal of Gastroenterology</i>. <b>21</b> (46): 12989–12995. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.3748%2Fwjg.v21.i46.12989\">10.3748/wjg.v21.i46.12989</a></span>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/2219-2840\">2219-2840</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674717\">4674717</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/26675364\">26675364</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=World+Journal+of+Gastroenterology&amp;rft.atitle=Nonalcoholic+fatty+liver+disease+and+hepatic+cirrhosis%3A+Comparison+with+viral+hepatitis-associated+steatosis&amp;rft.volume=21&amp;rft.issue=46&amp;rft.pages=12989-12995&amp;rft.date=2015-12-14&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4674717%23id-name%3DPMC&amp;rft.issn=2219-2840&amp;rft_id=info%3Apmid%2F26675364&amp;rft_id=info%3Adoi%2F10.3748%2Fwjg.v21.i46.12989&amp;rft.aulast=Haga&amp;rft.aufirst=Yuki&amp;rft.au=Kanda%2C+Tatsuo&amp;rft.au=Sasaki%2C+Reina&amp;rft.au=Nakamura%2C+Masato&amp;rft.au=Nakamoto%2C+Shingo&amp;rft.au=Yokosuka%2C+Osamu&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4674717&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-68\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-68\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFGrantNeuberger_J1999\" class=\"citation journal cs1\">Grant, A; Neuberger J (1999). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766696\">\"Guidelines on the use of liver biopsy in clinical practice\"</a>. <i>Gut</i>. <b>45</b> (Suppl 4): 1–11. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1136%2Fgut.45.2008.iv1\">10.1136/gut.45.2008.iv1</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766696\">1766696</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/10485854\">10485854</a>. <q>The main cause of mortality after percutaneous liver biopsy is intraperitoneal haemorrhage as shown in a retrospective Italian study of 68 000 percutaneous liver biopsies in which all six patients who died did so from intraperitoneal haemorrhage. Three of these patients had had a laparotomy, and all had either cirrhosis or malignant disease, both of which are risk factors for bleeding.</q></cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Gut&amp;rft.atitle=Guidelines+on+the+use+of+liver+biopsy+in+clinical+practice&amp;rft.volume=45&amp;rft.issue=Suppl+4&amp;rft.pages=1-11&amp;rft.date=1999&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1766696%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F10485854&amp;rft_id=info%3Adoi%2F10.1136%2Fgut.45.2008.iv1&amp;rft.aulast=Grant&amp;rft.aufirst=A&amp;rft.au=Neuberger+J&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1766696&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-69\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-69\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFGreenFlamm,_S2002\" class=\"citation journal cs1\">Green, RM; Flamm, S (October 2002). \"AGA technical review on the evaluation of liver chemistry tests\". <i>Gastroenterology</i>. <b>123</b> (4): 1367–84. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1053%2Fgast.2002.36061\">10.1053/gast.2002.36061</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/12360498\">12360498</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Gastroenterology&amp;rft.atitle=AGA+technical+review+on+the+evaluation+of+liver+chemistry+tests&amp;rft.volume=123&amp;rft.issue=4&amp;rft.pages=1367-84&amp;rft.date=2002-10&amp;rft_id=info%3Adoi%2F10.1053%2Fgast.2002.36061&amp;rft_id=info%3Apmid%2F12360498&amp;rft.aulast=Green&amp;rft.aufirst=RM&amp;rft.au=Flamm%2C+S&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-70\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-70\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFPrattKaplan,_MM2000\" class=\"citation journal cs1\">Pratt, DS; Kaplan, MM (Apr 27, 2000). \"Evaluation of abnormal liver-enzyme results in asymptomatic patients\". <i>The New England Journal of Medicine</i>. <b>342</b> (17): 1266–71. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1056%2FNEJM200004273421707\">10.1056/NEJM200004273421707</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/10781624\">10781624</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+England+Journal+of+Medicine&amp;rft.atitle=Evaluation+of+abnormal+liver-enzyme+results+in+asymptomatic+patients&amp;rft.volume=342&amp;rft.issue=17&amp;rft.pages=1266-71&amp;rft.date=2000-04-27&amp;rft_id=info%3Adoi%2F10.1056%2FNEJM200004273421707&amp;rft_id=info%3Apmid%2F10781624&amp;rft.aulast=Pratt&amp;rft.aufirst=DS&amp;rft.au=Kaplan%2C+MM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-71\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-71\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFItoMitchell2004\" class=\"citation journal cs1\">Ito, Katsuyoshi; Mitchell, Donald G. (2004). \"Imaging Diagnosis of Cirrhosis and Chronic Hepatitis\". <i>Intervirology</i>. <b>47</b> (3–5): 134–143. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1159%2F000078465\">10.1159/000078465</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/15383722\">15383722</a>. <a href=\"/wiki/S2CID_(identifier)\" class=\"mw-redirect\" title=\"S2CID (identifier)\">S2CID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://api.semanticscholar.org/CorpusID:36112368\">36112368</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Intervirology&amp;rft.atitle=Imaging+Diagnosis+of+Cirrhosis+and+Chronic+Hepatitis&amp;rft.volume=47&amp;rft.issue=3%E2%80%935&amp;rft.pages=134-143&amp;rft.date=2004&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A36112368%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F15383722&amp;rft_id=info%3Adoi%2F10.1159%2F000078465&amp;rft.aulast=Ito&amp;rft.aufirst=Katsuyoshi&amp;rft.au=Mitchell%2C+Donald+G.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-72\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-72\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFAllanThoirsPhillips2010\" class=\"citation journal cs1\">Allan, Richard; Thoirs, Kerry; Phillips, Maureen (2010-07-28). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2909550\">\"Accuracy of ultrasound to identify chronic liver disease\"</a>. <i>World Journal of Gastroenterology</i>. <b>16</b> (28): 3510–3520. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.3748%2Fwjg.v16.i28.3510\">10.3748/wjg.v16.i28.3510</a></span>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1007-9327\">1007-9327</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2909550\">2909550</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/20653059\">20653059</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=World+Journal+of+Gastroenterology&amp;rft.atitle=Accuracy+of+ultrasound+to+identify+chronic+liver+disease&amp;rft.volume=16&amp;rft.issue=28&amp;rft.pages=3510-3520&amp;rft.date=2010-07-28&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2909550%23id-name%3DPMC&amp;rft.issn=1007-9327&amp;rft_id=info%3Apmid%2F20653059&amp;rft_id=info%3Adoi%2F10.3748%2Fwjg.v16.i28.3510&amp;rft.aulast=Allan&amp;rft.aufirst=Richard&amp;rft.au=Thoirs%2C+Kerry&amp;rft.au=Phillips%2C+Maureen&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2909550&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-73\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-73\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFSahaniKalva2004\" class=\"citation journal cs1\">Sahani, Dushyant V.; Kalva, Sanjeeva P. (2004-07-01). <a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1634%2Ftheoncologist.9-4-385\">\"Imaging the Liver\"</a>. <i>The Oncologist</i>. <b>9</b> (4): 385–397. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1634%2Ftheoncologist.9-4-385\">10.1634/theoncologist.9-4-385</a></span>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1083-7159\">1083-7159</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/15266092\">15266092</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Oncologist&amp;rft.atitle=Imaging+the+Liver&amp;rft.volume=9&amp;rft.issue=4&amp;rft.pages=385-397&amp;rft.date=2004-07-01&amp;rft.issn=1083-7159&amp;rft_id=info%3Apmid%2F15266092&amp;rft_id=info%3Adoi%2F10.1634%2Ftheoncologist.9-4-385&amp;rft.aulast=Sahani&amp;rft.aufirst=Dushyant+V.&amp;rft.au=Kalva%2C+Sanjeeva+P.&amp;rft_id=https%3A%2F%2Fdoi.org%2F10.1634%252Ftheoncologist.9-4-385&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-pmid26568915-74\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid26568915_74-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid26568915_74-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFVillarCruzBarbosaBezerra2015\" class=\"citation journal cs1\">Villar LM, Cruz HM, Barbosa JR, Bezerra CS, Portilho MM, Scalioni Lde P (2015). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641225\">\"Update on hepatitis B and C virus diagnosis\"</a>. <i>World Journal of Virology</i>. <b>4</b> (4): 323–42. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.5501%2Fwjv.v4.i4.323\">10.5501/wjv.v4.i4.323</a></span>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641225\">4641225</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/26568915\">26568915</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=World+Journal+of+Virology&amp;rft.atitle=Update+on+hepatitis+B+and+C+virus+diagnosis&amp;rft.volume=4&amp;rft.issue=4&amp;rft.pages=323-42&amp;rft.date=2015&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4641225%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F26568915&amp;rft_id=info%3Adoi%2F10.5501%2Fwjv.v4.i4.323&amp;rft.aulast=Villar&amp;rft.aufirst=LM&amp;rft.au=Cruz%2C+HM&amp;rft.au=Barbosa%2C+JR&amp;rft.au=Bezerra%2C+CS&amp;rft.au=Portilho%2C+MM&amp;rft.au=Scalioni+Lde%2C+P&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4641225&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Neuman,_French,_et_al-75\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Neuman,_French,_et_al_75-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Neuman,_French,_et_al_75-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFNeumanFrenchFrenchSeitz2014\" class=\"citation journal cs1\">Neuman, Manuela G.; French, Samuel W.; French, Barbara A.; Seitz, Helmut K.; Cohen, Lawrence B.; Mueller, Sebastian; Osna, Natalia A.; Kharbanda, Kusum K.; Seth, Devanshi (2014-12-01). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696068\">\"Alcoholic and non-alcoholic steatohepatitis\"</a>. <i>Experimental and Molecular Pathology</i>. <b>97</b> (3): 492–510. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1016%2Fj.yexmp.2014.09.005\">10.1016/j.yexmp.2014.09.005</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696068\">4696068</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/25217800\">25217800</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Experimental+and+Molecular+Pathology&amp;rft.atitle=Alcoholic+and+non-alcoholic+steatohepatitis&amp;rft.volume=97&amp;rft.issue=3&amp;rft.pages=492-510&amp;rft.date=2014-12-01&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4696068%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F25217800&amp;rft_id=info%3Adoi%2F10.1016%2Fj.yexmp.2014.09.005&amp;rft.aulast=Neuman&amp;rft.aufirst=Manuela+G.&amp;rft.au=French%2C+Samuel+W.&amp;rft.au=French%2C+Barbara+A.&amp;rft.au=Seitz%2C+Helmut+K.&amp;rft.au=Cohen%2C+Lawrence+B.&amp;rft.au=Mueller%2C+Sebastian&amp;rft.au=Osna%2C+Natalia+A.&amp;rft.au=Kharbanda%2C+Kusum+K.&amp;rft.au=Seth%2C+Devanshi&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4696068&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-76\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-76\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.testing.com/hepatitis-testing/\">\"Hepatitis Testing\"</a>. <i>Testing.com</i>. 2021-08-13<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2023-05-12</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Testing.com&amp;rft.atitle=Hepatitis+Testing&amp;rft.date=2021-08-13&amp;rft_id=https%3A%2F%2Fwww.testing.com%2Fhepatitis-testing%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-77\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-77\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.cdc.gov/hepatitis/statistics/surveillanceguidelines.htm\">\"Guidelines For Viral Hepatitis Surveillance And Case Management\"</a>. <i>www.cdc.gov</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20160310094046/http://www.cdc.gov/hepatitis/statistics/surveillanceguidelines.htm\">Archived</a> from the original on 2016-03-10<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-03-12</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cdc.gov&amp;rft.atitle=Guidelines+For+Viral+Hepatitis+Surveillance+And+Case+Management&amp;rft_id=https%3A%2F%2Fwww.cdc.gov%2Fhepatitis%2Fstatistics%2Fsurveillanceguidelines.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-78\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-78\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFHarrison2013\" class=\"citation book cs1\">Harrison, Tindsley Randolph (2013). \"Chapter 164: Chronic Hepatitis\". In Longo, Dan L.; <a href=\"/wiki/Anthony_Fauci\" title=\"Anthony Fauci\">Fauci, Anthony S.</a>; Kasper, Dennis L.; Hauser, Stephen L.; Jameson, L. Jerry; Loscalzo, Jerry (eds.). <i>Harrison\\'s Manual of Medicine</i> (18&#160;ed.). New York, NY: McGraw-Hill.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Chapter+164%3A+Chronic+Hepatitis&amp;rft.btitle=Harrison%27s+Manual+of+Medicine&amp;rft.place=New+York%2C+NY&amp;rft.edition=18&amp;rft.pub=McGraw-Hill&amp;rft.date=2013&amp;rft.aulast=Harrison&amp;rft.aufirst=Tindsley+Randolph&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-WHO_Hep_A_Fact_Sheet_July_2015-79\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-WHO_Hep_A_Fact_Sheet_July_2015_79-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-WHO_Hep_A_Fact_Sheet_July_2015_79-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-WHO_Hep_A_Fact_Sheet_July_2015_79-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-WHO_Hep_A_Fact_Sheet_July_2015_79-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-WHO_Hep_A_Fact_Sheet_July_2015_79-4\"><sup><i><b>e</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.who.int/mediacentre/factsheets/fs328/en/\">\"Hepatitis A Fact sheet N°328\"</a>. <i>WHO Media Centre</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20140221042107/http://www.who.int/mediacentre/factsheets/fs328/en/\">Archived</a> from the original on February 21, 2014<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">March 7,</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=WHO+Media+Centre&amp;rft.atitle=Hepatitis+A+Fact+sheet+N%C2%B0328&amp;rft_id=https%3A%2F%2Fwww.who.int%2Fmediacentre%2Ffactsheets%2Ffs328%2Fen%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Voise_2011-80\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Voise_2011_80-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Voise_2011_80-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Voise_2011_80-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Voise_2011_80-3\"><sup><i><b>d</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFVoise2011\" class=\"citation journal cs1\">Voise, Nathan (Oct 2011). \"Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention. A shot at hepatitis prevention\". <i>J Am Osteopath Assoc</i>. <b>111</b> (10 Suppl 6): S13–6. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/22086888\">22086888</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J+Am+Osteopath+Assoc&amp;rft.atitle=Advisory+Committee+on+Immunization+Practices+%28ACIP%29+of+the+Centers+for+Disease+Control+and+Prevention.+A+shot+at+hepatitis+prevention.&amp;rft.volume=111&amp;rft.issue=10+Suppl+6&amp;rft.pages=S13-6&amp;rft.date=2011-10&amp;rft_id=info%3Apmid%2F22086888&amp;rft.aulast=Voise&amp;rft.aufirst=Nathan&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-CDC_Adult_Vaccine-81\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-CDC_Adult_Vaccine_81-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-CDC_Adult_Vaccine_81-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-CDC_Adult_Vaccine_81-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html\">\"Adult Immunization Schedule by Vaccine and Age Group\"</a>. <i>www.CDC.gov</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20160305212647/http://www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html\">Archived</a> from the original on March 5, 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">March 7,</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.CDC.gov&amp;rft.atitle=Adult+Immunization+Schedule+by+Vaccine+and+Age+Group&amp;rft_id=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fschedules%2Fhcp%2Fchild-adolescent.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-82\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-82\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFLongo,_Dan_L.2013\" class=\"citation book cs1\">Longo, Dan L.; et&#160;al. (2013). <i>Chapter 163: \"Acute Hepatitis.\" Harrison\\'s Manual of Medicine, 18e</i>. New York, NY: McGraw-Hill.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Chapter+163%3A+%22Acute+Hepatitis.%22+Harrison%27s+Manual+of+Medicine%2C+18e.&amp;rft.place=New+York%2C+NY&amp;rft.pub=McGraw-Hill&amp;rft.date=2013&amp;rft.au=Longo%2C+Dan+L.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-CDC_recommendations_for_Hepatitis_B-83\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-CDC_recommendations_for_Hepatitis_B_83-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-CDC_recommendations_for_Hepatitis_B_83-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-CDC_recommendations_for_Hepatitis_B_83-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-CDC_recommendations_for_Hepatitis_B_83-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-CDC_recommendations_for_Hepatitis_B_83-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-CDC_recommendations_for_Hepatitis_B_83-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-CDC_recommendations_for_Hepatitis_B_83-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-CDC_recommendations_for_Hepatitis_B_83-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-CDC_recommendations_for_Hepatitis_B_83-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-CDC_recommendations_for_Hepatitis_B_83-9\"><sup><i><b>j</b></i></sup></a> <a href=\"#cite_ref-CDC_recommendations_for_Hepatitis_B_83-10\"><sup><i><b>k</b></i></sup></a> <a href=\"#cite_ref-CDC_recommendations_for_Hepatitis_B_83-11\"><sup><i><b>l</b></i></sup></a> <a href=\"#cite_ref-CDC_recommendations_for_Hepatitis_B_83-12\"><sup><i><b>m</b></i></sup></a> <a href=\"#cite_ref-CDC_recommendations_for_Hepatitis_B_83-13\"><sup><i><b>n</b></i></sup></a> <a href=\"#cite_ref-CDC_recommendations_for_Hepatitis_B_83-14\"><sup><i><b>o</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5708a1.htm#fig3\">\"Recommendations for Identification and Public Health Management of Persons with Chronic Hepatitis B Virus Infection\"</a>. <i>www.cdc.gov</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20160306035320/http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5708a1.htm#fig3\">Archived</a> from the original on 2016-03-06<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-03-11</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cdc.gov&amp;rft.atitle=Recommendations+for+Identification+and+Public+Health+Management+of+Persons+with+Chronic+Hepatitis+B+Virus+Infection&amp;rft_id=https%3A%2F%2Fwww.cdc.gov%2Fmmwr%2Fpreview%2Fmmwrhtml%2Frr5708a1.htm%23fig3&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Screening_for_Hepatitis_B-84\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Screening_for_Hepatitis_B_84-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Screening_for_Hepatitis_B_84-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Screening_for_Hepatitis_B_84-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Screening_for_Hepatitis_B_84-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Screening_for_Hepatitis_B_84-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-Screening_for_Hepatitis_B_84-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-Screening_for_Hepatitis_B_84-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-Screening_for_Hepatitis_B_84-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-Screening_for_Hepatitis_B_84-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-Screening_for_Hepatitis_B_84-9\"><sup><i><b>j</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFChouDanaBougatsosBlazina2014\" class=\"citation book cs1\">Chou, Roger; Dana, Tracy; Bougatsos, Christina; Blazina, Ian; Zakher, Bernadette; Khangura, Jessi (2014-01-01). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/books/NBK208504/\"><i>Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults: Systematic Review to Update the 2004 U.S. Preventive Services Task Force Recommendation</i></a>. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. Rockville (MD): Agency for Healthcare Research and Quality (US). <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/24921112\">24921112</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Screening+for+Hepatitis+B+Virus+Infection+in+Nonpregnant+Adolescents+and+Adults%3A+Systematic+Review+to+Update+the+2004+U.S.+Preventive+Services+Task+Force+Recommendation&amp;rft.place=Rockville+%28MD%29&amp;rft.series=U.S.+Preventive+Services+Task+Force+Evidence+Syntheses%2C+formerly+Systematic+Evidence+Reviews&amp;rft.pub=Agency+for+Healthcare+Research+and+Quality+%28US%29&amp;rft.date=2014-01-01&amp;rft_id=info%3Apmid%2F24921112&amp;rft.aulast=Chou&amp;rft.aufirst=Roger&amp;rft.au=Dana%2C+Tracy&amp;rft.au=Bougatsos%2C+Christina&amp;rft.au=Blazina%2C+Ian&amp;rft.au=Zakher%2C+Bernadette&amp;rft.au=Khangura%2C+Jessi&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK208504%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-WHO_guidelines_for_chronic_Hepatitis_B-85\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-WHO_guidelines_for_chronic_Hepatitis_B_85-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-WHO_guidelines_for_chronic_Hepatitis_B_85-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-WHO_guidelines_for_chronic_Hepatitis_B_85-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-WHO_guidelines_for_chronic_Hepatitis_B_85-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-WHO_guidelines_for_chronic_Hepatitis_B_85-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-WHO_guidelines_for_chronic_Hepatitis_B_85-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-WHO_guidelines_for_chronic_Hepatitis_B_85-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-WHO_guidelines_for_chronic_Hepatitis_B_85-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-WHO_guidelines_for_chronic_Hepatitis_B_85-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-WHO_guidelines_for_chronic_Hepatitis_B_85-9\"><sup><i><b>j</b></i></sup></a> <a href=\"#cite_ref-WHO_guidelines_for_chronic_Hepatitis_B_85-10\"><sup><i><b>k</b></i></sup></a> <a href=\"#cite_ref-WHO_guidelines_for_chronic_Hepatitis_B_85-11\"><sup><i><b>l</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20160220104219/http://www.who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/\">\"Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection\"</a>. <i>World Health Organization</i>. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"https://www.who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/\">the original</a> on 2016-02-20<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-03-11</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=World+Health+Organization&amp;rft.atitle=Guidelines+for+the+prevention%2C+care+and+treatment+of+persons+with+chronic+hepatitis+B+infection&amp;rft_id=https%3A%2F%2Fwww.who.int%2Fhiv%2Fpub%2Fhepatitis%2Fhepatitis-b-guidelines%2Fen%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-ACOG_Practice_Bulletin-86\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-ACOG_Practice_Bulletin_86-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-ACOG_Practice_Bulletin_86-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-ACOG_Practice_Bulletin_86-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-ACOG_Practice_Bulletin_86-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-ACOG_Practice_Bulletin_86-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-ACOG_Practice_Bulletin_86-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-ACOG_Practice_Bulletin_86-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-ACOG_Practice_Bulletin_86-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-ACOG_Practice_Bulletin_86-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-ACOG_Practice_Bulletin_86-9\"><sup><i><b>j</b></i></sup></a> <a href=\"#cite_ref-ACOG_Practice_Bulletin_86-10\"><sup><i><b>k</b></i></sup></a> <a href=\"#cite_ref-ACOG_Practice_Bulletin_86-11\"><sup><i><b>l</b></i></sup></a> <a href=\"#cite_ref-ACOG_Practice_Bulletin_86-12\"><sup><i><b>m</b></i></sup></a> <a href=\"#cite_ref-ACOG_Practice_Bulletin_86-13\"><sup><i><b>n</b></i></sup></a> <a href=\"#cite_ref-ACOG_Practice_Bulletin_86-14\"><sup><i><b>o</b></i></sup></a> <a href=\"#cite_ref-ACOG_Practice_Bulletin_86-15\"><sup><i><b>p</b></i></sup></a> <a href=\"#cite_ref-ACOG_Practice_Bulletin_86-16\"><sup><i><b>q</b></i></sup></a> <a href=\"#cite_ref-ACOG_Practice_Bulletin_86-17\"><sup><i><b>r</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20200807231110/https://www.acog.org/Resources-And-Publications/Practice-Bulletins/Committee-on-Practice-Bulletins-Obstetrics/Viral-Hepatitis-in-Pregnancy\">\"ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists: Viral Hepatitis in Pregnancy\"</a>. <i>www.acog.org</i>. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://www.acog.org/Resources-And-Publications/Practice-Bulletins/Committee-on-Practice-Bulletins-Obstetrics/Viral-Hepatitis-in-Pregnancy\">the original</a> on 2020-08-07<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-03-12</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.acog.org&amp;rft.atitle=ACOG+Practice+Bulletin%3A+Clinical+Management+Guidelines+for+Obstetrician-Gynecologists%3A+Viral+Hepatitis+in+Pregnancy&amp;rft_id=http%3A%2F%2Fwww.acog.org%2FResources-And-Publications%2FPractice-Bulletins%2FCommittee-on-Practice-Bulletins-Obstetrics%2FViral-Hepatitis-in-Pregnancy&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-87\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-87\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFEsherick_JSClark_DSSlater_ED2015\" class=\"citation book cs1\">Esherick JS; Clark DS; Slater ED; et&#160;al. (2015). <i>CURRENT Practice Guidelines in Primary Care 2015</i>. New York, NY: McGraw-Hill.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=CURRENT+Practice+Guidelines+in+Primary+Care+2015&amp;rft.place=New+York%2C+NY&amp;rft.pub=McGraw-Hill&amp;rft.date=2015&amp;rft.au=Esherick+JS&amp;rft.au=Clark+DS&amp;rft.au=Slater+ED&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-CDC_-_HCV_prevention-88\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-CDC_-_HCV_prevention_88-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-CDC_-_HCV_prevention_88-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-CDC_-_HCV_prevention_88-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-CDC_-_HCV_prevention_88-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-CDC_-_HCV_prevention_88-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-CDC_-_HCV_prevention_88-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-CDC_-_HCV_prevention_88-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-CDC_-_HCV_prevention_88-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-CDC_-_HCV_prevention_88-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-CDC_-_HCV_prevention_88-9\"><sup><i><b>j</b></i></sup></a> <a href=\"#cite_ref-CDC_-_HCV_prevention_88-10\"><sup><i><b>k</b></i></sup></a> <a href=\"#cite_ref-CDC_-_HCV_prevention_88-11\"><sup><i><b>l</b></i></sup></a> <a href=\"#cite_ref-CDC_-_HCV_prevention_88-12\"><sup><i><b>m</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation journal cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.cdc.gov/mmwr/preview/mmwrhtml/00055154.htm\">\"Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-Related Chronic Disease\"</a>. <i>MMWR</i>. <b>47</b> (RR-19): 1–39. October 16, 1998. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/9790221\">9790221</a>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20160324082023/http://www.cdc.gov/mmwr/preview/mmwrhtml/00055154.htm\">Archived</a> from the original on March 24, 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">March 16,</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=MMWR&amp;rft.atitle=Recommendations+for+Prevention+and+Control+of+Hepatitis+C+Virus+%28HCV%29+Infection+and+HCV-Related+Chronic+Disease&amp;rft.volume=47&amp;rft.issue=RR-19&amp;rft.pages=1-39&amp;rft.date=1998-10-16&amp;rft_id=info%3Apmid%2F9790221&amp;rft_id=https%3A%2F%2Fwww.cdc.gov%2Fmmwr%2Fpreview%2Fmmwrhtml%2F00055154.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Final_Recommendation_Statement:_Hepatitis_C:_Screening-89\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-9\"><sup><i><b>j</b></i></sup></a> <a href=\"#cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-10\"><sup><i><b>k</b></i></sup></a> <a href=\"#cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-11\"><sup><i><b>l</b></i></sup></a> <a href=\"#cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-12\"><sup><i><b>m</b></i></sup></a> <a href=\"#cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-13\"><sup><i><b>n</b></i></sup></a> <a href=\"#cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-14\"><sup><i><b>o</b></i></sup></a> <a href=\"#cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-15\"><sup><i><b>p</b></i></sup></a> <a href=\"#cite_ref-Final_Recommendation_Statement:_Hepatitis_C:_Screening_89-16\"><sup><i><b>q</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.who.int/mediacentre/factsheets/fs164/en/\">\"Hepatitis C\"</a>. <i>World Health Organization</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20160131041006/http://www.who.int/mediacentre/factsheets/fs164/en/\">Archived</a> from the original on 2016-01-31<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-03-08</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=World+Health+Organization&amp;rft.atitle=Hepatitis+C&amp;rft_id=https%3A%2F%2Fwww.who.int%2Fmediacentre%2Ffactsheets%2Ffs164%2Fen%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Task_Force-90\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Task_Force_90-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Task_Force_90-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Task_Force_90-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Task_Force_90-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Task_Force_90-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-Task_Force_90-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-Task_Force_90-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-Task_Force_90-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-Task_Force_90-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-Task_Force_90-9\"><sup><i><b>j</b></i></sup></a> <a href=\"#cite_ref-Task_Force_90-10\"><sup><i><b>k</b></i></sup></a> <a href=\"#cite_ref-Task_Force_90-11\"><sup><i><b>l</b></i></sup></a> <a href=\"#cite_ref-Task_Force_90-12\"><sup><i><b>m</b></i></sup></a> <a href=\"#cite_ref-Task_Force_90-13\"><sup><i><b>n</b></i></sup></a> <a href=\"#cite_ref-Task_Force_90-14\"><sup><i><b>o</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/hepatitis-c-screening\">\"Final Recommendation Statement: Hepatitis C: Screening – US Preventive Services Task Force\"</a>. <i>www.uspreventiveservicestaskforce.org</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20160321180306/http://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/hepatitis-c-screening\">Archived</a> from the original on 2016-03-21<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-03-21</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.uspreventiveservicestaskforce.org&amp;rft.atitle=Final+Recommendation+Statement%3A+Hepatitis+C%3A+Screening+%E2%80%93+US+Preventive+Services+Task+Force&amp;rft_id=https%3A%2F%2Fwww.uspreventiveservicestaskforce.org%2FPage%2FDocument%2FRecommendationStatementFinal%2Fhepatitis-c-screening&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-CDC_Birth-18Y_Immunizations-91\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-CDC_Birth-18Y_Immunizations_91-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-CDC_Birth-18Y_Immunizations_91-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-CDC_Birth-18Y_Immunizations_91-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html\">\"Birth-18 Years and Catchup Immunization Schedules for Providers\"</a>. <i>www.CDC.gov</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20160306220930/http://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html\">Archived</a> from the original on March 6, 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">March 7,</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.CDC.gov&amp;rft.atitle=Birth-18+Years+and+Catchup+Immunization+Schedules+for+Providers.&amp;rft_id=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fschedules%2Fhcp%2Fimz%2Fchild-adolescent.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-CDC_Update_1999-92\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-CDC_Update_1999_92-0\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFCenters_for_Disease_Control1999\" class=\"citation web cs1\">Centers for Disease Control (1999). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.cdc.gov/mmwr/preview/mmwrhtml/00056293.htm\">\"Update: recommendations to prevent hepatitis B virus transmission—United States. MMWR 1999\"</a>. pp.&#160;33–4. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20160514225848/http://www.cdc.gov/mmwr/preview/mmwrhtml/00056293.htm\">Archived</a> from the original on May 14, 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">March 7,</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Update%3A+recommendations+to+prevent+hepatitis+B+virus+transmission%E2%80%94United+States.+MMWR+1999&amp;rft.pages=33-4&amp;rft.date=1999&amp;rft.au=Centers+for+Disease+Control&amp;rft_id=https%3A%2F%2Fwww.cdc.gov%2Fmmwr%2Fpreview%2Fmmwrhtml%2F00056293.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-93\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-93\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.mayoclinic.org/drugs-supplements/hepatitis-a-and-hepatitis-b-vaccine-intramuscular-route/description/drg-20061965\">\"Hepatitis A And Hepatitis B Vaccine (Intramuscular Route)\"</a>. <i>Mayo Clinic</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">25 January</span> 2018</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Mayo+Clinic&amp;rft.atitle=Hepatitis+A+And+Hepatitis+B+Vaccine+%28Intramuscular+Route%29&amp;rft_id=https%3A%2F%2Fwww.mayoclinic.org%2Fdrugs-supplements%2Fhepatitis-a-and-hepatitis-b-vaccine-intramuscular-route%2Fdescription%2Fdrg-20061965&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-WHO_-_Hepatitis_E-94\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-WHO_-_Hepatitis_E_94-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-WHO_-_Hepatitis_E_94-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-WHO_-_Hepatitis_E_94-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-WHO_-_Hepatitis_E_94-3\"><sup><i><b>d</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.who.int/mediacentre/factsheets/fs280/en/\">\"Hepatitis E\"</a>. <i>World Health Organization</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20160306175719/http://www.who.int/mediacentre/factsheets/fs280/en/\">Archived</a> from the original on 2016-03-06<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-03-09</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=World+Health+Organization&amp;rft.atitle=Hepatitis+E&amp;rft_id=https%3A%2F%2Fwww.who.int%2Fmediacentre%2Ffactsheets%2Ffs280%2Fen%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-WHO_Hepatitis_D-95\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-WHO_Hepatitis_D_95-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-WHO_Hepatitis_D_95-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.who.int/csr/disease/hepatitis/whocdscsrncs20011/en/index5.html\">\"WHO | Hepatitis D\"</a>. <i>www.who.int</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20160308152650/http://www.who.int/csr/disease/hepatitis/whocdscsrncs20011/en/index5.html\">Archived</a> from the original on 2016-03-08<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-03-09</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.who.int&amp;rft.atitle=WHO+%7C+Hepatitis+D&amp;rft_id=https%3A%2F%2Fwww.who.int%2Fcsr%2Fdisease%2Fhepatitis%2Fwhocdscsrncs20011%2Fen%2Findex5.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-96\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-96\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFZhang2015\" class=\"citation journal cs1\">Zhang; et&#160;al. (March 5, 2015). \"Long-Term Efficacy of a Hepatitis E Vaccine\". <i>NEJM</i>. <b>372</b> (10): 914–22. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1056%2FNEJMoa1406011\">10.1056/NEJMoa1406011</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/25738667\">25738667</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=NEJM&amp;rft.atitle=Long-Term+Efficacy+of+a+Hepatitis+E+Vaccine&amp;rft.volume=372&amp;rft.issue=10&amp;rft.pages=914-22&amp;rft.date=2015-03-05&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMoa1406011&amp;rft_id=info%3Apmid%2F25738667&amp;rft.au=Zhang&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-97\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-97\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://clinicaltrials.gov/ct2/show/NCT02189603\">\"Phase IV Clinical Trial of Recombinant Hepatitis E Vaccine（Hecolin） - Full Text View - ClinicalTrials.gov\"</a>. <i>clinicaltrials.gov</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20160309154410/https://clinicaltrials.gov/ct2/show/NCT02189603\">Archived</a> from the original on 2016-03-09<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-03-09</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=clinicaltrials.gov&amp;rft.atitle=Phase+IV+Clinical+Trial+of+Recombinant+Hepatitis+E+Vaccine%EF%BC%88Hecolin%EF%BC%89+-+Full+Text+View+-+ClinicalTrials.gov&amp;rft_id=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02189603&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-98\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-98\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFRizzetto2020\" class=\"citation journal cs1\">Rizzetto M (2020). <a class=\"external text\" href=\"https://en.wikiversity.org/wiki/WikiJournal_of_Medicine/Epidemiology_of_the_Hepatitis_D_virus\">\"Epidemiology of the Hepatitis D virus\"</a>. <i>WikiJournal of Medicine</i>. <b>7</b>: 7. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.15347%2Fwjm%2F2020.001\">10.15347/wjm/2020.001</a></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=WikiJournal+of+Medicine&amp;rft.atitle=Epidemiology+of+the+Hepatitis+D+virus&amp;rft.volume=7&amp;rft.pages=7&amp;rft.date=2020&amp;rft_id=info%3Adoi%2F10.15347%2Fwjm%2F2020.001&amp;rft.aulast=Rizzetto&amp;rft.aufirst=Mario&amp;rft_id=https%3A%2F%2Fen.wikiversity.org%2Fwiki%2FWikiJournal_of_Medicine%2FEpidemiology_of_the_Hepatitis_D_virus&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-99\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-99\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/moderate-binge-drinking\">\"Drinking Levels Defined | National Institute on Alcohol Abuse and Alcoholism (NIAAA)\"</a>. <i>www.niaaa.nih.gov</i>. 14 September 2011. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20160323085131/http://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/moderate-binge-drinking\">Archived</a> from the original on 2016-03-23<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-03-09</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.niaaa.nih.gov&amp;rft.atitle=Drinking+Levels+Defined+%7C+National+Institute+on+Alcohol+Abuse+and+Alcoholism+%28NIAAA%29&amp;rft.date=2011-09-14&amp;rft_id=http%3A%2F%2Fwww.niaaa.nih.gov%2Falcohol-health%2Foverview-alcohol-consumption%2Fmoderate-binge-drinking&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-100\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-100\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://wexnermedical.osu.edu/blog/fatty-liver-disease\">\"Preventing fatty liver disease before it\\'s too late\"</a>. <i>wexnermedical.osu.edu</i>. 17 June 2020<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">4 September</span> 2023</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=wexnermedical.osu.edu&amp;rft.atitle=Preventing+fatty+liver+disease+before+it%27s+too+late&amp;rft.date=2020-06-17&amp;rft_id=https%3A%2F%2Fwexnermedical.osu.edu%2Fblog%2Ffatty-liver-disease&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-101\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-101\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://liverfoundation.org/liver-diseases/fatty-liver-disease/nonalcoholic-fatty-liver-disease-nafld/\">\"Nonalcoholic Fatty Liver Disease (NAFLD)\"</a>. <i>liverfoundation.org</i>. 23 May 2022<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">4 September</span> 2023</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=liverfoundation.org&amp;rft.atitle=Nonalcoholic+Fatty+Liver+Disease+%28NAFLD%29&amp;rft.date=2022-05-23&amp;rft_id=https%3A%2F%2Fliverfoundation.org%2Fliver-diseases%2Ffatty-liver-disease%2Fnonalcoholic-fatty-liver-disease-nafld%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-102\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-102\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFFrancoMeleleoSerinoSorbara2012\" class=\"citation journal cs1\">Franco, Elisabetta; Meleleo, Cristina; Serino, Laura; Sorbara, Debora; Zaratti, Laura (2012-03-27). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3321492\">\"Hepatitis A: Epidemiology and prevention in developing countries\"</a>. <i>World Journal of Hepatology</i>. <b>4</b> (3): 68–73. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.4254%2Fwjh.v4.i3.68\">10.4254/wjh.v4.i3.68</a></span>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1948-5182\">1948-5182</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3321492\">3321492</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/22489258\">22489258</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=World+Journal+of+Hepatology&amp;rft.atitle=Hepatitis+A%3A+Epidemiology+and+prevention+in+developing+countries&amp;rft.volume=4&amp;rft.issue=3&amp;rft.pages=68-73&amp;rft.date=2012-03-27&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3321492%23id-name%3DPMC&amp;rft.issn=1948-5182&amp;rft_id=info%3Apmid%2F22489258&amp;rft_id=info%3Adoi%2F10.4254%2Fwjh.v4.i3.68&amp;rft.aulast=Franco&amp;rft.aufirst=Elisabetta&amp;rft.au=Meleleo%2C+Cristina&amp;rft.au=Serino%2C+Laura&amp;rft.au=Sorbara%2C+Debora&amp;rft.au=Zaratti%2C+Laura&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3321492&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-103\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-103\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.cdc.gov/vaccines/pubs/pinkbook/hepb.html\">\"Pinkbook | Hepatitis B | Epidemiology of Vaccine Preventable Diseases | CDC\"</a>. <i>www.cdc.gov</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20160307091653/http://www.cdc.gov/vaccines/pubs/pinkbook/hepb.html\">Archived</a> from the original on 2016-03-07<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-03-09</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cdc.gov&amp;rft.atitle=Pinkbook+%7C+Hepatitis+B+%7C+Epidemiology+of+Vaccine+Preventable+Diseases+%7C+CDC&amp;rft_id=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fpubs%2Fpinkbook%2Fhepb.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Carroll_chapter_35-104\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Carroll_chapter_35_104-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Carroll_chapter_35_104-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Carroll_chapter_35_104-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Carroll_chapter_35_104-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Carroll_chapter_35_104-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-Carroll_chapter_35_104-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-Carroll_chapter_35_104-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-Carroll_chapter_35_104-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-Carroll_chapter_35_104-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-Carroll_chapter_35_104-9\"><sup><i><b>j</b></i></sup></a> <a href=\"#cite_ref-Carroll_chapter_35_104-10\"><sup><i><b>k</b></i></sup></a> <a href=\"#cite_ref-Carroll_chapter_35_104-11\"><sup><i><b>l</b></i></sup></a> <a href=\"#cite_ref-Carroll_chapter_35_104-12\"><sup><i><b>m</b></i></sup></a> <a href=\"#cite_ref-Carroll_chapter_35_104-13\"><sup><i><b>n</b></i></sup></a> <a href=\"#cite_ref-Carroll_chapter_35_104-14\"><sup><i><b>o</b></i></sup></a> <a href=\"#cite_ref-Carroll_chapter_35_104-15\"><sup><i><b>p</b></i></sup></a> <a href=\"#cite_ref-Carroll_chapter_35_104-16\"><sup><i><b>q</b></i></sup></a> <a href=\"#cite_ref-Carroll_chapter_35_104-17\"><sup><i><b>r</b></i></sup></a> <a href=\"#cite_ref-Carroll_chapter_35_104-18\"><sup><i><b>s</b></i></sup></a> <a href=\"#cite_ref-Carroll_chapter_35_104-19\"><sup><i><b>t</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFCarroll2015\" class=\"citation book cs1\">Carroll, Karen (2015). \"Chapter 35: Hepatitis Viruses\". <i>Medical Microbiology</i>. New York: McGraw-Hill. <a href=\"/wiki/ISBN_(identifier)\" class=\"mw-redirect\" title=\"ISBN (identifier)\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-0071824989\" title=\"Special:BookSources/978-0071824989\"><bdi>978-0071824989</bdi></a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Chapter+35%3A+Hepatitis+Viruses&amp;rft.btitle=Medical+Microbiology&amp;rft.place=New+York&amp;rft.pub=McGraw-Hill&amp;rft.date=2015&amp;rft.isbn=978-0071824989&amp;rft.aulast=Carroll&amp;rft.aufirst=Karen&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-105\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-105\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.cdc.gov/hepatitis/statistics/2013surveillance/commentary.htm\">\"Commentary | U.S. 2013 Surveillance Data for Viral Hepatitis | Statistics &amp; Surveillance &#160;| Division of Viral Hepatitis | CDC\"</a>. <i>www.cdc.gov</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20160305151134/http://www.cdc.gov/hepatitis/statistics/2013surveillance/commentary.htm\">Archived</a> from the original on 2016-03-05<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-03-09</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cdc.gov&amp;rft.atitle=Commentary+%7C+U.S.+2013+Surveillance+Data+for+Viral+Hepatitis+%7C+Statistics+%26+Surveillance+%7C+Division+of+Viral+Hepatitis+%7C+CDC&amp;rft_id=https%3A%2F%2Fwww.cdc.gov%2Fhepatitis%2Fstatistics%2F2013surveillance%2Fcommentary.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-106\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-106\">^</a></b></span> <span class=\"reference-text\">Wright NMJ, Millson CE, Tompkins CNE (2005). What is the evidence for the effectiveness of interventions to reduce hepatitis C infection and the associated morbidity? Copenhagen, WHO Regional Office for Europe (Health Evidence Network report; <link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.euro.who.int/document/E86159.pdf\">\"WHO/Europe &#124; Home\"</a> <span class=\"cs1-format\">(PDF)</span>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20100501124733/http://www.euro.who.int/document/e86159.pdf\">Archived</a> <span class=\"cs1-format\">(PDF)</span> from the original on 2010-05-01<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-03-09</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=WHO%2FEurope+%26%23124%3B+Home&amp;rft_id=http%3A%2F%2Fwww.euro.who.int%2Fdocument%2FE86159.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span>, accessed 9 Mar 2016).</span>\\n</li>\\n<li id=\"cite_note-107\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-107\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFBasraAnand2011\" class=\"citation journal cs1\">Basra, Sarpreet; Anand, Bhupinderjit S (2011-05-27). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3124876\">\"Definition, epidemiology and magnitude of alcoholic hepatitis\"</a>. <i>World Journal of Hepatology</i>. <b>3</b> (5): 108–113. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.4254%2Fwjh.v3.i5.108\">10.4254/wjh.v3.i5.108</a></span>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1948-5182\">1948-5182</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3124876\">3124876</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/21731902\">21731902</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=World+Journal+of+Hepatology&amp;rft.atitle=Definition%2C+epidemiology+and+magnitude+of+alcoholic+hepatitis&amp;rft.volume=3&amp;rft.issue=5&amp;rft.pages=108-113&amp;rft.date=2011-05-27&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3124876%23id-name%3DPMC&amp;rft.issn=1948-5182&amp;rft_id=info%3Apmid%2F21731902&amp;rft_id=info%3Adoi%2F10.4254%2Fwjh.v3.i5.108&amp;rft.aulast=Basra&amp;rft.aufirst=Sarpreet&amp;rft.au=Anand%2C+Bhupinderjit+S&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3124876&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-108\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-108\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"http://pubs.niaaa.nih.gov/publications/arh27-3/209-219.htm\">\"The Epidemiology of Alcoholic Liver Disease\"</a>. <i>pubs.niaaa.nih.gov</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20160303180417/http://pubs.niaaa.nih.gov/publications/arh27-3/209-219.htm\">Archived</a> from the original on 2016-03-03<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-03-09</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=pubs.niaaa.nih.gov&amp;rft.atitle=The+Epidemiology+of+Alcoholic+Liver+Disease&amp;rft_id=http%3A%2F%2Fpubs.niaaa.nih.gov%2Fpublications%2Farh27-3%2F209-219.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Messori_Badiani_Tripoli-109\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Messori_Badiani_Tripoli_109-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Messori_Badiani_Tripoli_109-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFMessoriBadianiTrippoli2015\" class=\"citation journal cs1\">Messori, Andrea; Badiani, Brigitta; Trippoli, Sabrina (2015-12-01). \"Achieving Sustained Virological Response in Hepatitis C Reduces the Long-Term Risk of Hepatocellular Carcinoma: An Updated Meta-Analysis Employing Relative and Absolute Outcome Measures\". <i>Clinical Drug Investigation</i>. <b>35</b> (12): 843–850. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1007%2Fs40261-015-0338-y\">10.1007/s40261-015-0338-y</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1179-1918\">1179-1918</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/26446006\">26446006</a>. <a href=\"/wiki/S2CID_(identifier)\" class=\"mw-redirect\" title=\"S2CID (identifier)\">S2CID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://api.semanticscholar.org/CorpusID:41365729\">41365729</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clinical+Drug+Investigation&amp;rft.atitle=Achieving+Sustained+Virological+Response+in+Hepatitis+C+Reduces+the+Long-Term+Risk+of+Hepatocellular+Carcinoma%3A+An+Updated+Meta-Analysis+Employing+Relative+and+Absolute+Outcome+Measures&amp;rft.volume=35&amp;rft.issue=12&amp;rft.pages=843-850&amp;rft.date=2015-12-01&amp;rft.issn=1179-1918&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A41365729%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F26446006&amp;rft_id=info%3Adoi%2F10.1007%2Fs40261-015-0338-y&amp;rft.aulast=Messori&amp;rft.aufirst=Andrea&amp;rft.au=Badiani%2C+Brigitta&amp;rft.au=Trippoli%2C+Sabrina&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Revolution-110\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Revolution_110-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Revolution_110-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Revolution_110-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Revolution_110-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Revolution_110-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-Revolution_110-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-Revolution_110-6\"><sup><i><b>g</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFThiagarajanRyder2015\" class=\"citation journal cs1\">Thiagarajan, Prarthana; Ryder, Stephen D. (2015-12-01). \"The hepatitis C revolution part 1: antiviral treatment options\". <i>Current Opinion in Infectious Diseases</i>. <b>28</b> (6): 563–571. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1097%2FQCO.0000000000000205\">10.1097/QCO.0000000000000205</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1473-6527\">1473-6527</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/26524328\">26524328</a>. <a href=\"/wiki/S2CID_(identifier)\" class=\"mw-redirect\" title=\"S2CID (identifier)\">S2CID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://api.semanticscholar.org/CorpusID:11926260\">11926260</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Current+Opinion+in+Infectious+Diseases&amp;rft.atitle=The+hepatitis+C+revolution+part+1%3A+antiviral+treatment+options&amp;rft.volume=28&amp;rft.issue=6&amp;rft.pages=563-571&amp;rft.date=2015-12-01&amp;rft.issn=1473-6527&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A11926260%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F26524328&amp;rft_id=info%3Adoi%2F10.1097%2FQCO.0000000000000205&amp;rft.aulast=Thiagarajan&amp;rft.aufirst=Prarthana&amp;rft.au=Ryder%2C+Stephen+D.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Enhancing_our_understanding-111\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Enhancing_our_understanding_111-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Enhancing_our_understanding_111-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Enhancing_our_understanding_111-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Enhancing_our_understanding_111-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Enhancing_our_understanding_111-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-Enhancing_our_understanding_111-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-Enhancing_our_understanding_111-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-Enhancing_our_understanding_111-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-Enhancing_our_understanding_111-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-Enhancing_our_understanding_111-9\"><sup><i><b>j</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFGogelaLinWisockyChung2015\" class=\"citation journal cs1\">Gogela, Neliswa A.; Lin, Ming V.; Wisocky, Jessica L.; Chung, Raymond T. (2015-03-01). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4373591\">\"Enhancing our understanding of current therapies for Hepatitis C virus (HCV)\"</a>. <i>Current HIV/AIDS Reports</i>. <b>12</b> (1): 68–78. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1007%2Fs11904-014-0243-7\">10.1007/s11904-014-0243-7</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1548-3568\">1548-3568</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4373591\">4373591</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/25761432\">25761432</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Current+HIV%2FAIDS+Reports&amp;rft.atitle=Enhancing+our+understanding+of+current+therapies+for+Hepatitis+C+virus+%28HCV%29&amp;rft.volume=12&amp;rft.issue=1&amp;rft.pages=68-78&amp;rft.date=2015-03-01&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4373591%23id-name%3DPMC&amp;rft.issn=1548-3568&amp;rft_id=info%3Apmid%2F25761432&amp;rft_id=info%3Adoi%2F10.1007%2Fs11904-014-0243-7&amp;rft.aulast=Gogela&amp;rft.aufirst=Neliswa+A.&amp;rft.au=Lin%2C+Ming+V.&amp;rft.au=Wisocky%2C+Jessica+L.&amp;rft.au=Chung%2C+Raymond+T.&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4373591&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Interferon_alpha-112\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Interferon_alpha_112-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Interferon_alpha_112-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFAbbasKhanSalihJafri2011\" class=\"citation journal cs1\">Abbas, Zaigham; Khan, Muhammad Arsalan; Salih, Mohammad; Jafri, Wasim (2011-12-07). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823236\">\"Interferon alpha for chronic hepatitis D\"</a>. <i>Cochrane Database of Systematic Reviews</i>. <b>2011</b> (12): CD006002. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1002%2F14651858.cd006002.pub2\">10.1002/14651858.cd006002.pub2</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823236\">6823236</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/22161394\">22161394</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cochrane+Database+of+Systematic+Reviews&amp;rft.atitle=Interferon+alpha+for+chronic+hepatitis+D&amp;rft.volume=2011&amp;rft.issue=12&amp;rft.pages=CD006002&amp;rft.date=2011-12-07&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6823236%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F22161394&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.cd006002.pub2&amp;rft.aulast=Abbas&amp;rft.aufirst=Zaigham&amp;rft.au=Khan%2C+Muhammad+Arsalan&amp;rft.au=Salih%2C+Mohammad&amp;rft.au=Jafri%2C+Wasim&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6823236&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-CDC_-_HEV_FAQ-113\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-CDC_-_HEV_FAQ_113-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-CDC_-_HEV_FAQ_113-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.cdc.gov/hepatitis/hev/hevfaq.htm\">\"HEV FAQs for Health Professionals | Division of Viral Hepatitis | CDC\"</a>. <i>www.cdc.gov</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20160308031004/http://www.cdc.gov/hepatitis/hev/hevfaq.htm\">Archived</a> from the original on 2016-03-08<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-03-17</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cdc.gov&amp;rft.atitle=HEV+FAQs+for+Health+Professionals+%7C+Division+of+Viral+Hepatitis+%7C+CDC&amp;rft_id=https%3A%2F%2Fwww.cdc.gov%2Fhepatitis%2Fhev%2Fhevfaq.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Comparative_effectiveness_-_meta-analysis-114\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Comparative_effectiveness_-_meta-analysis_114-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Comparative_effectiveness_-_meta-analysis_114-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Comparative_effectiveness_-_meta-analysis_114-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Comparative_effectiveness_-_meta-analysis_114-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Comparative_effectiveness_-_meta-analysis_114-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-Comparative_effectiveness_-_meta-analysis_114-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-Comparative_effectiveness_-_meta-analysis_114-6\"><sup><i><b>g</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFSinghMuradChandarBongiorno2015\" class=\"citation journal cs1\">Singh, Siddharth; Murad, Mohammad Hassan; Chandar, Apoorva K.; Bongiorno, Connie M.; Singal, Ashwani K.; Atkinson, Stephen R.; Thursz, Mark R.; Loomba, Rohit; Shah, Vijay H. (2015-10-01). \"Comparative Effectiveness of Pharmacological Interventions for Severe Alcoholic Hepatitis: A Systematic Review and Network Meta-analysis\". <i>Gastroenterology</i>. <b>149</b> (4): 958–970.e12. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1053%2Fj.gastro.2015.06.006\">10.1053/j.gastro.2015.06.006</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1528-0012\">1528-0012</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/26091937\">26091937</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Gastroenterology&amp;rft.atitle=Comparative+Effectiveness+of+Pharmacological+Interventions+for+Severe+Alcoholic+Hepatitis%3A+A+Systematic+Review+and+Network+Meta-analysis&amp;rft.volume=149&amp;rft.issue=4&amp;rft.pages=958-970.e12&amp;rft.date=2015-10-01&amp;rft.issn=1528-0012&amp;rft_id=info%3Apmid%2F26091937&amp;rft_id=info%3Adoi%2F10.1053%2Fj.gastro.2015.06.006&amp;rft.aulast=Singh&amp;rft.aufirst=Siddharth&amp;rft.au=Murad%2C+Mohammad+Hassan&amp;rft.au=Chandar%2C+Apoorva+K.&amp;rft.au=Bongiorno%2C+Connie+M.&amp;rft.au=Singal%2C+Ashwani+K.&amp;rft.au=Atkinson%2C+Stephen+R.&amp;rft.au=Thursz%2C+Mark+R.&amp;rft.au=Loomba%2C+Rohit&amp;rft.au=Shah%2C+Vijay+H.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-STOPAH-115\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-STOPAH_115-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-STOPAH_115-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFThurszForrestRoderickDay2015\" class=\"citation journal cs1\">Thursz, Mark; Forrest, Ewan; Roderick, Paul; Day, Christopher; Austin, Andrew; O\\'Grady, John; Ryder, Stephen; Allison, Michael; Gleeson, Dermot (2015-12-01). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4781103\">\"The clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis (STOPAH): a 2 × 2 factorial randomised controlled trial\"</a>. <i>Health Technology Assessment</i>. <b>19</b> (102): 1–104. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.3310%2Fhta191020\">10.3310/hta191020</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/2046-4924\">2046-4924</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4781103\">4781103</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/26691209\">26691209</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Health+Technology+Assessment&amp;rft.atitle=The+clinical+effectiveness+and+cost-effectiveness+of+STeroids+Or+Pentoxifylline+for+Alcoholic+Hepatitis+%28STOPAH%29%3A+a+2+%C3%97+2+factorial+randomised+controlled+trial&amp;rft.volume=19&amp;rft.issue=102&amp;rft.pages=1-104&amp;rft.date=2015-12-01&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4781103%23id-name%3DPMC&amp;rft.issn=2046-4924&amp;rft_id=info%3Apmid%2F26691209&amp;rft_id=info%3Adoi%2F10.3310%2Fhta191020&amp;rft.aulast=Thursz&amp;rft.aufirst=Mark&amp;rft.au=Forrest%2C+Ewan&amp;rft.au=Roderick%2C+Paul&amp;rft.au=Day%2C+Christopher&amp;rft.au=Austin%2C+Andrew&amp;rft.au=O%27Grady%2C+John&amp;rft.au=Ryder%2C+Stephen&amp;rft.au=Allison%2C+Michael&amp;rft.au=Gleeson%2C+Dermot&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4781103&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-116\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-116\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFRambaldiJacobsGluud2007\" class=\"citation journal cs1\">Rambaldi, Andrea; Jacobs, Bradly P; Gluud, Christian (2007-10-17). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724782\">\"Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases\"</a>. <i>Protocols</i>. <b>2009</b> (4): CD003620. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1002%2F14651858.cd003620.pub3\">10.1002/14651858.cd003620.pub3</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1465-1858\">1465-1858</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724782\">8724782</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/17943794\">17943794</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Protocols&amp;rft.atitle=Milk+thistle+for+alcoholic+and%2For+hepatitis+B+or+C+virus+liver+diseases&amp;rft.volume=2009&amp;rft.issue=4&amp;rft.pages=CD003620&amp;rft.date=2007-10-17&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC8724782%23id-name%3DPMC&amp;rft.issn=1465-1858&amp;rft_id=info%3Apmid%2F17943794&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.cd003620.pub3&amp;rft.aulast=Rambaldi&amp;rft.aufirst=Andrea&amp;rft.au=Jacobs%2C+Bradly+P&amp;rft.au=Gluud%2C+Christian&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC8724782&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-117\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-117\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash/treatment\">\"Treatment for NAFLD &amp; NASH - NIDDK\"</a>. <i>National Institute of Diabetes and Digestive and Kidney Diseases</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">4 September</span> 2023</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=National+Institute+of+Diabetes+and+Digestive+and+Kidney+Diseases&amp;rft.atitle=Treatment+for+NAFLD+%26+NASH+-+NIDDK&amp;rft_id=https%3A%2F%2Fwww.niddk.nih.gov%2Fhealth-information%2Fliver-disease%2Fnafld-nash%2Ftreatment&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-118\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-118\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFSummerskillKormanAmmonBaggenstoss1975\" class=\"citation journal cs1\">Summerskill, W. H.; Korman, M. G.; Ammon, H. V.; Baggenstoss, A. H. (1975-11-01). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1413126\">\"Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared\"</a>. <i>Gut</i>. <b>16</b> (11): 876–883. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1136%2Fgut.16.11.876\">10.1136/gut.16.11.876</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/0017-5749\">0017-5749</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1413126\">1413126</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/1104411\">1104411</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Gut&amp;rft.atitle=Prednisone+for+chronic+active+liver+disease%3A+dose+titration%2C+standard+dose%2C+and+combination+with+azathioprine+compared&amp;rft.volume=16&amp;rft.issue=11&amp;rft.pages=876-883&amp;rft.date=1975-11-01&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1413126%23id-name%3DPMC&amp;rft.issn=0017-5749&amp;rft_id=info%3Apmid%2F1104411&amp;rft_id=info%3Adoi%2F10.1136%2Fgut.16.11.876&amp;rft.aulast=Summerskill&amp;rft.aufirst=W.+H.&amp;rft.au=Korman%2C+M.+G.&amp;rft.au=Ammon%2C+H.+V.&amp;rft.au=Baggenstoss%2C+A.+H.&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1413126&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-119\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-119\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFBartenschlager2013\" class=\"citation book cs1\">Bartenschlager, ed. (2013). <i>Hepatitis C Virus: From Molecular Virology to Antiviral Therapy</i>. Springer.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Hepatitis+C+Virus%3A+From+Molecular+Virology+to+Antiviral+Therapy&amp;rft.pub=Springer&amp;rft.date=2013&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-120\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-120\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFKhuroo1981\" class=\"citation journal cs1\">Khuroo, MS (1981). \"Incidence and severity of viral hepatitis in pregnancy\". <i>Am J Med</i>. <b>70</b> (2): 252–5. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1016%2F0002-9343%2881%2990796-8\">10.1016/0002-9343(81)90796-8</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/6781338\">6781338</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Am+J+Med&amp;rft.atitle=Incidence+and+severity+of+viral+hepatitis+in+pregnancy&amp;rft.volume=70&amp;rft.issue=2&amp;rft.pages=252-5&amp;rft.date=1981&amp;rft_id=info%3Adoi%2F10.1016%2F0002-9343%2881%2990796-8&amp;rft_id=info%3Apmid%2F6781338&amp;rft.aulast=Khuroo&amp;rft.aufirst=MS&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-121\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-121\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFGill2001\" class=\"citation journal cs1\">Gill, RQ (2001). \"Acute Liver Failure\". <i>J Clin Gastroenterol</i>. <b>33</b> (3): 191–8. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1097%2F00004836-200109000-00005\">10.1097/00004836-200109000-00005</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/11500606\">11500606</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J+Clin+Gastroenterol&amp;rft.atitle=Acute+Liver+Failure&amp;rft.volume=33&amp;rft.issue=3&amp;rft.pages=191-8&amp;rft.date=2001&amp;rft_id=info%3Adoi%2F10.1097%2F00004836-200109000-00005&amp;rft_id=info%3Apmid%2F11500606&amp;rft.aulast=Gill&amp;rft.aufirst=RQ&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-122\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-122\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFSmedile1981\" class=\"citation journal cs1\">Smedile, A; et&#160;al. (1981). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.gastrojournal.org/article/S0016-5085(81)80003-0/fulltext\">\"Infection with the delta agent in chronic HBsAg carriers\"</a>. <i>Gastroenterology</i>. <b>81</b> (6): 992–7. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1016%2FS0016-5085%2881%2980003-0\">10.1016/S0016-5085(81)80003-0</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/7286594\">7286594</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Gastroenterology&amp;rft.atitle=Infection+with+the+delta+agent+in+chronic+HBsAg+carriers&amp;rft.volume=81&amp;rft.issue=6&amp;rft.pages=992-7&amp;rft.date=1981&amp;rft_id=info%3Adoi%2F10.1016%2FS0016-5085%2881%2980003-0&amp;rft_id=info%3Apmid%2F7286594&amp;rft.aulast=Smedile&amp;rft.aufirst=A&amp;rft_id=https%3A%2F%2Fwww.gastrojournal.org%2Farticle%2FS0016-5085%2881%2980003-0%2Ffulltext&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-123\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-123\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFAbbasAliShazi2015\" class=\"citation journal cs1\">Abbas, Zaigham; Ali, Syed Salman; Shazi, Lubna (2015-06-02). \"Interferon alpha versus any other drug for chronic hepatitis D\". <i>Cochrane Database of Systematic Reviews</i>. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1002%2F14651858.cd011727\">10.1002/14651858.cd011727</a>. <a href=\"/wiki/S2CID_(identifier)\" class=\"mw-redirect\" title=\"S2CID (identifier)\">S2CID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://api.semanticscholar.org/CorpusID:70629280\">70629280</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cochrane+Database+of+Systematic+Reviews&amp;rft.atitle=Interferon+alpha+versus+any+other+drug+for+chronic+hepatitis+D&amp;rft.date=2015-06-02&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.cd011727&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A70629280%23id-name%3DS2CID&amp;rft.aulast=Abbas&amp;rft.aufirst=Zaigham&amp;rft.au=Ali%2C+Syed+Salman&amp;rft.au=Shazi%2C+Lubna&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-124\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-124\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFTheinYiDoreKrahn2008\" class=\"citation journal cs1\">Thein, Hla-Hla; Yi, Qilong; Dore, Gregory J.; Krahn, Murray D. (2008-08-01). <a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1002%2Fhep.22375\">\"Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression\"</a>. <i>Hepatology</i>. <b>48</b> (2): 418–431. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1002%2Fhep.22375\">10.1002/hep.22375</a></span>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1527-3350\">1527-3350</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/18563841\">18563841</a>. <a href=\"/wiki/S2CID_(identifier)\" class=\"mw-redirect\" title=\"S2CID (identifier)\">S2CID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://api.semanticscholar.org/CorpusID:20771903\">20771903</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Hepatology&amp;rft.atitle=Estimation+of+stage-specific+fibrosis+progression+rates+in+chronic+hepatitis+C+virus+infection%3A+a+meta-analysis+and+meta-regression&amp;rft.volume=48&amp;rft.issue=2&amp;rft.pages=418-431&amp;rft.date=2008-08-01&amp;rft.issn=1527-3350&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A20771903%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F18563841&amp;rft_id=info%3Adoi%2F10.1002%2Fhep.22375&amp;rft.aulast=Thein&amp;rft.aufirst=Hla-Hla&amp;rft.au=Yi%2C+Qilong&amp;rft.au=Dore%2C+Gregory+J.&amp;rft.au=Krahn%2C+Murray+D.&amp;rft_id=https%3A%2F%2Fdoi.org%2F10.1002%252Fhep.22375&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-125\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-125\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFFattovich1997\" class=\"citation journal cs1\">Fattovich, G (1997). \"Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients\". <i>Gastroenterology</i>. <b>112</b> (2): 463–72. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1053%2Fgast.1997.v112.pm9024300\">10.1053/gast.1997.v112.pm9024300</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/9024300\">9024300</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Gastroenterology&amp;rft.atitle=Morbidity+and+mortality+in+compensated+cirrhosis+type+C%3A+a+retrospective+follow-up+study+of+384+patients&amp;rft.volume=112&amp;rft.issue=2&amp;rft.pages=463-72&amp;rft.date=1997&amp;rft_id=info%3Adoi%2F10.1053%2Fgast.1997.v112.pm9024300&amp;rft_id=info%3Apmid%2F9024300&amp;rft.aulast=Fattovich&amp;rft.aufirst=G&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-126\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-126\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.cdc.gov/hepatitis/hav/\">\"Hepatitis A Information | Division of Viral Hepatitis | CDC\"</a>. <i>www.cdc.gov</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20160304081005/http://www.cdc.gov/hepatitis/hav/\">Archived</a> from the original on 2016-03-04<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-03-08</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cdc.gov&amp;rft.atitle=Hepatitis+A+Information+%7C+Division+of+Viral+Hepatitis+%7C+CDC&amp;rft_id=https%3A%2F%2Fwww.cdc.gov%2Fhepatitis%2Fhav%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Aggarwal_488–496-127\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Aggarwal_488–496_127-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Aggarwal_488–496_127-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFAggarwalGoel2015\" class=\"citation journal cs1\">Aggarwal, Rakesh; Goel, Amit (2015). \"Hepatitis A\". <i>Current Opinion in Infectious Diseases</i>. <b>28</b> (5): 488–496. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1097%2Fqco.0000000000000188\">10.1097/qco.0000000000000188</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/26203853\">26203853</a>. <a href=\"/wiki/S2CID_(identifier)\" class=\"mw-redirect\" title=\"S2CID (identifier)\">S2CID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://api.semanticscholar.org/CorpusID:22340290\">22340290</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Current+Opinion+in+Infectious+Diseases&amp;rft.atitle=Hepatitis+A&amp;rft.volume=28&amp;rft.issue=5&amp;rft.pages=488-496&amp;rft.date=2015&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A22340290%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F26203853&amp;rft_id=info%3Adoi%2F10.1097%2Fqco.0000000000000188&amp;rft.aulast=Aggarwal&amp;rft.aufirst=Rakesh&amp;rft.au=Goel%2C+Amit&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-128\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-128\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.who.int/mediacentre/factsheets/fs328/en/\">\"WHO | Hepatitis A\"</a>. <i>www.who.int</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20140221042107/http://www.who.int/mediacentre/factsheets/fs328/en/\">Archived</a> from the original on 2014-02-21<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-03-08</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.who.int&amp;rft.atitle=WHO+%7C+Hepatitis+A&amp;rft_id=https%3A%2F%2Fwww.who.int%2Fmediacentre%2Ffactsheets%2Ffs328%2Fen%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-129\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-129\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.cdc.gov/hepatitis/hav/havfaq.htm#general\">\"Hepatitis A Questions and Answers for Health Professionals | Division of Viral Hepatitis | CDC\"</a>. <i>www.cdc.gov</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20160306221037/http://www.cdc.gov/hepatitis/hav/havfaq.htm#general\">Archived</a> from the original on 2016-03-06<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-03-08</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cdc.gov&amp;rft.atitle=Hepatitis+A+Questions+and+Answers+for+Health+Professionals+%7C+Division+of+Viral+Hepatitis+%7C+CDC&amp;rft_id=https%3A%2F%2Fwww.cdc.gov%2Fhepatitis%2Fhav%2Fhavfaq.htm%23general&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Rosen_-_Clinical_Practice-130\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Rosen_-_Clinical_Practice_130-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Rosen_-_Clinical_Practice_130-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Rosen_-_Clinical_Practice_130-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Rosen_-_Clinical_Practice_130-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Rosen_-_Clinical_Practice_130-4\"><sup><i><b>e</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFRosen2011\" class=\"citation journal cs1\">Rosen, Hugo R. (2011-06-23). \"Clinical practice. Chronic hepatitis C infection\". <i>The New England Journal of Medicine</i>. <b>364</b> (25): 2429–2438. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1056%2FNEJMcp1006613\">10.1056/NEJMcp1006613</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1533-4406\">1533-4406</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/21696309\">21696309</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+England+Journal+of+Medicine&amp;rft.atitle=Clinical+practice.+Chronic+hepatitis+C+infection&amp;rft.volume=364&amp;rft.issue=25&amp;rft.pages=2429-2438&amp;rft.date=2011-06-23&amp;rft.issn=1533-4406&amp;rft_id=info%3Apmid%2F21696309&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMcp1006613&amp;rft.aulast=Rosen&amp;rft.aufirst=Hugo+R.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-131\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-131\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFEdlinEckhardtShuHolmberg2015\" class=\"citation journal cs1\">Edlin, Brian R.; Eckhardt, Benjamin J.; Shu, Marla A.; Holmberg, Scott D.; Swan, Tracy (2015-11-01). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751870\">\"Toward a more accurate estimate of the prevalence of hepatitis C in the United States\"</a>. <i>Hepatology</i>. <b>62</b> (5): 1353–1363. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1002%2Fhep.27978\">10.1002/hep.27978</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1527-3350\">1527-3350</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751870\">4751870</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/26171595\">26171595</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Hepatology&amp;rft.atitle=Toward+a+more+accurate+estimate+of+the+prevalence+of+hepatitis+C+in+the+United+States&amp;rft.volume=62&amp;rft.issue=5&amp;rft.pages=1353-1363&amp;rft.date=2015-11-01&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4751870%23id-name%3DPMC&amp;rft.issn=1527-3350&amp;rft_id=info%3Apmid%2F26171595&amp;rft_id=info%3Adoi%2F10.1002%2Fhep.27978&amp;rft.aulast=Edlin&amp;rft.aufirst=Brian+R.&amp;rft.au=Eckhardt%2C+Benjamin+J.&amp;rft.au=Shu%2C+Marla+A.&amp;rft.au=Holmberg%2C+Scott+D.&amp;rft.au=Swan%2C+Tracy&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4751870&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-HEV_FAQs_for_Health_Professionals-132\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-HEV_FAQs_for_Health_Professionals_132-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-HEV_FAQs_for_Health_Professionals_132-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-HEV_FAQs_for_Health_Professionals_132-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-HEV_FAQs_for_Health_Professionals_132-3\"><sup><i><b>d</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.cdc.gov/hepatitis/hev/hevfaq.htm#section1\">\"HEV FAQs for Health Professionals | Division of Viral Hepatitis | CDC\"</a>. <i>www.cdc.gov</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20160308031004/http://www.cdc.gov/hepatitis/hev/hevfaq.htm#section1\">Archived</a> from the original on 2016-03-08<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-03-09</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cdc.gov&amp;rft.atitle=HEV+FAQs+for+Health+Professionals+%7C+Division+of+Viral+Hepatitis+%7C+CDC&amp;rft_id=https%3A%2F%2Fwww.cdc.gov%2Fhepatitis%2Fhev%2Fhevfaq.htm%23section1&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Singal_Kamath_Gores_Shah-133\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Singal_Kamath_Gores_Shah_133-0\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFSingalKamathGoresShah2014\" class=\"citation journal cs1\">Singal, Ashwani K.; Kamath, Patrick S.; Gores, Gregory J.; Shah, Vijay H. (2014-04-01). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3883924\">\"Alcoholic hepatitis: current challenges and future directions\"</a>. <i>Clinical Gastroenterology and Hepatology</i>. <b>12</b> (4): 555–564, quiz e31–32. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1016%2Fj.cgh.2013.06.013\">10.1016/j.cgh.2013.06.013</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1542-7714\">1542-7714</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3883924\">3883924</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/23811249\">23811249</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clinical+Gastroenterology+and+Hepatology&amp;rft.atitle=Alcoholic+hepatitis%3A+current+challenges+and+future+directions&amp;rft.volume=12&amp;rft.issue=4&amp;rft.pages=555-564%2C+quiz+e31-32&amp;rft.date=2014-04-01&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3883924%23id-name%3DPMC&amp;rft.issn=1542-7714&amp;rft_id=info%3Apmid%2F23811249&amp;rft_id=info%3Adoi%2F10.1016%2Fj.cgh.2013.06.013&amp;rft.aulast=Singal&amp;rft.aufirst=Ashwani+K.&amp;rft.au=Kamath%2C+Patrick+S.&amp;rft.au=Gores%2C+Gregory+J.&amp;rft.au=Shah%2C+Vijay+H.&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3883924&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Shoreibah,_Bhupinderjit,_Singal-134\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Shoreibah,_Bhupinderjit,_Singal_134-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Shoreibah,_Bhupinderjit,_Singal_134-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFShoreibahAnandSingal2014\" class=\"citation journal cs1\">Shoreibah, Mohamed; Anand, Bhupinderjit S.; Singal, Ashwani K. (2014-09-14). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161778\">\"Alcoholic hepatitis and concomitant hepatitis C virus infection\"</a>. <i>World Journal of Gastroenterology</i>. <b>20</b> (34): 11929–11934. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.3748%2Fwjg.v20.i34.11929\">10.3748/wjg.v20.i34.11929</a></span>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/2219-2840\">2219-2840</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161778\">4161778</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/25232227\">25232227</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=World+Journal+of+Gastroenterology&amp;rft.atitle=Alcoholic+hepatitis+and+concomitant+hepatitis+C+virus+infection&amp;rft.volume=20&amp;rft.issue=34&amp;rft.pages=11929-11934&amp;rft.date=2014-09-14&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4161778%23id-name%3DPMC&amp;rft.issn=2219-2840&amp;rft_id=info%3Apmid%2F25232227&amp;rft_id=info%3Adoi%2F10.3748%2Fwjg.v20.i34.11929&amp;rft.aulast=Shoreibah&amp;rft.aufirst=Mohamed&amp;rft.au=Anand%2C+Bhupinderjit+S.&amp;rft.au=Singal%2C+Ashwani+K.&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4161778&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-135\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-135\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFSingalAnand2007\" class=\"citation journal cs1\">Singal, Ashwani K.; Anand, Bhupinder S. (2007-09-01). \"Mechanisms of synergy between alcohol and hepatitis C virus\". <i>Journal of Clinical Gastroenterology</i>. <b>41</b> (8): 761–772. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1097%2FMCG.0b013e3180381584\">10.1097/MCG.0b013e3180381584</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/0192-0790\">0192-0790</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/17700425\">17700425</a>. <a href=\"/wiki/S2CID_(identifier)\" class=\"mw-redirect\" title=\"S2CID (identifier)\">S2CID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://api.semanticscholar.org/CorpusID:19482895\">19482895</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Clinical+Gastroenterology&amp;rft.atitle=Mechanisms+of+synergy+between+alcohol+and+hepatitis+C+virus&amp;rft.volume=41&amp;rft.issue=8&amp;rft.pages=761-772&amp;rft.date=2007-09-01&amp;rft.issn=0192-0790&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A19482895%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F17700425&amp;rft_id=info%3Adoi%2F10.1097%2FMCG.0b013e3180381584&amp;rft.aulast=Singal&amp;rft.aufirst=Ashwani+K.&amp;rft.au=Anand%2C+Bhupinder+S.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-From_NAFLD_to_NASH-136\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-From_NAFLD_to_NASH_136-0\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFWreeBroderickCanbayHoffman2013\" class=\"citation journal cs1\">Wree, Alexander; Broderick, Lori; Canbay, Ali; Hoffman, Hal M.; Feldstein, Ariel E. (2013-11-01). \"From NAFLD to NASH to cirrhosis-new insights into disease mechanisms\". <i>Nature Reviews. Gastroenterology &amp; Hepatology</i>. <b>10</b> (11): 627–636. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1038%2Fnrgastro.2013.149\">10.1038/nrgastro.2013.149</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1759-5053\">1759-5053</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/23958599\">23958599</a>. <a href=\"/wiki/S2CID_(identifier)\" class=\"mw-redirect\" title=\"S2CID (identifier)\">S2CID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://api.semanticscholar.org/CorpusID:6899033\">6899033</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature+Reviews.+Gastroenterology+%26+Hepatology&amp;rft.atitle=From+NAFLD+to+NASH+to+cirrhosis-new+insights+into+disease+mechanisms&amp;rft.volume=10&amp;rft.issue=11&amp;rft.pages=627-636&amp;rft.date=2013-11-01&amp;rft.issn=1759-5053&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A6899033%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F23958599&amp;rft_id=info%3Adoi%2F10.1038%2Fnrgastro.2013.149&amp;rft.aulast=Wree&amp;rft.aufirst=Alexander&amp;rft.au=Broderick%2C+Lori&amp;rft.au=Canbay%2C+Ali&amp;rft.au=Hoffman%2C+Hal+M.&amp;rft.au=Feldstein%2C+Ariel+E.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Weiß,_Rau,_Geier-137\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Weiß,_Rau,_Geier_137-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Weiß,_Rau,_Geier_137-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFWeißRauGeier2014\" class=\"citation journal cs1\">Weiß, Johannes; Rau, Monika; Geier, Andreas (2014-06-27). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4101528\">\"Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment\"</a>. <i>Deutsches Ärzteblatt International</i>. <b>111</b> (26): 447–452. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.3238%2Farztebl.2014.0447\">10.3238/arztebl.2014.0447</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1866-0452\">1866-0452</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4101528\">4101528</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/25019921\">25019921</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Deutsches+%C3%84rzteblatt+International&amp;rft.atitle=Non-alcoholic+fatty+liver+disease%3A+epidemiology%2C+clinical+course%2C+investigation%2C+and+treatment&amp;rft.volume=111&amp;rft.issue=26&amp;rft.pages=447-452&amp;rft.date=2014-06-27&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4101528%23id-name%3DPMC&amp;rft.issn=1866-0452&amp;rft_id=info%3Apmid%2F25019921&amp;rft_id=info%3Adoi%2F10.3238%2Farztebl.2014.0447&amp;rft.aulast=Wei%C3%9F&amp;rft.aufirst=Johannes&amp;rft.au=Rau%2C+Monika&amp;rft.au=Geier%2C+Andreas&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4101528&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-NAFLD,_NASH_and_liver_cancer-138\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-NAFLD,_NASH_and_liver_cancer_138-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-NAFLD,_NASH_and_liver_cancer_138-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFMichelottiMachadoDiehl2013\" class=\"citation journal cs1\">Michelotti, Gregory A.; Machado, Mariana V.; Diehl, Anna Mae (2013-11-01). \"NAFLD, NASH and liver cancer\". <i>Nature Reviews. Gastroenterology &amp; Hepatology</i>. <b>10</b> (11): 656–665. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1038%2Fnrgastro.2013.183\">10.1038/nrgastro.2013.183</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1759-5053\">1759-5053</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/24080776\">24080776</a>. <a href=\"/wiki/S2CID_(identifier)\" class=\"mw-redirect\" title=\"S2CID (identifier)\">S2CID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://api.semanticscholar.org/CorpusID:22315274\">22315274</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature+Reviews.+Gastroenterology+%26+Hepatology&amp;rft.atitle=NAFLD%2C+NASH+and+liver+cancer&amp;rft.volume=10&amp;rft.issue=11&amp;rft.pages=656-665&amp;rft.date=2013-11-01&amp;rft.issn=1759-5053&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A22315274%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F24080776&amp;rft_id=info%3Adoi%2F10.1038%2Fnrgastro.2013.183&amp;rft.aulast=Michelotti&amp;rft.aufirst=Gregory+A.&amp;rft.au=Machado%2C+Mariana+V.&amp;rft.au=Diehl%2C+Anna+Mae&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-139\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-139\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFTrepo2014\" class=\"citation journal cs1\">Trepo, Christian (February 2014). <a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1111%2Fliv.12409\">\"A brief history of hepatitis milestones\"</a>. <i>Liver International</i>. <b>34</b> (Supplement s1): 29–37. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1111%2Fliv.12409\">10.1111/liv.12409</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/24373076\">24373076</a>. <a href=\"/wiki/S2CID_(identifier)\" class=\"mw-redirect\" title=\"S2CID (identifier)\">S2CID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://api.semanticscholar.org/CorpusID:41215392\">41215392</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Liver+International&amp;rft.atitle=A+brief+history+of+hepatitis+milestones&amp;rft.volume=34&amp;rft.issue=Supplement+s1&amp;rft.pages=29-37&amp;rft.date=2014-02&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A41215392%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F24373076&amp;rft_id=info%3Adoi%2F10.1111%2Fliv.12409&amp;rft.aulast=Trepo&amp;rft.aufirst=Christian&amp;rft_id=https%3A%2F%2Fdoi.org%2F10.1111%252Fliv.12409&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-140\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-140\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFOon2012\" class=\"citation journal cs1\">Oon, GC (July 2012). <a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.47102%2Fannals-acadmedsg.V41N7p279\">\"Viral hepatitis—the silent killer\"</a>. <i>Annals of the Academy of Medicine, Singapore</i>. <b>41</b> (7): 279–80. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.47102%2Fannals-acadmedsg.V41N7p279\">10.47102/annals-acadmedsg.V41N7p279</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/22892603\">22892603</a>. <a href=\"/wiki/S2CID_(identifier)\" class=\"mw-redirect\" title=\"S2CID (identifier)\">S2CID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://api.semanticscholar.org/CorpusID:2757948\">2757948</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Annals+of+the+Academy+of+Medicine%2C+Singapore&amp;rft.atitle=Viral+hepatitis%E2%80%94the+silent+killer.&amp;rft.volume=41&amp;rft.issue=7&amp;rft.pages=279-80&amp;rft.date=2012-07&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A2757948%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F22892603&amp;rft_id=info%3Adoi%2F10.47102%2Fannals-acadmedsg.V41N7p279&amp;rft.aulast=Oon&amp;rft.aufirst=GC&amp;rft_id=https%3A%2F%2Fdoi.org%2F10.47102%252Fannals-acadmedsg.V41N7p279&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-141\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-141\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFLeeThomas1988\" class=\"citation book cs1\">Lee, Christine A.; Thomas, Howard C., eds. (1988). <i>Classic papers in viral hepatitis</i>. Foreword by Dame Sheila Sherlock. London, England: Science Press. <a href=\"/wiki/ISBN_(identifier)\" class=\"mw-redirect\" title=\"ISBN (identifier)\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-1-870026-10-9\" title=\"Special:BookSources/978-1-870026-10-9\"><bdi>978-1-870026-10-9</bdi></a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Classic+papers+in+viral+hepatitis&amp;rft.place=London%2C+England&amp;rft.pub=Science+Press&amp;rft.date=1988&amp;rft.isbn=978-1-870026-10-9&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-142\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-142\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFPurcell1993\" class=\"citation journal cs1\">Purcell, RH (April 1993). \"The discovery of the hepatitis viruses\". <i>Gastroenterology</i>. <b>104</b> (4): 955–63. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1016%2F0016-5085%2893%2990261-a\">10.1016/0016-5085(93)90261-a</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/8385046\">8385046</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Gastroenterology&amp;rft.atitle=The+discovery+of+the+hepatitis+viruses.&amp;rft.volume=104&amp;rft.issue=4&amp;rft.pages=955-63&amp;rft.date=1993-04&amp;rft_id=info%3Adoi%2F10.1016%2F0016-5085%2893%2990261-a&amp;rft_id=info%3Apmid%2F8385046&amp;rft.aulast=Purcell&amp;rft.aufirst=RH&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-143\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-143\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFBradley1946\" class=\"citation journal cs1\">Bradley, WH (1946). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2181926\">\"Homologous Serum Jaundice\"</a>. <i>Proceedings of the Royal Society of Medicine</i>. <b>39</b> (10): 649–654. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1177%2F003591574603901012\">10.1177/003591574603901012</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2181926\">2181926</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/19993376\">19993376</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Proceedings+of+the+Royal+Society+of+Medicine&amp;rft.atitle=Homologous+Serum+Jaundice&amp;rft.volume=39&amp;rft.issue=10&amp;rft.pages=649-654&amp;rft.date=1946&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2181926%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F19993376&amp;rft_id=info%3Adoi%2F10.1177%2F003591574603901012&amp;rft.aulast=Bradley&amp;rft.aufirst=WH&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2181926&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-144\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-144\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFMunson1996\" class=\"citation book cs1\">Munson, Ronald (1996). <i>Intervention and Reflection: Basic Issues in Medical Ethics</i>. pp.&#160;273–281.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Intervention+and+Reflection%3A+Basic+Issues+in+Medical+Ethics&amp;rft.pages=273-281&amp;rft.date=1996&amp;rft.aulast=Munson&amp;rft.aufirst=Ronald&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-145\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-145\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFBeecher1966\" class=\"citation journal cs1\">Beecher, Henry (1966). \"Ethics and Clinical Research\". <i>The New England Journal of Medicine</i>. <b>274</b> (24): 1354–1360. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1056%2Fnejm196606162742405\">10.1056/nejm196606162742405</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/5327352\">5327352</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+England+Journal+of+Medicine&amp;rft.atitle=Ethics+and+Clinical+Research&amp;rft.volume=274&amp;rft.issue=24&amp;rft.pages=1354-1360&amp;rft.date=1966&amp;rft_id=info%3Adoi%2F10.1056%2Fnejm196606162742405&amp;rft_id=info%3Apmid%2F5327352&amp;rft.aulast=Beecher&amp;rft.aufirst=Henry&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span>; Reprinted in <link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFBeecher_HK2001\" class=\"citation journal cs1\">Beecher HK (2001). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2566401\">\"Ethics and clinical research. 1966\"</a>. <i>Bull World Health Organ</i>. <b>79</b> (4): 367–72. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2566401\">2566401</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/11368058\">11368058</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Bull+World+Health+Organ&amp;rft.atitle=Ethics+and+clinical+research.+1966&amp;rft.volume=79&amp;rft.issue=4&amp;rft.pages=367-72&amp;rft.date=2001&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2566401%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F11368058&amp;rft.au=Beecher+HK&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2566401&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-ReferenceA-146\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-ReferenceA_146-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-ReferenceA_146-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFPurcell1993\" class=\"citation journal cs1\">Purcell, RH (April 1993). \"The discovery of the hepatitis viruses\". <i>Gastroenterology</i>. <b>104</b> (4): 955–63. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1016%2F0016-5085%2893%2990261-a\">10.1016/0016-5085(93)90261-a</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/8385046\">8385046</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Gastroenterology&amp;rft.atitle=The+discovery+of+the+hepatitis+viruses.&amp;rft.volume=104&amp;rft.issue=4&amp;rft.pages=955-63&amp;rft.date=1993-04&amp;rft_id=info%3Adoi%2F10.1016%2F0016-5085%2893%2990261-a&amp;rft_id=info%3Apmid%2F8385046&amp;rft.aulast=Purcell&amp;rft.aufirst=RH&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-147\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-147\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFEmanuel2008\" class=\"citation book cs1\">Emanuel, Ezekiel (2008). <i>The Oxford Textbook of Clinical Research Ethics</i>. Oxford University Press. pp.&#160;80–85.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=The+Oxford+Textbook+of+Clinical+Research+Ethics&amp;rft.pages=80-85&amp;rft.pub=Oxford+University+Press&amp;rft.date=2008&amp;rft.aulast=Emanuel&amp;rft.aufirst=Ezekiel&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-148\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-148\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFOdelberg1976\" class=\"citation book cs1\">Odelberg, Wilhelm (1976). <i>Les Prix Nobel</i>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Les+Prix+Nobel&amp;rft.date=1976&amp;rft.aulast=Odelberg&amp;rft.aufirst=Wilhelm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-149\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-149\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFAlter2014\" class=\"citation journal cs1\">Alter, Harvey J. (2014-01-01). <a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1002%2Fhep.26787\">\"The road not taken or how I learned to love the liver: A personal perspective on hepatitis history\"</a>. <i>Hepatology</i>. <b>59</b> (1): 4–12. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1002%2Fhep.26787\">10.1002/hep.26787</a></span>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1527-3350\">1527-3350</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/24123147\">24123147</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Hepatology&amp;rft.atitle=The+road+not+taken+or+how+I+learned+to+love+the+liver%3A+A+personal+perspective+on+hepatitis+history&amp;rft.volume=59&amp;rft.issue=1&amp;rft.pages=4-12&amp;rft.date=2014-01-01&amp;rft.issn=1527-3350&amp;rft_id=info%3Apmid%2F24123147&amp;rft_id=info%3Adoi%2F10.1002%2Fhep.26787&amp;rft.aulast=Alter&amp;rft.aufirst=Harvey+J.&amp;rft_id=https%3A%2F%2Fdoi.org%2F10.1002%252Fhep.26787&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-150\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-150\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFBlumberg_BSAlter_HJ1965\" class=\"citation journal cs1\">Blumberg BS; Alter HJ (1965-02-15). \"A \"new\" antigen in leukemia sera\". <i>JAMA</i>. <b>191</b> (7): 541–546. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1001%2Fjama.1965.03080070025007\">10.1001/jama.1965.03080070025007</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/0098-7484\">0098-7484</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/14239025\">14239025</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=JAMA&amp;rft.atitle=A+%22new%22+antigen+in+leukemia+sera&amp;rft.volume=191&amp;rft.issue=7&amp;rft.pages=541-546&amp;rft.date=1965-02-15&amp;rft.issn=0098-7484&amp;rft_id=info%3Apmid%2F14239025&amp;rft_id=info%3Adoi%2F10.1001%2Fjama.1965.03080070025007&amp;rft.au=Blumberg+BS&amp;rft.au=Alter+HJ&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-151\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-151\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.nobelprize.org/prizes/medicine/1976/blumberg/biographical/\">\"The Nobel Prize in Physiology or Medicine 1976\"</a>. <i>NobelPrize.org</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2019-10-07</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=NobelPrize.org&amp;rft.atitle=The+Nobel+Prize+in+Physiology+or+Medicine+1976&amp;rft_id=https%3A%2F%2Fwww.nobelprize.org%2Fprizes%2Fmedicine%2F1976%2Fblumberg%2Fbiographical%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Udompap,_Kim_&amp;_Kim-152\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Udompap,_Kim_&amp;_Kim_152-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Udompap,_Kim_&amp;_Kim_152-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Udompap,_Kim_&amp;_Kim_152-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Udompap,_Kim_&amp;_Kim_152-3\"><sup><i><b>d</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFUdompapKimKim2015\" class=\"citation journal cs1\">Udompap, Prowpanga; Kim, Donghee; Kim, W. Ray (2015-11-01). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618163\">\"Current and Future Burden of Chronic Nonmalignant Liver Disease\"</a>. <i>Clinical Gastroenterology and Hepatology</i>. <b>13</b> (12): 2031–2041. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1016%2Fj.cgh.2015.08.015\">10.1016/j.cgh.2015.08.015</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1542-7714\">1542-7714</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618163\">4618163</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/26291665\">26291665</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clinical+Gastroenterology+and+Hepatology&amp;rft.atitle=Current+and+Future+Burden+of+Chronic+Nonmalignant+Liver+Disease&amp;rft.volume=13&amp;rft.issue=12&amp;rft.pages=2031-2041&amp;rft.date=2015-11-01&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4618163%23id-name%3DPMC&amp;rft.issn=1542-7714&amp;rft_id=info%3Apmid%2F26291665&amp;rft_id=info%3Adoi%2F10.1016%2Fj.cgh.2015.08.015&amp;rft.aulast=Udompap&amp;rft.aufirst=Prowpanga&amp;rft.au=Kim%2C+Donghee&amp;rft.au=Kim%2C+W.+Ray&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4618163&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Reducing_the_neglected_burden-153\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Reducing_the_neglected_burden_153-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Reducing_the_neglected_burden_153-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFLemoineEholiéLacombe2015\" class=\"citation journal cs1\">Lemoine, Maud; Eholié, Serge; Lacombe, Karine (2015). <a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1016%2Fj.jhep.2014.10.008\">\"Reducing the neglected burden of viral hepatitis in Africa: Strategies for a global approach\"</a>. <i>Journal of Hepatology</i>. <b>62</b> (2): 469–476. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1016%2Fj.jhep.2014.10.008\">10.1016/j.jhep.2014.10.008</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/25457207\">25457207</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Hepatology&amp;rft.atitle=Reducing+the+neglected+burden+of+viral+hepatitis+in+Africa%3A+Strategies+for+a+global+approach&amp;rft.volume=62&amp;rft.issue=2&amp;rft.pages=469-476&amp;rft.date=2015&amp;rft_id=info%3Adoi%2F10.1016%2Fj.jhep.2014.10.008&amp;rft_id=info%3Apmid%2F25457207&amp;rft.aulast=Lemoine&amp;rft.aufirst=Maud&amp;rft.au=Eholi%C3%A9%2C+Serge&amp;rft.au=Lacombe%2C+Karine&amp;rft_id=https%3A%2F%2Fdoi.org%2F10.1016%252Fj.jhep.2014.10.008&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Current_Childhood_Vaccination_Strategies-154\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Current_Childhood_Vaccination_Strategies_154-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Current_Childhood_Vaccination_Strategies_154-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFKoslap-PetracoShubJudelsohn2008\" class=\"citation journal cs1\">Koslap-Petraco, Mary Beth; Shub, Mitchell; Judelsohn, Richard (2008). \"Hepatitis A: Disease Burden and Current Childhood Vaccination Strategies in the United States\". <i>Journal of Pediatric Health Care</i>. <b>22</b> (1): 3–11. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1016%2Fj.pedhc.2006.12.011\">10.1016/j.pedhc.2006.12.011</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/18174084\">18174084</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Pediatric+Health+Care&amp;rft.atitle=Hepatitis+A%3A+Disease+Burden+and+Current+Childhood+Vaccination+Strategies+in+the+United+States&amp;rft.volume=22&amp;rft.issue=1&amp;rft.pages=3-11&amp;rft.date=2008&amp;rft_id=info%3Adoi%2F10.1016%2Fj.pedhc.2006.12.011&amp;rft_id=info%3Apmid%2F18174084&amp;rft.aulast=Koslap-Petraco&amp;rft.aufirst=Mary+Beth&amp;rft.au=Shub%2C+Mitchell&amp;rft.au=Judelsohn%2C+Richard&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-155\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-155\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFPrevisaniLavanchy2000\" class=\"citation web cs1\">Previsani, Nicoletta; Lavanchy, Daniel (2000). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.who.int/csr/disease/hepatitis/HepatitisA_whocdscsredc2000_7.pdf?ua=1\">\"Hepatitis A\"</a> <span class=\"cs1-format\">(PDF)</span>. <i>World Health Organization Global Alert and Response</i>. World Health Organization<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">March 5,</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=World+Health+Organization+Global+Alert+and+Response&amp;rft.atitle=Hepatitis+A&amp;rft.date=2000&amp;rft.aulast=Previsani&amp;rft.aufirst=Nicoletta&amp;rft.au=Lavanchy%2C+Daniel&amp;rft_id=https%3A%2F%2Fwww.who.int%2Fcsr%2Fdisease%2Fhepatitis%2FHepatitisA_whocdscsredc2000_7.pdf%3Fua%3D1&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-156\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-156\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFAnonychukTriccoBauchPham2008\" class=\"citation journal cs1\">Anonychuk, Andrea M.; Tricco, Andrea C.; Bauch, Chris T.; Pham, Ba\\'; Gilca, Vladimir; Duval, Bernard; John-Baptiste, Ava; Woo, Gloria; Krahn, Murray (2008-01-01). \"Cost-effectiveness analyses of hepatitis A vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies\". <i>PharmacoEconomics</i>. <b>26</b> (1): 17–32. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.2165%2F00019053-200826010-00003\">10.2165/00019053-200826010-00003</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1170-7690\">1170-7690</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/18088156\">18088156</a>. <a href=\"/wiki/S2CID_(identifier)\" class=\"mw-redirect\" title=\"S2CID (identifier)\">S2CID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://api.semanticscholar.org/CorpusID:46965673\">46965673</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=PharmacoEconomics&amp;rft.atitle=Cost-effectiveness+analyses+of+hepatitis+A+vaccine%3A+a+systematic+review+to+explore+the+effect+of+methodological+quality+on+the+economic+attractiveness+of+vaccination+strategies&amp;rft.volume=26&amp;rft.issue=1&amp;rft.pages=17-32&amp;rft.date=2008-01-01&amp;rft.issn=1170-7690&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A46965673%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F18088156&amp;rft_id=info%3Adoi%2F10.2165%2F00019053-200826010-00003&amp;rft.aulast=Anonychuk&amp;rft.aufirst=Andrea+M.&amp;rft.au=Tricco%2C+Andrea+C.&amp;rft.au=Bauch%2C+Chris+T.&amp;rft.au=Pham%2C+Ba%27&amp;rft.au=Gilca%2C+Vladimir&amp;rft.au=Duval%2C+Bernard&amp;rft.au=John-Baptiste%2C+Ava&amp;rft.au=Woo%2C+Gloria&amp;rft.au=Krahn%2C+Murray&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-157\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-157\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFChanJia2011\" class=\"citation journal cs1\">Chan, Henry Lik-Yuen; Jia, Jidong (2011-01-01). <a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1111%2Fj.1440-1746.2010.06544.x\">\"Chronic hepatitis B in Asia—new insights from the past decade\"</a>. <i>Journal of Gastroenterology and Hepatology</i>. <b>26</b>: 131–137. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1111%2Fj.1440-1746.2010.06544.x\">10.1111/j.1440-1746.2010.06544.x</a></span>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1440-1746\">1440-1746</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/21199524\">21199524</a>. <a href=\"/wiki/S2CID_(identifier)\" class=\"mw-redirect\" title=\"S2CID (identifier)\">S2CID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://api.semanticscholar.org/CorpusID:23548529\">23548529</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Gastroenterology+and+Hepatology&amp;rft.atitle=Chronic+hepatitis+B+in+Asia%E2%80%94new+insights+from+the+past+decade&amp;rft.volume=26&amp;rft.pages=131-137&amp;rft.date=2011-01-01&amp;rft.issn=1440-1746&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A23548529%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F21199524&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1440-1746.2010.06544.x&amp;rft.aulast=Chan&amp;rft.aufirst=Henry+Lik-Yuen&amp;rft.au=Jia%2C+Jidong&amp;rft_id=https%3A%2F%2Fdoi.org%2F10.1111%252Fj.1440-1746.2010.06544.x&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Economics_of_treating_in_Asia-158\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Economics_of_treating_in_Asia_158-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Economics_of_treating_in_Asia_158-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFDanAungLim2008\" class=\"citation journal cs1\">Dan, Yock Young; Aung, Myat Oo; Lim, Seng Gee (2008-09-01). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2716880\">\"The economics of treating chronic hepatitis B in Asia\"</a>. <i>Hepatology International</i>. <b>2</b> (3): 284–295. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1007%2Fs12072-008-9049-2\">10.1007/s12072-008-9049-2</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1936-0533\">1936-0533</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2716880\">2716880</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/19669256\">19669256</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Hepatology+International&amp;rft.atitle=The+economics+of+treating+chronic+hepatitis+B+in+Asia&amp;rft.volume=2&amp;rft.issue=3&amp;rft.pages=284-295&amp;rft.date=2008-09-01&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2716880%23id-name%3DPMC&amp;rft.issn=1936-0533&amp;rft_id=info%3Apmid%2F19669256&amp;rft_id=info%3Adoi%2F10.1007%2Fs12072-008-9049-2&amp;rft.aulast=Dan&amp;rft.aufirst=Yock+Young&amp;rft.au=Aung%2C+Myat+Oo&amp;rft.au=Lim%2C+Seng+Gee&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2716880&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-159\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-159\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFLavanchy2004\" class=\"citation journal cs1\">Lavanchy, D. (2004-03-01). \"Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures\". <i>Journal of Viral Hepatitis</i>. <b>11</b> (2): 97–107. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1046%2Fj.1365-2893.2003.00487.x\">10.1046/j.1365-2893.2003.00487.x</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1352-0504\">1352-0504</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/14996343\">14996343</a>. <a href=\"/wiki/S2CID_(identifier)\" class=\"mw-redirect\" title=\"S2CID (identifier)\">S2CID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://api.semanticscholar.org/CorpusID:163757\">163757</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Viral+Hepatitis&amp;rft.atitle=Hepatitis+B+virus+epidemiology%2C+disease+burden%2C+treatment%2C+and+current+and+emerging+prevention+and+control+measures&amp;rft.volume=11&amp;rft.issue=2&amp;rft.pages=97-107&amp;rft.date=2004-03-01&amp;rft.issn=1352-0504&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A163757%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F14996343&amp;rft_id=info%3Adoi%2F10.1046%2Fj.1365-2893.2003.00487.x&amp;rft.aulast=Lavanchy&amp;rft.aufirst=D.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Younossi,_Kanwal,_Saab,_et_al-160\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Younossi,_Kanwal,_Saab,_et_al_160-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Younossi,_Kanwal,_Saab,_et_al_160-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Younossi,_Kanwal,_Saab,_et_al_160-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFYounossiKanwalSaabBrown2014\" class=\"citation journal cs1\">Younossi, Z. M.; Kanwal, F.; Saab, S.; Brown, K. A.; El-Serag, H. B.; Kim, W. R.; Ahmed, A.; Kugelmas, M.; Gordon, S. C. (2014-03-01). <a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1111%2Fapt.12625\">\"The impact of hepatitis C burden: an evidence-based approach\"</a>. <i>Alimentary Pharmacology &amp; Therapeutics</i>. <b>39</b> (5): 518–531. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1111%2Fapt.12625\">10.1111/apt.12625</a></span>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1365-2036\">1365-2036</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/24461160\">24461160</a>. <a href=\"/wiki/S2CID_(identifier)\" class=\"mw-redirect\" title=\"S2CID (identifier)\">S2CID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://api.semanticscholar.org/CorpusID:21263906\">21263906</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Alimentary+Pharmacology+%26+Therapeutics&amp;rft.atitle=The+impact+of+hepatitis+C+burden%3A+an+evidence-based+approach&amp;rft.volume=39&amp;rft.issue=5&amp;rft.pages=518-531&amp;rft.date=2014-03-01&amp;rft.issn=1365-2036&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A21263906%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F24461160&amp;rft_id=info%3Adoi%2F10.1111%2Fapt.12625&amp;rft.aulast=Younossi&amp;rft.aufirst=Z.+M.&amp;rft.au=Kanwal%2C+F.&amp;rft.au=Saab%2C+S.&amp;rft.au=Brown%2C+K.+A.&amp;rft.au=El-Serag%2C+H.+B.&amp;rft.au=Kim%2C+W.+R.&amp;rft.au=Ahmed%2C+A.&amp;rft.au=Kugelmas%2C+M.&amp;rft.au=Gordon%2C+S.+C.&amp;rft_id=https%3A%2F%2Fdoi.org%2F10.1111%252Fapt.12625&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-161\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-161\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFMyersKrajdenBilodeauKaita2014\" class=\"citation journal cs1\">Myers, Robert P.; Krajden, Mel; Bilodeau, Marc; Kaita, Kelly; Marotta, Paul; Peltekian, Kevork; Ramji, Alnoor; Estes, Chris; Razavi, Homie (2014-05-01). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049256\">\"Burden of disease and cost of chronic hepatitis C infection in Canada\"</a>. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i>. <b>28</b> (5): 243–250. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1155%2F2014%2F317623\">10.1155/2014/317623</a></span>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/2291-2797\">2291-2797</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049256\">4049256</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/24839620\">24839620</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Canadian+Journal+of+Gastroenterology+%26+Hepatology&amp;rft.atitle=Burden+of+disease+and+cost+of+chronic+hepatitis+C+infection+in+Canada&amp;rft.volume=28&amp;rft.issue=5&amp;rft.pages=243-250&amp;rft.date=2014-05-01&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4049256%23id-name%3DPMC&amp;rft.issn=2291-2797&amp;rft_id=info%3Apmid%2F24839620&amp;rft_id=info%3Adoi%2F10.1155%2F2014%2F317623&amp;rft.aulast=Myers&amp;rft.aufirst=Robert+P.&amp;rft.au=Krajden%2C+Mel&amp;rft.au=Bilodeau%2C+Marc&amp;rft.au=Kaita%2C+Kelly&amp;rft.au=Marotta%2C+Paul&amp;rft.au=Peltekian%2C+Kevork&amp;rft.au=Ramji%2C+Alnoor&amp;rft.au=Estes%2C+Chris&amp;rft.au=Razavi%2C+Homie&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4049256&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-green_onions-162\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-green_onions_162-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-green_onions_162-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-green_onions_162-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-green_onions_162-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-green_onions_162-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-green_onions_162-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-green_onions_162-6\"><sup><i><b>g</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFCenters_for_Disease_Control_and_Prevention_(CDC)2003\" class=\"citation journal cs1\">Centers for Disease Control and Prevention (CDC) (2003-11-28). \"Hepatitis A outbreak associated with green onions at a restaurant—Monaca, Pennsylvania, 2003\". <i>MMWR. Morbidity and Mortality Weekly Report</i>. <b>52</b> (47): 1155–1157. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1545-861X\">1545-861X</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/14647018\">14647018</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=MMWR.+Morbidity+and+Mortality+Weekly+Report&amp;rft.atitle=Hepatitis+A+outbreak+associated+with+green+onions+at+a+restaurant%E2%80%94Monaca%2C+Pennsylvania%2C+2003&amp;rft.volume=52&amp;rft.issue=47&amp;rft.pages=1155-1157&amp;rft.date=2003-11-28&amp;rft_id=info%3Apmid%2F14647018&amp;rft.issn=1545-861X&amp;rft.au=Centers+for+Disease+Control+and+Prevention+%28CDC%29&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-163\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-163\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFPolgreen2003\" class=\"citation news cs1\">Polgreen, Lydia (November 16, 2003). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.nytimes.com/2003/11/17/us/community-is-reeling-from-hepatitis-outbreak.html\">\"Community Is Reeling From Hepatitis Outbreak\"</a>. <i><a href=\"/wiki/The_New_York_Times\" title=\"The New York Times\">The New York Times</a></i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20160322235231/http://www.nytimes.com/2003/11/17/us/community-is-reeling-from-hepatitis-outbreak.html\">Archived</a> from the original on March 22, 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">March 10,</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+York+Times&amp;rft.atitle=Community+Is+Reeling+From+Hepatitis+Outbreak&amp;rft.date=2003-11-16&amp;rft.aulast=Polgreen&amp;rft.aufirst=Lydia&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2003%2F11%2F17%2Fus%2Fcommunity-is-reeling-from-hepatitis-outbreak.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-HIV_co-infection-164\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-HIV_co-infection_164-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-HIV_co-infection_164-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFJordanPerlmanNeurerSmith2016\" class=\"citation journal cs1\">Jordan, Ashly E.; Perlman, David C.; Neurer, Joshua; Smith, Daniel J.; Des Jarlais, Don C.; Hagan, Holly (2016-01-28). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965334\">\"Prevalence of hepatitis C virus infection among HIV+ men who have sex with men: a systematic review and meta-analysis\"</a>. <i>International Journal of STD &amp; AIDS</i>. <b>28</b> (2): 145–159. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1177%2F0956462416630910\">10.1177/0956462416630910</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1758-1052\">1758-1052</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965334\">4965334</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/26826159\">26826159</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=International+Journal+of+STD+%26+AIDS&amp;rft.atitle=Prevalence+of+hepatitis+C+virus+infection+among+HIV%2B+men+who+have+sex+with+men%3A+a+systematic+review+and+meta-analysis&amp;rft.volume=28&amp;rft.issue=2&amp;rft.pages=145-159&amp;rft.date=2016-01-28&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4965334%23id-name%3DPMC&amp;rft.issn=1758-1052&amp;rft_id=info%3Apmid%2F26826159&amp;rft_id=info%3Adoi%2F10.1177%2F0956462416630910&amp;rft.aulast=Jordan&amp;rft.aufirst=Ashly+E.&amp;rft.au=Perlman%2C+David+C.&amp;rft.au=Neurer%2C+Joshua&amp;rft.au=Smith%2C+Daniel+J.&amp;rft.au=Des+Jarlais%2C+Don+C.&amp;rft.au=Hagan%2C+Holly&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4965334&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Platt,_Easterbrook_et_al-165\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Platt,_Easterbrook_et_al_165-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Platt,_Easterbrook_et_al_165-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Platt,_Easterbrook_et_al_165-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Platt,_Easterbrook_et_al_165-3\"><sup><i><b>d</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFPlattEasterbrookGowerMcDonald2016\" class=\"citation journal cs1\">Platt, Lucy; Easterbrook, Philippa; Gower, Erin; McDonald, Bethan; Sabin, Keith; McGowan, Catherine; Yanny, Irini; Razavi, Homie; Vickerman, Peter (2016-02-24). <a rel=\"nofollow\" class=\"external text\" href=\"http://researchonline.lshtm.ac.uk/2532806/1/PLATT%20Lancet%20Inf%20Dis%20250116%20final%20accepted.pdf\">\"Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis\"</a> <span class=\"cs1-format\">(PDF)</span>. <i>The Lancet. Infectious Diseases</i>. <b>16</b> (7): 797–808. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1016%2FS1473-3099%2815%2900485-5\">10.1016/S1473-3099(15)00485-5</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1474-4457\">1474-4457</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/26922272\">26922272</a>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20180719062234/http://researchonline.lshtm.ac.uk/2532806/1/PLATT%20Lancet%20Inf%20Dis%20250116%20final%20accepted.pdf\">Archived</a> <span class=\"cs1-format\">(PDF)</span> from the original on 2018-07-19.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Lancet.+Infectious+Diseases&amp;rft.atitle=Prevalence+and+burden+of+HCV+co-infection+in+people+living+with+HIV%3A+a+global+systematic+review+and+meta-analysis&amp;rft.volume=16&amp;rft.issue=7&amp;rft.pages=797-808&amp;rft.date=2016-02-24&amp;rft.issn=1474-4457&amp;rft_id=info%3Apmid%2F26922272&amp;rft_id=info%3Adoi%2F10.1016%2FS1473-3099%2815%2900485-5&amp;rft.aulast=Platt&amp;rft.aufirst=Lucy&amp;rft.au=Easterbrook%2C+Philippa&amp;rft.au=Gower%2C+Erin&amp;rft.au=McDonald%2C+Bethan&amp;rft.au=Sabin%2C+Keith&amp;rft.au=McGowan%2C+Catherine&amp;rft.au=Yanny%2C+Irini&amp;rft.au=Razavi%2C+Homie&amp;rft.au=Vickerman%2C+Peter&amp;rft_id=http%3A%2F%2Fresearchonline.lshtm.ac.uk%2F2532806%2F1%2FPLATT%2520Lancet%2520Inf%2520Dis%2520250116%2520final%2520accepted.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-mother-to-neonate-166\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-mother-to-neonate_166-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-mother-to-neonate_166-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-mother-to-neonate_166-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-mother-to-neonate_166-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-mother-to-neonate_166-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-mother-to-neonate_166-5\"><sup><i><b>f</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFCunningham2013\" class=\"citation book cs1\">Cunningham, F. Gary; et&#160;al. (2013). <i>\"Hepatic, Biliary, and Pancreatic Disorders.\" Williams Obstetrics, Twenty-Fourth Edition</i>. New York, NY: McGraw-Hill.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=%22Hepatic%2C+Biliary%2C+and+Pancreatic+Disorders.%22+Williams+Obstetrics%2C+Twenty-Fourth+Edition&amp;rft.place=New+York%2C+NY&amp;rft.pub=McGraw-Hill&amp;rft.date=2013&amp;rft.aulast=Cunningham&amp;rft.aufirst=F.+Gary&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-167\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-167\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFTassopoulos1987\" class=\"citation journal cs1\">Tassopoulos, NC; et&#160;al. (June 1987). \"Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults\". <i>Gastroenterology</i>. <b>92</b> (6): 1844–50. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1016%2F0016-5085%2887%2990614-7\">10.1016/0016-5085(87)90614-7</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/3569758\">3569758</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Gastroenterology&amp;rft.atitle=Natural+history+of+acute+hepatitis+B+surface+antigen-positive+hepatitis+in+Greek+adults.&amp;rft.volume=92&amp;rft.issue=6&amp;rft.pages=1844-50&amp;rft.date=1987-06&amp;rft_id=info%3Adoi%2F10.1016%2F0016-5085%2887%2990614-7&amp;rft_id=info%3Apmid%2F3569758&amp;rft.aulast=Tassopoulos&amp;rft.aufirst=NC&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-168\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-168\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite class=\"citation web cs1\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5416a1.htm?s_cid=rr5416a1_e\">\"A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1: Immunization of Infants, Children, and Adolescents\"</a>. <i>www.cdc.gov</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20160324191034/http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5416a1.htm?s_cid=rr5416a1_e\">Archived</a> from the original on 2016-03-24<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-03-16</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cdc.gov&amp;rft.atitle=A+Comprehensive+Immunization+Strategy+to+Eliminate+Transmission+of+Hepatitis+B+Virus+Infection+in+the+United+States+Recommendations+of+the+Advisory+Committee+on+Immunization+Practices+%28ACIP%29+Part+1%3A+Immunization+of+Infants%2C+Children%2C+and+Adolescents&amp;rft_id=https%3A%2F%2Fwww.cdc.gov%2Fmmwr%2Fpreview%2Fmmwrhtml%2Frr5416a1.htm%3Fs_cid%3Drr5416a1_e&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-AASLD_guidelines_for_chronic_B-169\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-AASLD_guidelines_for_chronic_B_169-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-AASLD_guidelines_for_chronic_B_169-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-AASLD_guidelines_for_chronic_B_169-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFTerraultBzowejChangHwang2016\" class=\"citation journal cs1\">Terrault, Norah A.; Bzowej, Natalie H.; Chang, Kyong-Mi; Hwang, Jessica P.; Jonas, Maureen M.; Murad, M. Hassan (2016-01-01). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987259\">\"AASLD guidelines for treatment of chronic hepatitis B\"</a>. <i>Hepatology</i>. <b>63</b> (1): 261–283. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1002%2Fhep.28156\">10.1002/hep.28156</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1527-3350\">1527-3350</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987259\">5987259</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/26566064\">26566064</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Hepatology&amp;rft.atitle=AASLD+guidelines+for+treatment+of+chronic+hepatitis+B&amp;rft.volume=63&amp;rft.issue=1&amp;rft.pages=261-283&amp;rft.date=2016-01-01&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5987259%23id-name%3DPMC&amp;rft.issn=1527-3350&amp;rft_id=info%3Apmid%2F26566064&amp;rft_id=info%3Adoi%2F10.1002%2Fhep.28156&amp;rft.aulast=Terrault&amp;rft.aufirst=Norah+A.&amp;rft.au=Bzowej%2C+Natalie+H.&amp;rft.au=Chang%2C+Kyong-Mi&amp;rft.au=Hwang%2C+Jessica+P.&amp;rft.au=Jonas%2C+Maureen+M.&amp;rft.au=Murad%2C+M.+Hassan&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5987259&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-170\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-170\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFWangKourtisEllingtonLegardy-Williams2013\" class=\"citation journal cs1\">Wang, Liming; Kourtis, Athena P.; Ellington, Sascha; Legardy-Williams, Jennifer; Bulterys, Marc (2013-12-01). <a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1093%2Fcid%2Fcit601\">\"Safety of tenofovir during pregnancy for the mother and fetus: a systematic review\"</a>. <i>Clinical Infectious Diseases</i>. <b>57</b> (12): 1773–1781. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1093%2Fcid%2Fcit601\">10.1093/cid/cit601</a></span>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1537-6591\">1537-6591</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/24046310\">24046310</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clinical+Infectious+Diseases&amp;rft.atitle=Safety+of+tenofovir+during+pregnancy+for+the+mother+and+fetus%3A+a+systematic+review&amp;rft.volume=57&amp;rft.issue=12&amp;rft.pages=1773-1781&amp;rft.date=2013-12-01&amp;rft.issn=1537-6591&amp;rft_id=info%3Apmid%2F24046310&amp;rft_id=info%3Adoi%2F10.1093%2Fcid%2Fcit601&amp;rft.aulast=Wang&amp;rft.aufirst=Liming&amp;rft.au=Kourtis%2C+Athena+P.&amp;rft.au=Ellington%2C+Sascha&amp;rft.au=Legardy-Williams%2C+Jennifer&amp;rft.au=Bulterys%2C+Marc&amp;rft_id=https%3A%2F%2Fdoi.org%2F10.1093%252Fcid%252Fcit601&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-171\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-171\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFShiYangMaLi2010\" class=\"citation journal cs1\">Shi, Zhongjie; Yang, Yuebo; Ma, Lin; Li, Xiaomao; Schreiber, Ann (2010-07-01). \"Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis\". <i>Obstetrics and Gynecology</i>. <b>116</b> (1): 147–159. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1097%2FAOG.0b013e3181e45951\">10.1097/AOG.0b013e3181e45951</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1873-233X\">1873-233X</a>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/20567182\">20567182</a>. <a href=\"/wiki/S2CID_(identifier)\" class=\"mw-redirect\" title=\"S2CID (identifier)\">S2CID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://api.semanticscholar.org/CorpusID:41784922\">41784922</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Obstetrics+and+Gynecology&amp;rft.atitle=Lamivudine+in+late+pregnancy+to+interrupt+in+utero+transmission+of+hepatitis+B+virus%3A+a+systematic+review+and+meta-analysis&amp;rft.volume=116&amp;rft.issue=1&amp;rft.pages=147-159&amp;rft.date=2010-07-01&amp;rft.issn=1873-233X&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A41784922%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F20567182&amp;rft_id=info%3Adoi%2F10.1097%2FAOG.0b013e3181e45951&amp;rft.aulast=Shi&amp;rft.aufirst=Zhongjie&amp;rft.au=Yang%2C+Yuebo&amp;rft.au=Ma%2C+Lin&amp;rft.au=Li%2C+Xiaomao&amp;rft.au=Schreiber%2C+Ann&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-Benova_-_vertical_transmission-172\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Benova_-_vertical_transmission_172-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Benova_-_vertical_transmission_172-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Benova_-_vertical_transmission_172-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFBenovaMohamoudCalvertAbu-Raddad2014\" class=\"citation journal cs1\">Benova, Lenka; Mohamoud, Yousra A.; Calvert, Clara; Abu-Raddad, Laith J. (2014-09-15). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4144266\">\"Vertical transmission of hepatitis C virus: systematic review and meta-analysis\"</a>. <i>Clinical Infectious Diseases</i>. <b>59</b> (6): 765–773. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1093%2Fcid%2Fciu447\">10.1093/cid/ciu447</a>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1537-6591\">1537-6591</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4144266\">4144266</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/24928290\">24928290</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clinical+Infectious+Diseases&amp;rft.atitle=Vertical+transmission+of+hepatitis+C+virus%3A+systematic+review+and+meta-analysis&amp;rft.volume=59&amp;rft.issue=6&amp;rft.pages=765-773&amp;rft.date=2014-09-15&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4144266%23id-name%3DPMC&amp;rft.issn=1537-6591&amp;rft_id=info%3Apmid%2F24928290&amp;rft_id=info%3Adoi%2F10.1093%2Fcid%2Fciu447&amp;rft.aulast=Benova&amp;rft.aufirst=Lenka&amp;rft.au=Mohamoud%2C+Yousra+A.&amp;rft.au=Calvert%2C+Clara&amp;rft.au=Abu-Raddad%2C+Laith+J.&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4144266&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n<li id=\"cite_note-173\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-173\">^</a></b></span> <span class=\"reference-text\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1133582631\"><cite id=\"CITEREFJinZhaoZhangWang2016\" class=\"citation journal cs1 cs1-prop-long-vol\">Jin, H.; Zhao, Y.; Zhang, X.; Wang, B.; Liu, P. (2016-03-01). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9150575\">\"Case-fatality risk of pregnant women with acute viral hepatitis type E: a systematic review and meta-analysis\"</a>. <i>Epidemiology &amp; Infection</i>. FirstView (10): 2098–2106. <a href=\"/wiki/Doi_(identifier)\" class=\"mw-redirect\" title=\"Doi (identifier)\">doi</a>:<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1017%2FS0950268816000418\">10.1017/S0950268816000418</a></span>. <a href=\"/wiki/ISSN_(identifier)\" class=\"mw-redirect\" title=\"ISSN (identifier)\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/issn/1469-4409\">1469-4409</a>. <a href=\"/wiki/PMC_(identifier)\" class=\"mw-redirect\" title=\"PMC (identifier)\">PMC</a>&#160;<span class=\"cs1-lock-free\" title=\"Freely accessible\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9150575\">9150575</a></span>. <a href=\"/wiki/PMID_(identifier)\" class=\"mw-redirect\" title=\"PMID (identifier)\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"https://pubmed.ncbi.nlm.nih.gov/26939626\">26939626</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Epidemiology+%26+Infection&amp;rft.atitle=Case-fatality+risk+of+pregnant+women+with+acute+viral+hepatitis+type+E%3A+a+systematic+review+and+meta-analysis&amp;rft.volume=FirstView&amp;rft.issue=10&amp;rft.pages=2098-2106&amp;rft.date=2016-03-01&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC9150575%23id-name%3DPMC&amp;rft.issn=1469-4409&amp;rft_id=info%3Apmid%2F26939626&amp;rft_id=info%3Adoi%2F10.1017%2FS0950268816000418&amp;rft.aulast=Jin&amp;rft.aufirst=H.&amp;rft.au=Zhao%2C+Y.&amp;rft.au=Zhang%2C+X.&amp;rft.au=Wang%2C+B.&amp;rft.au=Liu%2C+P.&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC9150575&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHepatitis\" class=\"Z3988\"></span></span>\\n</li>\\n</ol></div></div>\\n<h2><span class=\"mw-headline\" id=\"External_links\">External links</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Hepatitis&amp;action=edit&amp;section=84\" title=\"Edit section: External links\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\\n<div class=\"navbox-styles\"><style data-mw-deduplicate=\"TemplateStyles:r1061467846\">.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}</style><style data-mw-deduplicate=\"TemplateStyles:r1129693374\">.mw-parser-output .hlist dl,.mw-parser-output .hlist ol,.mw-parser-output .hlist ul{margin:0;padding:0}.mw-parser-output .hlist dd,.mw-parser-output .hlist dt,.mw-parser-output .hlist li{margin:0;display:inline}.mw-parser-output .hlist.inline,.mw-parser-output .hlist.inline dl,.mw-parser-output .hlist.inline ol,.mw-parser-output .hlist.inline ul,.mw-parser-output .hlist dl dl,.mw-parser-output .hlist dl ol,.mw-parser-output .hlist dl ul,.mw-parser-output .hlist ol dl,.mw-parser-output .hlist ol ol,.mw-parser-output .hlist ol ul,.mw-parser-output .hlist ul dl,.mw-parser-output .hlist ul ol,.mw-parser-output .hlist ul ul{display:inline}.mw-parser-output .hlist .mw-empty-li{display:none}.mw-parser-output .hlist dt::after{content:\": \"}.mw-parser-output .hlist dd::after,.mw-parser-output .hlist li::after{content:\" · \";font-weight:bold}.mw-parser-output .hlist dd:last-child::after,.mw-parser-output .hlist dt:last-child::after,.mw-parser-output .hlist li:last-child::after{content:none}.mw-parser-output .hlist dd dd:first-child::before,.mw-parser-output .hlist dd dt:first-child::before,.mw-parser-output .hlist dd li:first-child::before,.mw-parser-output .hlist dt dd:first-child::before,.mw-parser-output .hlist dt dt:first-child::before,.mw-parser-output .hlist dt li:first-child::before,.mw-parser-output .hlist li dd:first-child::before,.mw-parser-output .hlist li dt:first-child::before,.mw-parser-output .hlist li li:first-child::before{content:\" (\";font-weight:normal}.mw-parser-output .hlist dd dd:last-child::after,.mw-parser-output .hlist dd dt:last-child::after,.mw-parser-output .hlist dd li:last-child::after,.mw-parser-output .hlist dt dd:last-child::after,.mw-parser-output .hlist dt dt:last-child::after,.mw-parser-output .hlist dt li:last-child::after,.mw-parser-output .hlist li dd:last-child::after,.mw-parser-output .hlist li dt:last-child::after,.mw-parser-output .hlist li li:last-child::after{content:\")\";font-weight:normal}.mw-parser-output .hlist ol{counter-reset:listitem}.mw-parser-output .hlist ol>li{counter-increment:listitem}.mw-parser-output .hlist ol>li::before{content:\" \"counter(listitem)\"\\\\a0 \"}.mw-parser-output .hlist dd ol>li:first-child::before,.mw-parser-output .hlist dt ol>li:first-child::before,.mw-parser-output .hlist li ol>li:first-child::before{content:\" (\"counter(listitem)\"\\\\a0 \"}</style><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1129693374\"></div><div role=\"navigation\" class=\"navbox\" aria-label=\"Navbox\" style=\"width:100%; margin:0.5em 0 0.5em 0;;padding:3px\"><table class=\"nowraplinks navbox-inner\" style=\"border-spacing:0;background:transparent;color:inherit\"><tbody><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;background: #EAECF0\">Classification</th><td class=\"navbox-list-with-group navbox-list navbox-odd\" style=\"width:100%;padding:0\"><div style=\"padding:0 0.25em\"><div style=\"position:relative; float:right; font-size:0.8em;\"><a href=\"https://www.wikidata.org/wiki/Q131742\" class=\"extiw\" title=\"d:Q131742\">D</a></div><div class=\"hlist\" style=\"text-align:left;\"><ul><li><b><a href=\"/wiki/International_Statistical_Classification_of_Diseases_and_Related_Health_Problems\" class=\"mw-redirect\" title=\"International Statistical Classification of Diseases and Related Health Problems\">ICD</a>-<a href=\"/wiki/ICD-10\" title=\"ICD-10\">10</a></b>: <a rel=\"nofollow\" class=\"external text\" href=\"https://icd.who.int/browse10/2019/en#/K75.9\">K75.9</a></li><li><b><a href=\"/wiki/International_Statistical_Classification_of_Diseases_and_Related_Health_Problems\" class=\"mw-redirect\" title=\"International Statistical Classification of Diseases and Related Health Problems\">ICD</a>-<a href=\"/wiki/List_of_ICD-9_codes\" title=\"List of ICD-9 codes\">9-CM</a></b>: <a rel=\"nofollow\" class=\"external text\" href=\"http://www.icd9data.com/getICD9Code.ashx?icd9=573.3\">573.3</a></li><li><b><a href=\"/wiki/Medical_Subject_Headings\" title=\"Medical Subject Headings\">MeSH</a></b>: <a rel=\"nofollow\" class=\"external text\" href=\"https://meshb.nlm.nih.gov/record/ui?ui=D006505\">D006505</a></li><li><b><a href=\"/wiki/Diseases_Database\" title=\"Diseases Database\">DiseasesDB</a></b>: <a rel=\"nofollow\" class=\"external text\" href=\"http://www.diseasesdatabase.com/ddb20061.htm\">20061</a></li></ul></div></div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%;background: #EAECF0\">External resources</th><td class=\"navbox-list-with-group navbox-list navbox-even\" style=\"width:100%;padding:0\"><div style=\"padding:0 0.25em\"><div class=\"hlist\" style=\"text-align:left;\"><ul><li><b><a href=\"/wiki/MedlinePlus\" title=\"MedlinePlus\">MedlinePlus</a></b>: <a rel=\"nofollow\" class=\"external text\" href=\"https://www.nlm.nih.gov/medlineplus/ency/article/001154.htm\">001154</a></li></ul></div></div></td></tr></tbody></table></div>\\n<ul><li><a rel=\"nofollow\" class=\"external text\" href=\"https://www.cdc.gov/ncidod/diseases/hepatitis/\">Viral Hepatitis at the Centers for Disease Control</a></li>\\n<li><a rel=\"nofollow\" class=\"external text\" href=\"https://www.who.int/topics/hepatitis/en/\">WHO fact sheet of hepatitis</a></li></ul>\\n<div class=\"navbox-styles\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1129693374\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1061467846\"></div><div role=\"navigation\" class=\"navbox\" aria-labelledby=\"Diseases_of_the_digestive_system\" style=\"padding:3px\"><table class=\"nowraplinks mw-collapsible mw-collapsed navbox-inner\" style=\"border-spacing:0;background:transparent;color:inherit\"><tbody><tr><th scope=\"col\" class=\"navbox-title\" colspan=\"2\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1129693374\"><style data-mw-deduplicate=\"TemplateStyles:r1063604349\">.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:\"[ \"}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:\" ]\"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}</style><div class=\"navbar plainlinks hlist navbar-mini\"><ul><li class=\"nv-view\"><a href=\"/wiki/Template:Digestive_system_diseases\" title=\"Template:Digestive system diseases\"><abbr title=\"View this template\" style=\";;background:none transparent;border:none;box-shadow:none;padding:0;\">v</abbr></a></li><li class=\"nv-talk\"><a href=\"/wiki/Template_talk:Digestive_system_diseases\" title=\"Template talk:Digestive system diseases\"><abbr title=\"Discuss this template\" style=\";;background:none transparent;border:none;box-shadow:none;padding:0;\">t</abbr></a></li><li class=\"nv-edit\"><a class=\"external text\" href=\"https://en.wikipedia.org/w/index.php?title=Template:Digestive_system_diseases&amp;action=edit\"><abbr title=\"Edit this template\" style=\";;background:none transparent;border:none;box-shadow:none;padding:0;\">e</abbr></a></li></ul></div><div id=\"Diseases_of_the_digestive_system\" style=\"font-size:114%;margin:0 4em\">Diseases of the <a href=\"/wiki/Digestive_system\" class=\"mw-redirect\" title=\"Digestive system\">digestive system</a></div></th></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Gastrointestinal_tract#Upper_gastrointestinal_tract\" title=\"Gastrointestinal tract\">Upper GI tract</a></th><td class=\"navbox-list-with-group navbox-list navbox-odd hlist\" style=\"width:100%;padding:0\"><div style=\"padding:0 0.25em\"></div><table class=\"nowraplinks navbox-subgroup\" style=\"border-spacing:0\"><tbody><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Esophageal_disease\" title=\"Esophageal disease\">Esophagus</a></th><td class=\"navbox-list-with-group navbox-list navbox-odd\" style=\"width:100%;padding:0\"><div style=\"padding:0 0.25em\">\\n<ul><li><a href=\"/wiki/Esophagitis\" title=\"Esophagitis\">Esophagitis</a>\\n<ul><li><a href=\"/wiki/Esophageal_candidiasis\" title=\"Esophageal candidiasis\">Candidal</a></li>\\n<li><a href=\"/wiki/Eosinophilic_esophagitis\" title=\"Eosinophilic esophagitis\">Eosinophilic</a></li>\\n<li><a href=\"/wiki/Herpetiform_esophagitis\" class=\"mw-redirect\" title=\"Herpetiform esophagitis\">Herpetiform</a></li></ul></li>\\n<li><i>Rupture</i>\\n<ul><li><a href=\"/wiki/Boerhaave_syndrome\" class=\"mw-redirect\" title=\"Boerhaave syndrome\">Boerhaave syndrome</a></li>\\n<li><a href=\"/wiki/Mallory%E2%80%93Weiss_syndrome\" title=\"Mallory–Weiss syndrome\">Mallory–Weiss syndrome</a></li></ul></li>\\n<li><a href=\"/wiki/Esophagus#Sphincters\" title=\"Esophagus\">UES</a>\\n<ul><li><a href=\"/wiki/Zenker%27s_diverticulum\" title=\"Zenker&#39;s diverticulum\">Zenker\\'s diverticulum</a></li></ul></li>\\n<li><a href=\"/wiki/Esophagus#Sphincters\" title=\"Esophagus\">LES</a>\\n<ul><li><a href=\"/wiki/Barrett%27s_esophagus\" title=\"Barrett&#39;s esophagus\">Barrett\\'s esophagus</a></li></ul></li>\\n<li><a href=\"/wiki/Esophageal_motility_disorder\" title=\"Esophageal motility disorder\">Esophageal motility disorder</a>\\n<ul><li><a href=\"/wiki/Nutcracker_esophagus\" title=\"Nutcracker esophagus\">Nutcracker esophagus</a></li>\\n<li><a href=\"/wiki/Achalasia\" class=\"mw-redirect\" title=\"Achalasia\">Achalasia</a></li>\\n<li><a href=\"/wiki/Esophagogastric_junction_outflow_obstruction\" title=\"Esophagogastric junction outflow obstruction\">Esophagogastric junction outflow obstruction</a></li>\\n<li><a href=\"/wiki/Diffuse_esophageal_spasm\" title=\"Diffuse esophageal spasm\">Diffuse esophageal spasm</a></li>\\n<li><a href=\"/wiki/Gastroesophageal_reflux_disease\" title=\"Gastroesophageal reflux disease\">Gastroesophageal reflux disease</a> (GERD)</li></ul></li>\\n<li><a href=\"/wiki/Laryngopharyngeal_reflux\" title=\"Laryngopharyngeal reflux\">Laryngopharyngeal reflux</a> (LPR)</li>\\n<li><a href=\"/wiki/Esophageal_stricture\" title=\"Esophageal stricture\">Esophageal stricture</a></li>\\n<li><a href=\"/wiki/Megaesophagus\" title=\"Megaesophagus\">Megaesophagus</a></li>\\n<li><a href=\"/wiki/Esophageal_intramural_pseudodiverticulosis\" title=\"Esophageal intramural pseudodiverticulosis\">Esophageal intramural pseudodiverticulosis</a></li>\\n<li><a href=\"/wiki/Acute_esophageal_necrosis\" title=\"Acute esophageal necrosis\">Acute esophageal necrosis</a></li></ul>\\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Stomach_disease\" title=\"Stomach disease\">Stomach</a></th><td class=\"navbox-list-with-group navbox-list navbox-even\" style=\"width:100%;padding:0\"><div style=\"padding:0 0.25em\">\\n<ul><li><a href=\"/wiki/Gastritis\" title=\"Gastritis\">Gastritis</a>\\n<ul><li><a href=\"/wiki/Atrophic_gastritis\" title=\"Atrophic gastritis\">Atrophic</a></li>\\n<li><a href=\"/wiki/M%C3%A9n%C3%A9trier%27s_disease\" title=\"Ménétrier&#39;s disease\">Ménétrier\\'s disease</a></li>\\n<li><a href=\"/wiki/Gastroenteritis\" title=\"Gastroenteritis\">Gastroenteritis</a></li></ul></li>\\n<li><a href=\"/wiki/Peptic_ulcer\" class=\"mw-redirect\" title=\"Peptic ulcer\">Peptic (gastric) ulcer</a>\\n<ul><li><a href=\"/wiki/Cushing_ulcer\" title=\"Cushing ulcer\">Cushing ulcer</a></li>\\n<li><a href=\"/wiki/Dieulafoy%27s_lesion\" title=\"Dieulafoy&#39;s lesion\">Dieulafoy\\'s lesion</a></li></ul></li>\\n<li><a href=\"/wiki/Dyspepsia\" class=\"mw-redirect\" title=\"Dyspepsia\">Dyspepsia</a></li>\\n<li><a href=\"/wiki/Pyloric_stenosis\" title=\"Pyloric stenosis\">Pyloric stenosis</a></li>\\n<li><a href=\"/wiki/Achlorhydria\" title=\"Achlorhydria\">Achlorhydria</a></li>\\n<li><a href=\"/wiki/Gastroparesis\" title=\"Gastroparesis\">Gastroparesis</a></li>\\n<li><a href=\"/wiki/Gastroptosis\" title=\"Gastroptosis\">Gastroptosis</a></li>\\n<li><a href=\"/wiki/Portal_hypertensive_gastropathy\" title=\"Portal hypertensive gastropathy\">Portal hypertensive gastropathy</a></li>\\n<li><a href=\"/wiki/Gastric_antral_vascular_ectasia\" title=\"Gastric antral vascular ectasia\">Gastric antral vascular ectasia</a></li>\\n<li><a href=\"/wiki/Gastric_dumping_syndrome\" class=\"mw-redirect\" title=\"Gastric dumping syndrome\">Gastric dumping syndrome</a></li>\\n<li><a href=\"/wiki/Gastric_volvulus\" title=\"Gastric volvulus\">Gastric volvulus</a></li>\\n<li><a href=\"/wiki/Buried_bumper_syndrome\" title=\"Buried bumper syndrome\">Buried bumper syndrome</a></li>\\n<li><a href=\"/wiki/Gastrinoma\" title=\"Gastrinoma\">Gastrinoma</a>\\n<ul><li><a href=\"/wiki/Zollinger%E2%80%93Ellison_syndrome\" title=\"Zollinger–Ellison syndrome\">Zollinger–Ellison syndrome</a></li></ul></li></ul>\\n</div></td></tr></tbody></table><div></div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Gastrointestinal_tract#Lower_gastrointestinal_tract\" title=\"Gastrointestinal tract\">Lower GI tract</a> <br /> <a href=\"/wiki/Enteropathy\" title=\"Enteropathy\">Enteropathy</a></th><td class=\"navbox-list-with-group navbox-list navbox-odd hlist\" style=\"width:100%;padding:0\"><div style=\"padding:0 0.25em\"></div><table class=\"nowraplinks navbox-subgroup\" style=\"border-spacing:0\"><tbody><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Small_intestine\" title=\"Small intestine\">Small intestine</a> <br /> (<a href=\"/wiki/Duodenum\" title=\"Duodenum\">Duodenum</a>/<a href=\"/wiki/Jejunum\" title=\"Jejunum\">Jejunum</a>/<a href=\"/wiki/Ileum\" title=\"Ileum\">Ileum</a>)</th><td class=\"navbox-list-with-group navbox-list navbox-odd\" style=\"width:100%;padding:0\"><div style=\"padding:0 0.25em\">\\n<ul><li><a href=\"/wiki/Enteritis\" title=\"Enteritis\">Enteritis</a>\\n<ul><li><a href=\"/wiki/Duodenitis\" title=\"Duodenitis\">Duodenitis</a></li>\\n<li><a href=\"/wiki/Jejunitis\" class=\"mw-redirect\" title=\"Jejunitis\">Jejunitis</a></li>\\n<li><a href=\"/wiki/Ileitis\" title=\"Ileitis\">Ileitis</a></li></ul></li>\\n<li><a href=\"/wiki/Peptic_ulcer\" class=\"mw-redirect\" title=\"Peptic ulcer\">Peptic (duodenal) ulcer</a>\\n<ul><li><a href=\"/wiki/Curling%27s_ulcer\" title=\"Curling&#39;s ulcer\">Curling\\'s ulcer</a></li></ul></li>\\n<li><a href=\"/wiki/Malabsorption\" title=\"Malabsorption\">Malabsorption</a>: <a href=\"/wiki/Coeliac_disease\" title=\"Coeliac disease\">Coeliac</a></li>\\n<li><a href=\"/wiki/Tropical_sprue\" title=\"Tropical sprue\">Tropical sprue</a></li>\\n<li><a href=\"/wiki/Blind_loop_syndrome\" title=\"Blind loop syndrome\">Blind loop syndrome</a></li>\\n<li><a href=\"/wiki/Small_intestinal_bacterial_overgrowth\" title=\"Small intestinal bacterial overgrowth\">Small intestinal bacterial overgrowth</a></li>\\n<li><a href=\"/wiki/Whipple%27s_disease\" title=\"Whipple&#39;s disease\">Whipple\\'s</a></li>\\n<li><a href=\"/wiki/Short_bowel_syndrome\" title=\"Short bowel syndrome\">Short bowel syndrome</a></li>\\n<li><a href=\"/wiki/Steatorrhea\" title=\"Steatorrhea\">Steatorrhea</a></li>\\n<li><a href=\"/wiki/Milroy_disease\" class=\"mw-redirect\" title=\"Milroy disease\">Milroy disease</a></li>\\n<li><a href=\"/wiki/Bile_acid_malabsorption\" title=\"Bile acid malabsorption\">Bile acid malabsorption</a></li></ul>\\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Large_intestine\" title=\"Large intestine\">Large intestine</a> <br /> (<a href=\"/wiki/Vermiform_appendix\" class=\"mw-redirect\" title=\"Vermiform appendix\">Appendix</a>/<a href=\"/wiki/Colon_(anatomy)\" class=\"mw-redirect\" title=\"Colon (anatomy)\">Colon</a>)</th><td class=\"navbox-list-with-group navbox-list navbox-even\" style=\"width:100%;padding:0\"><div style=\"padding:0 0.25em\">\\n<ul><li><a href=\"/wiki/Appendicitis\" title=\"Appendicitis\">Appendicitis</a></li>\\n<li><a href=\"/wiki/Colitis\" title=\"Colitis\">Colitis</a>\\n<ul><li><a href=\"/wiki/Pseudomembranous_colitis\" class=\"mw-redirect\" title=\"Pseudomembranous colitis\">Pseudomembranous</a></li>\\n<li><a href=\"/wiki/Ulcerative_colitis\" title=\"Ulcerative colitis\">Ulcerative</a></li>\\n<li><a href=\"/wiki/Ischemic_colitis\" title=\"Ischemic colitis\">Ischemic</a></li>\\n<li><a href=\"/wiki/Microscopic_colitis\" title=\"Microscopic colitis\">Microscopic</a></li>\\n<li><a href=\"/wiki/Collagenous_colitis\" title=\"Collagenous colitis\">Collagenous</a></li>\\n<li><a href=\"/wiki/Lymphocytic_colitis\" title=\"Lymphocytic colitis\">Lymphocytic</a></li></ul></li>\\n<li><a href=\"/wiki/Dysentery\" title=\"Dysentery\">Dysentery</a></li>\\n<li><a href=\"/wiki/Functional_colonic_disease\" class=\"mw-redirect\" title=\"Functional colonic disease\">Functional colonic disease</a>\\n<ul><li><a href=\"/wiki/Irritable_bowel_syndrome\" title=\"Irritable bowel syndrome\">IBS</a></li>\\n<li><a href=\"/wiki/Intestinal_pseudoobstruction\" class=\"mw-redirect\" title=\"Intestinal pseudoobstruction\">Intestinal pseudoobstruction</a>&#160;/ <a href=\"/wiki/Ogilvie_syndrome\" title=\"Ogilvie syndrome\">Ogilvie syndrome</a></li></ul></li>\\n<li><a href=\"/wiki/Megacolon\" title=\"Megacolon\">Megacolon</a>&#160;/ <a href=\"/wiki/Toxic_megacolon\" title=\"Toxic megacolon\">Toxic megacolon</a></li>\\n<li><a href=\"/wiki/Diverticulitis\" title=\"Diverticulitis\">Diverticulitis</a>/<a href=\"/wiki/Diverticulosis\" title=\"Diverticulosis\">Diverticulosis</a>/<a href=\"/wiki/Segmental_colitis_associated_with_diverticulosis\" title=\"Segmental colitis associated with diverticulosis\">SCAD</a></li></ul>\\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\">Large and/or small</th><td class=\"navbox-list-with-group navbox-list navbox-odd\" style=\"width:100%;padding:0\"><div style=\"padding:0 0.25em\">\\n<ul><li><a href=\"/wiki/Enterocolitis\" title=\"Enterocolitis\">Enterocolitis</a>\\n<ul><li><a href=\"/wiki/Necrotizing_enterocolitis\" title=\"Necrotizing enterocolitis\">Necrotizing</a></li></ul></li>\\n<li><a href=\"/wiki/Gastroenterocolitis\" title=\"Gastroenterocolitis\">Gastroenterocolitis</a></li>\\n<li><a href=\"/wiki/Inflammatory_bowel_disease\" title=\"Inflammatory bowel disease\">IBD</a>\\n<ul><li><a href=\"/wiki/Crohn%27s_disease\" title=\"Crohn&#39;s disease\">Crohn\\'s disease</a></li></ul></li>\\n<li><i><a href=\"/wiki/Vascular_disease\" title=\"Vascular disease\">Vascular</a></i>: <a href=\"/wiki/Abdominal_angina\" title=\"Abdominal angina\">Abdominal angina</a></li>\\n<li><a href=\"/wiki/Mesenteric_ischemia\" class=\"mw-redirect\" title=\"Mesenteric ischemia\">Mesenteric ischemia</a></li>\\n<li><a href=\"/wiki/Angiodysplasia\" title=\"Angiodysplasia\">Angiodysplasia</a></li>\\n<li><a href=\"/wiki/Bowel_obstruction\" title=\"Bowel obstruction\">Bowel obstruction</a>: <a href=\"/wiki/Ileus\" title=\"Ileus\">Ileus</a></li>\\n<li><a href=\"/wiki/Intussusception_(medical_disorder)\" title=\"Intussusception (medical disorder)\">Intussusception</a></li>\\n<li><a href=\"/wiki/Volvulus\" title=\"Volvulus\">Volvulus</a></li>\\n<li><a href=\"/wiki/Fecal_impaction\" title=\"Fecal impaction\">Fecal impaction</a></li>\\n<li><a href=\"/wiki/Constipation\" title=\"Constipation\">Constipation</a></li>\\n<li><a href=\"/wiki/Diarrhea\" title=\"Diarrhea\">Diarrhea</a>\\n<ul><li><a href=\"/wiki/Infectious_diarrhea\" class=\"mw-redirect\" title=\"Infectious diarrhea\">Infectious</a></li></ul></li>\\n<li><a href=\"/wiki/Adhesion_(medicine)\" title=\"Adhesion (medicine)\">Intestinal adhesions</a></li></ul>\\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Rectum\" title=\"Rectum\">Rectum</a></th><td class=\"navbox-list-with-group navbox-list navbox-even\" style=\"width:100%;padding:0\"><div style=\"padding:0 0.25em\">\\n<ul><li><a href=\"/wiki/Proctitis\" title=\"Proctitis\">Proctitis</a>\\n<ul><li><a href=\"/wiki/Radiation_proctitis\" title=\"Radiation proctitis\">Radiation proctitis</a></li></ul></li>\\n<li><a href=\"/wiki/Proctalgia_fugax\" title=\"Proctalgia fugax\">Proctalgia fugax</a></li>\\n<li><a href=\"/wiki/Rectal_prolapse\" title=\"Rectal prolapse\">Rectal prolapse</a></li>\\n<li><a href=\"/wiki/Anismus\" title=\"Anismus\">Anismus</a></li>\\n<li><a href=\"/wiki/Solitary_rectal_ulcer_syndrome\" title=\"Solitary rectal ulcer syndrome\">Solitary rectal ulcer syndrome</a></li></ul>\\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Anal_canal\" title=\"Anal canal\">Anal canal</a></th><td class=\"navbox-list-with-group navbox-list navbox-odd\" style=\"width:100%;padding:0\"><div style=\"padding:0 0.25em\">\\n<ul><li><a href=\"/wiki/Anal_fissure\" title=\"Anal fissure\">Anal fissure</a>/<a href=\"/wiki/Anal_fistula\" title=\"Anal fistula\">Anal fistula</a></li>\\n<li><a href=\"/wiki/Anal_abscess\" class=\"mw-redirect\" title=\"Anal abscess\">Anal abscess</a></li>\\n<li><a href=\"/wiki/Hemorrhoid\" title=\"Hemorrhoid\">Hemorrhoid</a></li>\\n<li><a href=\"/wiki/Anal_dysplasia\" title=\"Anal dysplasia\">Anal dysplasia</a></li>\\n<li><a href=\"/wiki/Pruritus_ani\" title=\"Pruritus ani\">Pruritus ani</a></li></ul>\\n</div></td></tr></tbody></table><div></div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Gastrointestinal_bleeding\" title=\"Gastrointestinal bleeding\">GI bleeding</a></th><td class=\"navbox-list-with-group navbox-list navbox-even hlist\" style=\"width:100%;padding:0\"><div style=\"padding:0 0.25em\">\\n<ul><li><a href=\"/wiki/Blood_in_stool\" title=\"Blood in stool\">Blood in stool</a></li>\\n<li><a href=\"/wiki/Upper_gastrointestinal_bleeding\" title=\"Upper gastrointestinal bleeding\">Upper</a>\\n<ul><li><a href=\"/wiki/Hematemesis\" title=\"Hematemesis\">Hematemesis</a></li>\\n<li><a href=\"/wiki/Melena\" title=\"Melena\">Melena</a></li></ul></li>\\n<li><a href=\"/wiki/Lower_gastrointestinal_bleeding\" title=\"Lower gastrointestinal bleeding\">Lower</a>\\n<ul><li><a href=\"/wiki/Hematochezia\" title=\"Hematochezia\">Hematochezia</a></li></ul></li></ul>\\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Accessory_digestive_gland\" class=\"mw-redirect\" title=\"Accessory digestive gland\">Accessory</a></th><td class=\"navbox-list-with-group navbox-list navbox-odd hlist\" style=\"width:100%;padding:0\"><div style=\"padding:0 0.25em\"></div><table class=\"nowraplinks navbox-subgroup\" style=\"border-spacing:0\"><tbody><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Liver_disease\" title=\"Liver disease\">Liver</a></th><td class=\"navbox-list-with-group navbox-list navbox-odd\" style=\"width:100%;padding:0\"><div style=\"padding:0 0.25em\">\\n<ul><li><a class=\"mw-selflink selflink\">Hepatitis</a>\\n<ul><li><a href=\"/wiki/Viral_hepatitis\" title=\"Viral hepatitis\">Viral hepatitis</a></li>\\n<li><a href=\"/wiki/Autoimmune_hepatitis\" title=\"Autoimmune hepatitis\">Autoimmune hepatitis</a></li>\\n<li><a href=\"/wiki/Alcoholic_hepatitis\" title=\"Alcoholic hepatitis\">Alcoholic hepatitis</a></li></ul></li>\\n<li><a href=\"/wiki/Cirrhosis\" title=\"Cirrhosis\">Cirrhosis</a>\\n<ul><li><a href=\"/wiki/Primary_biliary_cirrhosis\" class=\"mw-redirect\" title=\"Primary biliary cirrhosis\">PBC</a></li></ul></li>\\n<li><a href=\"/wiki/Fatty_liver\" class=\"mw-redirect\" title=\"Fatty liver\">Fatty liver</a>\\n<ul><li><a href=\"/wiki/Non-alcoholic_fatty_liver_disease\" title=\"Non-alcoholic fatty liver disease\">NASH</a></li></ul></li>\\n<li><i><a href=\"/wiki/Vascular_disease\" title=\"Vascular disease\">Vascular</a></i>\\n<ul><li><a href=\"/wiki/Budd%E2%80%93Chiari_syndrome\" title=\"Budd–Chiari syndrome\">Budd–Chiari syndrome</a></li>\\n<li><a href=\"/wiki/Hepatic_veno-occlusive_disease\" title=\"Hepatic veno-occlusive disease\">Hepatic veno-occlusive disease</a></li>\\n<li><a href=\"/wiki/Portal_hypertension\" title=\"Portal hypertension\">Portal hypertension</a></li>\\n<li><a href=\"/wiki/Nutmeg_liver\" class=\"mw-redirect\" title=\"Nutmeg liver\">Nutmeg liver</a></li></ul></li>\\n<li><a href=\"/wiki/Alcoholic_liver_disease\" title=\"Alcoholic liver disease\">Alcoholic liver disease</a></li>\\n<li><a href=\"/wiki/Liver_failure\" title=\"Liver failure\">Liver failure</a>\\n<ul><li><a href=\"/wiki/Hepatic_encephalopathy\" title=\"Hepatic encephalopathy\">Hepatic encephalopathy</a></li>\\n<li><a href=\"/wiki/Acute_liver_failure\" title=\"Acute liver failure\">Acute liver failure</a></li></ul></li>\\n<li><a href=\"/wiki/Liver_abscess\" title=\"Liver abscess\">Liver abscess</a>\\n<ul><li><a href=\"/wiki/Pyogenic_liver_abscess\" title=\"Pyogenic liver abscess\">Pyogenic</a></li>\\n<li><a href=\"/wiki/Amoebic_liver_abscess\" title=\"Amoebic liver abscess\">Amoebic</a></li></ul></li>\\n<li><a href=\"/wiki/Hepatorenal_syndrome\" title=\"Hepatorenal syndrome\">Hepatorenal syndrome</a></li>\\n<li><a href=\"/wiki/Peliosis_hepatis\" title=\"Peliosis hepatis\">Peliosis hepatis</a></li>\\n<li><a href=\"/wiki/Metabolic_disorder\" title=\"Metabolic disorder\">Metabolic disorders</a>\\n<ul><li><a href=\"/wiki/Wilson%27s_disease\" title=\"Wilson&#39;s disease\">Wilson\\'s disease</a></li>\\n<li><a href=\"/wiki/Hemochromatosis\" class=\"mw-redirect\" title=\"Hemochromatosis\">Hemochromatosis</a></li></ul></li></ul>\\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Gallbladder_disease\" title=\"Gallbladder disease\">Gallbladder</a></th><td class=\"navbox-list-with-group navbox-list navbox-even\" style=\"width:100%;padding:0\"><div style=\"padding:0 0.25em\">\\n<ul><li><a href=\"/wiki/Cholecystitis\" title=\"Cholecystitis\">Cholecystitis</a></li>\\n<li><a href=\"/wiki/Gallstone\" title=\"Gallstone\">Gallstone / Cholelithiasis</a></li>\\n<li><a href=\"/wiki/Cholesterolosis_of_gallbladder\" title=\"Cholesterolosis of gallbladder\">Cholesterolosis</a></li>\\n<li><a href=\"/wiki/Adenomyomatosis\" title=\"Adenomyomatosis\">Adenomyomatosis</a></li>\\n<li><a href=\"/wiki/Postcholecystectomy_syndrome\" title=\"Postcholecystectomy syndrome\">Postcholecystectomy syndrome</a></li>\\n<li><a href=\"/wiki/Porcelain_gallbladder\" title=\"Porcelain gallbladder\">Porcelain gallbladder</a></li></ul>\\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Bile_duct\" title=\"Bile duct\">Bile duct</a>/ <br /> Other <a href=\"/wiki/Biliary_tree\" class=\"mw-redirect\" title=\"Biliary tree\">biliary tree</a></th><td class=\"navbox-list-with-group navbox-list navbox-odd\" style=\"width:100%;padding:0\"><div style=\"padding:0 0.25em\">\\n<ul><li><a href=\"/wiki/Cholangitis\" class=\"mw-redirect\" title=\"Cholangitis\">Cholangitis</a>\\n<ul><li><a href=\"/wiki/Primary_sclerosing_cholangitis\" title=\"Primary sclerosing cholangitis\">Primary sclerosing cholangitis</a></li>\\n<li><a href=\"/wiki/Secondary_sclerosing_cholangitis\" title=\"Secondary sclerosing cholangitis\">Secondary sclerosing cholangitis</a></li>\\n<li><a href=\"/wiki/Ascending_cholangitis\" title=\"Ascending cholangitis\">Ascending</a></li></ul></li>\\n<li><a href=\"/wiki/Cholestasis\" title=\"Cholestasis\">Cholestasis</a>/<a href=\"/wiki/Mirizzi%27s_syndrome\" title=\"Mirizzi&#39;s syndrome\">Mirizzi\\'s syndrome</a></li>\\n<li><a href=\"/wiki/Biliary_fistula\" title=\"Biliary fistula\">Biliary fistula</a></li>\\n<li><a href=\"/wiki/Haemobilia\" title=\"Haemobilia\">Haemobilia</a></li></ul>\\n<ul><li><i><a href=\"/wiki/Common_bile_duct\" title=\"Common bile duct\">Common bile duct</a></i>\\n<ul><li><a href=\"/wiki/Choledocholithiasis\" class=\"mw-redirect\" title=\"Choledocholithiasis\">Choledocholithiasis</a></li>\\n<li><a href=\"/wiki/Biliary_dyskinesia\" title=\"Biliary dyskinesia\">Biliary dyskinesia</a></li></ul></li>\\n<li><a href=\"/wiki/Sphincter_of_Oddi_dysfunction\" title=\"Sphincter of Oddi dysfunction\">Sphincter of Oddi dysfunction</a></li></ul>\\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Pancreatic_disease\" title=\"Pancreatic disease\">Pancreatic</a></th><td class=\"navbox-list-with-group navbox-list navbox-even\" style=\"width:100%;padding:0\"><div style=\"padding:0 0.25em\">\\n<ul><li><a href=\"/wiki/Pancreatitis\" title=\"Pancreatitis\">Pancreatitis</a>\\n<ul><li><a href=\"/wiki/Acute_pancreatitis\" title=\"Acute pancreatitis\">Acute</a></li>\\n<li><a href=\"/wiki/Chronic_pancreatitis\" title=\"Chronic pancreatitis\">Chronic</a></li>\\n<li><a href=\"/wiki/Hereditary_pancreatitis\" title=\"Hereditary pancreatitis\">Hereditary</a></li>\\n<li><a href=\"/wiki/Pancreatic_abscess\" title=\"Pancreatic abscess\">Pancreatic abscess</a></li></ul></li>\\n<li><a href=\"/wiki/Pancreatic_pseudocyst\" title=\"Pancreatic pseudocyst\">Pancreatic pseudocyst</a></li>\\n<li><a href=\"/wiki/Exocrine_pancreatic_insufficiency\" title=\"Exocrine pancreatic insufficiency\">Exocrine pancreatic insufficiency</a></li>\\n<li><a href=\"/wiki/Pancreatic_fistula\" title=\"Pancreatic fistula\">Pancreatic fistula</a></li></ul>\\n</div></td></tr></tbody></table><div></div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\">Other</th><td class=\"navbox-list-with-group navbox-list navbox-odd hlist\" style=\"width:100%;padding:0\"><div style=\"padding:0 0.25em\"></div><table class=\"nowraplinks navbox-subgroup\" style=\"border-spacing:0\"><tbody><tr><th id=\"Hernia\" scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Hernia\" title=\"Hernia\">Hernia</a></th><td class=\"navbox-list-with-group navbox-list navbox-odd\" style=\"width:100%;padding:0\"><div style=\"padding:0 0.25em\">\\n<ul><li><a href=\"/wiki/Diaphragmatic_hernia\" title=\"Diaphragmatic hernia\">Diaphragmatic</a>\\n<ul><li><a href=\"/wiki/Congenital_diaphragmatic_hernia\" title=\"Congenital diaphragmatic hernia\">Congenital</a></li></ul></li>\\n<li><a href=\"/wiki/Hiatus_hernia\" class=\"mw-redirect\" title=\"Hiatus hernia\">Hiatus</a></li></ul>\\n<ul><li><a href=\"/wiki/Inguinal_hernia\" title=\"Inguinal hernia\">Inguinal</a>\\n<ul><li><a href=\"/wiki/Indirect_inguinal_hernia\" class=\"mw-redirect\" title=\"Indirect inguinal hernia\">Indirect</a></li>\\n<li><a href=\"/wiki/Direct_inguinal_hernia\" class=\"mw-redirect\" title=\"Direct inguinal hernia\">Direct</a></li></ul></li>\\n<li><a href=\"/wiki/Umbilical_hernia\" title=\"Umbilical hernia\">Umbilical</a></li>\\n<li><a href=\"/wiki/Femoral_hernia\" title=\"Femoral hernia\">Femoral</a></li>\\n<li><a href=\"/wiki/Obturator_hernia\" title=\"Obturator hernia\">Obturator</a></li>\\n<li><a href=\"/wiki/Spigelian_hernia\" title=\"Spigelian hernia\">Spigelian</a></li></ul>\\n<ul><li><i><a href=\"/wiki/Lumbar_hernia\" class=\"mw-redirect\" title=\"Lumbar hernia\">Lumbar</a></i>\\n<ul><li><a href=\"/wiki/Petit%27s_hernia\" title=\"Petit&#39;s hernia\">Petit\\'s</a></li>\\n<li><a href=\"/wiki/Grynfeltt%E2%80%93Lesshaft_hernia\" title=\"Grynfeltt–Lesshaft hernia\">Grynfeltt–Lesshaft</a></li></ul></li></ul>\\n<ul><li><i>Undefined location</i>\\n<ul><li><a href=\"/wiki/Incisional_hernia\" title=\"Incisional hernia\">Incisional</a></li>\\n<li><a href=\"/wiki/Internal_hernia\" title=\"Internal hernia\">Internal hernia</a></li>\\n<li><a href=\"/wiki/Richter%27s_hernia\" title=\"Richter&#39;s hernia\">Richter\\'s</a></li></ul></li></ul>\\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Peritoneal_disease\" class=\"mw-redirect\" title=\"Peritoneal disease\">Peritoneal</a></th><td class=\"navbox-list-with-group navbox-list navbox-even\" style=\"width:100%;padding:0\"><div style=\"padding:0 0.25em\">\\n<ul><li><a href=\"/wiki/Peritonitis\" title=\"Peritonitis\">Peritonitis</a>\\n<ul><li><a href=\"/wiki/Spontaneous_bacterial_peritonitis\" title=\"Spontaneous bacterial peritonitis\">Spontaneous bacterial peritonitis</a></li></ul></li>\\n<li><a href=\"/wiki/Hemoperitoneum\" title=\"Hemoperitoneum\">Hemoperitoneum</a></li>\\n<li><a href=\"/wiki/Pneumoperitoneum\" title=\"Pneumoperitoneum\">Pneumoperitoneum</a></li></ul>\\n</div></td></tr></tbody></table><div></div></td></tr></tbody></table></div>\\n<div class=\"navbox-styles\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1129693374\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1061467846\"><style data-mw-deduplicate=\"TemplateStyles:r1038841319\">.mw-parser-output .tooltip-dotted{border-bottom:1px dotted;cursor:help}</style><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1038841319\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1038841319\"><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r1038841319\"></div><div role=\"navigation\" class=\"navbox authority-control\" aria-labelledby=\"Authority_control_databases_frameless&amp;#124;text-top&amp;#124;10px&amp;#124;alt=Edit_this_at_Wikidata&amp;#124;link=https&amp;#58;//www.wikidata.org/wiki/Q131742#identifiers&amp;#124;class=noprint&amp;#124;Edit_this_at_Wikidata\" style=\"padding:3px\"><table class=\"nowraplinks hlist mw-collapsible autocollapse navbox-inner\" style=\"border-spacing:0;background:transparent;color:inherit\"><tbody><tr><th scope=\"col\" class=\"navbox-title\" colspan=\"2\"><div id=\"Authority_control_databases_frameless&amp;#124;text-top&amp;#124;10px&amp;#124;alt=Edit_this_at_Wikidata&amp;#124;link=https&amp;#58;//www.wikidata.org/wiki/Q131742#identifiers&amp;#124;class=noprint&amp;#124;Edit_this_at_Wikidata\" style=\"font-size:114%;margin:0 4em\"><a href=\"/wiki/Help:Authority_control\" title=\"Help:Authority control\">Authority control databases</a> <span class=\"mw-valign-text-top noprint\" typeof=\"mw:File/Frameless\"><a href=\"https://www.wikidata.org/wiki/Q131742#identifiers\" title=\"Edit this at Wikidata\"><img alt=\"Edit this at Wikidata\" src=\"//upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/10px-OOjs_UI_icon_edit-ltr-progressive.svg.png\" decoding=\"async\" width=\"10\" height=\"10\" class=\"mw-file-element\" srcset=\"//upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/15px-OOjs_UI_icon_edit-ltr-progressive.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/20px-OOjs_UI_icon_edit-ltr-progressive.svg.png 2x\" data-file-width=\"20\" data-file-height=\"20\" /></a></span></div></th></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\">National</th><td class=\"navbox-list-with-group navbox-list navbox-odd\" style=\"width:100%;padding:0\"><div style=\"padding:0 0.25em\">\\n<ul><li><span class=\"uid\"><span class=\"rt-commentedText tooltip tooltip-dotted\" title=\"Hépatites\"><a rel=\"nofollow\" class=\"external text\" href=\"https://catalogue.bnf.fr/ark:/12148/cb12153771t\">France</a></span></span></li>\\n<li><span class=\"uid\"><span class=\"rt-commentedText tooltip tooltip-dotted\" title=\"Hépatites\"><a rel=\"nofollow\" class=\"external text\" href=\"https://data.bnf.fr/ark:/12148/cb12153771t\">BnF data</a></span></span></li>\\n<li><span class=\"uid\"><a rel=\"nofollow\" class=\"external text\" href=\"https://d-nb.info/gnd/4024427-1\">Germany</a></span></li>\\n<li><span class=\"uid\"><a rel=\"nofollow\" class=\"external text\" href=\"http://uli.nli.org.il/F/?func=find-b&amp;local_base=NLX10&amp;find_code=UID&amp;request=987007555639105171\">Israel</a></span></li>\\n<li><span class=\"uid\"><span class=\"rt-commentedText tooltip tooltip-dotted\" title=\"Hepatitis\"><a rel=\"nofollow\" class=\"external text\" href=\"https://id.loc.gov/authorities/sh85060288\">United States</a></span></span></li>\\n<li><span class=\"uid\"><a rel=\"nofollow\" class=\"external text\" href=\"https://kopkatalogs.lv/F?func=direct&amp;local_base=lnc10&amp;doc_number=000303741&amp;P_CON_LNG=ENG\">Latvia</a></span></li>\\n<li><span class=\"uid\"><a rel=\"nofollow\" class=\"external text\" href=\"https://id.ndl.go.jp/auth/ndlna/00564863\">Japan</a></span></li>\\n<li><span class=\"uid\"><span class=\"rt-commentedText tooltip tooltip-dotted\" title=\"hepatitida\"><a rel=\"nofollow\" class=\"external text\" href=\"https://aleph.nkp.cz/F/?func=find-c&amp;local_base=aut&amp;ccl_term=ica=ph120674&amp;CON_LNG=ENG\">Czech Republic</a></span></span></li>\\n<li><span class=\"uid\"><a rel=\"nofollow\" class=\"external text\" href=\"http://katalog.nsk.hr/F/?func=direct&amp;doc_number=002104740&amp;local_base=nsk10\">Croatia</a></span></li></ul>\\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\">Other</th><td class=\"navbox-list-with-group navbox-list navbox-even\" style=\"width:100%;padding:0\"><div style=\"padding:0 0.25em\">\\n<ul><li><span class=\"uid\"><a rel=\"nofollow\" class=\"external text\" href=\"https://catalog.archives.gov/id/10641635\">NARA</a></span></li></ul>\\n</div></td></tr></tbody></table></div></div>'"
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "page_obj.html()"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-23T03:42:53.581889700Z",
     "start_time": "2023-09-23T03:42:48.655661Z"
    }
   },
   "id": "caf03e9a0111d64e"
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "outputs": [],
   "source": [
    "symp = pickle.load(open('pickles/sypmtoms.pkl', 'rb'))"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-21T10:48:15.483539900Z",
     "start_time": "2023-09-21T10:48:13.000581800Z"
    }
   },
   "id": "24de54055e2b4af2"
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "yellowish_skin\n",
      "yellow_urine\n",
      "yellowing_of_eyes\n",
      "yellow_crust_ooze\n"
     ]
    }
   ],
   "source": [
    "for item in list(symp):\n",
    "    if 'yello' in item.lower():\n",
    "        print(item)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-21T10:51:50.600723800Z",
     "start_time": "2023-09-21T10:51:50.587611200Z"
    }
   },
   "id": "34314029bb7d450b"
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "outputs": [],
   "source": [
    "from bs4 import BeautifulSoup"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-25T14:33:33.781384300Z",
     "start_time": "2023-09-25T14:33:33.593380600Z"
    }
   },
   "id": "6790839dd74163d3"
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "outputs": [],
   "source": [
    "html = page_obj.html()"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-25T14:34:08.626276200Z",
     "start_time": "2023-09-25T14:34:03.478702Z"
    }
   },
   "id": "21d6aabd2c870610"
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "outputs": [],
   "source": [
    "soup = BeautifulSoup(html, 'html.parser')"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-25T14:45:42.992043800Z",
     "start_time": "2023-09-25T14:45:41.474565900Z"
    }
   },
   "id": "90858dd1cd6cdfa3"
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "outputs": [
    {
     "data": {
      "text/plain": "[]"
     },
     "execution_count": 38,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "soup.find_all('p', string='signs')"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-25T14:49:32.349037400Z",
     "start_time": "2023-09-25T14:49:32.274689900Z"
    }
   },
   "id": "41d7d82e67d18d8c"
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "outputs": [
    {
     "data": {
      "text/plain": "['Signs and symptoms',\n 'Acute hepatitis',\n 'Fulminant hepatitis',\n 'Chronic hepatitis',\n 'Causes',\n 'Infectious',\n 'Viral hepatitis',\n 'Parasitic hepatitis',\n 'Bacterial hepatitis',\n 'Metabolic',\n 'Alcoholic hepatitis',\n 'Toxic and drug-induced hepatitis',\n 'Non-alcoholic fatty liver disease',\n 'Autoimmune',\n 'Genetic',\n 'Ischemic hepatitis',\n 'Other',\n 'Mechanism',\n 'Viral hepatitis',\n 'Steatohepatitis',\n 'Diagnosis',\n 'Viral hepatitis',\n 'Alcoholic versus non-alcoholic',\n 'Virus screening',\n 'Hepatitis A',\n 'Hepatitis B',\n 'Hepatitis C',\n 'Hepatitis D',\n 'Prevention',\n 'Vaccines',\n 'Hepatitis A',\n 'Hepatitis B',\n 'Other',\n 'Behavioral changes',\n 'Hepatitis A',\n 'Hepatitis B and C',\n 'Hepatitis D',\n 'Hepatitis E',\n 'Alcoholic and metabolic hepatitis',\n 'Successes',\n 'Hepatitis A',\n 'Hepatitis B',\n 'Hepatitis C',\n 'Alcoholic hepatitis',\n 'Treatment',\n 'Hepatitis A',\n 'Hepatitis B',\n 'Acute',\n 'Chronic',\n 'Hepatitis C',\n 'Hepatitis D',\n 'Hepatitis E',\n 'Alcoholic hepatitis',\n 'Metabolic hepatitis',\n 'Autoimmune hepatitis',\n 'Prognosis',\n 'Acute hepatitis',\n 'Fulminant hepatitis',\n 'Chronic hepatitis',\n 'Epidemiology',\n 'Viral hepatitis',\n 'Hepatitis A',\n 'Hepatitis B',\n 'Hepatitis C',\n 'Hepatitis D',\n 'Hepatitis E',\n 'Alcoholic hepatitis',\n 'Non-alcoholic steatohepatitis',\n 'History',\n 'Early observations',\n 'Willowbrook State School experiments',\n 'Australia antigen',\n 'Society and culture',\n 'Economic burden',\n '2003 Monaca outbreak',\n 'Special populations',\n 'HIV co-infection',\n 'Pregnancy',\n 'Hepatitis B',\n 'Hepatitis C',\n 'Hepatitis E',\n 'See also',\n 'References',\n 'External links']"
     },
     "execution_count": 35,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "page_obj.sections"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-25T14:48:36.799202100Z",
     "start_time": "2023-09-25T14:48:34.944893Z"
    }
   },
   "id": "53e0c93e0284669c"
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "outputs": [],
   "source": [
    "def find_a_string(value):\n",
    "    return lambda text: value in text"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-25T14:49:53.016460500Z",
     "start_time": "2023-09-25T14:49:52.968203400Z"
    }
   },
   "id": "363707686a1d02ec"
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "outputs": [
    {
     "data": {
      "text/plain": "[]"
     },
     "execution_count": 51,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "soup.find_all('section')"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-25T14:55:03.779209Z",
     "start_time": "2023-09-25T14:55:03.680829400Z"
    }
   },
   "id": "ebf7fbb5b6e36b7"
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "outputs": [],
   "source": [
    "page_obj = wikipedia.page('Hepatitis')"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-25T15:01:32.755450500Z",
     "start_time": "2023-09-25T15:01:31.086859100Z"
    }
   },
   "id": "fa0e48beeffd019"
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Fulminant hepatitis, or massive hepatic cell death, is a rare and life-threatening complication of acute hepatitis that can occur in cases of hepatitis B, D, and E, in addition to drug-induced and autoimmune hepatitis. The complication more frequently occurs in instances of hepatitis B and D co-infection at a rate of 2–20% and in pregnant women with hepatitis E at rate of 15–20% of cases. In addition to the signs of acute hepatitis, people can also demonstrate signs of coagulopathy (abnormal coagulation studies with easy bruising and bleeding) and encephalopathy (confusion, disorientation, and sleepiness). Mortality due to fulminant hepatitis is typically the result of various complications including cerebral edema, gastrointestinal bleeding, sepsis, respiratory failure, or kidney failure.\n"
     ]
    }
   ],
   "source": [
    "print(page_obj.section('Fulminant hepatitis'))"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-25T15:02:49.167658600Z",
     "start_time": "2023-09-25T15:02:49.097687500Z"
    }
   },
   "id": "1063af52ec292cc2"
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "outputs": [
    {
     "data": {
      "text/plain": "['Signs and symptoms',\n 'Acute hepatitis',\n 'Fulminant hepatitis',\n 'Chronic hepatitis',\n 'Causes',\n 'Infectious',\n 'Viral hepatitis',\n 'Parasitic hepatitis',\n 'Bacterial hepatitis',\n 'Metabolic',\n 'Alcoholic hepatitis',\n 'Toxic and drug-induced hepatitis',\n 'Non-alcoholic fatty liver disease',\n 'Autoimmune',\n 'Genetic',\n 'Ischemic hepatitis',\n 'Other',\n 'Mechanism',\n 'Viral hepatitis',\n 'Steatohepatitis',\n 'Diagnosis',\n 'Viral hepatitis',\n 'Alcoholic versus non-alcoholic',\n 'Virus screening',\n 'Hepatitis A',\n 'Hepatitis B',\n 'Hepatitis C',\n 'Hepatitis D',\n 'Prevention',\n 'Vaccines',\n 'Hepatitis A',\n 'Hepatitis B',\n 'Other',\n 'Behavioral changes',\n 'Hepatitis A',\n 'Hepatitis B and C',\n 'Hepatitis D',\n 'Hepatitis E',\n 'Alcoholic and metabolic hepatitis',\n 'Successes',\n 'Hepatitis A',\n 'Hepatitis B',\n 'Hepatitis C',\n 'Alcoholic hepatitis',\n 'Treatment',\n 'Hepatitis A',\n 'Hepatitis B',\n 'Acute',\n 'Chronic',\n 'Hepatitis C',\n 'Hepatitis D',\n 'Hepatitis E',\n 'Alcoholic hepatitis',\n 'Metabolic hepatitis',\n 'Autoimmune hepatitis',\n 'Prognosis',\n 'Acute hepatitis',\n 'Fulminant hepatitis',\n 'Chronic hepatitis',\n 'Epidemiology',\n 'Viral hepatitis',\n 'Hepatitis A',\n 'Hepatitis B',\n 'Hepatitis C',\n 'Hepatitis D',\n 'Hepatitis E',\n 'Alcoholic hepatitis',\n 'Non-alcoholic steatohepatitis',\n 'History',\n 'Early observations',\n 'Willowbrook State School experiments',\n 'Australia antigen',\n 'Society and culture',\n 'Economic burden',\n '2003 Monaca outbreak',\n 'Special populations',\n 'HIV co-infection',\n 'Pregnancy',\n 'Hepatitis B',\n 'Hepatitis C',\n 'Hepatitis E',\n 'See also',\n 'References',\n 'External links']"
     },
     "execution_count": 75,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "page_obj.sections"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-25T15:02:51.103958700Z",
     "start_time": "2023-09-25T15:02:51.088329400Z"
    }
   },
   "id": "f3ef7bcee2aa575f"
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "outputs": [
    {
     "data": {
      "text/plain": "['Fungal infection',\n 'Onychomycosis',\n 'Dermatophytosis',\n 'Skin infection',\n 'List of skin conditions',\n 'Antifungal',\n 'Osteomyelitis',\n 'Candidiasis',\n 'Fungal sinusitis',\n 'Plant pathology']"
     },
     "execution_count": 77,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "wikipedia.search('Fungal Infection')"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-25T15:03:56.393594700Z",
     "start_time": "2023-09-25T15:03:55.178554400Z"
    }
   },
   "id": "d84cfb7b6b6534ef"
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "outputs": [],
   "source": [
    "import pickle"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-26T13:44:09.104378Z",
     "start_time": "2023-09-26T13:44:09.024215800Z"
    }
   },
   "id": "1596ebd954cf7daa"
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "outputs": [],
   "source": [
    "with open('../pickles/wikipedia_search_list.pkl', 'rb') as fl:\n",
    "    dl = pickle.load(fl)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-26T13:44:51.124746500Z",
     "start_time": "2023-09-26T13:44:50.926397500Z"
    }
   },
   "id": "76ffc7161fc5a79f"
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'wikipedia' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001B[1;31m---------------------------------------------------------------------------\u001B[0m",
      "\u001B[1;31mNameError\u001B[0m                                 Traceback (most recent call last)",
      "Cell \u001B[1;32mIn[3], line 2\u001B[0m\n\u001B[0;32m      1\u001B[0m \u001B[38;5;28;01mfor\u001B[39;00m i \u001B[38;5;129;01min\u001B[39;00m dl:\n\u001B[1;32m----> 2\u001B[0m     res \u001B[38;5;241m=\u001B[39m \u001B[43mwikipedia\u001B[49m\u001B[38;5;241m.\u001B[39msearch(i, results\u001B[38;5;241m=\u001B[39m\u001B[38;5;241m2\u001B[39m)\n\u001B[0;32m      3\u001B[0m     \u001B[38;5;28mprint\u001B[39m(i, res[\u001B[38;5;241m0\u001B[39m])\n",
      "\u001B[1;31mNameError\u001B[0m: name 'wikipedia' is not defined"
     ]
    }
   ],
   "source": [
    "for i in dl:\n",
    "    res = wikipedia.search(i, results=2)\n",
    "    print(i, res[0])"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-26T13:44:10.178162800Z",
     "start_time": "2023-09-26T13:44:09.059383600Z"
    }
   },
   "id": "1b6a4667b044a29f"
  },
  {
   "cell_type": "code",
   "execution_count": 272,
   "outputs": [],
   "source": [
    "# with open('../pickles/wikipedia_search_list.pkl', 'wb') as fl:\n",
    "#     pickle.dump(dl, fl)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-25T16:43:15.697963100Z",
     "start_time": "2023-09-25T16:43:15.663998300Z"
    }
   },
   "id": "bc9f47922cca456b"
  },
  {
   "cell_type": "code",
   "execution_count": 111,
   "outputs": [
    {
     "data": {
      "text/plain": "['Benign paroxysmal positional vertigo', 'Vertigo']"
     },
     "execution_count": 111,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "wikipedia.search('Paroxysmal Positional Vertigo', results=2)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-25T15:16:36.480509300Z",
     "start_time": "2023-09-25T15:16:33.755064500Z"
    }
   },
   "id": "d61a17ad54d28218"
  },
  {
   "cell_type": "code",
   "execution_count": 276,
   "outputs": [],
   "source": [
    "def get_wiki_content(disease: str, cat: str = 'about'):\n",
    "    search = wikipedia.search(disease)[0]\n",
    "    page = wikipedia.page(search, auto_suggest=False)\n",
    "    \n",
    "    sections = list(page.sections)\n",
    "    \n",
    "    if 'precaution' in cat:\n",
    "        searchLi = ['precaution', 'prevention']\n",
    "    elif 'cause' in cat:\n",
    "        searchLi = ['cause']\n",
    "    elif 'symptom' in cat:\n",
    "        searchLi = ['sign', 'symptom']\n",
    "    elif 'treatment' in cat:\n",
    "        searchLi = ['treatment', 'vaccine']\n",
    "    else:\n",
    "        searchLi = ['about']\n",
    "\n",
    "    if 'about' not in searchLi:        \n",
    "        for find in searchLi:\n",
    "            for idx, sectionName in enumerate(sections):\n",
    "                if find in sectionName.lower():\n",
    "                    content = str(page.section(sectionName))\n",
    "                    \n",
    "                    if content != \"\":\n",
    "                        return content\n",
    "                    else:\n",
    "                        content = ''\n",
    "                        pageAPI = \n",
    "    else:\n",
    "        print(search)\n",
    "        return str(wikipedia.summary(search, sentences=3, auto_suggest=False))\n",
    "                            "
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-25T16:47:04.798763600Z",
     "start_time": "2023-09-25T16:47:04.710789900Z"
    }
   },
   "id": "2e4b752ff257033c"
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Fungal infection\tChronic cholestasis\tDrug Reaction\tPeptic ulcer disease\tAIDS\tDiabetes \tGastroenteritis\tBronchial Asthma\tHypertension \tMigraine\tCervical spondylosis\tJaundice\tMalaria\tChicken pox\tDengue\tTyphoid\tTuberculosis\tCommon Cold\tPneumonia\tPiles\tHeart attack\tVaricose veins\tHypothyroidism\tHyperthyroidism\tHypoglycemia\tOsteoarthritis\tArthritis\tParoxysmal Positional Vertigo\tAcne\tUrinary tract infection\tPsoriasis\tImpetigo\tHepatitis\tGastroesophageal reflux disease\tAllergic Diseases\tParalysis\t"
     ]
    }
   ],
   "source": [
    "for item in dl:\n",
    "    print(item, end=\"\\t\")"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-26T13:44:58.606423700Z",
     "start_time": "2023-09-26T13:44:57.807666Z"
    }
   },
   "id": "dfc91009e27bcdce"
  },
  {
   "cell_type": "code",
   "execution_count": 278,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Fungal infection\n",
      "Keeping the skin clean and dry, as well as maintaining good hygiene, will help larger topical mycoses. Because some fungal infections are contagious, it is important to wash hands after touching other people or animals. Sports clothing should also be washed after use.\n",
      "\n",
      "\n",
      "\n",
      "Chronic cholestasis\n",
      "None\n",
      "\n",
      "\n",
      "\n",
      "Drug Reaction\n",
      "None\n",
      "\n",
      "\n",
      "\n",
      "Peptic ulcer disease\n",
      "Prevention of peptic ulcer disease for those who are taking NSAIDs (with low cardiovascular risk) can be achieved by adding a proton pump inhibitor (PPI), an H2 antagonist, or misoprostol. NSAIDs of the COX-2 inhibitors type may reduce the rate of ulcers when compared to non-selective NSAIDs. PPI is the most popular agent in peptic ulcer prevention. However, there is no evidence that H2 antagonists can prevent stomach bleeding for those taking NSAIDs. Although misoprostol is effective in preventing peptic ulcer, its properties of promoting abortion and causing gastrointestinal distress limit its use. For those with high cardiovascular risk, naproxen with PPI can be a useful choice. Otherwise, low-dose aspirin, celecoxib, and PPI can also be used.\n",
      "\n",
      "\n",
      "\n",
      "AIDS\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Diabetes \n",
      "There is no known preventive measure for type 1 diabetes. However, islet autoimmunity and multiple antibodies can be a strong predictor of the onset of type 1 diabetes.  Type 2 diabetes—which accounts for 85–90% of all cases worldwide—can often be prevented or delayed by maintaining a normal body weight, engaging in physical activity, and eating a healthy diet. Higher levels of physical activity (more than 90 minutes per day) reduce the risk of diabetes by 28%. Dietary changes known to be effective in helping to prevent diabetes include maintaining a diet rich in whole grains and fiber, and choosing good fats, such as the polyunsaturated fats found in nuts, vegetable oils, and fish. Limiting sugary beverages and eating less red meat and other sources of saturated fat can also help prevent diabetes. Tobacco smoking is also associated with an increased risk of diabetes and its complications, so smoking cessation can be an important preventive measure as well.The relationship between type 2 diabetes and the main modifiable risk factors (excess weight, unhealthy diet, physical inactivity and tobacco use) is similar in all regions of the world. There is growing evidence that the underlying determinants of diabetes are a reflection of the major forces driving social, economic and cultural change: globalization, urbanization, population aging, and the general health policy environment.\n",
      "\n",
      "\n",
      "\n",
      "Gastroenteritis\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Bronchial Asthma\n",
      "The evidence for the effectiveness of measures to prevent the development of asthma is weak. The World Health Organization recommends decreasing risk factors such as tobacco smoke, air pollution, chemical irritants including perfume, and the number of lower respiratory infections. Other efforts that show promise include: limiting smoke exposure in utero, breastfeeding, and increased exposure to daycare or large families, but none are well supported enough to be recommended for this indication.Early pet exposure may be useful. Results from exposure to pets at other times are inconclusive and it is only recommended that pets be removed from the home if a person has allergic symptoms to said pet.Dietary restrictions during pregnancy or when breast feeding have not been found to be effective at preventing asthma in children and are not recommended. Omega-3 consumption, mediterranean diet and anti-oxidants have been suggested by some studies that might help preventing crisis but the evidence is still inconclusive.Reducing or eliminating compounds known to sensitive people from the work place may be effective. It is not clear if annual influenza vaccinations affects the risk of exacerbations. Immunization, however, is recommended by the World Health Organization. Smoking bans are effective in decreasing exacerbations of asthma.\n",
      "\n",
      "\n",
      "\n",
      "Hypertension \n",
      "Much of the disease burden of high blood pressure is experienced by people who are not labeled as hypertensive. Consequently, population strategies are required to reduce the consequences of high blood pressure and reduce the need for antihypertensive medications. Lifestyle changes are recommended to lower blood pressure, before starting medications. The 2004 British Hypertension Society guidelines proposed lifestyle changes consistent with those outlined by the US National High BP Education Program in 2002 for the primary prevention of hypertension:\n",
      "\n",
      "maintain normal body weight for adults (e.g. body mass index 20–25 kg/m2)\n",
      "reduce dietary sodium intake to <100 mmol/ day (<6 g of sodium chloride or <2.4 g of sodium per day)\n",
      "engage in regular aerobic physical activity such as brisk walking (≥30 min per day, most days of the week)\n",
      "limit alcohol consumption to no more than 3 units/day in men and no more than 2 units/day in women\n",
      "consume a diet rich in fruit and vegetables (e.g. at least five portions per day);\n",
      "Stress reductionAvoiding or learning to manage stress can help a person control blood pressure.\n",
      "A few relaxation techniques that can help relieve stress are:\n",
      "\n",
      "meditation\n",
      "warm baths\n",
      "yoga\n",
      "going on long walksEffective lifestyle modification may lower blood pressure as much as an individual antihypertensive medication. Combinations of two or more lifestyle modifications can achieve even better results. There is considerable evidence that reducing dietary salt intake lowers blood pressure, but whether this translates into a reduction in mortality and cardiovascular disease remains uncertain. Estimated sodium intake ≥6g/day and <3g/day are both associated with high risk of death or major cardiovascular disease, but the association between high sodium intake and adverse outcomes is only observed in people with hypertension. Consequently, in the absence of results from randomized controlled trials, the wisdom of reducing levels of dietary salt intake below 3g/day has been questioned. ESC guidelines mention periodontitis is associated with poor cardiovascular health status.The value of routine screening for hypertension is debated. In 2004, the National High Blood Pressure Education Program recommended that children aged 3 years and older have blood pressure measurement at least once at every health care visit and the National Heart, Lung, and Blood Institute and American Academy of Pediatrics made a similar recommendation. However, the American Academy of Family Physicians supports the view of the U.S. Preventive Services Task Force that the available evidence is insufficient to determine the balance of benefits and harms of screening for hypertension in children and adolescents who do not have symptoms. The US Preventive Services Task Force recommends screening adults 18 years or older for hypertension with office blood pressure measurement.\n",
      "\n",
      "\n",
      "\n",
      "Migraine\n",
      "Preventive treatments of migraine include medications, nutritional supplements, lifestyle alterations, and surgery. Prevention is recommended in those who have headaches more than two days a week, cannot tolerate the medications used to treat acute attacks, or those with severe attacks that are not easily controlled. Recommended lifestyle changes include stopping tobacco use and reducing behaviors that interfere with sleep.The goal is to reduce the frequency, painfulness, and duration of migraine episodes, and to increase the effectiveness of abortive therapy. Another reason for prevention is to avoid medication overuse headache. This is a common problem and can result in chronic daily headache.\n",
      "\n",
      "\n",
      "\n",
      "Cervical spondylosis\n",
      "None\n",
      "\n",
      "\n",
      "\n",
      "Jaundice\n",
      "None\n",
      "\n",
      "\n",
      "\n",
      "Malaria\n",
      "Methods used to prevent malaria include medications, mosquito elimination and the prevention of bites. As of 2022, there is one malaria vaccine for children which is licensed for use known as RTS,S. The presence of malaria in an area requires a combination of high human population density, high Anopheles mosquito population density and high rates of transmission from humans to mosquitoes and from mosquitoes to humans. If any of these is lowered sufficiently, the parasite eventually disappears from that area, as happened in North America, Europe, and parts of the Middle East. However, unless the parasite is eliminated from the whole world, it could re-establish if conditions revert to a combination that favors the parasite's reproduction. Furthermore, the cost per person of eliminating anopheles mosquitoes rises with decreasing population density, making it economically unfeasible in some areas.Prevention of malaria may be more cost-effective than treatment of the disease in the long run, but the initial costs required are out of reach of many of the world's poorest people. There is a wide difference in the costs of control (i.e. maintenance of low endemicity) and elimination programs between countries. For example, in China—whose government in 2010 announced a strategy to pursue malaria elimination in the Chinese provinces—the required investment is a small proportion of public expenditure on health. In contrast, a similar programme in Tanzania would cost an estimated one-fifth of the public health budget. In 2021, the World Health Organization confirmed that China has eliminated malaria.In areas where malaria is common, children under five years old often have anaemia, which is sometimes due to malaria. Giving children with anaemia in these areas preventive antimalarial medication improves red blood cell levels slightly but does not affect the risk of death or need for hospitalisation.\n",
      "\n",
      "\n",
      "\n",
      "Chicken pox\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Dengue\n",
      "Prevention depends on control of and protection from the bites of the mosquito that transmits it. The World Health Organization recommends an Integrated Vector Control program consisting of five elements:\n",
      "Advocacy, social mobilization and legislation to ensure that public health bodies and communities are strengthened;\n",
      "Collaboration between the health and other sectors (public and private);\n",
      "An integrated approach to disease control to maximize the use of resources;\n",
      "Evidence-based decision making to ensure any interventions are targeted appropriately; and\n",
      "Capacity-building to ensure an adequate response to the local situation.The primary method of controlling A. aegypti is by eliminating its habitats. This is done by getting rid of open sources of water, or if this is not possible, by adding insecticides or biological control agents to these areas. Generalized spraying with organophosphate or pyrethroid insecticides, while sometimes done, is not thought to be effective. Reducing open collections of water through environmental modification is the preferred method of control, given the concerns of negative health effects from insecticides and greater logistical difficulties with control agents. People can prevent mosquito bites by wearing clothing that fully covers the skin, using mosquito netting while resting, and/or the application of insect repellent (DEET being the most effective). While these measures can be an effective means of reducing an individual's risk of exposure, they do little in terms of mitigating the frequency of outbreaks, which appear to be on the rise in some areas, probably due to urbanization increasing the habitat of A. aegypti. The range of the disease also appears to be expanding possibly due to climate change.\n",
      "\n",
      "\n",
      "\n",
      "Typhoid\n",
      "Sanitation and hygiene are important to prevent typhoid. It can spread only in environments where human feces can come into contact with food or drinking water. Careful food preparation and washing of hands are crucial to prevent typhoid. Industrialization contributed greatly to the elimination of typhoid fever, as it eliminated the public-health hazards associated with having horse manure in public streets, which led to a large number of flies, which are vectors of many pathogens, including Salmonella spp. According to statistics from the U.S. Centers for Disease Control and Prevention, the chlorination of drinking water has led to dramatic decreases in the transmission of typhoid fever.\n",
      "\n",
      "\n",
      "\n",
      "Tuberculosis\n",
      "Tuberculosis prevention and control efforts rely primarily on the vaccination of infants and the detection and appropriate treatment of active cases. The World Health Organization (WHO) has achieved some success with improved treatment regimens, and a small decrease in case numbers. Some countries have legislation to involuntarily detain or examine those suspected to have tuberculosis, or involuntarily treat them if infected.\n",
      "\n",
      "\n",
      "\n",
      "Common Cold\n",
      "The only useful ways to reduce the spread of cold viruses are physical measures such as using correct hand washing technique and face masks; in the healthcare environment, gowns and disposable gloves are also used. Isolation or quarantine is not used as the disease is so widespread and symptoms are non-specific. There is no vaccine to protect against the common cold. Vaccination has proven difficult as there are many viruses involved and they mutate rapidly. Creation of a broadly effective vaccine is, therefore, highly improbable.Regular hand washing appears to be effective in reducing the transmission of cold viruses, especially among children. Whether the addition of antivirals or antibacterials to normal hand washing provides greater benefit is unknown. Wearing face masks when around people who are infected may be beneficial; however, there is insufficient evidence for maintaining a greater social distance.It is unclear whether zinc supplements affect the likelihood of contracting a cold. Routine vitamin C supplements do not reduce the risk or severity of the common cold, though they may reduce its duration. Gargling with water was found useful in one small trial.\n",
      "\n",
      "\n",
      "\n",
      "Pneumonia\n",
      "Prevention includes vaccination, environmental measures, and appropriate treatment of other health problems. It is believed that, if appropriate preventive measures were instituted globally, mortality among children could be reduced by 400,000; and, if proper treatment were universally available, childhood deaths could be decreased by another 600,000.\n",
      "\n",
      "\n",
      "\n",
      "Piles\n",
      "A number of preventative measures are recommended, including avoiding straining while attempting to defecate, avoiding constipation and diarrhea either by eating a high-fiber diet and drinking plenty of fluid or by taking fiber supplements and getting sufficient exercise. Spending less time attempting to defecate, avoiding reading while on the toilet, and losing weight for overweight persons and avoiding heavy lifting are also recommended.\n",
      "\n",
      "\n",
      "\n",
      "Heart attack\n",
      "There is a large crossover between the lifestyle and activity recommendations to prevent a myocardial infarction, and those that may be adopted as secondary prevention after an initial myocardial infarction, because of shared risk factors and an aim to reduce atherosclerosis affecting heart vessels. The influenza vaccine also appear to protect against myocardial infarction with a benefit of 15 to 45%.\n",
      "\n",
      "\n",
      "\n",
      "Varicose veins\n",
      "None\n",
      "\n",
      "\n",
      "\n",
      "Hypothyroidism\n",
      "Hypothyroidism may be prevented in a population by adding iodine to commonly used foods. This public health measure has eliminated endemic childhood hypothyroidism in countries where it was once common. In addition to promoting the consumption of iodine-rich foods such as dairy and fish, many countries with moderate iodine deficiency have implemented universal salt iodization. Encouraged by the World Health Organization, 70% of the world's population across 130 countries are receiving iodized salt. In some countries, iodized salt is added to bread. Despite this, iodine deficiency has reappeared in some Western countries as a result of attempts to reduce salt intake.Pregnant and breastfeeding women, who require 66% more daily iodine than non-pregnant women, may still not be getting enough iodine. The World Health Organization recommends a daily intake of 250 µg for pregnant and breastfeeding women. As many women will not achieve this from dietary sources alone, the American Thyroid Association recommends a 150 µg daily supplement by mouth.\n",
      "\n",
      "\n",
      "\n",
      "Hyperthyroidism\n",
      "None\n",
      "\n",
      "\n",
      "\n",
      "Hypoglycemia\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Osteoarthritis\n",
      "None\n",
      "\n",
      "\n",
      "\n",
      "Arthritis\n",
      "None\n",
      "\n",
      "\n",
      "\n",
      "Paroxysmal Positional Vertigo\n",
      "None\n",
      "\n",
      "\n",
      "\n",
      "Acne\n",
      "None\n",
      "\n",
      "\n",
      "\n",
      "Urinary tract infection\n",
      "A number of measures have not been confirmed to affect UTI frequency including: urinating immediately after intercourse, the type of underwear used, personal hygiene methods used after urinating or defecating, or whether a person typically bathes or showers. There is similarly a lack of evidence surrounding the effect of holding one's urine, tampon use, and douching. In those with frequent urinary tract infections who use spermicide or a diaphragm as a method of contraception, they are advised to use alternative methods. In those with benign prostatic hyperplasia urinating in a sitting position appears to improve bladder emptying which might decrease urinary tract infections in this group.Using urinary catheters as little and as short of time as possible and appropriate care of the catheter when used prevents catheter-associated urinary tract infections.\n",
      "They should be inserted using sterile technique in hospital however non-sterile technique may be appropriate in those who self catheterize. The urinary catheter set up should also be kept sealed. Evidence does not support a significant decrease in risk when silver-alloy catheters are used.\n",
      "\n",
      "\n",
      "\n",
      "Psoriasis\n",
      "None\n",
      "\n",
      "\n",
      "\n",
      "Impetigo\n",
      "To prevent the spread of impetigo the skin and any open wounds should be kept clean and covered. Care should be taken to keep fluids from an infected person away from the skin of a non-infected person. Washing hands, linens, and affected areas will lower the likelihood of contact with infected fluids. Scratching can spread the sores; keeping nails short will reduce the chances of spreading. Infected people should avoid contact with others and eliminate sharing of clothing or linens. Children with impetigo can return to school 24 hours after starting antibiotic therapy as long as their draining lesions are covered.\n",
      "\n",
      "\n",
      "\n",
      "Hepatitis\n",
      "\n",
      "Hepatitis A causes an acute illness that does not progress to chronic liver disease. Therefore, the role of screening is to assess immune status in people who are at high risk of contracting the virus, as well as in people with known liver disease for whom hepatitis A infection could lead to liver failure. People in these groups who are not already immune can receive the hepatitis A vaccine.Those at high risk and in need of screening include:\n",
      "People in close contact (either living with or having sexual contact) with someone who has hepatitis A\n",
      "People traveling to an area with endemic hepatitis A\n",
      "People who do not have access to clean water\n",
      "People who use illicit drugs\n",
      "People with liver disease\n",
      "People with poor sanitary habits such as not washing hands after using the restroom or changing diapersThe presence of anti-hepatitis A IgG in the blood indicates past infection with the virus or prior vaccination.\n",
      "The CDC, WHO, USPSTF, and ACOG recommend routine hepatitis B screening for certain high-risk populations. Specifically, these populations include people who are:\n",
      "\n",
      "Beginning immunosuppressive or cytotoxic therapy\n",
      "Blood, organ, or tissue donors\n",
      "Born in countries where the prevalence of hepatitis B is high (defined as ≥2% of the population), whether or not they have been vaccinated\n",
      "Born in the United States whose parents are from countries where the prevalence of hepatitis B is very high (defined as ≥8% of the population), and who were not vaccinated\n",
      "Found to have elevated liver enzymes without a known cause\n",
      "HIV positive\n",
      "In close contact with (i.e. live or have sex with) people known to have hepatitis B\n",
      "Incarcerated\n",
      "Intravenous drug users\n",
      "Men who have sex with men\n",
      "On hemodialysis\n",
      "PregnantScreening consists of a blood test that detects hepatitis B surface antigen (HBsAg). If HBsAg is present, a second test – usually done on the same blood sample – that detects the antibody for the hepatitis B core antigen (anti-HBcAg) can differentiate between acute and chronic infection. People who are high-risk whose blood tests negative for HBsAg can receive the hepatitis B vaccine to prevent future infection.\n",
      "\n",
      "\n",
      "\n",
      "Gastroesophageal reflux disease\n",
      "None\n",
      "\n",
      "\n",
      "\n",
      "Allergic Diseases\n",
      "Giving peanut products early may decrease the risk of allergies while only breastfeeding during at least the first few months of life may decrease the risk of dermatitis. There is no good evidence that a mother's diet during pregnancy or breastfeeding affects the risk of allergies, nor is there evidence that delayed introduction of certain foods is useful. Early exposure to potential allergens may actually be protective.Fish oil supplementation during pregnancy is associated with a lower risk. Probiotic supplements during pregnancy or infancy may help to prevent atopic dermatitis.\n",
      "\n",
      "\n",
      "\n",
      "Paralysis\n",
      "None\n"
     ]
    }
   ],
   "source": [
    "precautionLi = []\n",
    "for disease in dl:\n",
    "    print(disease)\n",
    "    try:\n",
    "        content = get_wiki_content(disease, 'precaution')\n",
    "        precautionLi.append(content)\n",
    "        print(content)\n",
    "    except Exception as exp:\n",
    "        print(f\"Exception {exp} occured while trying to process the disease {disease}\")\n",
    "        break\n",
    "    except ConnectionError:\n",
    "        content = get_wiki_content(disease)\n",
    "        precautionLi.append(content)\n",
    "        print(content)\n",
    "    \n",
    "    print(\"\\n\\n\")"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-25T16:49:56.346946600Z",
     "start_time": "2023-09-25T16:47:06.996293300Z"
    }
   },
   "id": "59d046577e1f1b3f"
  },
  {
   "cell_type": "code",
   "execution_count": 282,
   "outputs": [],
   "source": [
    "page_obj = wikipedia.page('Hypoglycemia')"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-25T16:55:20.623671700Z",
     "start_time": "2023-09-25T16:54:54.175856900Z"
    }
   },
   "id": "fe2d489816b0bd8a"
  },
  {
   "cell_type": "code",
   "execution_count": 283,
   "outputs": [
    {
     "data": {
      "text/plain": "['Fungal infection, also known as mycosis, is a disease caused by fungi. Different types are traditionally divided according to the part of the body affected; superficial, subcutaneous, and systemic. Superficial fungal infections include common tinea of the skin, such as tinea of the body, groin, hands, feet and beard, and yeast infections such as pityriasis versicolor.',\n 'Cholestasis is a condition where bile cannot flow from the liver to the duodenum. The two basic distinctions are an obstructive type of cholestasis where there is a mechanical blockage in the duct system that can occur from a gallstone or malignancy, and metabolic types of cholestasis which are disturbances in bile formation that can occur because of genetic defects or acquired as a side effect of many medications. Classification is further divided into acute or chronic and extrahepatic or intrahepatic.',\n 'An adverse drug reaction (ADR) is a harmful, unintended result caused by taking medication.:\\u200a1.1 Adverse Drug Reaction (ADR)\\u200a ADRs may occur following a single dose or prolonged administration of a drug or may result from the combination of two or more drugs. The meaning of this term differs from the term \"side effect\" because side effects can be beneficial as well as detrimental. The study of ADRs is the concern of the field known as pharmacovigilance.',\n 'Peptic ulcer disease (PUD) is a break in the inner lining of the stomach, the first part of the small intestine, or sometimes the lower esophagus. An ulcer in the stomach is called a gastric ulcer, while one in the first part of the intestines is a duodenal ulcer. The most common symptoms of a duodenal ulcer are waking at night with upper abdominal pain, and upper abdominal pain that improves with eating.',\n 'Infection with HIV (Human Immunodeficiency Virus), a retrovirus, can be managed with treatment but  without treatment can lead to a spectrum of conditions including AIDS (Acquired ImmunoDeficiency Syndrome).Effective treatment for HIV-positive people (people living with HIV) involves a life-long regimen of medicine to suppress the virus, making the viral load undetectable.  There is not yet a vaccine nor a cure.  An HIV-positive person on treatment can expect to live a normal life, and die with the virus, not of it.',\n \"Diabetes mellitus, often known simply as diabetes, is a group of common endocrine diseases characterized by sustained high blood sugar levels. Diabetes is due to either the pancreas not producing enough insulin, or the cells of the body becoming unresponsive to the hormone's effects. Classic symptoms include thirst, polyuria, weight loss, and blurred vision.\",\n 'Gastroenteritis, also known as infectious diarrhea or simply as gastro, is an inflammation of the gastrointestinal tract including the stomach and intestine. Symptoms may include diarrhea, vomiting, and abdominal pain. Fever, lack of energy, and dehydration may also occur.',\n 'Asthma is a long-term inflammatory disease of the airways of the lungs. It is characterized by variable and recurring symptoms, reversible airflow obstruction, and easily triggered bronchospasms. Symptoms include episodes of wheezing, coughing, chest tightness, and shortness of breath.',\n 'Hypertension, also known as high blood pressure, is a long-term medical condition in which the blood pressure in the arteries is persistently elevated. High blood pressure usually does not cause symptoms. It is, however, a major risk factor for stroke, coronary artery disease, heart failure, atrial fibrillation, peripheral arterial disease, vision loss, chronic kidney disease, and dementia.',\n 'Migraine (UK: , US: ) is a genetically influenced complex neurological disorder characterized by episodes of moderate-to-severe headache, most often unilateral and generally associated with nausea and light and sound sensitivity. Other characterizing symptoms may include nausea, vomiting, cognitive dysfunction, allodynia, and dizziness. Exacerbation of headache symptoms during physical activity is another distinguishing feature.',\n 'Spondylosis is the degeneration of the vertebral column from any cause. In the more narrow sense it refers to spinal osteoarthritis, the age-related degeneration of the spinal column, which is the most common cause of spondylosis. The degenerative process in osteoarthritis chiefly affects the vertebral bodies, the neural foramina and the facet joints (facet syndrome).',\n 'Jaundice, also known as icterus, is a yellowish or greenish pigmentation of the skin and sclera due to high bilirubin levels. Jaundice in adults is typically a sign indicating the presence of underlying diseases involving abnormal heme metabolism, liver dysfunction, or biliary-tract obstruction. The prevalence of jaundice in adults is rare, while jaundice in babies is common, with an estimated 80% affected during their first week of life.',\n 'Malaria is a mosquito-borne infectious disease that affects humans and other vertebrates. Human malaria causes symptoms that typically include fever, fatigue, vomiting, and headaches. In severe cases, it can cause jaundice, seizures, coma, or death.',\n 'Chickenpox, or chicken pox, also known as varicella, is a highly contagious, vaccine-preventable disease caused by the initial infection with varicella zoster virus (VZV), a member of the herpesvirus family. The disease results in a characteristic skin rash that forms small, itchy blisters, which eventually scab over. It usually starts on the chest, back, and face.',\n 'Dengue fever is a mosquito-borne tropical disease caused by the dengue virus. Symptoms typically begin three to fourteen days after infection. These may include a high fever, headache, vomiting, muscle and joint pains, and a characteristic skin itching and skin rash.',\n 'Typhoid fever, also known as typhoid, is a disease caused by Salmonella serotype Typhi bacteria. Symptoms vary from mild to severe, and usually begin six to 30 days after exposure. Often there is a gradual onset of a high fever over several days.',\n 'Tuberculosis (TB) is an infectious disease usually caused by Mycobacterium tuberculosis (MTB) bacteria. Tuberculosis generally affects the lungs, but it can also affect other parts of the body. Most infections show no symptoms, in which case it is known as latent tuberculosis.',\n 'The common cold or the cold is a viral infectious disease of the upper respiratory tract that primarily affects the respiratory mucosa of the nose, throat, sinuses, and larynx. Signs and symptoms may appear fewer than two days after exposure to the virus. These may include coughing, sore throat, runny nose, sneezing, headache, and fever.',\n 'Pneumonia is an inflammatory condition of the lung primarily affecting the small air sacs known as alveoli. Symptoms typically include some combination of productive or dry cough, chest pain, fever, and difficulty breathing. The severity of the condition is variable.Pneumonia is usually caused by infection with viruses or bacteria, and less commonly by other microorganisms.',\n 'Hemorrhoids (or haemorrhoids), also known as piles, are vascular structures in the anal canal. In their normal state, they are cushions that help with stool control. They become a disease when swollen or inflamed; the unqualified term hemorrhoid is often used to refer to the disease.',\n 'A myocardial infarction (MI), commonly known as a heart attack, occurs when blood flow decreases or stops in one of the coronary arteries of the heart, causing damage to the heart muscle. The most common symptom is chest pain or discomfort which may travel into the shoulder, arm, back, neck or jaw. Often it occurs in the center or left side of the chest and lasts for more than a few minutes.',\n 'Varicose veins, also known as varicoses, are a medical condition in which superficial veins become enlarged and twisted. These veins typically develop in the legs, just under the skin. Varicose veins usually cause few symptoms.',\n 'Hypothyroidism (also called underactive thyroid, low thyroid or hypothyreosis) is a disorder of the endocrine system in which the thyroid gland does not produce enough thyroid hormone. It can cause a number of symptoms, such as poor ability to tolerate cold, a feeling of tiredness, constipation, slow heart rate,  depression, and weight gain. Occasionally there may be swelling of the front part of the neck due to goitre.',\n 'Hyperthyroidism is the condition that occurs due to excessive production of thyroid hormones by the thyroid gland. Thyrotoxicosis is the condition that occurs due to excessive thyroid hormone of any cause and therefore includes hyperthyroidism. Some, however, use the terms interchangeably.',\n \"Hypoglycemia, also called low blood sugar, is a fall in blood sugar to levels below normal, typically below 70 mg/dL (3.9 mmol/L). Whipple's triad is used to properly identify hypoglycemic episodes. It is defined as blood glucose below 70 mg/dL (3.9 mmol/L), symptoms associated with hypoglycemia, and resolution of symptoms when blood sugar returns to normal.\",\n 'Osteoarthritis (OA) is a type of degenerative joint disease that results from breakdown of joint cartilage and underlying bone which affects 1 in 7 adults in the United States. It is believed to be the fourth leading cause of disability in the world. The most common symptoms are joint pain and stiffness.',\n 'Arthritis is a term often used to mean any disorder that affects joints. Symptoms generally include joint pain and stiffness. Other symptoms may include redness, warmth, swelling, and decreased range of motion of the affected joints.',\n 'Benign paroxysmal positional vertigo (BPPV) is a disorder arising from a problem in the inner ear. Symptoms are repeated, brief periods of vertigo with movement, characterized by a spinning sensation upon changes in the position of the head. This can occur with turning in bed or changing position.',\n 'Acne, also known as acne vulgaris, is a long-term skin condition that occurs when dead skin cells and oil from the skin clog hair follicles. Typical features of the condition include blackheads or whiteheads, pimples, oily skin, and possible scarring. It primarily affects skin with a relatively high number of oil glands, including the face, upper part of the chest, and back.',\n 'A urinary tract infection (UTI) is an infection that affects part of the urinary tract. When it affects the lower urinary tract it is known as a bladder infection (cystitis) and when it affects the upper urinary tract it is known as a kidney infection (pyelonephritis). Symptoms from a lower urinary tract infection include pain with urination, frequent urination, and feeling the need to urinate despite having an empty bladder.',\n 'Psoriasis is a long-lasting, noncontagious autoimmune disease characterized by patches of abnormal skin. These areas are red, pink, or purple, dry, itchy, and scaly. Psoriasis varies in severity from small localized patches to complete body coverage.',\n 'Impetigo is a bacterial infection that involves the superficial skin. The most common presentation is yellowish crusts on the face, arms, or legs. Less commonly there may be large blisters which affect the groin or armpits.',\n 'Hepatitis is inflammation of the liver tissue. Some people or animals with hepatitis have no symptoms, whereas others develop yellow discoloration of the skin and whites of the eyes (jaundice), poor appetite, vomiting, tiredness, abdominal pain, and diarrhea. Hepatitis is acute if it resolves within six months, and chronic if it lasts longer than six months.',\n \"Gastroesophageal reflux disease (GERD) or gastro-oesophageal reflux disease (GORD)  is one of the upper gastrointestinal chronic diseases in which stomach content persistently and regularly flows up into the esophagus, resulting in symptoms and/or complications. Symptoms include dental corrosion, dysphagia, heartburn, odynophagia, regurgitation, non-cardiac chest pain, extraesophageal symptoms such as chronic cough, hoarseness, reflux-induced laryngitis, or asthma. In the long term, and when not treated, complications such as esophagitis, esophageal stricture, and Barrett's esophagus may arise.Risk factors include obesity, pregnancy, smoking, hiatal hernia, and taking certain medications.\",\n 'Allergies, also known as allergic diseases, are various conditions caused by hypersensitivity of the immune system to typically harmless substances in the environment. These diseases include hay fever, food allergies, atopic dermatitis, allergic asthma, and anaphylaxis. Symptoms may include red eyes, an itchy rash, sneezing, coughing, a runny nose, shortness of breath, or swelling.',\n 'Paralysis (PL: paralyses; also known as plegia) is a loss of motor function in one or more muscles. Paralysis can also be accompanied by a loss of feeling (sensory loss) in the affected area if there is sensory damage. In the United States, roughly 1 in 50 people have been diagnosed with some form of permanent or transient paralysis.']"
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "aboutLi"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-25T16:55:20.638325Z",
     "start_time": "2023-09-25T16:55:20.629196400Z"
    }
   },
   "id": "1da83932fc1180d8"
  },
  {
   "cell_type": "code",
   "execution_count": 290,
   "outputs": [
    {
     "data": {
      "text/plain": "['All pages needing factual verification',\n 'Articles with short description',\n 'CS1 maint: location missing publisher',\n 'Disorders causing seizures',\n 'Disorders of endocrine pancreas',\n 'Medical emergencies',\n 'Short description is different from Wikidata',\n 'Use dmy dates from June 2022',\n 'Wikipedia articles needing factual verification from June 2022',\n 'Wikipedia emergency medicine articles ready to translate',\n 'Wikipedia medicine articles ready to translate']"
     },
     "execution_count": 290,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "page_obj.categories"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-25T16:58:28.833958600Z",
     "start_time": "2023-09-25T16:58:28.769134Z"
    }
   },
   "id": "490932d37694fcac"
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "outputs": [],
   "source": [
    "import wikipediaapi\n",
    "import wikipedia"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-26T13:46:34.205879100Z",
     "start_time": "2023-09-26T13:46:33.693916400Z"
    }
   },
   "id": "b483c7abafe266e9"
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "outputs": [],
   "source": [
    "api = wikipediaapi.Wikipedia('SchoolScienceFestModel (4n0nym0us1147@gmail.com)', 'en')"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-26T13:46:35.286230100Z",
     "start_time": "2023-09-26T13:46:35.199305600Z"
    }
   },
   "id": "115452d4fd0f7e54"
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "outputs": [],
   "source": [
    "def get_wiki_content_api(disease: str, cat: str = 'summary', summaryLen: int = 5):\n",
    "    search = wikipedia.search(disease)[0]\n",
    "    page = api.page(search)\n",
    "    sections = page.sections\n",
    "    \n",
    "    if 'precaution' in cat:\n",
    "        searchLi = ['precaution', 'prevention']\n",
    "    elif 'cause' in cat:\n",
    "        searchLi = ['cause']\n",
    "    elif 'symptom' in cat:\n",
    "        searchLi = ['sign', 'symptom']\n",
    "    elif 'treatment' in cat:\n",
    "        searchLi = ['treatment', 'vaccine', 'management']\n",
    "    else:\n",
    "        return \". \".join(page.summary.split(\". \")[:summaryLen]) + \".\"\n",
    "        \n",
    "    for find in searchLi:\n",
    "        for section in sections:\n",
    "            if find in section.title.lower():\n",
    "                if section.text != \"\":\n",
    "                    return section.text\n",
    "                else:\n",
    "                    txt = \"\"\n",
    "                    for subsection in page.section_by_title(section.title).sections:\n",
    "                        if subsection.text == \"\":\n",
    "                            for subsubseciton in page.section_by_title(subsection.title).sections:\n",
    "                                txt += subsubseciton.title + \"\\n\" + subsubseciton.text + \"\\n\"\n",
    "                            txt += \"\\n\\n\"\n",
    "                            \n",
    "                    if txt == \"\" and cat == 'precaution':\n",
    "                        subsection = [sub for sub in page.section_by_title('Treatment').sections if sub.title == 'Conservative']\n",
    "                        txt = subsection[0].text\n",
    "                    # print(txt)\n",
    "                    return txt"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-26T14:35:01.456141200Z",
     "start_time": "2023-09-26T14:35:01.364265500Z"
    }
   },
   "id": "abc8eab2fc8a501c"
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "outputs": [],
   "source": [
    "aboutLi = []\n",
    "for disease in dl:\n",
    "    aboutLi.append(get_wiki_content_api(disease))"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-26T13:47:46.359359200Z",
     "start_time": "2023-09-26T13:46:39.316285500Z"
    }
   },
   "id": "303cd9499d70f7e8"
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Consistent condom use reduces the risk of HIV transmission by approximately 80% over the long term. When condoms are used consistently by a couple in which one person is infected, the rate of HIV infection is less than 1% per year. There is some evidence to suggest that female condoms may provide an equivalent level of protection. Application of a vaginal gel containing tenofovir (a reverse transcriptase inhibitor) immediately before sex seems to reduce infection rates by approximately 40% among African women. By contrast, use of the spermicide nonoxynol-9 may increase the risk of transmission due to its tendency to cause vaginal and rectal irritation.Circumcision in sub-Saharan Africa \"reduces the acquisition of HIV by heterosexual men by between 38% and 66% over 24 months\". Owing to these studies, both the World Health Organization and UNAIDS recommended male circumcision in 2007 as a method of preventing female-to-male HIV transmission in areas with high rates of HIV. However, whether it protects against male-to-female transmission is disputed, and whether it is of benefit in developed countries and among men who have sex with men is undetermined.Programs encouraging sexual abstinence do not appear to affect subsequent HIV risk. Evidence of any benefit from peer education is equally poor. Comprehensive sexual education provided at school may decrease high-risk behavior. A substantial minority of young people continues to engage in high-risk practices despite knowing about HIV/AIDS, underestimating their own risk of becoming infected with HIV. Voluntary counseling and testing people for HIV does not affect risky behavior in those who test negative but does increase condom use in those who test positive. Enhanced family planning services appear to increase the likelihood of women with HIV using contraception, compared to basic services. It is not known whether treating other sexually transmitted infections is effective in preventing HIV.\n",
      "\n",
      "Antiretroviral treatment among people with HIV whose CD4 count ≤ 550 cells/µL is a very effective way to prevent HIV infection of their partner (a strategy known as treatment as prevention, or TASP). TASP is associated with a 10- to 20-fold reduction in transmission risk. Pre-exposure prophylaxis (PrEP) with a daily dose of the medications tenofovir, with or without emtricitabine, is effective in people at high risk including men who have sex with men, couples where one is HIV-positive, and young heterosexuals in Africa. It may also be effective in intravenous drug users, with a study finding a decrease in risk of 0.7 to 0.4 per 100 person years. The USPSTF, in 2019, recommended PrEP in those who are at high risk.Universal precautions within the health care environment are believed to be effective in decreasing the risk of HIV. Intravenous drug use is an important risk factor, and harm reduction strategies such as needle-exchange programs and opioid substitution therapy appear effective in decreasing this risk.\n",
      "\n",
      "A course of antiretrovirals administered within 48 to 72 hours after exposure to HIV-positive blood or genital secretions is referred to as post-exposure prophylaxis (PEP). The use of the single agent zidovudine reduces the risk of an HIV infection five-fold following a needle-stick injury. As of 2013, the prevention regimen recommended in the United States consists of three medications—tenofovir, emtricitabine and raltegravir—as this may reduce the risk further.PEP treatment is recommended after a sexual assault when the perpetrator is known to be HIV-positive, but is controversial when their HIV status is unknown. The duration of treatment is usually four weeks and is frequently associated with adverse effects—where zidovudine is used, about 70% of cases result in adverse effects such as nausea (24%), fatigue (22%), emotional distress (13%) and headaches (9%).\n",
      "\n",
      "Programs to prevent the vertical transmission of HIV (from mothers to children) can reduce rates of transmission by 92–99%. This primarily involves the use of a combination of antiviral medications during pregnancy and after birth in the infant, and potentially includes bottle feeding rather than breastfeeding. If replacement feeding is acceptable, feasible, affordable, sustainable and safe, mothers should avoid breastfeeding their infants; however, exclusive breastfeeding is recommended during the first months of life if this is not the case. If exclusive breastfeeding is carried out, the provision of extended antiretroviral prophylaxis to the infant decreases the risk of transmission. In 2015, Cuba became the first country in the world to eradicate mother-to-child transmission of HIV.\n",
      "\n",
      "Currently there is no licensed vaccine for HIV or AIDS. The most effective vaccine trial to date, RV 144, was published in 2009; it found a partial reduction in the risk of transmission of roughly 30%, stimulating some hope in the research community of developing a truly effective vaccine.\n",
      "\n",
      "A supply of easily accessible uncontaminated water and good sanitation practices are important for reducing rates of infection and clinically significant gastroenteritis. Personal hygiene measures (such as hand washing with soap) have been found to decrease rates of gastroenteritis in both the developing and developed world by as much as 30%. Alcohol-based gels may also be effective. Food or drink that is thought to be contaminated should be avoided.Breastfeeding is important, especially in places with poor hygiene, as is improvement of hygiene generally. Breast milk reduces both the frequency of infections and their duration.\n",
      "\n",
      "Due to both its effectiveness and safety, in 2009 the World Health Organization recommended that the rotavirus vaccine be offered to all children globally. Two commercial rotavirus vaccines exist and several more are in development. In Africa and Asia these vaccines reduced severe disease among infants and countries that have put in place national immunization programs have seen a decline in the rates and severity of disease. This vaccine may also prevent illness in non-vaccinated children by reducing the number of circulating infections. Since 2000, the implementation of a rotavirus vaccination program in the United States has substantially decreased the number of cases of diarrhea by as much as 80 percent. The first dose of vaccine should be given to infants between 6 and 15 weeks of age. The oral cholera vaccine has been found to be 50–60% effective over two years.There are a number of vaccines against gastroenteritis in development. For example, vaccines against Shigella and enterotoxigenic Escherichia coli (ETEC), which are two of the leading bacterial causes of gastroenteritis worldwide.\n",
      "\n",
      "The spread of chickenpox can be prevented by isolating affected individuals. Contagion is by exposure to respiratory droplets, or direct contact with lesions, within a period lasting from three days before the onset of the rash, to four days after the onset of the rash. The chickenpox virus is susceptible to disinfectants, notably chlorine bleach (i.e., sodium hypochlorite). Like all enveloped viruses, it is sensitive to drying, heat and detergents.\n",
      "\n",
      "Chickenpox can be prevented by vaccination. The side effects are usually mild, such as some pain or swelling at the injection site.A live attenuated varicella vaccine, the Oka strain, was developed by Michiaki Takahashi and his colleagues in Japan in the early 1970s. In 1995, Merck & Co. licensed the \"Oka\" strain of the varicella virus in the United States, and Maurice Hilleman's team at Merck invented a varicella vaccine in the same year.The varicella vaccine is recommended in many countries. Some countries require the varicella vaccination or an exemption before entering elementary school. A second dose is recommended five years after the initial immunization. A vaccinated person is likely to have a milder case of chickenpox if they become infected. Immunization within three days following household contact reduces infection rates and severity in children. Being exposed to chickenpox as an adult (for example, through contact with infected children) may boost immunity to shingles. Therefore, it was thought that when the majority of children were vaccinated against chickenpox, adults might lose this natural boosting, so immunity would drop and more shingles cases would occur. On the other hand, current observations suggest that exposure to children with varicella is not a critical factor in the maintenance of immunity. Multiple subclinical reactivations of varicella zoster virus may occur spontaneously and, despite not causing clinical disease, may still provide an endogenous boost to immunity against zoster.The vaccine is part of the routine immunization schedule in the US. Some European countries include it as part of universal vaccinations in children, but not all countries provide the vaccine. In the UK as of 2014, the vaccine is only recommended in people who are particularly vulnerable to chickenpox. This is to keep the virus in circulation, thereby exposing the population to the virus at an early age, when it is less harmful, and to reduce the occurrence of shingles through repeated exposure to the virus later in life. In populations that have not been immunized or if immunity is questionable, a clinician may order an enzyme immunoassay. An immunoassay measures the levels of antibodies against the virus that give immunity to a person. If the levels of antibodies are low (low titer) or questionable, reimmunization may be done.\n",
      "\n",
      "The prevention of hypoglycemia depends on the cause. In those with diabetes treated by insulin, glinides, or sulfonylurea, the prevention of hypoglycemia has a large focus on patient education and medication adjustments. The foundation of diabetes education is learning how to recognize the signs and symptoms of hypoglycemia, as well as learning how to act quickly to prevent worsening of an episode. Another cornerstone of prevention is strong self-monitoring of blood glucose, with consistent and frequent measurements. Research has shown that patients with type 1 diabetes who use continuous glucose monitoring systems with insulin pumps significantly improve blood glucose control. Insulin pumps help to prevent high glucose spikes, and help prevent inappropriate insulin dosing. Continuous glucose monitors can sound alarms when blood glucose is too low or too high, especially helping those with nocturnal hypoglycemia or hypoglycemic unawareness. In terms of medication adjustments, medication doses and timing can be adjusted to prevent hypoglycemia, or a medication can be stopped altogether.\n",
      "\n",
      "In those with hypoglycemia who do not have diabetes, there are a number of preventative measures dependent on the cause. Hypoglycemia caused by hormonal dysfunction like lack of cortisol in Addison's disease or lack of growth hormone in hypopituitarism can be prevented with appropriate hormone replacement. The hypoglycemic episodes associated with non-B cell tumors can be decreased following surgical removal of the tumor, as well as following radiotherapy or chemotherapy to reduce the size of the tumor. In some cases, those with non-B cell tumors may have hormone therapy with growth hormone, glucocorticoid, or octreotide to also lessen hypoglycemic episodes. Post-gastric bypass hypoglycemia can be prevented by eating smaller, more frequent meals, avoiding sugar-filled foods, as well as medical treatment with an alpha-glucosidase inhibitor, diazoxide, or octreotide.Some causes of hypoglycemia require treatment of the underlying cause to best prevent hypoglycemia. This is the case for insulinomas which often require surgical removal of the tumor for hypoglycemia to remit. In patients who cannot undergo surgery for removal of the insulinoma, diazoxide or octreotide may be used.\n"
     ]
    }
   ],
   "source": [
    "precautionLi = []\n",
    "for disease in dl:\n",
    "    precautionLi.append(get_wiki_content_api(disease, 'precaution'))"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-26T13:48:12.103918900Z",
     "start_time": "2023-09-26T13:47:46.364882800Z"
    }
   },
   "id": "75c309b1bbe2b8de"
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "In cervical spondylosis, a patient may be presented with dull neck pain with neck stiffness in the initial stages of the disease. As the disease progresses, symptoms related to radiculopathy (due to compression of exiting spinal nerve by narrowed intervertebral foramen) or myelopathy (due to compression on the spinal cord) can occur. Reduced range of motion of the neck is the most frequent objective finding on physical examination.In cervical radiculopathy, there would be numbness, tingling, or burning pain at the skin area supplied by the spinal nerve, shooting pain along the course of the spinal nerve, or weakness or absent tendon reflex of the muscle supplied by the nerve. This symptom can be provoked by neck extension. Therefore, Spurling's test, which take advantage of this phenomenon, is performed by extending and laterally flexing the patient's head and placing downward pressure on it to narrow the intervertebral foramen. Neck or shoulder pain on the ipsilateral side (i.e., the side to which the head is flexed) indicates a positive result for this test. A positive test result is not necessarily a positive result for spondylosis and as such additional testing is required.In cervical myelopathy, almost always involves both the upper and lower limbs. A person may experience difficult gait or limb stiffness in the early stages of the disease. Iliopsoas muscle is the first group of muscles that is affected. Lower limb weaknesses without any upper limb involvement should raise the suspicion of thoracic cord compression. Finger escape sign is performed to detect the weakness of the fingers. A person's forearm is pronated and the fingers are extended. If the person has myelopathy, there will be slow abduction and flexion of the fingers on the ulnar side. The degree of loss of sensation maybe different on both upper limbs. Lhermitte sign is performed by asking a person to gently extend the neck. Those with cervical myelopathy will produce a feeling of electrical shock down the spine or arms. Muscle spasticity, hyperreflexia or even clonus are characteristic of myelopathy. Other abnormal reflexes such as Hoffmann's reflex, upward response of plantar reflex (Babinski response), and Wartenberg's sign (abnormal abduction of little finger) can also be elicited.\n",
      "\n",
      "Since the spinal cord ends at L1 or L2 vertebral levels, the job of nerve transmission is continued by spinal nerves for the remaining part of the vertebral canal. Degenerative process of spondylosis such as disc bulging, osteophyte formation, and hypertrophy of the superior articular process all contributes to the narrowing of the spinal canal and intervertebral foramen, leading to compression of these spinal nerves that results in radiculopathy-related symptoms.Narrowing of the lumbar spinal canal causes a clinical condition known as neurogenic claudication, characterised by symptoms such as lower back pain, leg pain, leg numbness, and leg weakness that worsens with standing and walking and improves with sitting and lying down.\n",
      "\n",
      "A rare but severe complication of this disease is vertebrobasilar insufficiency. This is a result of the vertebral artery becoming occluded as it passes up in the transverse foramen. The spinal joints become stiff in cervical spondylosis. Thus the chondrocytes which maintain the disc become deprived of nutrition and die. Secondary osteophytes may cause stenosis for spinal nerves, manifesting as radiculopathy.\n",
      "\n",
      "Psoriasis vulgaris (also known as chronic stationary psoriasis or plaque-like psoriasis) is the most common form and affects 85–90% of people with psoriasis. Plaque psoriasis typically appears as raised areas of inflamed skin covered with silvery-white, scaly skin. These areas are called plaques and are most commonly found on the elbows, knees, scalp, and back.\n",
      "\n",
      "Additional types of psoriasis comprise about 10% of cases. They include pustular, inverse, napkin, guttate, oral, and seborrheic-like forms.\n",
      "\n",
      "Psoriatic arthritis is a form of chronic inflammatory arthritis that has a highly variable clinical presentation and frequently occurs in association with skin and nail psoriasis. It typically involves painful inflammation of the joints and surrounding connective tissue, and can occur in any joint, but most commonly affects the joints of the fingers and toes. This can result in a sausage-shaped swelling of the fingers and toes known as dactylitis. Psoriatic arthritis can also affect the hips, knees, spine (spondylitis), and sacroiliac joint (sacroiliitis). About 30% of individuals with psoriasis will develop psoriatic arthritis. Skin manifestations of psoriasis tend to occur before arthritic manifestations in about 75% of cases.\n",
      "\n",
      "Psoriasis can affect the nails and produces a variety of changes in the appearance of fingers and toenails. Nail psoriasis occurs in 40–45% of people with psoriasis affecting the skin, and has a lifetime incidence of 80–90% in those with psoriatic arthritis. These changes include pitting of the nails (pinhead-sized depressions in the nail is seen in 70% with nail psoriasis), whitening of the nail, small areas of bleeding from capillaries under the nail, yellow-reddish discoloration of the nails known as the oil drop or salmon spots, dryness, thickening of the skin under the nail (subungual hyperkeratosis), loosening and separation of the nail (onycholysis), and crumbling of the nail.\n",
      "\n",
      "In addition to the appearance and distribution of the rash, specific medical signs may be used by medical practitioners to assist with diagnosis. These may include Auspitz's sign (pinpoint bleeding when scale is removed), Koebner phenomenon (psoriatic skin lesions induced by trauma to the skin), and itching and pain localized to papules and plaques.\n",
      "\n",
      "This most common form of impetigo, also called nonbullous impetigo, most often begins as a red sore near the nose or mouth which soon breaks, leaking pus or fluid, and forms a honey-colored scab, followed by a red mark which often heals without leaving a scar. Sores are not painful, but they may be itchy. Lymph nodes in the affected area may be swollen, but fever is rare. Touching or scratching the sores may easily spread the infection to other parts of the body.Skin ulcers with redness and scarring also may result from scratching or abrading the skin.\n",
      "\n",
      "Bullous impetigo, mainly seen in children younger than 2 years, involves painless, fluid-filled blisters, mostly on the arms, legs, and trunk, surrounded by red and itchy (but not sore) skin. The blisters may be large or small. After they break, they form yellow scabs.\n",
      "\n",
      "Ecthyma, the nonbullous form of impetigo, produces painful fluid- or pus-filled sores with redness of skin, usually on the arms and legs, become ulcers that penetrate deeper into the dermis. After they break open, they form hard, thick, gray-yellow scabs, which sometimes leave scars. Ecthyma may be accompanied by swollen lymph nodes in the affected area.\n",
      "\n",
      "The most common symptoms of GERD in adults are an acidic taste in the mouth, regurgitation, and heartburn. Less common symptoms include pain with swallowing/sore throat, increased salivation (also known as water brash), nausea, chest pain, coughing, and globus sensation. The acid reflux can induce asthma attack symptoms like shortness of breath, cough, and wheezing in those with underlying asthma.GERD sometimes causes injury to the esophagus. These injuries may include one or more of the following:\n",
      "\n",
      "Reflux esophagitis – inflammation of esophageal epithelium which can cause ulcers near the junction of the stomach and esophagus\n",
      "Esophageal strictures – the persistent narrowing of the esophagus caused by reflux-induced inflammation\n",
      "Barrett's esophagus – intestinal metaplasia (changes of the epithelial cells from squamous to intestinal columnar epithelium) of the distal esophagus\n",
      "Esophageal adenocarcinoma – a form of cancerGERD sometimes causes injury of the larynx (LPR). Other complications can include aspiration pneumonia.\n",
      "\n",
      "GERD may be difficult to detect in infants and children since they cannot describe what they are feeling and indicators must be observed. Symptoms may vary from typical adult symptoms. GERD in children may cause repeated vomiting, effortless spitting up, coughing, and other respiratory problems, such as wheezing. Inconsolable crying, refusing food, crying for food and then pulling off the bottle or breast only to cry for it again, failure to gain adequate weight, bad breath, and burping are also common. Children may have one symptom or many; no single symptom is universal in all children with GERD.\n",
      "Of the estimated 4 million babies born in the US each year, up to 35% of them may have difficulties with reflux in the first few months of their lives, known as 'spitting up'. About 90% of infants will outgrow their reflux by their first birthday.\n",
      "\n",
      "Acid reflux into the mouth can cause breakdown of the enamel, especially on the inside surface of the teeth. A dry mouth, acid or burning sensation in the mouth, bad breath and redness of the palate may occur. Less common symptoms of GERD include difficulty in swallowing, water brash, chronic cough, hoarse voice, nausea and vomiting.Signs of enamel erosion are the appearance of a smooth, silky-glazed, sometimes dull, enamel surface with the absence of perikymata, together with intact enamel along the gum margin. It will be evident in people with restorations as tooth structure typically dissolves much faster than the restorative material, causing it to seem as if it \"stands above\" the surrounding tooth structure.\n",
      "\n",
      "GERD may lead to Barrett's esophagus, a type of intestinal metaplasia, which is in turn a precursor condition for esophageal cancer. The risk of progression from Barrett's to dysplasia is uncertain, but is estimated at 20% of cases. Due to the risk of chronic heartburn progressing to Barrett's, EGD every five years is recommended for people with chronic heartburn, or who take drugs for chronic GERD.\n"
     ]
    }
   ],
   "source": [
    "symptomsLi = []\n",
    "for disease in dl:\n",
    "    symptomsLi.append(get_wiki_content_api(disease, 'symptom'))"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-26T13:48:36.061282300Z",
     "start_time": "2023-09-26T13:48:12.111446Z"
    }
   },
   "id": "e1a6f03a77e02f69"
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "outputs": [],
   "source": [
    "treatmentLi = []\n",
    "for disease in dl:\n",
    "    treatmentLi.append(get_wiki_content_api(disease, 'treatment'))"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-26T13:55:39.814570600Z",
     "start_time": "2023-09-26T13:55:09.537682900Z"
    }
   },
   "id": "81cca9e029ad2749"
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "outputs": [
    {
     "data": {
      "text/plain": "36"
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(treatmentLi)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-26T13:55:39.835954200Z",
     "start_time": "2023-09-26T13:55:39.821717900Z"
    }
   },
   "id": "2065ace9d476735c"
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "outputs": [],
   "source": [
    "json_list = []\n",
    "\n",
    "for i in range(36):\n",
    "    disease = dl[i]\n",
    "    \n",
    "    about = aboutLi[i]\n",
    "    precaution = precautionLi[i]\n",
    "    symptoms = symptomsLi[i]\n",
    "    treatment = treatmentLi[i]\n",
    "    \n",
    "    json_list.append({\"name\": [disease], \"about\": [about], \"precaution\": [precaution], \"symptoms\": [symptoms], \"treatments\": [treatment]})"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-26T13:56:24.166661900Z",
     "start_time": "2023-09-26T13:56:24.152151700Z"
    }
   },
   "id": "d9d22d7e1304ac71"
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "outputs": [
    {
     "data": {
      "text/plain": "[{'name': ['Fungal infection'],\n  'about': ['Fungal infection, also known as mycosis, is a disease caused by fungi. Different types are traditionally divided according to the part of the body affected; superficial, subcutaneous, and systemic. Superficial fungal infections include common tinea of the skin, such as tinea of the body, groin, hands, feet and beard, and yeast infections such as pityriasis versicolor. Subcutaneous types include eumycetoma and chromoblastomycosis, which generally affect tissues in and beneath the skin. Systemic fungal infections are more serious and include cryptococcosis, histoplasmosis, pneumocystis pneumonia, aspergillosis and mucormycosis.'],\n  'precaution': ['Keeping the skin clean and dry, as well as maintaining good hygiene, will help larger topical mycoses. Because some fungal infections are contagious, it is important to wash hands after touching other people or animals. Sports clothing should also be washed after use.'],\n  'symptoms': ['Most common mild mycoses often present with a rash. Infections within the skin or under the skin may present with a lump and skin changes. Less common deeper fungal infections may present with pneumonia like symptoms or meningitis.'],\n  'treatments': ['Treatment depends on the type of fungal infection, and usually requires topical or systemic antifungal medicines. Pneumocystosis that does not respond to anti-fungals is treated with co-trimoxazole. Sometimes, infected tissue needs to be surgically cut away.']},\n {'name': ['Chronic cholestasis'],\n  'about': ['Cholestasis is a condition where bile cannot flow from the liver to the duodenum. The two basic distinctions are an obstructive type of cholestasis where there is a mechanical blockage in the duct system that can occur from a gallstone or malignancy, and metabolic types of cholestasis which are disturbances in bile formation that can occur because of genetic defects or acquired as a side effect of many medications. Classification is further divided into acute or chronic and extrahepatic or intrahepatic..'],\n  'precaution': [None],\n  'symptoms': ['The signs and symptoms of cholestasis vary according to the cause. In case of sudden onset, the disease is likely to be acute, while the gradual appearance of symptoms suggests chronic pathology. In many cases, patients may experience pain in the abdominal area. Localization of pain to the upper right quadrant can be indicative of cholecystitis or choledocholithiasis, which can progress to cholestasis.Pruritus or itching is often present in many patients with cholestasis. Patients may present with visible scratch marks as a result of scratching. Pruritus is often misdiagnosed as a dermatological condition, especially in patients that do not have jaundice as an accompanying symptom. In a typical day, pruritus worsens as the day progresses, particularly during the evening time. Overnight, pruritus dramatically improves. This cycle can be attributed to an increase in the concentration of biliary elements during the day due to food consumption, and a decline at night. Pruritus is mostly localized to the limbs, but can also be more generalized.  The efficacy of naltrexone for cholestatic pruritus suggests involvement of the endogenous opioid system.\\nMany patients may experience jaundice as a result of cholestasis. This is usually evident after physical examination as yellow pigment deposits on the skin, in the oral mucosa, or conjunctiva. Jaundice is an uncommon occurrence in intrahepatic (metabolic) cholestasis, but is common in obstructive cholestasis. The majority of patients with chronic cholestasis also experience fatigue. This is likely a result of defects in the corticotrophin hormone axis or other abnormalities with neurotransmission. Some patients may also have xanthomas, which are fat deposits that accumulate below the skin. These usually appear waxy and yellow, predominantly around the eyes and joints. This condition results from an accumulation of lipids within the blood. If gallstones prevent bile flowing from the pancreas to the small intestine, it can lead to gallstone pancreatitis. Physical symptoms include nausea, vomiting, and abdominal pain.\\nBile is required for the absorption of fat-soluble vitamins. As such, patients with cholestasis may present with a deficiency in vitamins A, D, E, or K due to a decline in bile flow. Patients with cholestasis may also experience pale stool and dark urine.'],\n  'treatments': [\"In cases involving obstructive cholestasis, the primary treatment includes biliary decompression. If bile stones are present in the common bile duct, an endoscopic sphincterotomy can be conducted either with or without placing a stent. To do this, a duodenoscope is placed by the endoscopist in the second portion of the duodenum. A catheter and guidewire is moved up into the common bile duct. A sphincterotome can then enlarge the ampulla of Vater and release the stones. Later, the endoscopist can place a stent in the common bile duct to soften any remaining stones and allow for bile drainage. If needed, a balloon catheter is available to remove any leftover stones. If these stones are too large with these methods, surgical removal may be needed. Patients can also request an elective cholecystectomy to prevent future cases of choledocholithiasis. In case of narrowing of the common bile duct, a stent can be placed after dilating the constriction to resolve the obstruction.The treatment approach for patients with obstructive cholestasis resulting from cancer varies based on whether they are a suitable candidate for surgery. In most cases, surgical intervention is the best option. For patients whom complete removal of the biliary obstruction is not possible, a combination of a gastric bypass and hepaticojejunostomy can be used. This can reestablish bile flow into the small intestine, thereby bypassing the blockage. In cases where a patient is not a suitable candidate for surgery, an endoscopic stent can be placed. If this is not possible or successful, a percutaneous transhepatic cholangiogram and percutaneous biliary drainage can be used to visualize the blockage and re-establish bile flow.\\n\\nA significant portion of patients with cholestasis (80%) will experience pruritus at some point during their disease. This is a condition that can severely decrease a patient's quality of life as it can impact sleep, concentration, work ability, and mood. Many treatments exist, but how effective each option is depends on the patient and their condition. Assessment using a scale, such as a visual analogue scale or a 5-D itch scale will be useful to identify an appropriate treatment. Possible treatment options include antihistamines, ursodeoxycholic acid, and phenobarbital. Nalfurafine hydrochloride can also be used to treat pruritus caused by chronic liver disease and was recently approved in Japan for this purpose.Bile acid binding resins like cholestyramine are the most common treatment. Side effects of this treatment are limited and include constipation and bloating. Other commonly used treatments include rifampin, naloxone, and sertraline.\\nIn cholestatic liver disease, when bilirubin concentration starts to build up, a deficiency of fat soluble vitamins may also occur. To manage this, doses of vitamin A, D, E, and K are recommended to retain appropriate vitamin levels.\\nCholestatic liver disease can impact lipids, and possibly lead to dyslipidemia, which may present a risk for coronary artery disease. Statins and fibrates are generally used as lipid lowering therapy to treat patients with cholestatic liver disease.\\nFor intrahepatic cholestasis in pregnant women, S-adenosylmethionine has proven to be an effective treatment. Dexamethasone is a viable treatment in regards to the symptom of intensive itching.\\n\\n\"]},\n {'name': ['Drug Reaction'],\n  'about': ['An adverse drug reaction (ADR) is a harmful, unintended result caused by taking medication.:\\u200a1.1 Adverse Drug Reaction (ADR)\\u200a ADRs may occur following a single dose or prolonged administration of a drug or may result from the combination of two or more drugs. The meaning of this term differs from the term \"side effect\" because side effects can be beneficial as well as detrimental. The study of ADRs is the concern of the field known as pharmacovigilance. An adverse event (AE) refers to any unexpected and inappropriate occurrence at the time a drug is used, whether or not the event is associated with the administration of the drug.:\\u200a1.2 Adverse Event (AE)\\u200a An ADR is a special type of AE in which a causative relationship can be shown. ADRs are only one type of medication-related harm.'],\n  'precaution': [None],\n  'symptoms': [None],\n  'treatments': [None]},\n {'name': ['Peptic ulcer disease'],\n  'about': ['Peptic ulcer disease (PUD) is a break in the inner lining of the stomach, the first part of the small intestine, or sometimes the lower esophagus. An ulcer in the stomach is called a gastric ulcer, while one in the first part of the intestines is a duodenal ulcer. The most common symptoms of a duodenal ulcer are waking at night with upper abdominal pain, and upper abdominal pain that improves with eating. With a gastric ulcer, the pain may worsen with eating. The pain is often described as a burning or dull ache.'],\n  'precaution': ['Prevention of peptic ulcer disease for those who are taking NSAIDs (with low cardiovascular risk) can be achieved by adding a proton pump inhibitor (PPI), an H2 antagonist, or misoprostol. NSAIDs of the COX-2 inhibitors type may reduce the rate of ulcers when compared to non-selective NSAIDs. PPI is the most popular agent in peptic ulcer prevention. However, there is no evidence that H2 antagonists can prevent stomach bleeding for those taking NSAIDs. Although misoprostol is effective in preventing peptic ulcer, its properties of promoting abortion and causing gastrointestinal distress limit its use. For those with high cardiovascular risk, naproxen with PPI can be a useful choice. Otherwise, low-dose aspirin, celecoxib, and PPI can also be used.'],\n  'symptoms': [\"Signs and symptoms of a peptic ulcer can include one or more of the following:\\nabdominal pain, classically epigastric, strongly correlated with mealtimes. In case of duodenal ulcers, the pain appears about three hours after taking a meal and wakes the person from sleep;\\nbloating and abdominal fullness;\\nwaterbrash (a rush of saliva after an episode of regurgitation to dilute the acid in esophagus, although this is more associated with gastroesophageal reflux disease);\\nnausea and copious vomiting;\\nloss of appetite and weight loss, in gastric ulcer;\\nweight gain, in duodenal ulcer, as the pain is relieved by eating;\\nhematemesis (vomiting of blood); this can occur due to bleeding directly from a gastric ulcer or from damage to the esophagus from severe/continuing vomiting.\\nmelena (tarry, foul-smelling feces due to presence of oxidized iron from hemoglobin);\\nrarely, an ulcer can lead to a gastric or duodenal perforation, which leads to acute peritonitis and extreme, stabbing pain, and requires immediate surgery.A history of heartburn or gastroesophageal reflux disease (GERD) and use of certain medications can raise the suspicion for peptic ulcer. Medicines associated with peptic ulcer include NSAIDs (non-steroid anti-inflammatory drugs) that inhibit cyclooxygenase and most glucocorticoids (e.g., dexamethasone and prednisolone).In people over the age of 45 with more than two weeks of the above symptoms, the odds for peptic ulceration are high enough to warrant rapid investigation by esophagogastroduodenoscopy.The timing of symptoms in relation to the meal may differentiate between gastric and duodenal ulcers. A gastric ulcer would give epigastric pain during the meal, associated with nausea and vomiting, as gastric acid production is increased as food enters the stomach. Pain in duodenal ulcers would be aggravated by hunger and relieved by a meal and is associated with night pain.Also, the symptoms of peptic ulcers may vary with the location of the ulcer and the person's age. Furthermore, typical ulcers tend to heal and recur, and as a result the pain may occur for few days and weeks and then wane or disappear. Usually, children and the elderly do not develop any symptoms unless complications have arisen.\\nA burning or gnawing feeling in the stomach area lasting between 30 minutes and 3 hours commonly accompanies ulcers. This pain can be misinterpreted as hunger, indigestion, or heartburn. Pain is usually caused by the ulcer, but it may be aggravated by the stomach acid when it comes into contact with the ulcerated area. The pain caused by peptic ulcers can be felt anywhere from the navel up to the sternum, it may last from few minutes to several hours, and it may be worse when the stomach is empty. Also, sometimes the pain may flare at night, and it can commonly be temporarily relieved by eating foods that buffer stomach acid or by taking anti-acid medication. However, peptic ulcer disease symptoms may be different for everyone.\"],\n  'treatments': ['Once the diagnosis of H. pylori is confirmed, the first-line treatment would be a triple regimen in which pantoprazole and clarithromycin are combined with either amoxicillin or metronidazole. This treatment regimen can be given for 7–14 days. However, its effectiveness in eradicating H. pylori has been reducing from 90% to 70%. However, the rate of eradication can be increased by doubling the dosage of pantoprazole or increasing the duration of treatment to 14 days. Quadruple therapy (pantoprazole, clarithromycin, amoxicillin, and metronidazole) can also be used. The quadruple therapy can achieve an eradication rate of 90%. If the clarithromycin resistance rate is higher than 15% in an area, the usage of clarithromycin should be abandoned. Instead, bismuth-containing quadruple therapy can be used (pantoprazole, bismuth citrate, tetracycline, and metronidazole) for 14 days. The bismuth therapy can also achieve an eradication rate of 90% and can be used as second-line therapy when the first-line triple-regimen therapy has failed\\n\\nNSAID-associated ulcers heal in 6 to 8 weeks provided the NSAIDs are withdrawn with the introduction of proton pump inhibitors (PPI).\\n\\nFor those with bleeding peptic ulcers, fluid replacement with crystalloids is sometimes given to maintain volume in the blood vessels. Maintaining haemoglobin at greater than 7 g/dL (70 g/L) through restrictive blood transfusion has been associated with reduced rate of death. Glasgow-Blatchford score is used to determine whether a person should be treated inside a hospital or as an outpatient. Intravenous PPIs can suppress stomach bleeding more quickly than oral ones. A neutral stomach pH is required to keep platelets in place and prevent clot lysis. Tranexamic acid and antifibrinolytic agents are not useful in treating peptic ulcer disease.Early endoscopic therapy can help to stop bleeding by using cautery, endoclip, or epinephrine injection. Treatment is indicated if there is active bleeding in the stomach, visible vessels, or an adherent clot. Endoscopy is also helpful in identifying people who are suitable for hospital discharge. Prokinetic agents such as erythromycin and metoclopramide can be given before endoscopy to improve endoscopic view. Either high- or low-dose PPIs are equally effective in reducing bleeding after endoscopy. High-dose intravenous PPI is defined as a bolus dose of 80 mg followed by an infusion of 8 mg per hour for 72 hours—in other words, the continuous infusion of PPI of greater than 192 mg per day. Intravenous PPI can be changed to oral once there is no high risk of rebleeding from peptic ulcer.For those with hypovolemic shock and ulcer size of greater than 2 cm, there is a high chance that the endoscopic treatment would fail. Therefore, surgery and angiographic embolism are reserved for these complicated cases. However, there is a higher rate of complication for those who underwent surgery to patch the stomach bleeding site when compared to repeated endoscopy. Angiographic embolisation has a higher rebleeding rate but a similar rate of death to surgery.\\n\\nAccording to expert opinion, for those who are already on anticoagulants, the international normalized ratio (INR) should be kept at 1.5. For aspirin users who required endoscopic treatment for bleeding peptic ulcer, there is two times increased risk of rebleeding but with 10 times reduced risk of death at 8 weeks following the resumption of aspirin. For those who were on double antiplatelet agents for indwelling stent in blood vessels, both antiplatelet agents should not be stopped because there is a high risk of stent thrombosis. For those who were under warfarin treatment, fresh frozen plasma (FFP), vitamin K, prothrombin complex concentrates, or recombinant factor VIIa can be given to reverse the effect of warfarin. High doses of vitamin K should be avoided to reduce the time for rewarfarinisation once the stomach bleeding has stopped. Prothrombin complex concentrates are preferred for severe bleeding. Recombinant factor VIIa is reserved for life-threatening bleeding because of its high risk of thromboembolism. Direct oral anticoagulants (DOAC) are recommended instead of warfarin as they are more effective in preventing thromboembolism. In case of bleeding caused by DOAC, activated charcoal within 4 hours is the antidote of choice.\\n\\n']},\n {'name': ['AIDS'],\n  'about': ['Infection with HIV (Human Immunodeficiency Virus), a retrovirus, can be managed with treatment but  without treatment can lead to a spectrum of conditions including AIDS (Acquired ImmunoDeficiency Syndrome).Effective treatment for HIV-positive people (people living with HIV) involves a life-long regimen of medicine to suppress the virus, making the viral load undetectable.  There is not yet a vaccine nor a cure.  An HIV-positive person on treatment can expect to live a normal life, and die with the virus, not of it. An HIV-positive person who has an undetectable viral load as a result of long-term treatment has effectively no risk of transmitting HIV sexually.Without treatment the infection can interfere with the immune system, and eventually progress to AIDS, sometimes taking many years.  Following initial infection an individual may not notice any symptoms, or may experience a brief period of influenza-like illness.'],\n  'precaution': ['Consistent condom use reduces the risk of HIV transmission by approximately 80% over the long term. When condoms are used consistently by a couple in which one person is infected, the rate of HIV infection is less than 1% per year. There is some evidence to suggest that female condoms may provide an equivalent level of protection. Application of a vaginal gel containing tenofovir (a reverse transcriptase inhibitor) immediately before sex seems to reduce infection rates by approximately 40% among African women. By contrast, use of the spermicide nonoxynol-9 may increase the risk of transmission due to its tendency to cause vaginal and rectal irritation.Circumcision in sub-Saharan Africa \"reduces the acquisition of HIV by heterosexual men by between 38% and 66% over 24 months\". Owing to these studies, both the World Health Organization and UNAIDS recommended male circumcision in 2007 as a method of preventing female-to-male HIV transmission in areas with high rates of HIV. However, whether it protects against male-to-female transmission is disputed, and whether it is of benefit in developed countries and among men who have sex with men is undetermined.Programs encouraging sexual abstinence do not appear to affect subsequent HIV risk. Evidence of any benefit from peer education is equally poor. Comprehensive sexual education provided at school may decrease high-risk behavior. A substantial minority of young people continues to engage in high-risk practices despite knowing about HIV/AIDS, underestimating their own risk of becoming infected with HIV. Voluntary counseling and testing people for HIV does not affect risky behavior in those who test negative but does increase condom use in those who test positive. Enhanced family planning services appear to increase the likelihood of women with HIV using contraception, compared to basic services. It is not known whether treating other sexually transmitted infections is effective in preventing HIV.\\n\\nAntiretroviral treatment among people with HIV whose CD4 count ≤ 550 cells/µL is a very effective way to prevent HIV infection of their partner (a strategy known as treatment as prevention, or TASP). TASP is associated with a 10- to 20-fold reduction in transmission risk. Pre-exposure prophylaxis (PrEP) with a daily dose of the medications tenofovir, with or without emtricitabine, is effective in people at high risk including men who have sex with men, couples where one is HIV-positive, and young heterosexuals in Africa. It may also be effective in intravenous drug users, with a study finding a decrease in risk of 0.7 to 0.4 per 100 person years. The USPSTF, in 2019, recommended PrEP in those who are at high risk.Universal precautions within the health care environment are believed to be effective in decreasing the risk of HIV. Intravenous drug use is an important risk factor, and harm reduction strategies such as needle-exchange programs and opioid substitution therapy appear effective in decreasing this risk.\\n\\nA course of antiretrovirals administered within 48 to 72 hours after exposure to HIV-positive blood or genital secretions is referred to as post-exposure prophylaxis (PEP). The use of the single agent zidovudine reduces the risk of an HIV infection five-fold following a needle-stick injury. As of 2013, the prevention regimen recommended in the United States consists of three medications—tenofovir, emtricitabine and raltegravir—as this may reduce the risk further.PEP treatment is recommended after a sexual assault when the perpetrator is known to be HIV-positive, but is controversial when their HIV status is unknown. The duration of treatment is usually four weeks and is frequently associated with adverse effects—where zidovudine is used, about 70% of cases result in adverse effects such as nausea (24%), fatigue (22%), emotional distress (13%) and headaches (9%).\\n\\nPrograms to prevent the vertical transmission of HIV (from mothers to children) can reduce rates of transmission by 92–99%. This primarily involves the use of a combination of antiviral medications during pregnancy and after birth in the infant, and potentially includes bottle feeding rather than breastfeeding. If replacement feeding is acceptable, feasible, affordable, sustainable and safe, mothers should avoid breastfeeding their infants; however, exclusive breastfeeding is recommended during the first months of life if this is not the case. If exclusive breastfeeding is carried out, the provision of extended antiretroviral prophylaxis to the infant decreases the risk of transmission. In 2015, Cuba became the first country in the world to eradicate mother-to-child transmission of HIV.\\n\\nCurrently there is no licensed vaccine for HIV or AIDS. The most effective vaccine trial to date, RV 144, was published in 2009; it found a partial reduction in the risk of transmission of roughly 30%, stimulating some hope in the research community of developing a truly effective vaccine.\\n\\n'],\n  'symptoms': ['There are three main stages of HIV infection: acute infection, clinical latency, and AIDS.'],\n  'treatments': ['There is currently no cure, nor an effective HIV vaccine. Treatment consists of highly active antiretroviral therapy (HAART), which slows progression of the disease. As of 2010, more than 6.6 million people were receiving HAART in low- and middle-income countries. Treatment also includes preventive and active treatment of opportunistic infections. As of July 2022, four people have been successfully cleared of HIV. Rapid initiation of antiretroviral therapy within one week of diagnosis appear to improve treatment outcomes in low and medium-income settings and is recommend for newly diagnosed HIV patients.']},\n {'name': ['Diabetes '],\n  'about': [\"Diabetes mellitus, often known simply as diabetes, is a group of common endocrine diseases characterized by sustained high blood sugar levels. Diabetes is due to either the pancreas not producing enough insulin, or the cells of the body becoming unresponsive to the hormone's effects. Classic symptoms include thirst, polyuria, weight loss, and blurred vision. If left untreated, the disease can lead to various health complications, including disorders of the cardiovascular system, eye, kidney, and nerves. Untreated or poorly treated diabetes accounts for approximately 1.5 million deaths every year.The major types of diabetes are type 1 and type 2, though other forms also exist.\"],\n  'precaution': ['There is no known preventive measure for type 1 diabetes. However, islet autoimmunity and multiple antibodies can be a strong predictor of the onset of type 1 diabetes.  Type 2 diabetes—which accounts for 85–90% of all cases worldwide—can often be prevented or delayed by maintaining a normal body weight, engaging in physical activity, and eating a healthy diet. Higher levels of physical activity (more than 90 minutes per day) reduce the risk of diabetes by 28%. Dietary changes known to be effective in helping to prevent diabetes include maintaining a diet rich in whole grains and fiber, and choosing good fats, such as the polyunsaturated fats found in nuts, vegetable oils, and fish. Limiting sugary beverages and eating less red meat and other sources of saturated fat can also help prevent diabetes. Tobacco smoking is also associated with an increased risk of diabetes and its complications, so smoking cessation can be an important preventive measure as well.The relationship between type 2 diabetes and the main modifiable risk factors (excess weight, unhealthy diet, physical inactivity and tobacco use) is similar in all regions of the world. There is growing evidence that the underlying determinants of diabetes are a reflection of the major forces driving social, economic and cultural change: globalization, urbanization, population aging, and the general health policy environment.'],\n  'symptoms': ['The classic symptoms of untreated diabetes are polyuria, thirst, and weight loss. Several other non-specific signs and symptoms may also occur, including fatigue, blurred vision, and genital itchiness due to Candida infection. About half of affected individuals may also be asymptomatic. Type 1 presents abruptly following a pre-clinical phase, while type 2 has a more insidious onset; patients may remain asymptomatic for many years.Diabetic ketoacidosis is a medical emergency that occurs most commonly in type 1, but may also occur in type 2 if it has been longstanding or if the individual has significant β-cell dysfunction. Excessive production of ketone bodies leads to signs and symptoms including nausea, vomiting, abdominal pain, the smell of acetone in the breath, deep breathing known as Kussmaul breathing, and in severe cases decreased level of consciousness. Hyperosmolar hyperglycemic state is another emergency characterised by dehydration secondary to severe hyperglycaemia, with resultant hypernatremia leading to an altered mental state and possibly coma.Hypoglycaemia is a recognised complication of insulin treatment used in diabetes. An acute presentation can include mild symptoms such as sweating, trembling, and palpitations, to more serious effects including impaired cognition, confusion, seizures, coma, and rarely death. Recurrent hypoglycaemic episodes may lower the glycaemic threshold at which symptoms occur, meaning mild symptoms may not appear before cognitive deterioration begins to occur.'],\n  'treatments': ['Diabetes management concentrates on keeping blood sugar levels close to normal, without causing low blood sugar. This can usually be accomplished with dietary changes, exercise, weight loss, and use of appropriate medications (insulin, oral medications).Learning about the disease and actively participating in the treatment is important, since complications are far less common and less severe in people who have well-managed blood sugar levels. The goal of treatment is an A1C level below 7%. Attention is also paid to other health problems that may accelerate the negative effects of diabetes. These include smoking, high blood pressure, metabolic syndrome obesity, and lack of regular exercise. Specialized footwear is widely used to reduce the risk of diabetic foot ulcers by relieving the pressure on the foot. Foot examination for patients living with diabetes should be done annually which includes sensation testing, foot biomechanics, vascular integrity and foot structure.Concerning those with severe mental illness, the efficacy of type 2 diabetes self-management interventions is still poorly explored, with insufficient scientific evidence to show whether these interventions have similar results to those observed in the general population.']},\n {'name': ['Gastroenteritis'],\n  'about': ['Gastroenteritis, also known as infectious diarrhea or simply as gastro, is an inflammation of the gastrointestinal tract including the stomach and intestine. Symptoms may include diarrhea, vomiting, and abdominal pain. Fever, lack of energy, and dehydration may also occur. This typically lasts less than two weeks. Although it is not related to influenza, in the U.S.'],\n  'precaution': ['A supply of easily accessible uncontaminated water and good sanitation practices are important for reducing rates of infection and clinically significant gastroenteritis. Personal hygiene measures (such as hand washing with soap) have been found to decrease rates of gastroenteritis in both the developing and developed world by as much as 30%. Alcohol-based gels may also be effective. Food or drink that is thought to be contaminated should be avoided.Breastfeeding is important, especially in places with poor hygiene, as is improvement of hygiene generally. Breast milk reduces both the frequency of infections and their duration.\\n\\nDue to both its effectiveness and safety, in 2009 the World Health Organization recommended that the rotavirus vaccine be offered to all children globally. Two commercial rotavirus vaccines exist and several more are in development. In Africa and Asia these vaccines reduced severe disease among infants and countries that have put in place national immunization programs have seen a decline in the rates and severity of disease. This vaccine may also prevent illness in non-vaccinated children by reducing the number of circulating infections. Since 2000, the implementation of a rotavirus vaccination program in the United States has substantially decreased the number of cases of diarrhea by as much as 80 percent. The first dose of vaccine should be given to infants between 6 and 15 weeks of age. The oral cholera vaccine has been found to be 50–60% effective over two years.There are a number of vaccines against gastroenteritis in development. For example, vaccines against Shigella and enterotoxigenic Escherichia coli (ETEC), which are two of the leading bacterial causes of gastroenteritis worldwide.\\n\\n'],\n  'symptoms': ['Gastroenteritis usually involves both diarrhea and vomiting. Sometimes, only one or the other is present. This may be accompanied by abdominal cramps. Signs and symptoms usually begin 12–72 hours after contracting the infectious agent. If due to a virus, the condition usually resolves within one week. Some viral infections also involve fever, fatigue, headache and muscle pain. If the stool is bloody, the cause is less likely to be viral and more likely to be bacterial. Some bacterial infections cause severe abdominal pain and may persist for several weeks.Children infected with rotavirus usually make a full recovery within three to eight days. However, in poor countries treatment for severe infections is often out of reach and persistent diarrhea is common.  Dehydration is a common complication of diarrhea. Severe dehydration in children may be recognized if the skin color and position returns slowly when pressed. This is called \"prolonged capillary refill\" and \"poor skin turgor\". Abnormal breathing is another sign of severe dehydration. Repeat infections are typically seen in areas with poor sanitation, and malnutrition. Stunted growth and long-term cognitive delays can result.Reactive arthritis occurs in 1% of people following infections with Campylobacter species. Guillain–Barré syndrome occurs in 0.1%. Hemolytic uremic syndrome (HUS) may occur due to infection with Shiga toxin-producing Escherichia coli or Shigella species. HUS causes low platelet counts, poor kidney function, and low red blood cell count (due to their breakdown). Children are more predisposed to getting HUS than adults. Some viral infections may produce benign infantile seizures.'],\n  'treatments': ['Gastroenteritis is usually an acute and self-limiting disease that does not require medication. The preferred treatment in those with mild to moderate dehydration is oral rehydration therapy (ORT). For children at risk of dehydration from vomiting, taking a single dose of the anti vomiting medication metoclopramide or ondansetron, may be helpful, and butylscopolamine is useful in treating abdominal pain.']},\n {'name': ['Bronchial Asthma'],\n  'about': ['Asthma is a long-term inflammatory disease of the airways of the lungs. It is characterized by variable and recurring symptoms, reversible airflow obstruction, and easily triggered bronchospasms. Symptoms include episodes of wheezing, coughing, chest tightness, and shortness of breath. These may occur a few times a day or a few times per week. Depending on the person, asthma symptoms may become worse at night or with exercise.Asthma is thought to be caused by a combination of genetic and environmental factors.'],\n  'precaution': ['The evidence for the effectiveness of measures to prevent the development of asthma is weak. The World Health Organization recommends decreasing risk factors such as tobacco smoke, air pollution, chemical irritants including perfume, and the number of lower respiratory infections. Other efforts that show promise include: limiting smoke exposure in utero, breastfeeding, and increased exposure to daycare or large families, but none are well supported enough to be recommended for this indication.Early pet exposure may be useful. Results from exposure to pets at other times are inconclusive and it is only recommended that pets be removed from the home if a person has allergic symptoms to said pet.Dietary restrictions during pregnancy or when breast feeding have not been found to be effective at preventing asthma in children and are not recommended. Omega-3 consumption, mediterranean diet and anti-oxidants have been suggested by some studies that might help preventing crisis but the evidence is still inconclusive.Reducing or eliminating compounds known to sensitive people from the work place may be effective. It is not clear if annual influenza vaccinations affects the risk of exacerbations. Immunization, however, is recommended by the World Health Organization. Smoking bans are effective in decreasing exacerbations of asthma.'],\n  'symptoms': ['Asthma is characterized by recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing. Sputum may be produced from the lung by coughing but is often hard to bring up. During recovery from an asthma attack (exacerbation), it may appear pus-like due to high levels of white blood cells called eosinophils. Symptoms are usually worse at night and in the early morning or in response to exercise or cold air. Some people with asthma rarely experience symptoms, usually in response to triggers, whereas others may react frequently and readily and experience persistent symptoms.'],\n  'treatments': ['While there is no cure for asthma, symptoms can typically be improved. The most effective treatment for asthma is identifying triggers, such as cigarette smoke, pets or other allergens, and eliminating exposure to them. If trigger avoidance is insufficient, the use of medication is recommended. Pharmaceutical drugs are selected based on, among other things, the severity of illness and the frequency of symptoms. Specific medications for asthma are broadly classified into fast-acting and long-acting categories. The medications listed below have demonstrated efficacy in improving asthma symptoms, however \"real world\" use-effectiveness is limited as around half of people with asthma worldwide remain sub-optimally controlled, even when treated. People with asthma may remain sub-optimally controlled either because optimum doses of asthma medications do not work (called \"refractory\" asthma) or because individuals are either unable (e.g. inability to afford treatment, poor inhaler technique) or unwilling (e.g., wish to avoid side effects of corticosteroids) to take optimum doses of prescribed asthma medications (called \"difficult to treat\" asthma). In practice, it is not possible to distinguish \"refractory\" from \"difficult to treat\" categories for patients who have never taken optimum doses of asthma medications. A related issue is that the asthma efficacy trials upon which the pharmacological treatment guidelines are based have systematically excluded the majority of people with asthma. For example, asthma efficacy treatment trials always exclude otherwise eligible people who smoke, and smoking blunts the efficacy of inhaled corticosteroids, the mainstay of asthma control management.Bronchodilators are recommended for short-term relief of symptoms. In those with occasional attacks, no other medication is needed. If mild persistent disease is present (more than two attacks a week), low-dose inhaled corticosteroids or alternatively, a leukotriene antagonist or a mast cell stabilizer by mouth is recommended. For those who have daily attacks, a higher dose of inhaled corticosteroids is used. In a moderate or severe exacerbation, corticosteroids by mouth are added to these treatments.People with asthma have higher rates of anxiety, psychological stress, and depression. This is associated with poorer asthma control. Cognitive behavioral therapy may improve quality of life, asthma control, and anxiety levels in people with asthma.Improving people\\'s knowledge about asthma and using a written action plan has been identified as an important component of managing asthma. Providing educational sessions that include information specific to a person\\'s culture is likely effective. More research is necessary to determine if increasing preparedness and knowledge of asthma among school staff and families using home-based and school interventions results in long term improvements in safety for children with asthma. School-based asthma self-management interventions, which attempt to improve knowledge of asthma, its triggers and the importance of regular practitioner review, may reduce hospital admissions and emergency department visits. These interventions may also reduce the number of days children experience asthma symptoms and may lead to small improvements in asthma-related quality of life. More research is necessary to determine if shared-decision-making is helpful for managing adults with asthma or if a personalized asthma action plan is effective and necessary. Some people with asthma use pulse oximeters to monitor their own blood oxygen levels during an asthma attack. However, there is no evidence regarding the use in these instances.']},\n {'name': ['Hypertension '],\n  'about': ['Hypertension, also known as high blood pressure, is a long-term medical condition in which the blood pressure in the arteries is persistently elevated. High blood pressure usually does not cause symptoms. It is, however, a major risk factor for stroke, coronary artery disease, heart failure, atrial fibrillation, peripheral arterial disease, vision loss, chronic kidney disease, and dementia. Hypertension is a major cause of premature death worldwide.High blood pressure is classified as primary (essential) hypertension or secondary hypertension. About 90–95% of cases are primary, defined as high blood pressure due to nonspecific lifestyle and genetic factors.'],\n  'precaution': ['Much of the disease burden of high blood pressure is experienced by people who are not labeled as hypertensive. Consequently, population strategies are required to reduce the consequences of high blood pressure and reduce the need for antihypertensive medications. Lifestyle changes are recommended to lower blood pressure, before starting medications. The 2004 British Hypertension Society guidelines proposed lifestyle changes consistent with those outlined by the US National High BP Education Program in 2002 for the primary prevention of hypertension:\\n\\nmaintain normal body weight for adults (e.g. body mass index 20–25 kg/m2)\\nreduce dietary sodium intake to <100 mmol/ day (<6 g of sodium chloride or <2.4 g of sodium per day)\\nengage in regular aerobic physical activity such as brisk walking (≥30 min per day, most days of the week)\\nlimit alcohol consumption to no more than 3 units/day in men and no more than 2 units/day in women\\nconsume a diet rich in fruit and vegetables (e.g. at least five portions per day);\\nStress reductionAvoiding or learning to manage stress can help a person control blood pressure.\\nA few relaxation techniques that can help relieve stress are:\\n\\nmeditation\\nwarm baths\\nyoga\\ngoing on long walksEffective lifestyle modification may lower blood pressure as much as an individual antihypertensive medication. Combinations of two or more lifestyle modifications can achieve even better results. There is considerable evidence that reducing dietary salt intake lowers blood pressure, but whether this translates into a reduction in mortality and cardiovascular disease remains uncertain. Estimated sodium intake ≥6g/day and <3g/day are both associated with high risk of death or major cardiovascular disease, but the association between high sodium intake and adverse outcomes is only observed in people with hypertension. Consequently, in the absence of results from randomized controlled trials, the wisdom of reducing levels of dietary salt intake below 3g/day has been questioned. ESC guidelines mention periodontitis is associated with poor cardiovascular health status.The value of routine screening for hypertension is debated. In 2004, the National High Blood Pressure Education Program recommended that children aged 3 years and older have blood pressure measurement at least once at every health care visit and the National Heart, Lung, and Blood Institute and American Academy of Pediatrics made a similar recommendation. However, the American Academy of Family Physicians supports the view of the U.S. Preventive Services Task Force that the available evidence is insufficient to determine the balance of benefits and harms of screening for hypertension in children and adolescents who do not have symptoms. The US Preventive Services Task Force recommends screening adults 18 years or older for hypertension with office blood pressure measurement.'],\n  'symptoms': ['Hypertension is rarely accompanied by symptoms, and its identification is usually through health  screening, or when seeking healthcare for an unrelated problem. Some people with high blood pressure report headaches (particularly at the back of the head and in the morning), as well as lightheadedness, vertigo, tinnitus (buzzing or hissing in the ears), altered vision or fainting episodes. These symptoms, however, might be related to associated anxiety rather than the high blood pressure itself.On physical examination, hypertension may be associated with the presence of changes in the optic fundus seen by ophthalmoscopy. The severity of the changes typical of hypertensive retinopathy is graded from I to IV; grades I and II may be difficult to differentiate. The severity of the retinopathy correlates roughly with the duration or the severity of the hypertension.'],\n  'treatments': ['According to one review published in 2003, reduction of the blood pressure by 5 mmHg can decrease the risk of stroke by 34%, of ischemic heart disease by 21%, and reduce the likelihood of dementia, heart failure, and mortality from cardiovascular disease.']},\n {'name': ['Migraine'],\n  'about': ['Migraine (UK: , US: ) is a genetically influenced complex neurological disorder characterized by episodes of moderate-to-severe headache, most often unilateral and generally associated with nausea and light and sound sensitivity. Other characterizing symptoms may include nausea, vomiting, cognitive dysfunction, allodynia, and dizziness. Exacerbation of headache symptoms during physical activity is another distinguishing feature. Up to one-third of migraine sufferers experience aura: a premonitory period of sensory disturbance widely accepted to be caused by cortical spreading depression at the onset of a migraine attack. Although primarily considered to be a headache disorder, migraine is highly heterogenous in its clinical presentation and is better thought of as a spectrum disease rather than a distinct clinical entity.'],\n  'precaution': ['Preventive treatments of migraine include medications, nutritional supplements, lifestyle alterations, and surgery. Prevention is recommended in those who have headaches more than two days a week, cannot tolerate the medications used to treat acute attacks, or those with severe attacks that are not easily controlled. Recommended lifestyle changes include stopping tobacco use and reducing behaviors that interfere with sleep.The goal is to reduce the frequency, painfulness, and duration of migraine episodes, and to increase the effectiveness of abortive therapy. Another reason for prevention is to avoid medication overuse headache. This is a common problem and can result in chronic daily headache.'],\n  'symptoms': ['Migraine typically presents with self-limited, recurrent severe headache associated with autonomic symptoms. About 15–30% of people living with migraine experience episodes with aura, and they also frequently experience episodes without aura. The severity of the pain, duration of the headache, and frequency of attacks are variable. A migraine attack lasting longer than 72 hours is termed status migrainosus. There are four possible phases to a migraine attack, although not all the phases are necessarily experienced:\\nThe prodrome, which occurs hours or days before the headache\\nThe aura, which immediately precedes the headache\\nThe pain phase, also known as headache phase\\nThe postdrome, the effects experienced following the end of a migraine attackMigraine is associated with major depression, bipolar disorder, anxiety disorders, and obsessive–compulsive disorder. These psychiatric disorders are approximately 2–5 times more common in people without aura, and 3–10 times more common in people with aura.'],\n  'treatments': ['There are three main aspects of treatment: trigger avoidance, acute symptomatic control, and medication for prevention. Medications are more effective if used earlier in an attack. The frequent use of medications may result in medication overuse headache, in which the headaches become more severe and more frequent. This may occur with triptans, ergotamines, and analgesics, especially opioid analgesics. Due to these concerns simple analgesics are recommended to be used less than three days per week at most.']},\n {'name': ['Cervical spondylosis'],\n  'about': ['Spondylosis is the degeneration of the vertebral column from any cause. In the more narrow sense it refers to spinal osteoarthritis, the age-related degeneration of the spinal column, which is the most common cause of spondylosis. The degenerative process in osteoarthritis chiefly affects the vertebral bodies, the neural foramina and the facet joints (facet syndrome). If severe, it may cause pressure on the spinal cord or nerve roots with subsequent sensory or motor disturbances, such as pain, paresthesia, imbalance, and muscle weakness in the limbs.\\nWhen the space between two adjacent vertebrae narrows, compression of a nerve root emerging from the spinal cord may result in radiculopathy (sensory and motor disturbances, such as severe pain in the neck, shoulder, arm, back, or leg, accompanied by muscle weakness).  Less commonly, direct pressure on the spinal cord (typically in the cervical spine) may result in myelopathy, characterized by global weakness, gait dysfunction, loss of balance, and loss of bowel or bladder control.'],\n  'precaution': [None],\n  'symptoms': [\"In cervical spondylosis, a patient may be presented with dull neck pain with neck stiffness in the initial stages of the disease. As the disease progresses, symptoms related to radiculopathy (due to compression of exiting spinal nerve by narrowed intervertebral foramen) or myelopathy (due to compression on the spinal cord) can occur. Reduced range of motion of the neck is the most frequent objective finding on physical examination.In cervical radiculopathy, there would be numbness, tingling, or burning pain at the skin area supplied by the spinal nerve, shooting pain along the course of the spinal nerve, or weakness or absent tendon reflex of the muscle supplied by the nerve. This symptom can be provoked by neck extension. Therefore, Spurling's test, which take advantage of this phenomenon, is performed by extending and laterally flexing the patient's head and placing downward pressure on it to narrow the intervertebral foramen. Neck or shoulder pain on the ipsilateral side (i.e., the side to which the head is flexed) indicates a positive result for this test. A positive test result is not necessarily a positive result for spondylosis and as such additional testing is required.In cervical myelopathy, almost always involves both the upper and lower limbs. A person may experience difficult gait or limb stiffness in the early stages of the disease. Iliopsoas muscle is the first group of muscles that is affected. Lower limb weaknesses without any upper limb involvement should raise the suspicion of thoracic cord compression. Finger escape sign is performed to detect the weakness of the fingers. A person's forearm is pronated and the fingers are extended. If the person has myelopathy, there will be slow abduction and flexion of the fingers on the ulnar side. The degree of loss of sensation maybe different on both upper limbs. Lhermitte sign is performed by asking a person to gently extend the neck. Those with cervical myelopathy will produce a feeling of electrical shock down the spine or arms. Muscle spasticity, hyperreflexia or even clonus are characteristic of myelopathy. Other abnormal reflexes such as Hoffmann's reflex, upward response of plantar reflex (Babinski response), and Wartenberg's sign (abnormal abduction of little finger) can also be elicited.\\n\\nSince the spinal cord ends at L1 or L2 vertebral levels, the job of nerve transmission is continued by spinal nerves for the remaining part of the vertebral canal. Degenerative process of spondylosis such as disc bulging, osteophyte formation, and hypertrophy of the superior articular process all contributes to the narrowing of the spinal canal and intervertebral foramen, leading to compression of these spinal nerves that results in radiculopathy-related symptoms.Narrowing of the lumbar spinal canal causes a clinical condition known as neurogenic claudication, characterised by symptoms such as lower back pain, leg pain, leg numbness, and leg weakness that worsens with standing and walking and improves with sitting and lying down.\\n\\nA rare but severe complication of this disease is vertebrobasilar insufficiency. This is a result of the vertebral artery becoming occluded as it passes up in the transverse foramen. The spinal joints become stiff in cervical spondylosis. Thus the chondrocytes which maintain the disc become deprived of nutrition and die. Secondary osteophytes may cause stenosis for spinal nerves, manifesting as radiculopathy.\\n\\n\"],\n  'treatments': ['Many of the treatments for cervical spondylosis have not been subjected to rigorous, controlled trials. Surgery is advocated for cervical radiculopathy in patients who have intractable pain, progressive symptoms, or weakness that fails to improve with conservative therapy. Surgical indications for cervical spondylosis with myelopathy (CSM) remain somewhat controversial, but \"most clinicians recommend operative therapy over conservative therapy for moderate-to-severe myelopathy\".Physical therapy may be effective for restoring range of motion, flexibility and core strengthening. Decompressive therapies (i.e., manual mobilization, mechanical traction) may also help alleviate pain. However, physical therapy and osteopathy cannot \"cure\" the degeneration, and some people view that strong compliance with postural modification is necessary to realize maximum benefit from decompression, adjustments and flexibility rehabilitation.']},\n {'name': ['Jaundice'],\n  'about': ['Jaundice, also known as icterus, is a yellowish or greenish pigmentation of the skin and sclera due to high bilirubin levels. Jaundice in adults is typically a sign indicating the presence of underlying diseases involving abnormal heme metabolism, liver dysfunction, or biliary-tract obstruction. The prevalence of jaundice in adults is rare, while jaundice in babies is common, with an estimated 80% affected during their first week of life. The most commonly associated symptoms of jaundice are itchiness, pale feces, and dark urine.Normal levels of bilirubin in blood are below 1.0 mg/dl (17 μmol/L), while levels over 2–3 mg/dl (34–51 μmol/L) typically result in jaundice. High blood bilirubin is divided into two types – unconjugated and conjugated bilirubin.Causes of jaundice vary from relatively benign to potentially fatal.'],\n  'precaution': [None],\n  'symptoms': ['The most common signs of jaundice in adults are a yellowish discoloration of the white area of the eye (sclera) and skin with scleral icterus presence indicating a serum bilirubin of at least 3 mg/dl. Other common signs include dark urine (bilirubinuria) and pale (acholia) fatty stool (steatorrhea). Because bilirubin is a skin irritant, jaundice is commonly associated with severe itchiness.Eye conjunctiva has a particularly high affinity for bilirubin deposition due to high elastin content. Slight increases in serum bilirubin can, therefore, be detected early on by observing the yellowing of sclerae. Traditionally referred to as scleral icterus, this term is actually a misnomer, because bilirubin deposition technically occurs in the conjunctival membranes overlying the avascular sclera. Thus, the proper term for the yellowing of \"white of the eyes\" is conjunctival icterus.A much less common sign of jaundice specifically during childhood is yellowish or greenish teeth. In developing children, hyperbilirubinemia may cause a yellow or green discoloration of teeth due to bilirubin deposition during the process of tooth calcification. While this may occur in children with hyperbilirubinemia, tooth discoloration due to hyperbilirubinemia is not observed in individuals with adult-onset liver disease. Disorders associated with a rise in serum levels of conjugated bilirubin during early development can also cause dental hypoplasia.'],\n  'treatments': ['Treatment of jaundice varies depending on the underlying cause. If a bile duct blockage is present, surgery is typically required; otherwise, management is medical.']},\n {'name': ['Malaria'],\n  'about': ['Malaria is a mosquito-borne infectious disease that affects humans and other vertebrates. Human malaria causes symptoms that typically include fever, fatigue, vomiting, and headaches. In severe cases, it can cause jaundice, seizures, coma, or death. Symptoms usually begin 10 to 15 days after being bitten by an infected mosquito. If not properly treated, people may have recurrences of the disease months later.'],\n  'precaution': [\"Methods used to prevent malaria include medications, mosquito elimination and the prevention of bites. As of 2022, there is one malaria vaccine for children which is licensed for use known as RTS,S. The presence of malaria in an area requires a combination of high human population density, high Anopheles mosquito population density and high rates of transmission from humans to mosquitoes and from mosquitoes to humans. If any of these is lowered sufficiently, the parasite eventually disappears from that area, as happened in North America, Europe, and parts of the Middle East. However, unless the parasite is eliminated from the whole world, it could re-establish if conditions revert to a combination that favors the parasite's reproduction. Furthermore, the cost per person of eliminating anopheles mosquitoes rises with decreasing population density, making it economically unfeasible in some areas.Prevention of malaria may be more cost-effective than treatment of the disease in the long run, but the initial costs required are out of reach of many of the world's poorest people. There is a wide difference in the costs of control (i.e. maintenance of low endemicity) and elimination programs between countries. For example, in China—whose government in 2010 announced a strategy to pursue malaria elimination in the Chinese provinces—the required investment is a small proportion of public expenditure on health. In contrast, a similar programme in Tanzania would cost an estimated one-fifth of the public health budget. In 2021, the World Health Organization confirmed that China has eliminated malaria.In areas where malaria is common, children under five years old often have anaemia, which is sometimes due to malaria. Giving children with anaemia in these areas preventive antimalarial medication improves red blood cell levels slightly but does not affect the risk of death or need for hospitalisation.\"],\n  'symptoms': ['Adults with malaria tend to experience chills and fever – classically in periodic intense bouts lasting around six hours, followed by a period of sweating and fever relief – as well as headache, fatigue, abdominal discomfort, and muscle pain. Children tend to have more general symptoms: fever, cough, vomiting, and diarrhea.Initial manifestations of the disease—common to all malaria species—are similar to flu-like symptoms, and can resemble other conditions such as sepsis, gastroenteritis, and viral diseases. The presentation may include headache, fever, shivering, joint pain, vomiting, hemolytic anemia, jaundice, hemoglobin in the urine, retinal damage, and convulsions.The classic symptom of malaria is paroxysm—a cyclical occurrence of sudden coldness followed by shivering and then fever and sweating, occurring every two days (tertian fever) in P. vivax and P. ovale infections, and every three days (quartan fever) for P. malariae. P. falciparum infection can cause recurrent fever every 36–48 hours, or a less pronounced and almost continuous fever.Symptoms typically begin 10–15 days after the initial mosquito bite, but can occur as late as several months after infection with some P. vivax strains. Travellers taking preventative malaria medications may develop symptoms once they stop taking the drugs.Severe malaria is usually caused by P. falciparum (often referred to as falciparum malaria). Symptoms of falciparum malaria arise 9–30 days after infection. Individuals with cerebral malaria frequently exhibit neurological symptoms, including abnormal posturing, nystagmus, conjugate gaze palsy (failure of the eyes to turn together in the same direction), opisthotonus, seizures, or coma.'],\n  'treatments': ['Malaria is treated with antimalarial medications; the ones used depends on the type and severity of the disease. While medications against fever are commonly used, their effects on outcomes are not clear. Providing free antimalarial drugs to households may reduce childhood deaths when used appropriately. Programmes which presumptively treat all causes of fever with antimalarial drugs may lead to overuse of antimalarials and undertreat other causes of fever. Nevertheless, the use of malaria rapid-diagnostic kits can help to reduce over-usage of antimalarials.']},\n {'name': ['Chicken pox'],\n  'about': ['Chickenpox, or chicken pox, also known as varicella, is a highly contagious, vaccine-preventable disease caused by the initial infection with varicella zoster virus (VZV), a member of the herpesvirus family. The disease results in a characteristic skin rash that forms small, itchy blisters, which eventually scab over. It usually starts on the chest, back, and face. It then spreads to the rest of the body. The rash and other symptoms, such as fever, tiredness, and headaches, usually last five to seven days.'],\n  'precaution': ['The spread of chickenpox can be prevented by isolating affected individuals. Contagion is by exposure to respiratory droplets, or direct contact with lesions, within a period lasting from three days before the onset of the rash, to four days after the onset of the rash. The chickenpox virus is susceptible to disinfectants, notably chlorine bleach (i.e., sodium hypochlorite). Like all enveloped viruses, it is sensitive to drying, heat and detergents.\\n\\nChickenpox can be prevented by vaccination. The side effects are usually mild, such as some pain or swelling at the injection site.A live attenuated varicella vaccine, the Oka strain, was developed by Michiaki Takahashi and his colleagues in Japan in the early 1970s. In 1995, Merck & Co. licensed the \"Oka\" strain of the varicella virus in the United States, and Maurice Hilleman\\'s team at Merck invented a varicella vaccine in the same year.The varicella vaccine is recommended in many countries. Some countries require the varicella vaccination or an exemption before entering elementary school. A second dose is recommended five years after the initial immunization. A vaccinated person is likely to have a milder case of chickenpox if they become infected. Immunization within three days following household contact reduces infection rates and severity in children. Being exposed to chickenpox as an adult (for example, through contact with infected children) may boost immunity to shingles. Therefore, it was thought that when the majority of children were vaccinated against chickenpox, adults might lose this natural boosting, so immunity would drop and more shingles cases would occur. On the other hand, current observations suggest that exposure to children with varicella is not a critical factor in the maintenance of immunity. Multiple subclinical reactivations of varicella zoster virus may occur spontaneously and, despite not causing clinical disease, may still provide an endogenous boost to immunity against zoster.The vaccine is part of the routine immunization schedule in the US. Some European countries include it as part of universal vaccinations in children, but not all countries provide the vaccine. In the UK as of 2014, the vaccine is only recommended in people who are particularly vulnerable to chickenpox. This is to keep the virus in circulation, thereby exposing the population to the virus at an early age, when it is less harmful, and to reduce the occurrence of shingles through repeated exposure to the virus later in life. In populations that have not been immunized or if immunity is questionable, a clinician may order an enzyme immunoassay. An immunoassay measures the levels of antibodies against the virus that give immunity to a person. If the levels of antibodies are low (low titer) or questionable, reimmunization may be done.\\n\\n'],\n  'symptoms': ['The early (prodromal) symptoms in adolescents and adults are nausea, loss of appetite, aching muscles, and headache. This is followed by the characteristic rash or oral sores, malaise, and a low-grade fever that signal the presence of the disease. Oral manifestations of the disease (enanthem) not uncommonly may precede the external rash (exanthem). In children the illness is not usually preceded by prodromal symptoms, and the first sign is the rash or the spots in the oral cavity. The rash begins as small red dots on the face, scalp, torso, upper arms and legs; progressing over 10–12 hours to small bumps, blisters and pustules; followed by umbilication and the formation of scabs.At the blister stage, intense itching is usually present. Blisters may also occur on the palms, soles, and genital area. Commonly, visible evidence of the disease develops in the oral cavity and tonsil areas in the form of small ulcers which can be painful or itchy or both; this enanthem (internal rash) can precede the exanthem (external rash) by 1 to 3 days or can be concurrent. These symptoms of chickenpox appear 10 to 21 days after exposure to a contagious person. Adults may have a more widespread rash and longer fever, and they are more likely to experience complications, such as varicella pneumonia.Because watery nasal discharge containing live virus usually precedes both exanthem (external rash) and enanthem (oral ulcers) by 1 to 2 days, the infected person actually becomes contagious one to two days before recognition of the disease. Contagiousness persists until all vesicular lesions have become dry crusts (scabs), which usually entails four or five days, by which time nasal shedding of live virus ceases. The condition usually resolves by itself within a week or two. The rash may, however, last for up to one month.Chickenpox is rarely fatal, although it is generally more severe in adult men than in women or children. Non-immune pregnant women and those with a suppressed immune system are at highest risk of serious complications. Arterial ischemic stroke (AIS) associated with chickenpox in the previous year accounts for nearly one third of childhood AIS. The most common late complication of chickenpox is shingles (herpes zoster), caused by reactivation of the varicella zoster virus decades after the initial, often childhood, chickenpox infection.'],\n  'treatments': ['Treatment mainly consists of easing the symptoms. As a protective measure, people are usually required to stay at home while they are infectious to avoid spreading the disease to others. Cutting the fingernails short or wearing gloves may prevent scratching and minimize the risk of secondary infections.Although there have been no formal clinical studies evaluating the effectiveness of topical application of calamine lotion (a topical barrier preparation containing zinc oxide, and one of the most commonly used interventions), it has an excellent safety profile. Maintaining good hygiene and daily cleaning of skin with warm water can help to avoid secondary bacterial infection; scratching may increase the risk of secondary infection.Paracetamol (acetaminophen) but not aspirin may be used to reduce fever. Aspirin use by someone with chickenpox may cause serious, sometimes fatal disease of the liver and brain, Reye syndrome. People at risk of developing severe complications who have had significant exposure to the virus may be given intra-muscular varicella zoster immune globulin (VZIG), a preparation containing high titres of antibodies to varicella zoster virus, to ward off the disease.Antivirals are sometimes used.']},\n {'name': ['Dengue'],\n  'about': ['Dengue fever is a mosquito-borne tropical disease caused by the dengue virus. Symptoms typically begin three to fourteen days after infection. These may include a high fever, headache, vomiting, muscle and joint pains, and a characteristic skin itching and skin rash. Recovery generally takes two to seven days. In a small proportion of cases, the disease develops into a more severe dengue hemorrhagic fever, resulting in bleeding, low levels of blood platelets and blood plasma leakage, or into dengue shock syndrome, where dangerously low blood pressure occurs.Dengue is spread by several species of female mosquitoes of the Aedes genus, principally Aedes aegypti.'],\n  'precaution': [\"Prevention depends on control of and protection from the bites of the mosquito that transmits it. The World Health Organization recommends an Integrated Vector Control program consisting of five elements:\\nAdvocacy, social mobilization and legislation to ensure that public health bodies and communities are strengthened;\\nCollaboration between the health and other sectors (public and private);\\nAn integrated approach to disease control to maximize the use of resources;\\nEvidence-based decision making to ensure any interventions are targeted appropriately; and\\nCapacity-building to ensure an adequate response to the local situation.The primary method of controlling A. aegypti is by eliminating its habitats. This is done by getting rid of open sources of water, or if this is not possible, by adding insecticides or biological control agents to these areas. Generalized spraying with organophosphate or pyrethroid insecticides, while sometimes done, is not thought to be effective. Reducing open collections of water through environmental modification is the preferred method of control, given the concerns of negative health effects from insecticides and greater logistical difficulties with control agents. People can prevent mosquito bites by wearing clothing that fully covers the skin, using mosquito netting while resting, and/or the application of insect repellent (DEET being the most effective). While these measures can be an effective means of reducing an individual's risk of exposure, they do little in terms of mitigating the frequency of outbreaks, which appear to be on the rise in some areas, probably due to urbanization increasing the habitat of A. aegypti. The range of the disease also appears to be expanding possibly due to climate change.\"],\n  'symptoms': ['Typically, people infected with dengue virus are asymptomatic (80%) or have only mild symptoms such as an uncomplicated fever. Others have more severe illness (5%), and in a small proportion it is life-threatening. The incubation period (time between exposure and onset of symptoms) ranges from 3 to 14 days, but most often it is 4 to 7 days. Therefore, travelers returning from endemic areas are unlikely to have dengue fever if symptoms start more than 14 days after arriving home. Children often experience symptoms similar to those of the common cold and gastroenteritis (vomiting and diarrhea) and have a greater risk of severe complications, though initial symptoms are generally mild but include high fever.'],\n  'treatments': ['There are no specific antiviral drugs for dengue; however, maintaining proper fluid balance is important. Treatment depends on the symptoms. Those who can drink, are passing urine, have no \"warning signs\" and are otherwise healthy can be managed at home with daily follow-up and oral rehydration therapy. Those who have other health problems, have \"warning signs\", or cannot manage regular follow-up should be cared for in hospital. In those with severe dengue care should be provided in an area where there is access to an intensive care unit.Intravenous hydration, if required, is typically only needed for one or two days. In children with shock due to dengue a rapid dose of 20 mL/kg is reasonable. The rate of fluid administration is then titrated to a urinary output of 0.5–1 mL/kg/h, stable vital signs and normalization of hematocrit. The smallest amount of fluid required to achieve this is recommended.Invasive medical procedures such as nasogastric intubation, intramuscular injections and arterial punctures are avoided, in view of the bleeding risk. Paracetamol (acetaminophen) is used for fever and discomfort while NSAIDs such as ibuprofen and aspirin are avoided as they might aggravate the risk of bleeding. Blood transfusion is initiated early in people presenting with unstable vital signs in the face of a decreasing hematocrit, rather than waiting for the hemoglobin concentration to decrease to some predetermined \"transfusion trigger\" level. Packed red blood cells or whole blood are recommended, while platelets and fresh frozen plasma are usually not. There is not enough evidence to determine if corticosteroids have a positive or negative effect in dengue fever.During the recovery phase intravenous fluids are discontinued to prevent a state of fluid overload. If fluid overload occurs and vital signs are stable, stopping further fluid may be all that is needed. If a person is outside of the critical phase, a loop diuretic such as furosemide may be used to eliminate excess fluid from the circulation.']},\n {'name': ['Typhoid'],\n  'about': ['Typhoid fever, also known as typhoid, is a disease caused by Salmonella serotype Typhi bacteria. Symptoms vary from mild to severe, and usually begin six to 30 days after exposure. Often there is a gradual onset of a high fever over several days. This is commonly accompanied by weakness, abdominal pain, constipation, headaches, and mild vomiting. Some people develop a skin rash with rose colored spots.'],\n  'precaution': ['Sanitation and hygiene are important to prevent typhoid. It can spread only in environments where human feces can come into contact with food or drinking water. Careful food preparation and washing of hands are crucial to prevent typhoid. Industrialization contributed greatly to the elimination of typhoid fever, as it eliminated the public-health hazards associated with having horse manure in public streets, which led to a large number of flies, which are vectors of many pathogens, including Salmonella spp. According to statistics from the U.S. Centers for Disease Control and Prevention, the chlorination of drinking water has led to dramatic decreases in the transmission of typhoid fever.'],\n  'symptoms': ['Classically, the progression of untreated typhoid fever has three distinct stages, each lasting about a week. Over the course of these stages, the patient becomes exhausted and emaciated.\\nIn the first week, the body temperature rises slowly, and fever fluctuations are seen with relative bradycardia (Faget sign), malaise, headache, and cough. A bloody nose (epistaxis) is seen in a quarter of cases, and abdominal pain is also possible. A decrease in the number of circulating white blood cells (leukopenia) occurs with eosinopenia and relative lymphocytosis; blood cultures are positive for S. enterica subsp. enterica serovar Typhi. The Widal test is usually negative.\\nIn the second week, the person is often too tired to get up, with high fever in plateau around 40 °C (104 °F) and bradycardia (sphygmothermic dissociation or Faget sign), classically with a dicrotic pulse wave. Delirium can occur, where the patient is often calm, but sometimes becomes agitated. This delirium has given typhoid the nickname \"nervous fever\". Rose spots appear on the lower chest and abdomen in around a third of patients. Rhonchi (rattling breathing sounds) are heard in the base of the lungs. The abdomen is distended and painful in the right lower quadrant, where a rumbling sound can be heard. Diarrhea can occur in this stage, but constipation is also common. The spleen and liver are enlarged (hepatosplenomegaly) and tender, and liver transaminases are elevated. The Widal test is strongly positive, with antiO and antiH antibodies. Blood cultures are sometimes still positive.\\nIn the third week of typhoid fever, a number of complications can occur:\\nThe fever is still very high and oscillates very little over 24 hours. Dehydration ensues along with malnutrition, and the patient is delirious. A third of affected people develop a macular rash on the trunk.\\nIntestinal haemorrhage due to bleeding in congested Peyer\\'s patches occurs; this can be very serious, but is usually not fatal.\\nIntestinal perforation in the distal ileum is a very serious complication and often fatal. It may occur without alarming symptoms until septicaemia or diffuse peritonitis sets in.\\nRespiratory diseases such as pneumonia and acute bronchitis\\nEncephalitis\\nNeuropsychiatric symptoms (described as \"muttering delirium\" or \"coma vigil\"), with picking at bedclothes or imaginary objects.\\nMetastatic abscesses, cholecystitis, endocarditis, and osteitis.\\nLow platelet count (thrombocytopenia) is sometimes seen.'],\n  'treatments': ['The rediscovery of oral rehydration therapy in the 1960s provided a simple way to prevent many of the deaths of diarrheal diseases in general.\\n\\nWhere resistance is uncommon, the treatment of choice is a fluoroquinolone such as ciprofloxacin. Otherwise, a third-generation cephalosporin such as ceftriaxone or cefotaxime is the first choice. Cefixime is a suitable oral alternative.Properly treated, typhoid fever is not fatal in most cases. Antibiotics such as ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole, amoxicillin, and ciprofloxacin have been commonly used to treat it. Treatment with antibiotics reduces the case-fatality rate to about 1%.Without treatment, some patients develop sustained fever, bradycardia, hepatosplenomegaly, abdominal symptoms, and occasionally pneumonia. In white-skinned patients, pink spots, which fade on pressure, appear on the skin of the trunk in up to 20% of cases. In the third week, untreated cases may develop gastrointestinal and cerebral complications, which may prove fatal in 10%–20% of cases. The highest case fatality rates are reported in children under 4. Around 2%–5% of those who contract typhoid fever become chronic carriers, as bacteria persist in the biliary tract after symptoms have resolved.\\n\\nSurgery is usually indicated if intestinal perforation occurs. One study found a 30-day mortality rate of 9% (8/88), and surgical site infections at 67% (59/88), with the disease burden borne predominantly by low-resource countries.For surgical treatment, most surgeons prefer simple closure of the perforation with drainage of the peritoneum. Small-bowel resection is indicated for patients with multiple perforations. If antibiotic treatment fails to eradicate the hepatobiliary carriage, the gallbladder should be resected. Cholecystectomy is sometimes successful, especially in patients with gallstones, but is not always successful in eradicating the carrier state because of persisting hepatic infection.\\n\\nAs resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole, and streptomycin is now common, these agents are no longer used as first–line treatment of typhoid fever. Typhoid resistant to these agents is known as multidrug-resistant typhoid.Ciprofloxacin resistance is an increasing problem, especially in the Indian subcontinent and Southeast Asia. Many centres are shifting from ciprofloxacin to ceftriaxone as the first line for treating suspected typhoid originating in South America, India, Pakistan, Bangladesh, Thailand, or Vietnam. Also, it has been suggested that azithromycin is better at treating resistant typhoid than both fluoroquinolone drugs and ceftriaxone. Azithromycin can be taken by mouth and is less expensive than ceftriaxone, which is given by injection.A separate problem exists with laboratory testing for reduced susceptibility to ciprofloxacin; current recommendations are that isolates should be tested simultaneously against ciprofloxacin (CIP) and against nalidixic acid (NAL), that isolates sensitive to both CIP and NAL should be reported as \"sensitive to ciprofloxacin\", and that isolates sensitive to CIP but not to NAL should be reported as \"reduced sensitivity to ciprofloxacin\". But an analysis of 271 isolates found that around 18% of isolates with a reduced susceptibility to fluoroquinolones, the class which CIP belongs (MIC 0.125–1.0 mg/L), would not be detected by this method.\\n\\n']},\n {'name': ['Tuberculosis'],\n  'about': ['Tuberculosis (TB) is an infectious disease usually caused by Mycobacterium tuberculosis (MTB) bacteria. Tuberculosis generally affects the lungs, but it can also affect other parts of the body. Most infections show no symptoms, in which case it is known as latent tuberculosis. Around 10% of latent infections progress to active disease which, if left untreated, kill about half of those affected. Typical symptoms of active TB are chronic cough with blood-containing mucus, fever, night sweats, and weight loss.'],\n  'precaution': ['Tuberculosis prevention and control efforts rely primarily on the vaccination of infants and the detection and appropriate treatment of active cases. The World Health Organization (WHO) has achieved some success with improved treatment regimens, and a small decrease in case numbers. Some countries have legislation to involuntarily detain or examine those suspected to have tuberculosis, or involuntarily treat them if infected.'],\n  'symptoms': ['Tuberculosis may infect any part of the body, but most commonly occurs in the lungs (known as pulmonary tuberculosis). Extrapulmonary TB occurs when tuberculosis develops outside of the lungs, although extrapulmonary TB may coexist with pulmonary TB.General signs and symptoms include fever, chills, night sweats, loss of appetite, weight loss, and fatigue. Significant nail clubbing may also occur.'],\n  'treatments': ['Treatment of TB uses antibiotics to kill the bacteria. Effective TB treatment is difficult, due to the unusual structure and chemical composition of the mycobacterial cell wall, which hinders the entry of drugs and makes many antibiotics ineffective.Active TB is best treated with combinations of several antibiotics to reduce the risk of the bacteria developing antibiotic resistance. The routine use of rifabutin instead of rifampicin in HIV-positive people with tuberculosis is of unclear benefit as of 2007.']},\n {'name': ['Common Cold'],\n  'about': ['The common cold or the cold is a viral infectious disease of the upper respiratory tract that primarily affects the respiratory mucosa of the nose, throat, sinuses, and larynx. Signs and symptoms may appear fewer than two days after exposure to the virus. These may include coughing, sore throat, runny nose, sneezing, headache, and fever. People usually recover in seven to ten days, but some symptoms may last up to three weeks. Occasionally, those with other health problems may develop pneumonia.Well over 200 virus strains are implicated in causing the common cold, with rhinoviruses, coronaviruses, adenoviruses and enteroviruses being the most common.'],\n  'precaution': ['The only useful ways to reduce the spread of cold viruses are physical measures such as using correct hand washing technique and face masks; in the healthcare environment, gowns and disposable gloves are also used. Isolation or quarantine is not used as the disease is so widespread and symptoms are non-specific. There is no vaccine to protect against the common cold. Vaccination has proven difficult as there are many viruses involved and they mutate rapidly. Creation of a broadly effective vaccine is, therefore, highly improbable.Regular hand washing appears to be effective in reducing the transmission of cold viruses, especially among children. Whether the addition of antivirals or antibacterials to normal hand washing provides greater benefit is unknown. Wearing face masks when around people who are infected may be beneficial; however, there is insufficient evidence for maintaining a greater social distance.It is unclear whether zinc supplements affect the likelihood of contracting a cold. Routine vitamin C supplements do not reduce the risk or severity of the common cold, though they may reduce its duration. Gargling with water was found useful in one small trial.'],\n  'symptoms': ['The typical symptoms of a cold include cough, runny nose, sneezing, nasal congestion, and a sore throat, sometimes accompanied by muscle ache, fatigue, headache, and loss of appetite. A sore throat is present in about 40% of cases, a cough in about 50%, and muscle ache likewise in about 50%. In adults, a fever is generally not present but it is common in infants and young children. The cough is usually mild compared to that accompanying influenza. While a cough and a fever indicate a higher likelihood of influenza in adults, a great deal of similarity exists between these two conditions. A number of the viruses that cause the common cold may also result in asymptomatic infections.The color of the mucus or nasal secretion may vary from clear to yellow to green and does not indicate the class of agent causing the infection.'],\n  'treatments': ['Treatments of the common cold primarily involve medications and other therapies for symptomatic relief. Getting plenty of rest, drinking fluids to maintain hydration, and gargling with warm salt water are reasonable conservative measures. Much of the benefit from symptomatic treatment is, however, attributed to the placebo effect. As of 2010, no medications or herbal remedies had been conclusively demonstrated to shorten the duration of infection.']},\n {'name': ['Pneumonia'],\n  'about': ['Pneumonia is an inflammatory condition of the lung primarily affecting the small air sacs known as alveoli. Symptoms typically include some combination of productive or dry cough, chest pain, fever, and difficulty breathing. The severity of the condition is variable.Pneumonia is usually caused by infection with viruses or bacteria, and less commonly by other microorganisms. Identifying the responsible pathogen can be difficult. Diagnosis is often based on symptoms and physical examination.'],\n  'precaution': ['Prevention includes vaccination, environmental measures, and appropriate treatment of other health problems. It is believed that, if appropriate preventive measures were instituted globally, mortality among children could be reduced by 400,000; and, if proper treatment were universally available, childhood deaths could be decreased by another 600,000.'],\n  'symptoms': ['People with infectious pneumonia often have a productive cough, fever accompanied by shaking chills, shortness of breath, sharp or stabbing chest pain during deep breaths, and an increased rate of breathing. In elderly people, confusion may be the most prominent sign.The typical signs and symptoms in children under five are fever, cough, and fast or difficult breathing. Fever is not very specific, as it occurs in many other common illnesses and may be absent in those with severe disease, malnutrition or in the elderly. In addition, a cough is frequently absent in children less than 2 months old. More severe signs and symptoms in children may include blue-tinged skin, unwillingness to drink, convulsions, ongoing vomiting, extremes of temperature, or a decreased level of consciousness.Bacterial and viral cases of pneumonia usually result in similar symptoms. Some causes are associated with classic, but non-specific, clinical characteristics. Pneumonia caused by Legionella may occur with abdominal pain, diarrhea, or confusion. Pneumonia caused by Streptococcus pneumoniae is associated with rusty colored sputum. Pneumonia caused by Klebsiella may have bloody sputum often described as \"currant jelly\". Bloody sputum (known as hemoptysis) may also occur with tuberculosis, Gram-negative pneumonia, lung abscesses and more commonly acute bronchitis. Pneumonia caused by Mycoplasma pneumoniae may occur in association with swelling of the lymph nodes in the neck, joint pain, or a middle ear infection. Viral pneumonia presents more commonly with wheezing than bacterial pneumonia. Pneumonia was historically divided into \"typical\" and \"atypical\" based on the belief that the presentation predicted the underlying cause. However, evidence has not supported this distinction, therefore it is no longer emphasized.'],\n  'treatments': ['Antibiotics by mouth, rest, simple analgesics, and fluids usually suffice for complete resolution. However, those with other medical conditions, the elderly, or those with significant trouble breathing may require more advanced care. If the symptoms worsen, the pneumonia does not improve with home treatment, or complications occur, hospitalization may be required. Worldwide, approximately 7–13% of cases in children result in hospitalization, whereas in the developed world between 22 and 42% of adults with community-acquired pneumonia are admitted. The CURB-65 score is useful for determining the need for admission in adults. If the score is 0 or 1, people can typically be managed at home; if it is 2, a short hospital stay or close follow-up is needed; if it is 3–5, hospitalization is recommended. In children those with respiratory distress or oxygen saturations of less than 90% should be hospitalized. The utility of chest physiotherapy in pneumonia has not yet been determined. Over-the-counter cough medicine has not been found to be effective, nor has the use of zinc supplementation in children. There is insufficient evidence for mucolytics. There is no strong evidence to recommend that children who have non-measles related pneumonia take vitamin A supplements. Vitamin D, as of 2023 is of unclear benefit in children. Vitamin C administration in pneumonia needs further research, although it can be given to patient of low plasma vitamin C because it is not expensive and low risk.Pneumonia can cause severe illness in a number of ways, and pneumonia with evidence of organ dysfunction may require intensive care unit admission for observation and specific treatment. The main impact is on the respiratory and the circulatory system. Respiratory failure not responding to normal oxygen therapy may require heated humidified high-flow therapy delivered through nasal cannulae, non-invasive ventilation, or in severe cases mechanical ventilation through an endotracheal tube. Regarding circulatory problems as part of sepsis, evidence of poor blood flow or low blood pressure is initially treated with 30 mL/kg of crystalloid infused intravenously. In situations where fluids alone are ineffective, vasopressor medication may be required.For adults with moderate or severe acute respiratory distress syndrome (ARDS) undergoing mechanical ventilation, there is a reduction in mortality when people lie on their front for at least 12 hours a day. However, this increases the risk of endotracheal tube obstruction and pressure sores.']},\n {'name': ['Piles'],\n  'about': ['Hemorrhoids (or haemorrhoids), also known as piles, are vascular structures in the anal canal. In their normal state, they are cushions that help with stool control. They become a disease when swollen or inflamed; the unqualified term hemorrhoid is often used to refer to the disease. The signs and symptoms of hemorrhoids depend on the type present. Internal hemorrhoids often result in painless, bright red rectal bleeding when defecating.'],\n  'precaution': ['A number of preventative measures are recommended, including avoiding straining while attempting to defecate, avoiding constipation and diarrhea either by eating a high-fiber diet and drinking plenty of fluid or by taking fiber supplements and getting sufficient exercise. Spending less time attempting to defecate, avoiding reading while on the toilet, and losing weight for overweight persons and avoiding heavy lifting are also recommended.'],\n  'symptoms': ['In about 40% of people with pathological hemorrhoids, there are no significant symptoms. Internal and external hemorrhoids may present differently; however, many people may have a combination of the two. Bleeding enough to cause anemia is rare, and life-threatening bleeding is even more uncommon. Many people feel embarrassed when facing the problem and often seek medical care only when the case is advanced.'],\n  'treatments': ['Conservative treatment typically consists of foods rich in dietary fiber, intake of oral fluids to maintain hydration, nonsteroidal anti-inflammatory drugs, sitz baths, and rest. Increased fiber intake has been shown to improve outcomes and may be achieved by dietary alterations or the consumption of fiber supplements. Evidence for benefits from sitz baths during any point in treatment, however, is lacking. If they are used, they should be limited to 15 minutes at a time.:\\u200a182\\u200a Decreasing time spent on the toilet and not straining is also recommended.While many topical agents and suppositories are available for the treatment of hemorrhoids, little evidence supports their use. As such, they are not recommended by the American Society of Colon and Rectal Surgeons. Steroid-containing agents should not be used for more than 14 days, as they may cause thinning of the skin. Most agents include a combination of active ingredients. These may include a barrier cream such as petroleum jelly or zinc oxide, an analgesic agent such as lidocaine, and a vasoconstrictor such as epinephrine. Some contain Balsam of Peru to which certain people may be allergic.Flavonoids are of questionable benefit, with potential side effects. Symptoms usually resolve following pregnancy; thus active treatment is often delayed until after delivery. Evidence does not support the use of traditional Chinese herbal treatment.Several professional organizations weakly recommend the use of phlebotonics in the treatment of the symptoms of haemorrhoids grade I to II, although these drugs are not approved in the United States as of 2013 and in Germany, and restricted in Spain for the treatment of chronic venous diseases.\\n\\nA number of office-based procedures may be performed. While generally safe, rare serious side effects such as perianal sepsis may occur.\\nRubber band ligation is typically recommended as the first-line treatment in those with grade I to III disease. It is a procedure in which elastic bands are applied onto internal hemorrhoid at least 1 cm above the pectinate line to cut off its blood supply. Within 5–7 days, the withered hemorrhoid falls off. If the band is placed too close to the pectinate line, intense pain results immediately afterwards. The cure rate has been found to be about 87%, with a complication rate of up to 3%.\\nSclerotherapy involves the injection of a sclerosing agent, such as phenol, into the hemorrhoid. This causes the vein walls to collapse and the hemorrhoids to shrivel up. The success rate four years after treatment is about 70%.\\nA number of cauterization methods have been shown to be effective for hemorrhoids, but are usually used only when other methods fail. This procedure can be done using electrocautery, infrared radiation, laser surgery, or cryosurgery. Infrared cauterization may be an option for grade I or II disease. In those with grade III or IV disease, reoccurrence rates are high.\\n\\nA number of surgical techniques may be used if conservative management and simple procedures fail. All surgical treatments are associated with some degree of complications, including bleeding, infection, anal strictures, and urinary retention, due to the close proximity of the rectum to the nerves that supply the bladder. Also, a small risk of fecal incontinence occurs, particularly of liquid, with rates reported between 0% and 28%. Mucosal ectropion is another condition which may occur after hemorrhoidectomy (often together with anal stenosis). This is where the anal mucosa becomes everted from the anus, similar to a very mild form of rectal prolapse.\\nExcisional hemorrhoidectomy is a surgical excision of the hemorrhoid used primarily only in severe cases. It is associated with significant postoperative pain and usually requires two to four weeks for recovery. However, the long-term benefit is greater in those with grade III hemorrhoids as compared to rubber band ligation. It is the recommended treatment in those with a thrombosed external hemorrhoid if carried out within 24–72 hours. Evidence to support this is weak, however. Glyceryl trinitrate ointment after the procedure helps both with pain and with healing.\\nDoppler-guided transanal hemorrhoidal dearterialization is a minimally invasive treatment using an ultrasound Doppler to accurately locate the arterial blood inflow. These arteries are then \"tied off\" and the prolapsed tissue is sutured back to its normal position. It has a slightly higher recurrence rate but fewer complications compared to a hemorrhoidectomy.\\nStapled hemorrhoidectomy, also known as stapled hemorrhoidopexy, involves the removal of much of the abnormally enlarged hemorrhoidal tissue, followed by a repositioning of the remaining hemorrhoidal tissue back to its normal anatomical position. It is generally less painful and is associated with faster healing compared to complete removal of hemorrhoids. However, the chance of symptomatic hemorrhoids returning is greater than for conventional hemorrhoidectomy, so it is typically recommended only for grade II or III disease.\\n\\n']},\n {'name': ['Heart attack'],\n  'about': ['A myocardial infarction (MI), commonly known as a heart attack, occurs when blood flow decreases or stops in one of the coronary arteries of the heart, causing damage to the heart muscle. The most common symptom is chest pain or discomfort which may travel into the shoulder, arm, back, neck or jaw. Often it occurs in the center or left side of the chest and lasts for more than a few minutes. The discomfort may occasionally feel like heartburn. Other symptoms may include shortness of breath, nausea, feeling faint, a cold sweat or feeling tired.'],\n  'precaution': ['There is a large crossover between the lifestyle and activity recommendations to prevent a myocardial infarction, and those that may be adopted as secondary prevention after an initial myocardial infarction, because of shared risk factors and an aim to reduce atherosclerosis affecting heart vessels. The influenza vaccine also appear to protect against myocardial infarction with a benefit of 15 to 45%.'],\n  'symptoms': ['Chest pain that may or may not radiate to other parts of the body is the most typical and significant symptom of myocardial infarction. It might be accompanied by other symptoms such as sweating.'],\n  'treatments': ['A myocardial infarction requires immediate medical attention. Treatment aims to preserve as much heart muscle as possible, and to prevent further complications. Treatment depends on whether the myocardial infarction is a STEMI or NSTEMI. Treatment in general aims to unblock blood vessels, reduce blood clot enlargement, reduce ischemia, and modify risk factors with the aim of preventing future MIs. In addition, the main treatment for myocardial infarctions with ECG evidence of ST elevation (STEMI) include thrombolysis or percutaneous coronary intervention, although PCI is also ideally conducted within 1–3 days for NSTEMI. In addition to clinical judgement, risk stratification may be used to guide treatment, such as with the TIMI and GRACE scoring systems.']},\n {'name': ['Varicose veins'],\n  'about': ['Varicose veins, also known as varicoses, are a medical condition in which superficial veins become enlarged and twisted. These veins typically develop in the legs, just under the skin. Varicose veins usually cause few symptoms. However, some individuals may experience fatigue or pain in the area. Complications can include bleeding or superficial thrombophlebitis.'],\n  'precaution': [None],\n  'symptoms': ['Aching, heavy legs\\nAppearance of spider veins (telangiectasia) in the affected leg\\nAnkle swelling\\nA brownish-yellow shiny skin discoloration near the affected veins\\nRedness, dryness, and itchiness of areas of skin, termed stasis dermatitis or venous eczema\\nMuscle cramps when making sudden movements, such as standing\\nAbnormal bleeding or healing time for injuries in the affected area\\nLipodermatosclerosis or shrinking skin near the ankles\\nRestless legs syndrome appears to be a common overlapping clinical syndrome in people with varicose veins and other chronic venous insufficiency\\nAtrophie blanche, or white, scar-like formations\\nBurning or throbbing sensation in the legsPeople with varicose veins might have a positive D-dimer blood test result due to chronic low-level thrombosis within dilated veins (varices).'],\n  'treatments': ['Treatment can be either active or conservative.']},\n {'name': ['Hypothyroidism'],\n  'about': [\"Hypothyroidism (also called underactive thyroid, low thyroid or hypothyreosis) is a disorder of the endocrine system in which the thyroid gland does not produce enough thyroid hormone. It can cause a number of symptoms, such as poor ability to tolerate cold, a feeling of tiredness, constipation, slow heart rate,  depression, and weight gain. Occasionally there may be swelling of the front part of the neck due to goitre. Untreated cases of hypothyroidism during pregnancy can lead to delays in growth and intellectual development in the baby or congenital iodine deficiency syndrome.Worldwide, too little iodine in the diet is the most common cause of hypothyroidism. Hashimoto's thyroiditis is the most common cause of hypothyroidism in countries with sufficient dietary iodine.\"],\n  'precaution': [\"Hypothyroidism may be prevented in a population by adding iodine to commonly used foods. This public health measure has eliminated endemic childhood hypothyroidism in countries where it was once common. In addition to promoting the consumption of iodine-rich foods such as dairy and fish, many countries with moderate iodine deficiency have implemented universal salt iodization. Encouraged by the World Health Organization, 70% of the world's population across 130 countries are receiving iodized salt. In some countries, iodized salt is added to bread. Despite this, iodine deficiency has reappeared in some Western countries as a result of attempts to reduce salt intake.Pregnant and breastfeeding women, who require 66% more daily iodine than non-pregnant women, may still not be getting enough iodine. The World Health Organization recommends a daily intake of 250 µg for pregnant and breastfeeding women. As many women will not achieve this from dietary sources alone, the American Thyroid Association recommends a 150 µg daily supplement by mouth.\"],\n  'symptoms': [\"People with hypothyroidism often have no or only mild symptoms. Numerous symptoms and signs are associated with hypothyroidism and can be related to the underlying cause, or a direct effect of having not enough thyroid hormones. Hashimoto's thyroiditis may present with the mass effect of a goitre (enlarged thyroid gland). In middle-aged women, the symptoms may be mistaken for those of menopause.\\nDelayed relaxation after testing the ankle jerk reflex is a characteristic sign of hypothyroidism and is associated with the severity of the hormone deficit.\"],\n  'treatments': ['Most people with hypothyroidism symptoms and confirmed thyroxine deficiency are treated with a synthetic long-acting form of thyroxine, known as levothyroxine (L-thyroxine). In young and otherwise healthy people with overt hypothyroidism, a full replacement dose (adjusted by weight) can be started immediately; in the elderly and people with heart disease a lower starting dose is recommended to prevent over supplementation and risk of complications. Lower doses may be sufficient in those with subclinical hypothyroidism, while people with central hypothyroidism may require a higher than average dose.Blood free thyroxine and TSH levels are monitored to help determine whether the dose is adequate. This is done 4–8 weeks after the start of treatment or a change in levothyroxine dose. Once the adequate replacement dose has been established, the tests can be repeated after 6 and then 12 months, unless there is a change in symptoms. Normalization of TSH does not mean that other abnormalities associated with hypothyroidism improve entirely, such as elevated cholesterol levels.In people with central/secondary hypothyroidism, TSH is not a reliable marker of hormone replacement and decisions are based mainly on the free T4 level. Levothyroxine is best taken 30–60 minutes before breakfast, or four hours after food, as certain substances such as food and calcium can inhibit the absorption of levothyroxine. There is no direct way of increasing thyroid hormone secretion by the thyroid gland.\\n\\nThere is no evidence of a benefit from treating subclinical hypothyroidism in those who are not pregnant, and there are potential risks of overtreatment. Untreated subclinical hypothyroidism may be associated with a modest increase in the risk of coronary artery disease when the TSH is over 10 mIU/L. A 2007 review found no benefit of thyroid hormone replacement except for \"some parameters of lipid profiles and left ventricular function\". There is no association between subclinical hypothyroidism and an increased risk of bone fractures, nor is there a link with cognitive decline.Since 2008, consensus American opinion has been that in general people with TSH under 10 to 20 mIU/L do not require treatment.American guidelines recommend that treatment should be considered in people with symptoms of hypothyroidism, detectable antibodies against thyroid peroxidase, a history of heart disease or are at an increased risk for heart disease, if the TSH is elevated but below 10 mIU/L. NICE recommends that those with a TSH above 10 mIU/L should be treated in the same way as overt hypothyroidism. Those with an elevated TSH but below 10 mIU/L who have symptoms suggestive of hypothyroidism should have a trial of treatment but with the aim to stopping this if the symptoms persist despite normalisation of the TSH.A recent meta-analysis, however, found an increased risk for cardiovascular death in subclinical hypothyroidism.\\n\\nMyxedema coma or severe decompensated hypothyroidism usually requires admission to the intensive care, close observation and treatment of abnormalities in breathing, temperature control, blood pressure, and sodium levels. Mechanical ventilation may be required, as well as fluid replacement, vasopressor agents, careful rewarming, and corticosteroids (for possible adrenal insufficiency which can occur together with hypothyroidism). Careful correction of low sodium levels may be achieved with hypertonic saline solutions or vasopressin receptor antagonists. For rapid treatment of the hypothyroidism, levothyroxine or liothyronine may be administered intravenously, particularly if the level of consciousness is too low to be able to safely swallow medication. While administration through a nasogastric tube is possible, this may be unsafe and is discouraged.\\n\\nIn women with known hypothyroidism who become pregnant, it is recommended that serum TSH levels are closely monitored. Levothyroxine should be used to keep TSH levels within the normal range for that trimester. The first trimester normal range is below 2.5 mIU/L and the second and third trimesters normal range is below 3.0 mIU/L. Treatment should be guided by total (rather than free) thyroxine or by the free T4 index. Similarly to TSH, the thyroxine results should be interpreted according to the appropriate reference range for that stage of pregnancy. The levothyroxine dose often needs to be increased after pregnancy is confirmed, although this is based on limited evidence and some recommend that it is not always required; decisions may need to based on TSH levels.Women with anti-TPO antibodies who are trying to become pregnant (naturally or by assisted means) may require thyroid hormone supplementation even if the TSH level is normal. This is particularly true if they have had previous miscarriages or have been hypothyroid in the past. Supplementary levothyroxine may reduce the risk of preterm birth and possibly miscarriage. The recommendation is stronger in pregnant women with subclinical hypothyroidism (defined as TSH 2.5–10 mIU/L) who are anti-TPO positive, in view of the risk of overt hypothyroidism. If a decision is made not to treat, close monitoring of the thyroid function (every 4 weeks in the first 20 weeks of pregnancy) is recommended. If anti-TPO is not positive, treatment for subclinical hypothyroidism is not currently recommended. It has been suggested that many of the aforementioned recommendations could lead to unnecessary treatment, in the sense that the TSH cutoff levels may be too restrictive in some ethnic groups; there may be little benefit from treatment of subclinical hypothyroidism in certain cases.\\n\\nThe effectiveness and safety of using Chinese herbal medicines to treat hypothyroidism is not known.\\n\\n']},\n {'name': ['Hyperthyroidism'],\n  'about': ['Hyperthyroidism is the condition that occurs due to excessive production of thyroid hormones by the thyroid gland. Thyrotoxicosis is the condition that occurs due to excessive thyroid hormone of any cause and therefore includes hyperthyroidism. Some, however, use the terms interchangeably. Signs and symptoms vary between people and may include irritability, muscle weakness, sleeping problems, a fast heartbeat, heat intolerance, diarrhea, enlargement of the thyroid, hand tremor, and weight loss. Symptoms are typically less severe in the elderly and during pregnancy.'],\n  'precaution': [None],\n  'symptoms': ['Hyperthyroidism may be asymptomatic or present with significant symptoms. Some of the symptoms of hyperthyroidism include nervousness, irritability, increased perspiration, heart racing, hand tremors, anxiety, trouble sleeping, thinning of the skin, fine brittle hair, and muscular weakness—especially in the upper arms and thighs. More frequent bowel movements may occur, and diarrhea is common. Weight loss, sometimes significant, may occur despite a good appetite (though 10% of people with a hyperactive thyroid experience weight gain), vomiting may occur, and, for women, menstrual flow may lighten and menstrual periods may occur less often, or with longer cycles than usual.Thyroid hormone is critical to normal function of cells. In excess, it both overstimulates metabolism and disrupts the normal functioning of sympathetic nervous system, causing \"speeding up\" of various body systems and symptoms resembling an overdose of epinephrine (adrenaline). These include fast heartbeat and symptoms of palpitations, nervous system tremor such as of the hands and anxiety symptoms, digestive system hypermotility, unintended weight loss, and, in lipid panel blood tests, a lower and sometimes unusually low serum cholesterol.Major clinical signs of hyperthyroidism include weight loss (often accompanied by an increased appetite), anxiety, heat intolerance, hair loss (especially of the outer third of the eyebrows), muscle aches, weakness, fatigue, hyperactivity, irritability, high blood sugar, excessive urination, excessive thirst, delirium, tremor, pretibial myxedema (in Graves\\' disease), emotional lability, and sweating.  Panic attacks, inability to concentrate, and memory problems may also occur. Psychosis and paranoia, common during thyroid storm, are rare with milder hyperthyroidism. Many persons will experience complete remission of symptoms 1 to 2 months after a euthyroid state is obtained, with a marked reduction in anxiety, sense of exhaustion, irritability, and depression. Some individuals may have an increased rate of anxiety or persistence of affective and cognitive symptoms for several months to up to 10 years after a euthyroid state is established. In addition, those with hyperthyroidism may present with a variety of physical symptoms such as palpitations and abnormal heart rhythms (the notable ones being atrial fibrillation), shortness of breath (dyspnea), loss of libido, amenorrhea, nausea, vomiting, diarrhea, gynecomastia and feminization. Long term untreated hyperthyroidism can lead to osteoporosis. These classical symptoms may not be present often in the elderly.Bone loss, which is associated with overt but not subclinical hyperthyroidism, may occur in 10 to 20% of patients. This may be due to an increase in bone remodelling and a decrease in bone density, and increases fracture risk. It is more common in postmenopausal women; less so in younger women, and men. Bone disease related to hyperthyroidism was first described by Frederick von Recklinghausen, in 1891; he described the bones of a woman who died of hyperthyroidism as appearing \"worm-eaten\".Neurological manifestations can include tremors, chorea, myopathy, and in some susceptible individuals (in particular of Asian descent) periodic paralysis. An association between thyroid disease and myasthenia gravis has been recognized. Thyroid disease, in this condition, is autoimmune in nature and approximately 5% of people with myasthenia gravis also have hyperthyroidism. Myasthenia gravis rarely improves after thyroid treatment and the relationship between the two entities is not well understood.In Graves\\' disease, ophthalmopathy may cause the eyes to look enlarged because the eye muscles swell and push the eye forward. Sometimes, one or both eyes may bulge. Some have swelling of the front of the neck from an enlarged thyroid gland (a goiter).Minor ocular (eye) signs, which may be present in any type of hyperthyroidism, are eyelid retraction (\"stare\"), extraocular muscle weakness, and lid-lag. In hyperthyroid stare (Dalrymple sign) the eyelids are retracted upward more than normal (the normal position is at the superior corneoscleral limbus, where the \"white\" of the eye begins at the upper border of the iris). Extraocular muscle weakness may present with double vision. In lid-lag (von Graefe\\'s sign), when the person tracks an object downward with their eyes, the eyelid fails to follow the downward moving iris, and the same type of upper globe exposure which is seen with lid retraction occurs, temporarily. These signs disappear with treatment of the hyperthyroidism.Neither of these ocular signs should be confused with exophthalmos (protrusion of the eyeball), which occurs specifically and uniquely in hyperthyroidism caused by Graves\\' disease (note that not all exophthalmos is caused by Graves\\' disease, but when present with hyperthyroidism is diagnostic of Graves\\' disease). This forward protrusion of the eyes is due to immune-mediated inflammation in the retro-orbital (eye socket) fat. Exophthalmos, when present, may exacerbate hyperthyroid lid-lag and stare.'],\n  'treatments': ['Thyrostatics (antithyroid drugs) are drugs that inhibit the production of thyroid hormones, such as carbimazole (used in the UK) and methimazole (used in the US, Germany and Russia), and propylthiouracil. Thyrostatics are believed to work by inhibiting the iodination of thyroglobulin by thyroperoxidase and, thus, the formation of tetraiodothyronine (T4). Propylthiouracil also works outside the thyroid gland, preventing the conversion of (mostly inactive) T4 to the active form T3. Because thyroid tissue usually contains a substantial reserve of thyroid hormone, thyrostatics can take weeks to become effective and the dose often needs to be carefully titrated over a period of months, with regular doctor visits and blood tests to monitor results.A very high dose is often needed early in treatment, but, if too high a dose is used persistently, people can develop symptoms of hypothyroidism. This titrating of the dose is difficult to do accurately, and so sometimes a \"block and replace\" attitude is taken. In block and replace treatments thyrostatics are taken in sufficient quantities to completely block thyroid hormones, and the person treated as though they have complete hypothyroidism.\\n\\nMany of the common symptoms of hyperthyroidism such as palpitations, trembling, and anxiety are mediated by increases in beta-adrenergic receptors on cell surfaces. Beta blockers, typically used to treat high blood pressure, are a class of drugs that offset this effect, reducing rapid pulse associated with the sensation of palpitations, and decreasing tremor and anxiety. Thus, a person with hyperthyroidism can often obtain immediate temporary relief until the hyperthyroidism can be characterized with the Radioiodine test noted above and more permanent treatment take place. Note that these drugs do not treat hyperthyroidism or any of its long-term effects if left untreated, but, rather, they treat or reduce only symptoms of the condition.Some minimal effect on thyroid hormone production however also comes with propranolol—which has two roles in the treatment of hyperthyroidism, determined by the different isomers of propranolol. L-propranolol causes beta-blockade, thus treating the symptoms associated with hyperthyroidism such as tremor, palpitations, anxiety, and heat intolerance. D-propranolol inhibits thyroxine deiodinase, thereby blocking the conversion of T4 to T3, providing some though minimal therapeutic effect. Other beta-blockers are used to treat only the symptoms associated with hyperthyroidism. Propranolol in the UK, and metoprolol in the US, are most frequently used to augment treatment for people with hyperthyroid .\\n\\nPeople with autoimmune hyperthyroidism (such as in Grave\\'s disease) should not eat foods high in iodine, such as edible seaweed and seafood.From a public health perspective, the general introduction of iodized salt in the United States in 1924 resulted in lower disease, goiters, as well as improving the lives of children whose mothers would not have eaten enough iodine during pregnancy which would have lowered the IQs of their children.\\n\\nSurgery (thyroidectomy to remove the whole thyroid or a part of it) is not extensively used because most common forms of hyperthyroidism are quite effectively treated by the radioactive iodine method, and because there is a risk of also removing the parathyroid glands, and of cutting the recurrent laryngeal nerve, making swallowing difficult, and even simply generalized staphylococcal infection as with any major surgery. Some people with Graves\\' may opt for surgical intervention. This includes those that cannot tolerate medicines for one reason or another, people that are allergic to iodine, or people that refuse radioiodine.A 2019 systematic review concluded that the available evidence shows no difference between visually identifying the nerve or utilizing intraoperative neuroimaging during surgery, when trying to prevent injury to recurrent laryngeal nerve during thyroid surgery.If people have toxic nodules treatments typically include either removal or injection of the nodule with alcohol.\\n\\nIn iodine-131 (radioiodine) radioisotope therapy, which was first pioneered by Dr. Saul Hertz, radioactive iodine-131 is given orally (either by pill or liquid) on a one-time basis, to severely restrict, or altogether destroy the function of a hyperactive thyroid gland. This isotope of radioactive iodine used for ablative treatment is more potent than diagnostic radioiodine (usually iodine-123 or a very low amount of iodine-131), which has a biological half-life from 8–13 hours. Iodine-131, which also emits beta particles that are far more damaging to tissues at short range, has a half-life of approximately 8 days.  People not responding sufficiently to the first dose are sometimes given an additional radioiodine treatment, at a larger dose. Iodine-131 in this treatment is picked up by the active cells in the thyroid and destroys them, rendering the thyroid gland mostly or completely inactive.Since iodine is picked up more readily (though not exclusively) by thyroid cells, and (more important) is picked up even more readily by over-active thyroid cells, the destruction is local, and there are no widespread side effects with this therapy. Radioiodine ablation has been used for over 50 years, and the only major reasons for not using it are pregnancy and breastfeeding (breast tissue also picks up and concentrates iodine). Once the thyroid function is reduced, replacement hormone therapy (levothyroxine) taken orally each day replaces the thyroid hormone that is normally produced by the body.There is extensive experience, over many years, of the use of radioiodine in the treatment of thyroid overactivity and this experience does not indicate any increased risk of thyroid cancer following treatment. However, a study from 2007 has reported an increased number of cancer cases after radioiodine treatment for hyperthyroidism.The principal advantage of radioiodine treatment for hyperthyroidism is that it tends to have a much higher success rate than medications. Depending on the dose of radioiodine chosen, and the disease under treatment (Graves\\' vs. toxic goiter, vs. hot nodule etc.), the success rate in achieving definitive resolution of the hyperthyroidism may vary from 75 to 100%. A major expected side-effect of radioiodine in people with Graves\\' disease is the development of lifelong hypothyroidism, requiring daily treatment with thyroid hormone. On occasion, some people may require more than one radioactive treatment, depending on the type of disease present, the size of the thyroid, and the initial dose administered.People with Graves\\' disease manifesting moderate or severe Graves\\' ophthalmopathy are cautioned against radioactive iodine-131 treatment, since it has been shown to exacerbate existing thyroid eye disease. People with mild or no ophthalmic symptoms can mitigate their risk with a concurrent six-week course of prednisone. The mechanisms proposed for this side effect involve a TSH receptor common to both thyrocytes and retro-orbital tissue.As radioactive iodine treatment results in the destruction of thyroid tissue, there is often a transient period of several days to weeks when the symptoms of hyperthyroidism may actually worsen following radioactive iodine therapy. In general, this happens as a result of thyroid hormones being released into the blood following the radioactive iodine-mediated destruction of thyroid cells that contain thyroid hormone. In some people, treatment with medications such as beta blockers (propranolol, atenolol, etc.) may be useful during this period of time. Most people do not experience any difficulty after the radioactive iodine treatment, usually given as a small pill. On occasion, neck tenderness or a sore throat may become apparent after a few days, if moderate inflammation in the thyroid develops and produces discomfort in the neck or throat area. This is usually transient, and not associated with a fever, etc.It is recommended that breastfeeding be stopped at least six weeks before radioactive iodine treatment and that it not be resumed, although it can be done in future pregnancies. It also shouldn\\'t be done during pregnancy, and pregnancy should be put off until at least 6–12 months after treatment.A common outcome following radioiodine is a swing from hyperthyroidism to the easily treatable hypothyroidism, which occurs in 78% of those treated for Graves\\' thyrotoxicosis and in 40% of those with toxic multinodular goiter or solitary toxic adenoma. Use of higher doses of radioiodine reduces the number of cases of treatment failure, with penalty for higher response to treatment consisting mostly of higher rates of eventual hypothyroidism which requires hormone treatment for life.There is increased sensitivity to radioiodine therapy in thyroids appearing on ultrasound scans as more uniform (hypoechogenic), due to densely packed large cells, with 81% later becoming hypothyroid, compared to just 37% in those with more normal scan appearances (normoechogenic).\\n\\nThyroid storm presents with extreme symptoms of hyperthyroidism.  It is treated aggressively with resuscitation measures along with a combination of the above modalities including: an intravenous beta blockers such as propranolol, followed by a thioamide such as methimazole, an iodinated radiocontrast agent or an iodine solution if the radiocontrast agent is not available, and an intravenous steroid such as hydrocortisone.\\n\\nIn countries such as China, herbs used alone or with antithyroid medications are used to treat hyperthyroidism. Very low quality evidence suggests that traditional Chinese herbal medications may be beneficial when taken along with routine hyperthyroid medications, however, there is no reliable evidence to determine the effectiveness of Chinese herbal medications for treating hyperthyroidism.\\n\\n']},\n {'name': ['Hypoglycemia'],\n  'about': [\"Hypoglycemia, also called low blood sugar, is a fall in blood sugar to levels below normal, typically below 70 mg/dL (3.9 mmol/L). Whipple's triad is used to properly identify hypoglycemic episodes. It is defined as blood glucose below 70 mg/dL (3.9 mmol/L), symptoms associated with hypoglycemia, and resolution of symptoms when blood sugar returns to normal. Hypoglycemia may result in headache, tiredness, clumsiness, trouble talking, confusion, fast heart rate, sweating, shakiness, nervousness, hunger, loss of consciousness, seizures, or death. Symptoms typically come on quickly.The most common cause of hypoglycemia is medications used to treat diabetes such as insulin, sulfonylureas, and biguanides.\"],\n  'precaution': [\"The prevention of hypoglycemia depends on the cause. In those with diabetes treated by insulin, glinides, or sulfonylurea, the prevention of hypoglycemia has a large focus on patient education and medication adjustments. The foundation of diabetes education is learning how to recognize the signs and symptoms of hypoglycemia, as well as learning how to act quickly to prevent worsening of an episode. Another cornerstone of prevention is strong self-monitoring of blood glucose, with consistent and frequent measurements. Research has shown that patients with type 1 diabetes who use continuous glucose monitoring systems with insulin pumps significantly improve blood glucose control. Insulin pumps help to prevent high glucose spikes, and help prevent inappropriate insulin dosing. Continuous glucose monitors can sound alarms when blood glucose is too low or too high, especially helping those with nocturnal hypoglycemia or hypoglycemic unawareness. In terms of medication adjustments, medication doses and timing can be adjusted to prevent hypoglycemia, or a medication can be stopped altogether.\\n\\nIn those with hypoglycemia who do not have diabetes, there are a number of preventative measures dependent on the cause. Hypoglycemia caused by hormonal dysfunction like lack of cortisol in Addison's disease or lack of growth hormone in hypopituitarism can be prevented with appropriate hormone replacement. The hypoglycemic episodes associated with non-B cell tumors can be decreased following surgical removal of the tumor, as well as following radiotherapy or chemotherapy to reduce the size of the tumor. In some cases, those with non-B cell tumors may have hormone therapy with growth hormone, glucocorticoid, or octreotide to also lessen hypoglycemic episodes. Post-gastric bypass hypoglycemia can be prevented by eating smaller, more frequent meals, avoiding sugar-filled foods, as well as medical treatment with an alpha-glucosidase inhibitor, diazoxide, or octreotide.Some causes of hypoglycemia require treatment of the underlying cause to best prevent hypoglycemia. This is the case for insulinomas which often require surgical removal of the tumor for hypoglycemia to remit. In patients who cannot undergo surgery for removal of the insulinoma, diazoxide or octreotide may be used.\\n\\n\"],\n  'symptoms': [\"Hypoglycemic symptoms are divided into two main categories. The first category is symptoms caused by low glucose in the brain, called neuroglycopenic symptoms. The second category of symptoms is caused by the body's reaction to low glucose in the brain, called adrenergic symptoms.\\nEveryone experiences different symptoms of hypoglycemia, so someone with hypoglycemia may not have all of the symptoms listed above. Symptoms also tend to have quick onset. It is important to quickly obtain a blood glucose measurement in someone presenting with symptoms of hypoglycemia to properly identify the hypoglycemic episode.\"],\n  'treatments': ['After hypoglycemia in a person is identified, rapid treatment is necessary and can be life-saving. The main goal of treatment is to raise blood glucose back to normal levels, which is done through various ways of administering glucose, depending on the severity of the hypoglycemia, what is on-hand to treat, and who is administering the treatment. A general rule used by the American Diabetes Association is the \"15-15 Rule,\" which suggests consuming or administering 15 grams of a carbohydrate, followed by a 15-minute wait and re-measurement of blood glucose level to assess if blood glucose has returned to normal levels.']},\n {'name': ['Osteoarthritis'],\n  'about': ['Osteoarthritis (OA) is a type of degenerative joint disease that results from breakdown of joint cartilage and underlying bone which affects 1 in 7 adults in the United States. It is believed to be the fourth leading cause of disability in the world. The most common symptoms are joint pain and stiffness. Usually the symptoms progress slowly over years. Other symptoms may include joint swelling, decreased range of motion, and, when the back is affected, weakness or numbness of the arms and legs.'],\n  'precaution': [None],\n  'symptoms': ['The main symptom is pain, causing loss of ability and often stiffness. The pain is typically made worse by prolonged activity and relieved by rest. Stiffness is most common in the morning, and typically lasts less than thirty minutes after beginning daily activities, but may return after periods of inactivity. Osteoarthritis can cause a crackling noise (called \"crepitus\") when the affected joint is moved, especially shoulder and knee joint. A person may also complain of joint locking and joint instability. These symptoms would affect their daily activities due to pain and stiffness. Some people report increased pain associated with cold temperature, high humidity, or a drop in barometric pressure, but studies have had mixed results.Osteoarthritis commonly affects the hands, feet, spine, and the large weight-bearing joints, such as the hips and knees, although in theory, any joint in the body can be affected. As osteoarthritis progresses, movement patterns (such as gait), are typically affected. Osteoarthritis is the most common cause of a joint effusion of the knee.In smaller joints, such as at the fingers, hard bony enlargements, called Heberden\\'s nodes (on the distal interphalangeal joints) or Bouchard\\'s nodes (on the proximal interphalangeal joints), may form, and though they are not necessarily painful, they do limit the movement of the fingers significantly. Osteoarthritis of the toes may be a factor causing formation of bunions, rendering them red or swollen.'],\n  'treatments': [\"Lifestyle modification (such as weight loss and exercise) and pain medications are the mainstays of treatment. Acetaminophen (also known as paracetamol) is recommended first line, with NSAIDs being used as add-on therapy only if pain relief is not sufficient. Medications that alter the course of the disease have not been found as of 2018. Recommendations include modification of risk factors through targeted interventions including 1) obesity and overweight, 2) physical activity, 3) dietary exposures, 4) comorbidity, 5) biomechanical factors, 6) occupational factors.Successful management of the condition is often made more difficult by differing priorities and poor communication between clinicians and people with osteoarthritis. Realistic treatment goals can be achieved by developing a shared understanding of the condition, actively listening to patient concerns, avoiding medical jargon and tailoring treatment plans to the patient's needs.\"]},\n {'name': ['Arthritis'],\n  'about': ['Arthritis is a term often used to mean any disorder that affects joints. Symptoms generally include joint pain and stiffness. Other symptoms may include redness, warmth, swelling, and decreased range of motion of the affected joints. In some types of arthritis, other organs are also affected. Onset can be gradual or sudden.There are over 100 types of arthritis.'],\n  'precaution': [None],\n  'symptoms': ['Pain, which can vary in severity, is a common symptom in virtually all types of arthritis. Other symptoms include swelling, joint stiffness, redness, and aching around the joint(s). Arthritic disorders like lupus and rheumatoid arthritis can affect other organs in the body, leading to a variety of symptoms. Symptoms may include:\\nInability to use the hand or walk\\nStiffness in one or more joints\\nRash or itch\\nMalaise and fatigue\\nWeight loss\\nPoor sleep\\nMuscle aches and pains\\nTenderness\\nDifficulty moving the jointIt is common in advanced arthritis for significant secondary changes to occur. For example, arthritic symptoms might make it difficult for a person to move around and/or exercise, which can lead to secondary effects, such as:\\n\\nMuscle weakness\\nLoss of flexibility\\nDecreased aerobic fitnessThese changes, in addition to the primary symptoms, can have a huge impact on quality of life.'],\n  'treatments': ['There is no known cure for arthritis and rheumatic diseases. Treatment options vary depending on the type of arthritis and include physical therapy, exercise and diet, orthopedic bracing, and oral and topical medications. Joint replacement surgery may be required to repair damage, restore function, or relieve pain.']},\n {'name': ['Paroxysmal Positional Vertigo'],\n  'about': ['Benign paroxysmal positional vertigo (BPPV) is a disorder arising from a problem in the inner ear. Symptoms are repeated, brief periods of vertigo with movement, characterized by a spinning sensation upon changes in the position of the head. This can occur with turning in bed or changing position. Each episode of vertigo typically lasts less than one minute. Nausea is commonly associated.'],\n  'precaution': [None],\n  'symptoms': ['Symptoms:\\n\\nParoxysmal—appears suddenly, and in episodes of short duration: lasts only seconds to minutes\\nPositional—is induced by a change in position, even slight\\nVertigo—a spinning dizziness, which must have a rotational component\\nTorsional nystagmus—a diagnostic symptom where the top of the eye rotates toward the affected ear in a beating or twitching fashion, which has a latency and can be fatigued (vertigo should lessen with deliberate repetition of the provoking maneuver): nystagmus should only last for 30 seconds to one minute\\nPre-syncope—(feeling faint) or syncope (fainting) is unusual, but possible\\nVisual disturbance—due to associated nystagmus, making it difficult to read or see during an attack\\nNausea—is often associated\\nVomiting—is common, depending on the strength of vertigo itself and the causes for this illnessMany people will report a history of vertigo as a result of fast head movements. Many are also capable of describing the exact head movements that provoke their vertigo. Purely horizontal nystagmus and symptoms of vertigo lasting more than one minute can also indicate BPPV occurring in the horizontal semicircular canal.\\nThe spinning sensation experienced from BPPV is usually triggered by movement of the head, will have a sudden onset, and can last anywhere from a few seconds to several minutes. The most common movements people report triggering a spinning sensation are tilting their heads upward in order to look at something and when rolling over in bed.People with BPPV do not experience other neurological deficits such as numbness or weakness. If those symptoms are present, a more serious etiology, such as posterior circulation stroke or ischemia, must be considered.\\nThe most significant symptom is nystagmus as it is essential to determine the kind of nystagmus ( horizontal, vertical, or diagonal ) to select the correct cure maneuver.'],\n  'treatments': [\"A number of maneuvers have been found to be effective including Canalith Repositioning Procedures (CRP) such as the Epley maneuver, the Half Somersault Maneuver (HSM), the Semont maneuver, and to a lesser degree the non-CRP Brandt–Daroff exercises. Both the Epley and the Semont maneuvers are equally effective. The HSM can have better long-term success than the Epley, is more comfortable to experience, and has less risk of causing subsequent horizontal canal BPPV (H-BPPV).None of these maneuvers addresses the presence of the particles (otoconia); rather it changes their location. The maneuvers aim to move these particles from some locations in the inner ear that cause symptoms such as vertigo and reposition them to where they do not cause these problems. These maneuvers are easily performed at home and online resources are available to patients.The Epley maneuver is popular because it is designed to address posterior canal BPPV (PC-BPPV), which is caused by particles in the posterior semicircular canal, the most common cause of BPPV. This might give the wrong impression that PC-BPPV is the only kind of BPPV. Misdiagnosing which semicircular canal is affected, typically by confusing horizontal and diagonal nystagmus, or simply ignoring the identification of the affected canal, and then using the wrong treatment maneuver, regularly results in no cure.\\nUsing the appropriate maneuver for the affected canal is essential. The maneuvers may be uncomfortable for the patient as they might induce strong vertigo and the patient might then resist performing them. Though some treatments, such as the Epley, are much more uncomfortable than others, such as the HSM. If the maneuver is not uncomfortable then it is possible the wrong maneuver has been selected by a misdiagnosis of the affected semicircular canal.\\nAll the maneuvers consist of a series of steps in which the head is held in a specific position, typically for 30 to 60 seconds until any nystagmus stops. Movement from one position to the position of the next step has to be done fluently to give the particles enough momentum to move. A position has to be held until any nystagmus has completely resided, which indicates that the particles have stopped moving, before one proceeds to the next step.\\n\\nMedical treatment with anti-vertigo medications may be considered in acute, severe exacerbation of BPPV, but in most cases are not indicated. These primarily include drugs of the antihistamine and anticholinergic class, such as meclizine and hyoscine butylbromide (scopolamine), respectively. The medical management of vestibular syndromes has become increasingly popular over the last decade, and numerous novel drug therapies (including existing drugs with new indications) have emerged for the treatment of vertigo/dizziness syndromes. These drugs vary considerably in their mechanisms of action, with many of them being receptor- or ion channel-specific. Among them are betahistine or dexamethasone/gentamicin for the treatment of Ménière's disease, carbamazepine/oxcarbazepine for the treatment of paroxysmal dysarthria and ataxia in multiple sclerosis, metoprolol/topiramate or valproic acid/tricyclic antidepressant for the treatment of vestibular migraine, and 4-aminopyridine for the treatment of episodic ataxia type 2 and both downbeat and upbeat nystagmus. These drug therapies offer symptomatic treatment, and do not affect the disease process or resolution rate. Medications may be used to suppress symptoms during the positioning maneuvers if the person's symptoms are severe and intolerable. More dose-specific studies are required, however, in order to determine the most effective drug(s) for both acute symptom relief and long-term remission of the condition.\\n\\nSurgical treatments, such as a semi-circular canal occlusion, exist for severe and persistent cases that fail vestibular rehabilitation (including particle repositioning and habituation therapy). As they carry the same risks as any neurosurgical procedure, they are reserved as last resorts.\\n\\n\"]},\n {'name': ['Acne'],\n  'about': ['Acne, also known as acne vulgaris, is a long-term skin condition that occurs when dead skin cells and oil from the skin clog hair follicles. Typical features of the condition include blackheads or whiteheads, pimples, oily skin, and possible scarring. It primarily affects skin with a relatively high number of oil glands, including the face, upper part of the chest, and back. The resulting appearance can lead to lack of confidence, anxiety, reduced self-esteem, and, in extreme cases, depression or thoughts of suicide.Susceptibility to acne is primarily genetic in 80% of cases. The roles of diet and cigarette smoking in the condition are unclear, and neither cleanliness nor exposure to sunlight appear to play a part.'],\n  'precaution': [None],\n  'symptoms': ['Typical features of acne include increased secretion of oily sebum by the skin, microcomedones, comedones, papules, nodules (large papules), pustules, and often results in scarring. The appearance of acne varies with skin color. It may result in psychological and social problems.'],\n  'treatments': ['Many different treatments exist for acne. These include alpha hydroxy acid, anti-androgen medications, antibiotics, antiseborrheic medications, azelaic acid, benzoyl peroxide, hormonal treatments, keratolytic soaps, nicotinamide, retinoids, and salicylic acid. Acne treatments work in at least four different ways, including the following: reducing inflammation, hormonal manipulation, killing C. acnes, and normalizing skin cell shedding and sebum production in the pore to prevent blockage. Typical treatments include topical therapies such as antibiotics, benzoyl peroxide, and retinoids, and systemic therapies, including antibiotics, hormonal agents, and oral retinoids.Recommended therapies for first-line use in acne vulgaris treatment include topical retinoids, benzoyl peroxide, and topical or oral antibiotics. Procedures such as light therapy and laser therapy are not first-line treatments and typically have only an add on role due to their high cost and limited evidence. Blue light therapy is of unclear benefit. Medications for acne target the early stages of comedo formation and are generally ineffective for visible skin lesions; acne generally improves between eight and twelve weeks after starting therapy.People often view acne as a short-term condition, some expecting it to disappear after puberty. This misconception can lead to depending on self-management or problems with long-term adherence to treatment. Communicating the long-term nature of the condition and better access to reliable information about acne can help people know what to expect from treatments.']},\n {'name': ['Urinary tract infection'],\n  'about': ['A urinary tract infection (UTI) is an infection that affects part of the urinary tract. When it affects the lower urinary tract it is known as a bladder infection (cystitis) and when it affects the upper urinary tract it is known as a kidney infection (pyelonephritis). Symptoms from a lower urinary tract infection include pain with urination, frequent urination, and feeling the need to urinate despite having an empty bladder. Symptoms of a kidney infection include fever and flank pain usually in addition to the symptoms of a lower UTI. Rarely the urine may appear bloody.'],\n  'precaution': [\"A number of measures have not been confirmed to affect UTI frequency including: urinating immediately after intercourse, the type of underwear used, personal hygiene methods used after urinating or defecating, or whether a person typically bathes or showers. There is similarly a lack of evidence surrounding the effect of holding one's urine, tampon use, and douching. In those with frequent urinary tract infections who use spermicide or a diaphragm as a method of contraception, they are advised to use alternative methods. In those with benign prostatic hyperplasia urinating in a sitting position appears to improve bladder emptying which might decrease urinary tract infections in this group.Using urinary catheters as little and as short of time as possible and appropriate care of the catheter when used prevents catheter-associated urinary tract infections.\\nThey should be inserted using sterile technique in hospital however non-sterile technique may be appropriate in those who self catheterize. The urinary catheter set up should also be kept sealed. Evidence does not support a significant decrease in risk when silver-alloy catheters are used.\"],\n  'symptoms': ['Lower urinary tract infection is also referred to as a bladder infection. The most common symptoms are burning with urination and having to urinate frequently (or an urge to urinate) in the absence of vaginal discharge and significant pain. These symptoms may vary from mild to severe and in healthy women last an average of six days. Some pain above the pubic bone or in the lower back may be present. People experiencing an upper urinary tract infection, or pyelonephritis, may experience flank pain, fever, or nausea and vomiting in addition to the classic symptoms of a lower urinary tract infection. Rarely, the urine may appear bloody or contain visible pus in the urine.UTIs have been associated with onset or worsening of delirium, dementia, and neuropsychiatric disorders such as depression and psychosis. However, there is insufficient evidence to determine whether UTI causes confusion. The reasons for this are unknown, but may involve a UTI-mediated systemic inflammatory response which affects the brain. Cytokines such as interleukin-6 produced as part of the inflammatory response may produce neuroinflammation, in turn affecting dopaminergic and/or glutamatergic neurotransmission as well as brain glucose metabolism.'],\n  'treatments': ['The mainstay of treatment is antibiotics. Phenazopyridine is occasionally prescribed during the first few days in addition to antibiotics to help with the burning and urgency sometimes felt during a bladder infection. However, it is not routinely recommended due to safety concerns with its use, specifically an elevated risk of methemoglobinemia (higher than normal level of methemoglobin in the blood). Paracetamol may be used for fevers. There is no good evidence for the use of cranberry products for treating current infections.Fosfomycin can be used as an effective treatment for both UTIs and complicated UTIs including acute pyelonephritis. The standard regimen for complicated UTIs is an oral 3g dose administered once every 48 or 72 hours for a total of 3 doses or a 6 grams every 8 hours for 7 days to 14 days when fosfomycin is given in IV form.']},\n {'name': ['Psoriasis'],\n  'about': ['Psoriasis is a long-lasting, noncontagious autoimmune disease characterized by patches of abnormal skin. These areas are red, pink, or purple, dry, itchy, and scaly. Psoriasis varies in severity from small localized patches to complete body coverage. Injury to the skin can trigger psoriatic skin changes at that spot, which is known as the Koebner phenomenon.The five main types of psoriasis are plaque, guttate, inverse, pustular, and erythrodermic. Plaque psoriasis, also known as psoriasis vulgaris, makes up about 90% of cases.'],\n  'precaution': [None],\n  'symptoms': [\"Psoriasis vulgaris (also known as chronic stationary psoriasis or plaque-like psoriasis) is the most common form and affects 85–90% of people with psoriasis. Plaque psoriasis typically appears as raised areas of inflamed skin covered with silvery-white, scaly skin. These areas are called plaques and are most commonly found on the elbows, knees, scalp, and back.\\n\\nAdditional types of psoriasis comprise about 10% of cases. They include pustular, inverse, napkin, guttate, oral, and seborrheic-like forms.\\n\\nPsoriatic arthritis is a form of chronic inflammatory arthritis that has a highly variable clinical presentation and frequently occurs in association with skin and nail psoriasis. It typically involves painful inflammation of the joints and surrounding connective tissue, and can occur in any joint, but most commonly affects the joints of the fingers and toes. This can result in a sausage-shaped swelling of the fingers and toes known as dactylitis. Psoriatic arthritis can also affect the hips, knees, spine (spondylitis), and sacroiliac joint (sacroiliitis). About 30% of individuals with psoriasis will develop psoriatic arthritis. Skin manifestations of psoriasis tend to occur before arthritic manifestations in about 75% of cases.\\n\\nPsoriasis can affect the nails and produces a variety of changes in the appearance of fingers and toenails. Nail psoriasis occurs in 40–45% of people with psoriasis affecting the skin, and has a lifetime incidence of 80–90% in those with psoriatic arthritis. These changes include pitting of the nails (pinhead-sized depressions in the nail is seen in 70% with nail psoriasis), whitening of the nail, small areas of bleeding from capillaries under the nail, yellow-reddish discoloration of the nails known as the oil drop or salmon spots, dryness, thickening of the skin under the nail (subungual hyperkeratosis), loosening and separation of the nail (onycholysis), and crumbling of the nail.\\n\\nIn addition to the appearance and distribution of the rash, specific medical signs may be used by medical practitioners to assist with diagnosis. These may include Auspitz's sign (pinpoint bleeding when scale is removed), Koebner phenomenon (psoriatic skin lesions induced by trauma to the skin), and itching and pain localized to papules and plaques.\\n\\n\"],\n  'treatments': ['While no cure is available for psoriasis, many treatment options exist. Topical agents are typically used for mild disease, phototherapy for moderate disease, and systemic agents for severe disease. There is no evidence to support the effectiveness of conventional topical and systemic drugs, biological therapy, or phototherapy for acute guttate psoriasis or an acute guttate flare of chronic psoriasis.']},\n {'name': ['Impetigo'],\n  'about': ['Impetigo is a bacterial infection that involves the superficial skin. The most common presentation is yellowish crusts on the face, arms, or legs. Less commonly there may be large blisters which affect the groin or armpits. The lesions may be painful or itchy. Fever is uncommon.It is typically due to either Staphylococcus aureus or Streptococcus pyogenes.'],\n  'precaution': ['To prevent the spread of impetigo the skin and any open wounds should be kept clean and covered. Care should be taken to keep fluids from an infected person away from the skin of a non-infected person. Washing hands, linens, and affected areas will lower the likelihood of contact with infected fluids. Scratching can spread the sores; keeping nails short will reduce the chances of spreading. Infected people should avoid contact with others and eliminate sharing of clothing or linens. Children with impetigo can return to school 24 hours after starting antibiotic therapy as long as their draining lesions are covered.'],\n  'symptoms': ['This most common form of impetigo, also called nonbullous impetigo, most often begins as a red sore near the nose or mouth which soon breaks, leaking pus or fluid, and forms a honey-colored scab, followed by a red mark which often heals without leaving a scar. Sores are not painful, but they may be itchy. Lymph nodes in the affected area may be swollen, but fever is rare. Touching or scratching the sores may easily spread the infection to other parts of the body.Skin ulcers with redness and scarring also may result from scratching or abrading the skin.\\n\\nBullous impetigo, mainly seen in children younger than 2 years, involves painless, fluid-filled blisters, mostly on the arms, legs, and trunk, surrounded by red and itchy (but not sore) skin. The blisters may be large or small. After they break, they form yellow scabs.\\n\\nEcthyma, the nonbullous form of impetigo, produces painful fluid- or pus-filled sores with redness of skin, usually on the arms and legs, become ulcers that penetrate deeper into the dermis. After they break open, they form hard, thick, gray-yellow scabs, which sometimes leave scars. Ecthyma may be accompanied by swollen lymph nodes in the affected area.\\n\\n'],\n  'treatments': ['Antibiotics, either as a cream or by mouth, are usually prescribed. Mild cases may be treated with mupirocin ointments. In 95% of cases, a single 7-day antibiotic course results in resolution in children. It has been advocated that topical antiseptics are inferior to topical antibiotics, and therefore should not be used as a replacement. However, the National Institute for Health and Care Excellence (NICE) as of February 2020 recommends a hydrogen peroxide 1% cream antiseptic rather than topical antibiotics for localised non-bullous impetigo in otherwise well individuals. This recommendation is part of an effort to reduce the overuse of antimicrobials that may contribute to the development of resistant organisms such as MRSA.\\nMore severe cases require oral antibiotics, such as dicloxacillin, flucloxacillin, or erythromycin. Alternatively, amoxicillin combined with clavulanate potassium, cephalosporins (first-generation) and many others may also be used as an antibiotic treatment. Alternatives for people who are seriously allergic to penicillin or infections with methicillin-resistant Staphococcus aureus include doxycycline, clindamycin, and trimethoprim-sulphamethoxazole, although doxycycline should not be used in children under the age of eight years old due to the risk of drug-induced tooth discolouration. When streptococci alone are the cause, penicillin is the drug of choice. When the condition presents with ulcers, valacyclovir, an antiviral, may be given in case a viral infection is causing the ulcer.']},\n {'name': ['Hepatitis'],\n  'about': ['Hepatitis is inflammation of the liver tissue. Some people or animals with hepatitis have no symptoms, whereas others develop yellow discoloration of the skin and whites of the eyes (jaundice), poor appetite, vomiting, tiredness, abdominal pain, and diarrhea. Hepatitis is acute if it resolves within six months, and chronic if it lasts longer than six months. Acute hepatitis can resolve on its own, progress to chronic hepatitis, or (rarely) result in acute liver failure. Chronic hepatitis may progress to scarring of the liver (cirrhosis), liver failure, and liver cancer.Hepatitis is most commonly caused by the virus hepatovirus A, B, C, D, and E.'],\n  'precaution': ['\\n\\n\\n\\n\\n\\n'],\n  'symptoms': ['Hepatitis has a broad spectrum of presentations that range from a complete lack of symptoms to severe liver failure. The acute form of hepatitis, generally caused by viral infection, is characterized by constitutional symptoms that are typically self-limiting. Chronic hepatitis presents similarly, but can manifest signs and symptoms specific to liver dysfunction with long-standing inflammation and damage to the organ.'],\n  'treatments': ['The treatment of hepatitis varies according to the type, whether it is acute or chronic, and the severity of the disease.\\n\\nActivity: Many people with hepatitis prefer bed rest, though it is not necessary to avoid all physical activity while recovering.\\nDiet: A high-calorie diet is recommended. Many people develop nausea and cannot tolerate food later in the day, so the bulk of intake may be concentrated in the earlier part of the day. In the acute phase of the disease, intravenous feeding may be needed if patients cannot tolerate food and have poor oral intake subsequent to nausea and vomiting.\\nDrugs: People with hepatitis should avoid taking drugs metabolized by the liver. Glucocorticoids are not recommended as a treatment option for acute viral hepatitis and may even cause harm, such as development of chronic hepatitis.\\nPrecautions: Universal precautions should be observed. Isolation is usually not needed, except in cases of hepatitis A and E who have fecal incontinence, and  in cases of hepatitis B and C who have uncontrolled bleeding.']},\n {'name': ['Gastroesophageal reflux disease'],\n  'about': [\"Gastroesophageal reflux disease (GERD) or gastro-oesophageal reflux disease (GORD)  is one of the upper gastrointestinal chronic diseases in which stomach content persistently and regularly flows up into the esophagus, resulting in symptoms and/or complications. Symptoms include dental corrosion, dysphagia, heartburn, odynophagia, regurgitation, non-cardiac chest pain, extraesophageal symptoms such as chronic cough, hoarseness, reflux-induced laryngitis, or asthma. In the long term, and when not treated, complications such as esophagitis, esophageal stricture, and Barrett's esophagus may arise.Risk factors include obesity, pregnancy, smoking, hiatal hernia, and taking certain medications. Medications that may cause or worsen the disease include benzodiazepines, calcium channel blockers, tricyclic antidepressants, NSAIDs, and certain asthma medicines. Acid reflux is due to poor closure of the lower esophageal sphincter, which is at the junction between the stomach and the esophagus.\"],\n  'precaution': [None],\n  'symptoms': ['The most common symptoms of GERD in adults are an acidic taste in the mouth, regurgitation, and heartburn. Less common symptoms include pain with swallowing/sore throat, increased salivation (also known as water brash), nausea, chest pain, coughing, and globus sensation. The acid reflux can induce asthma attack symptoms like shortness of breath, cough, and wheezing in those with underlying asthma.GERD sometimes causes injury to the esophagus. These injuries may include one or more of the following:\\n\\nReflux esophagitis – inflammation of esophageal epithelium which can cause ulcers near the junction of the stomach and esophagus\\nEsophageal strictures – the persistent narrowing of the esophagus caused by reflux-induced inflammation\\nBarrett\\'s esophagus – intestinal metaplasia (changes of the epithelial cells from squamous to intestinal columnar epithelium) of the distal esophagus\\nEsophageal adenocarcinoma – a form of cancerGERD sometimes causes injury of the larynx (LPR). Other complications can include aspiration pneumonia.\\n\\nGERD may be difficult to detect in infants and children since they cannot describe what they are feeling and indicators must be observed. Symptoms may vary from typical adult symptoms. GERD in children may cause repeated vomiting, effortless spitting up, coughing, and other respiratory problems, such as wheezing. Inconsolable crying, refusing food, crying for food and then pulling off the bottle or breast only to cry for it again, failure to gain adequate weight, bad breath, and burping are also common. Children may have one symptom or many; no single symptom is universal in all children with GERD.\\nOf the estimated 4 million babies born in the US each year, up to 35% of them may have difficulties with reflux in the first few months of their lives, known as \\'spitting up\\'. About 90% of infants will outgrow their reflux by their first birthday.\\n\\nAcid reflux into the mouth can cause breakdown of the enamel, especially on the inside surface of the teeth. A dry mouth, acid or burning sensation in the mouth, bad breath and redness of the palate may occur. Less common symptoms of GERD include difficulty in swallowing, water brash, chronic cough, hoarse voice, nausea and vomiting.Signs of enamel erosion are the appearance of a smooth, silky-glazed, sometimes dull, enamel surface with the absence of perikymata, together with intact enamel along the gum margin. It will be evident in people with restorations as tooth structure typically dissolves much faster than the restorative material, causing it to seem as if it \"stands above\" the surrounding tooth structure.\\n\\nGERD may lead to Barrett\\'s esophagus, a type of intestinal metaplasia, which is in turn a precursor condition for esophageal cancer. The risk of progression from Barrett\\'s to dysplasia is uncertain, but is estimated at 20% of cases. Due to the risk of chronic heartburn progressing to Barrett\\'s, EGD every five years is recommended for people with chronic heartburn, or who take drugs for chronic GERD.\\n\\n'],\n  'treatments': ['The treatments for GERD may include food choices, lifestyle changes, medications, and possibly surgery. Initial treatment is frequently with a proton-pump inhibitor such as omeprazole. In some cases, a person with GERD symptoms can manage them by taking over-the-counter drugs. This is often safer and less expensive than taking prescription drugs. Some guidelines recommend trying to treat symptoms with an H2 antagonist before using a proton-pump inhibitor because of cost and safety concerns.']},\n {'name': ['Allergic Diseases'],\n  'about': ['Allergies, also known as allergic diseases, are various conditions caused by hypersensitivity of the immune system to typically harmless substances in the environment. These diseases include hay fever, food allergies, atopic dermatitis, allergic asthma, and anaphylaxis. Symptoms may include red eyes, an itchy rash, sneezing, coughing, a runny nose, shortness of breath, or swelling. Note that food intolerances and food poisoning are separate conditions.Common allergens include pollen and certain foods. Metals and other substances may also cause such problems.'],\n  'precaution': [\"Giving peanut products early may decrease the risk of allergies while only breastfeeding during at least the first few months of life may decrease the risk of dermatitis. There is no good evidence that a mother's diet during pregnancy or breastfeeding affects the risk of allergies, nor is there evidence that delayed introduction of certain foods is useful. Early exposure to potential allergens may actually be protective.Fish oil supplementation during pregnancy is associated with a lower risk. Probiotic supplements during pregnancy or infancy may help to prevent atopic dermatitis.\"],\n  'symptoms': ['Many allergens such as dust or pollen are airborne particles. In these cases, symptoms arise in areas in contact with air, such as the eyes, nose, and lungs. For instance, allergic rhinitis, also known as hay fever, causes irritation of the nose, sneezing, itching, and redness of the eyes. Inhaled allergens can also lead to increased production of mucus in the lungs, shortness of breath, coughing, and wheezing.Aside from these ambient allergens, allergic reactions can result from foods, insect stings, and reactions to medications like aspirin and antibiotics such as penicillin. Symptoms of food allergy include abdominal pain, bloating, vomiting, diarrhea, itchy skin, and hives. Food allergies rarely cause respiratory (asthmatic) reactions, or rhinitis. Insect stings, food, antibiotics, and certain medicines may produce a systemic allergic response that is also called anaphylaxis; multiple organ systems can be affected, including the digestive system, the respiratory system, and the circulatory system. Depending on the severity, anaphylaxis can include skin reactions, bronchoconstriction, swelling, low blood pressure, coma, and death. This type of reaction can be triggered suddenly, or the onset can be delayed. The nature of anaphylaxis is such that the reaction can seem to be subsiding but may recur throughout a period of time.'],\n  'treatments': ['Management of allergies typically involves avoiding the allergy trigger and taking medications to improve the symptoms. Allergen immunotherapy may be useful for some types of allergies.']},\n {'name': ['Paralysis'],\n  'about': ['Paralysis (PL: paralyses; also known as plegia) is a loss of motor function in one or more muscles. Paralysis can also be accompanied by a loss of feeling (sensory loss) in the affected area if there is sensory damage. In the United States, roughly 1 in 50 people have been diagnosed with some form of permanent or transient paralysis. The word \"paralysis\" derives from the Greek παράλυσις, meaning \"disabling of the nerves\" from παρά (para) meaning \"beside, by\" and λύσις (lysis) meaning \"making loose\". A paralysis accompanied by involuntary tremors is usually called \"palsy\"..'],\n  'precaution': [None],\n  'symptoms': [None],\n  'treatments': [None]}]"
     },
     "execution_count": 31,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "json_list"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-26T13:56:24.810359200Z",
     "start_time": "2023-09-26T13:56:24.758449700Z"
    }
   },
   "id": "699bf4bf59067b71"
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "outputs": [],
   "source": [
    "import json"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-26T13:57:15.009607500Z",
     "start_time": "2023-09-26T13:57:14.892327800Z"
    }
   },
   "id": "a3811e46fcfaafc3"
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "outputs": [],
   "source": [
    "with open(\"../jsons/knowledge_base.json\", \"w\") as fl:\n",
    "    json.dump({\"diseases\": json_list}, fl)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-26T13:58:06.194715100Z",
     "start_time": "2023-09-26T13:58:06.081323400Z"
    }
   },
   "id": "974afdeba04b8a12"
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Hepatitis A\n",
      "The CDC recommends the hepatitis A vaccine for all children beginning at age one, as well as for those who have not been previously immunized and are at high risk for contracting the disease.For children 12 months of age or older, the vaccination is given as a shot into the muscle in two doses 6–18 months apart and should be started before the age 24 months.  The dosing is slightly different for adults depending on the type of the vaccine.  If the vaccine is for hepatitis A only, two doses are given 6–18 months apart depending on the manufacturer.  If the vaccine is combined hepatitis A and hepatitis B, up to 4 doses may be required.\n",
      "Hepatitis B\n",
      "The CDC recommends the routine vaccination of all children under the age of 19 with the hepatitis B vaccine. They also recommend it for those who desire it or are at high risk.Routine vaccination for hepatitis B starts with the first dose administered as  a shot into the muscle before the newborn is discharged from the hospital.  An additional two doses should be administered before the child is 18 months.For babies born to a mother with hepatitis B surface antigen positivity, the first dose is unique – in addition to the vaccine, the hepatitis immune globulin should also be administered, both within 12 hours of birth.  These newborns should also be regularly tested for infection for at least the first year of life.There is also a combination formulation that includes both hepatitis A and B vaccines.\n",
      "Other\n",
      "There are currently no vaccines available in the United States for hepatitis C or E. In 2015, a group in China published an article regarding the development of a vaccine for hepatitis E. As of March 2016, the United States government was in the process of recruiting participants for the phase IV trial of the hepatitis E vaccine.\n",
      "\n",
      "\n",
      "Hepatitis A\n",
      "Because hepatitis A is transmitted primarily through the oral-fecal route, the mainstay of prevention aside from vaccination is good hygiene, access to clean water and proper handling of sewage.\n",
      "Hepatitis B and C\n",
      "As hepatitis B and C are transmitted through blood and multiple bodily fluids, prevention is aimed at screening blood prior to transfusion, abstaining from the use of injection drugs, safe needle and sharps practices in healthcare settings, and safe sex practices.\n",
      "Hepatitis D\n",
      "The hepatitis D virus requires that a person first be infected with hepatitis B virus, so prevention efforts should focus on limiting the spread of hepatitis B. In people who have chronic hepatitis B infection and are at risk for superinfection with the hepatitis D virus, the preventive strategies are the same as for hepatitis B.\n",
      "Hepatitis E\n",
      "Hepatitis E is spread primarily through the oral-fecal route but may also be spread by blood and from mother to fetus.  The mainstay of hepatitis E prevention is similar to that for hepatitis A (namely, good hygiene and clean water practices).\n",
      "Alcoholic and metabolic hepatitis\n",
      "As excessive alcohol consumption can lead to hepatitis and cirrhosis, the following are maximal recommendations for alcohol consumption:\n",
      "Men – ≤ 4 drinks on any given day and ≤ 14 drinks per week\n",
      "Women – ≤ 3 drinks on any given day and ≤ 7 drinks per weekTo prevent MAFLD it is recommended to maintain a normal weight, eat a healthy diet, avoid added sugar, and exercise regularly.\n",
      "\n",
      "\n",
      "Hepatitis A\n",
      "In the United States, universal immunization has led to a two-thirds decrease in hospital admissions and medical expenses due to hepatitis A.\n",
      "Hepatitis B\n",
      "In the United States new cases of hepatitis B decreased 75% from 1990 to 2004.  The group that saw the greatest decrease was children and adolescents, likely reflecting the implementation of the 1999 guidelines.\n",
      "Hepatitis C\n",
      "Hepatitis C infections each year had been declining since the 1980s, but began to increase again in 2006.  The data are unclear as to whether the decline can be attributed to needle exchange programmes.\n",
      "Alcoholic hepatitis\n",
      "Because people with alcoholic hepatitis may have no symptoms, it can be difficult to diagnose and the number of people with the disease is probably higher than many estimates. Programs such as Alcoholics Anonymous have been successful in decreasing death due to cirrhosis, but it is difficult to evaluate their success in decreasing the incidence of alcoholic hepatitis.\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print(get_wiki_content_api(\"Hepatitis\", 'precaution'))"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-09-26T14:35:09.441123700Z",
     "start_time": "2023-09-26T14:35:08.587146Z"
    }
   },
   "id": "8dbf8b0b9187c560"
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "outputs": [],
   "source": [],
   "metadata": {
    "collapsed": false
   },
   "id": "17233fc7afe42a37"
  }
 ],
 "metadata": {
  "kernelspec": {
   "name": ".venv",
   "language": "python",
   "display_name": ".venv"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 2
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython2",
   "version": "2.7.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
